

REFINITIV

DELTA REPORT

10-K

DOCGO INC.

10-K - DECEMBER 31, 2023 COMPARED TO 10-K - DECEMBER 31, 2022

The following comparison report has been automatically generated

TOTAL DELTAS	5407
--------------	------

 CHANGES	158
---	-----

 DELETIONS	2392
---	------

 ADDITIONS	2857
---	------

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 10-K

(Mark One)
☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the fiscal year ended December 31, 2022

December 31, 2023

OR

OR

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission File Number 001-39618

DocGo Inc.

(Exact name of Registrant as specified in its Charter)

Delaware

85-2515483

(State or other jurisdiction of

(I.R.S. Employer

incorporation or organization)

Identification No.)

35 West 35th Street, Floor 6

New York, New York

10001

(Address of principal executive offices)

(Zip Code)

Registrant's telephone number, including area code: (844) 443-6246

Securities registered pursuant to Section 12(b) of the Act:

Name of each exchange on which

registered

registered

Title of each class

Trading Symbol(s)

Common Stock, par value \$0.0001 per share

DCGO

The Nasdaq Stock Market LLC

Securities registered pursuant to Section 12(g) of the Act: None

Indicate by check mark if the Registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. YES Yes ☐ NO No ☒



Indicate by check mark if the Registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act. YES ☒ Yes ☐ NO ☒ No ☐ x

Indicate by check mark whether the Registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes YES ☒ No ☐ NO ☐

o

Indicate by check mark whether the Registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the Registrant was required to submit such files). Yes YES ☒ No ☐ NO ☐ o

Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	<input type="checkbox"/> x	Accelerated filer	<input checked="" type="checkbox"/> o
Non-accelerated filer	<input type="checkbox"/> o	Smaller reporting company	<input checked="" type="checkbox"/> o
Emerging growth company	<input checked="" type="checkbox"/> o		

If an emerging growth company, indicate by check mark if the Registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

o

Indicate by check mark whether the Registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. ☐

x

If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. o

Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant’s executive officers during the relevant recovery period pursuant to §240.10D-1(b). o

Indicate by check mark whether the Registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). YES ☐ o NO ☒ x

The aggregate market value of the voting and non-voting common equity held by non-affiliates of the Registrant as of June 30, 2022 June 30, 2023, based on the closing price of the shares of the Registrant’s common stock (“Common Stock”) on The Nasdaq Stock Market as of such date, was \$615,536,965. \$860,817,702. Shares of common stock Common Stock held by each executive officer and director and by each person who is known to own 10% or more of the outstanding common stock Common Stock have been excluded in that such persons may be deemed to be affiliates of the Registrant. This determination of affiliate status is not necessarily a conclusive determination for other purposes.

The number of shares of Registrant’s Common Stock outstanding as of March 10, 2023 February 26, 2024 was 102,508,188. 104,171,369.

DOCUMENTS INCORPORATED BY REFERENCE

Portions of the Registrant’s Proxy Statement for its 2023 2024 Annual Meeting of Stockholders are incorporated by reference into Part III of this Annual Report on Form 10-K where indicated. The Registrant expects to file such proxy statement with the Securities and Exchange Commission within 120 days of the Registrant’s fiscal year ended December 31, 2022 December 31, 2023.

Table of Contents

	Page
PART I	
Item 1. Business	1
Item 1.1A. Business Risk Factors	12
Item 1B. Unresolved Staff Comments	46
Item 1C. Cybersecurity	146
Item 1A.2. Risk Factors Properties	1247
Item 1B.3. Unresolved Staff Comments Legal Proceedings	48
Item 2. Properties	48
Item Legal	
3. Proceedings	48
Item Mine Safety Disclosures	
4.	48
PART II	
Item 5. Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities	49
Item 6. Reserved	4950
Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations	4950
Item 7A. Quantitative and Qualitative Disclosures About Market Risk	6269
Item 8. Financial Statements and Supplementary Data	6269
Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure	6370
Item 9A. Controls and Procedures	6370
Item 9B. Other Information	6471
Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections	6471
PART III	
Item 10. Directors, Executive Officers and Corporate Governance	6572
Item 11. Executive Compensation	6572
Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters	6572
Item 13. Certain Relationships and Related Transactions and Director Independence	6572
Item 14. Principal Accountant Fees and Services	6572
PART IV	
Item 15. Exhibits and Financial Statement Schedules	6673
Item 16 Form 10-K Summary	75
Signatures	68

Risks Related to DocGo's Business Strategy

- DocGo's failure to successfully implement its business strategy could adversely affect its business.
- DocGo relies on its contractual relationships with healthcare provider partners and other strategic partners.
- DocGo's failure to successfully implement its business strategy could adversely affect its business.
- DocGo incurs significant up-front costs in its client relationships and any inability to maintain and grow these client relationships could adversely affect its business.
- DocGo relies on its contractual relationships with healthcare provider partners and other strategic partners.
- DocGo incurs significant up-front costs in its client relationships and any inability to maintain and grow these client relationships over time or to recover these costs could adversely affect its business.

Risks Related to DocGo's Business and Industry

- DocGo faces a high level of competition in its industry and its revenues could be adversely affected if it loses some or all of its business under existing contracts.
- Negative media coverage could damage DocGo's reputation and harm its ability to bid for and win government and other contracts.
- The COVID-19 pandemic has materially impacted DocGo's business.
- DocGo's reliance on government contracts and a small number of large customers could adversely affect its business.
- DocGo's participation in partnerships based value-based reimbursement models may have a material adverse effect on its business.
- DocGo's faces a high level of competition in its industry and its revenue could be adversely affected if it loses some or all of its business under existing contracts.
- A future pandemic or health crisis may have a material impact on DocGo's business.

Risks Related to DocGo's Limited Operating History

- DocGo has a limited operating history and a history of losses and expects its operating expenses to increase significantly in the future.
- DocGo may not be able to effectively manage its growth.
- DocGo has a limited operating history and has a history of losses and expects its operating expenses to increase significantly in the future.
- DocGo may not be able to effectively manage its growth.
- DocGo's reduced disclosure requirements may make its Common Stock less attractive to investors.

Risks Related to Information Technology

- DocGo relies on data center providers, Internet infrastructure, bandwidth providers, third-party hardware and software, other third parties and its own systems, some of which contain open-source software, to provide services to its clients.
- DocGo's proprietary software may not operate properly, or DocGo may not be able to implement its solution for clients or resolve technical issues in a timely manner.
- DocGo relies on data center providers, Internet infrastructure, bandwidth providers, third-party hardware and software, other third parties and its own systems, some of which contain open-source software, to provide services to its clients.
- Security breaches, loss of data and other disruptions or cybersecurity incidents could compromise sensitive business, customer or patient information or prevent DocGo from accessing critical information and expose it to liability.
- DocGo's proprietary software may not operate properly, or it may not be able to implement its solution for clients or resolve technical issues in a timely manner.
- Security breaches, loss of data and other disruptions could compromise sensitive business, customer or patient information or prevent DocGo from accessing critical information and expose it to liability.

Risks Related to DocGo's Operations

- DocGo's success depends on its key management personnel as well as its ability to successfully recruit, train and retain qualified healthcare professionals, and its labor costs are significant.

Caution DocGo's inability to collect on its receivables or unfavorable payor mix could adversely affect its business.

- [illegible]

Risk Relating to the Ownership of DocGo Common Stock

- The Nasdaq Capital Market (“Nasdaq”) may delist DocGo’s securities from trading on its exchange.

- The market price and trading volume of Common Stock may be volatile, and the value of Common Stock has declined and may continue to decline, and you may not receive any return on your investment in Common Stock.
- Provisions in DocGo's organizational documents could delay or prevent a change of control or limit stockholders' ability to obtain a favorable judicial forum for disputes with DocGo or its directors, officers, employees or stockholders.

- Nasdaq may delist DocGo's securities from trading on its exchange.
- The market price and trading volume of Common Stock may be volatile and you may not receive any return on your investment in DocGo's Common Stock.
- Provisions in DocGo's organizational documents could delay or prevent a change of control or limit stockholders' ability to obtain a favorable judicial forum for disputes with DocGo or its directors, officers, employees or stockholders.

PART I

Our Company


DocGo Inc. (“is redefining healthcare. DocGo” “we,” “us,” “our” is leading the proactive healthcare revolution with an innovative care delivery platform that includes mobile health services, virtual care management and “the Company”) aims ambulance services. DocGo is helping to redefine access reshape the traditional four-wall healthcare system by providing high quality, highly accessible care to healthcare. We strive to deliver high-quality, cost-effective healthcare mobility solutions patients where and unlock the further promise and potential of telehealth treatment through our “last-mile” care capabilities. We do so by leveraging our when they need it.

DocGo's proprietary technology platform, powered by artificial intelligence (“AI”), and our dedicated network of healthcare certified health professionals which has provided service and robust fleet of medical response vehicles provide services in 2930 states and in the United Kingdom. DocGo's vertically integrated approach helps elevate the quality of patient care and drive business efficiencies for facilities, hospital networks and health insurance providers. We often provide our services in collaboration with leading healthcare organizations via long-term relationships that are intended to drive meaningful revenue, help provide efficient and effective capital allocation and create low-risk opportunities for significant growth.

Our mission is to provide high quality, highly accessible healthcare for all, empowering the delivery of medical transportation and mobile healthcare outside the traditional “brick-and-mortar” facilities, with more accessible, affordable and efficient patient-centered care. Since our founding in 2015, through more than 8 million nearly 8 million patient interactions, we have created a care delivery model that helps provide better care outside of the physical walls of the healthcare system.

We began by developing a state-of-the-art, intuitive platform designed to drive greater efficiency and improved access to patient care. Our innovative technology can change the way healthcare facilities manage patient transportation and eliminate many of the common obstacles faced when scheduling service, ultimately freeing medical professionals to focus more time and their valuable resources on what they do best — providing patient care. Additionally, in certain markets, our Mobile Health mobile health in-person care model facilitates medical treatment directly to patients in the comfort of their homes, workplaces and other non-traditional locations. Working under the guidance of prescribing physicians, our network of more than 700 medical clinicians as of December 31, 2023 (which includes both company Company employees, and personnel from a variety of subcontracted labor agencies and some independent contractors) of more than 5,000 medical clinicians including Emergency Medical Technicians (“EMTs”), paramedics, licensed practical nurses (“LPNs”), registered nurses (“RNs”) Advanced Practice Providers (“APPs”) and support staff, provides a wide range of tests, procedures, care gap closures and interventions that previously required a visit to a traditional healthcare setting.

Such clinicians include, among others, licensed practical nurses (“LPNs”), registered nurses (“RNs”) and Advanced Practice Providers (“APPs”) assisted by additional support staff.



Our Segments

DocGo has three reporting segments: Mobile Health Solutions Services, Transportation Services and Corporate.

Mobile Health Services

The traditional healthcare model requires patients to interact with many levels of healthcare providers — including receptionists, nurses, lab technicians and physicians — for even the most routine tests, procedures and interventions. We recognized that a number of these services could easily be performed by EMTs, paramedics LPNs, RNs, APPs and LPNs other clinicians under the guidance of physicians, higher licensed practitioners, but in the comfort of a patient's home or workplace. Our patient-centered approach helps limit the need for individuals to seek routine treatment in more expensive and environmentally exposed, less comfortable settings such as emergency departments and urgent care clinics. In addition to providing greater convenience to patients, our Mobile Health Solutions Services help reduce unnecessary burdens on healthcare systems by freeing up their finite, in-person resources to address more urgent and critical patient needs. DocGo's clinical Mobile Health clinical services, Services, which we expanded into the home and workplace in 2020, facilitate medical care via a turnkey suite of integrated, “last-mile” technology-enabled solutions. Through DocGo On-Demand and additional Mobile Health Services programs, we provide care for a diverse group of customers, including municipalities, hospitals and health systems, insurers, physician practices,

businesses and employers. Additionally, our expanded population health offerings we provide holistic health, social and shelter coordination services to underserved communities.

Our services and solutions include encompass on-site evaluation, diagnostics, triage and treatment, as including the services detailed in the following table:



We place an emphasis on early intervention, preventive care and chronic disease management. DocGo can address over 30 gaps in care for health plans, especially Medicare and Medicaid plans focused on HEDIS Star Ratings. Our work with health plans on patient engagement and gap closure programs is growing, with programs in several states. As of the date of this Annual Report, we have active programs with Elevance Health, HealthFirst, EmblemHealth and others. These programs allow us to address gaps in care for Medicare and Medicaid populations and help manage multiple chronic diseases. Our priority and strategic focus is to grow and launch new programs and new geographies with our existing health plan partners who collectively cover approximately 80 million lives.

Our virtual care management programs monitor patients remotely and intervene before minor issues become major health crises. Our remote monitoring team currently works with more than 50,000 patients living with chronic

conditions – and we intend to launch specialized virtual care programs with nephrology and additional specialty practice groups, including endocrinology and pulmonology.



Proactive healthcare not only improves patient health outcomes but can also significantly reduce overall cost burdens on the system. Based on Accountable Care Organization data from the Centers for Medicaid & Medicare Services (“CMS”), we estimate that our services have saved more than \$167 million in 2023 by preventing unnecessary emergency department visits. We also intend to enter into additional partnerships with health plans that use value-based reimbursement models that involve risk-sharing. These payment models are specifically designed to improve patient health outcomes while reducing overall costs, as reimbursement is tied to quality of care and effectively managing total cost of care.

As patients seek more efficient, more convenient healthcare options, we believe our virtual care-enabling solutions are poised for significant growth by delivering a combination of in-person and virtual patient care previously inaccessible outside of the more traditional healthcare settings. The power of our model is the modality of care, specifically its scalability and lowered cost basis. We aim to combine the efficiency of telehealth by virtually pairing a specialized Physician Assistant (“PA”) with an LPN on-site in the patient’s home to be the PA’s eyes, ears, hands and feet.

We partner with leading national health systems, insurance carriers, private organizations and employers, state and local governments and managed care organizations to provide our Mobile Health solutions, Services, including NYC Health + Hospitals, New York City Department of Homeless Services, Housing Preservation and Development, Dollar General and Mount Sinai Health System. Martin Luther King Jr. Memorial Hospital in Los Angeles, CA. In recent years, our government contract work has represented a substantial portion of our overall revenue, representing approximately 73%, 64% and 65% of revenues for the years ended December 31, 2023, 2022 and 2021, respectively, and maintaining and continuing to grow this revenue stream is an important part of our growth strategy. For the fiscal year ended December 31, 2022 December 31, 2023, we generated approximately 74.0% 71% of our revenues from the solutions provided by our Mobile Health Services segment.

The success of our care delivery model is reflected in our NPS, or Net Promoter Score (“NPS”), which is one of the most widely accepted standards of customer experience metrics. Scores are measured from a range of -100 to +100 with scores over 30 commonly viewed as good and over 50 considered excellent. Our Q4 mobile health Mobile Health Services NPS score for the year ended December 31, 2023 was 76, 81, which is a testament to our customers’ strong perception regarding the value of DocGo’s our services.

Transportation Services

DocGo’s digitally-enabled medical mobility transportation solutions are offered under the Ambulnz brand. We help provide reliable, efficient access to local clinical services, including primary and specialty care, dialysis treatments for chronic care management and transfers between clinical settings. Every

vehicle in our fleet is equipped with our proprietary technology platform, which is integrated with some of the nation's largest electronic medical record ("EMR") systems.

This integration with EMR systems is designed to provide seamless transfer of electronic patient information and discharge data to our healthcare provider customers, which helps improve order speed and accuracy and helps eliminate a myriad of manual processes. Consequently, In addition, our healthcare facility customers are better able to order, track and manage transportation requests and patient movement, thereby enhancing utilization of resources and cost. Our ShareLink™ technology is designed to provide our healthcare partners and patients with real-time vehicle locations and accurate estimated time of arrivals and helps deliver valuable peace of mind. Consequently, our healthcare facility customers are better able to order, track and manage transportation requests and patient movement, thereby enhancing utilization of resources and cost. As of December 31, 2022 December 31, 2023, we had 381 ambulances 580 vehicles in service throughout the United States and more than 300 another 294 in the United Kingdom. For the fiscal year ended December 31, 2022 December 31, 2023, we generated approximately 26.0% 29% of our revenues from this our Transportation Services segment.

Corporate

Our Corporate segment primarily represents shared services and personnel that support both the Transportation Services and Mobile Health Services segments. It contains operating expenses such as information technology costs, certain insurance costs and the compensation costs of senior and executive leadership. None of the Company's revenues or costs of goods sold are reported within the Corporate segment.

Human Capital Resources

We strive to hire the best talent across our industry, with a focus on inspiring performance. As of December 31, 2022 December 31, 2023, we had over 3,200 4,100 employees, including healthcare professionals, field management personnel and corporate support staff, as represented in the table below. Healthcare professionals consist of EMTs, emergency medical technicians ("EMTs"), paramedics, LPNs, RNs, APPs, clinicians and related support staff; field management personnel includes supervisors and managers; and corporate support staff includes software development, billing, finance, human resources, legal and compliance, sales, marketing and executives.

	Full-time	Part-time	Total
Healthcare Professionals	2,176	1,234	3,410
Field Management Personnel	469	6	475
Corporate Support Staff	270	9	279
Total	2,915	1,249	4,164

	Full-time	Part-time	Total
Healthcare Professionals	1,570	1,180	2,750
Field Management	138	3	141
Corporate Support	356	5	361
Total	2,064	1,188	3,252

None of our employees are represented by a labor union or subject to any collective bargaining agreement. In addition to the employees above, as of December 31, 2022 December 31, 2023, the Company engaged the services of approximately 2,135 3,456 people, primarily in the healthcare professional area, some through a variety of subcontracted labor agencies and some as independent contractors.

Recruiting

Recruiting

We consider our employees to be our most valuable assets. Our employee experience begins with identifying and attracting people who embody our core values and share our vision to provide high-quality patient care. We are committed to building a company that our employees are proud to be a part of and fostering an environment in which our employees can grow, evolve and discover their existing and untapped potential. We believe our focused approach to recruiting and developing talent allows us to attract strong candidates to continue growing and scaling our business.

Compensation and Benefits

Ongoing evolution in the healthcare system and an aging population mean EMTs, paramedics and nurses are more critical to medical care than ever before, yet EMTs and paramedics remain the lowest paid professionals in the chain of care. Most companies in the industry pay an hourly wage only and offer no benefits, often resulting in low employee morale, high turnover and ultimately a less efficient business. We take pride in our high-quality medical professionals and have created an attractive compensation model that demonstrates their vital importance to our business and motivates them to deliver exceptional care.

We offer a pay package which that we believe is innovative within our industry. In addition to base hourly wages, DocGo also offers employees bonuses based on certain performance metrics, medical insurance, paid time off and an equity incentive plan for our frontline clinicians with broad-based rank and file participation — a program that provides the opportunity to acquire an ownership stake in our company, the Company. This is in line with our belief that all of our employees are partners in the business, and we want everyone to “think like an owner,” with the best long-term interests of the Company and its

shareholders stockholders as a driver of decision making. We believe that this approach makes us a more attractive employer and supports a strong pipeline of top-tier talent across all levels of our company.
the Company.

Employee Engagement

We routinely monitor employee satisfaction and work to maintain an environment where employees can contribute and thrive. DocGo has been recognized for its excellent workplace culture and employee satisfaction. One measure of this are the hundreds of positive reviews our employees have given DocGo on leading recruitment websites. As of the date of this Annual Report, DocGo's employee rating on Indeed is currently 4.3 out of 5.0, and our employee rating on Glassdoor is 4.8 out of 5.0 - ratings that are significantly higher than many of our competitors in the healthcare industry averages. Additionally, DocGo earned a Great Place to Work™ certification, which is based entirely on feedback from employees, for the second year in a row in 2023.

Training

Training

We have also created a number of programs to foster the professional development of our employees and to help attract top-tier talent. To help our staff continue to build clinical skills, we created a Medical Mentorship Program whereby EMTs and paramedics can learn advanced medical techniques including phlebotomy, mobile ultrasound, EKG training, point of care testing, vaccine administration, and wound care. Once certified, our employees can put these newly acquired skills to use while providing our Mobile Healthservices.

Our staff of ten training coordinators Training and Education Coordinators runs a robust, in-person onboarding program to help train employees and keep them up to date in relevant procedures and protocols. We are also an official American Heart Association Training Site and offer all of our employees in-house basic life support (BLS), advanced cardiovascular life support (ACLS), and pediatric advanced life support (PALS) training and certification. certification to our clinicians who require such training. We are also a:

- Private Authorized Training Center of the Airway Management Education Center offering The Difficult Airway Course: EMS and other courses;
- National Association of Emergency Medical Technicians Training Center offering Advanced Medical Life Support, Prehospital Trauma Life Support and other courses;
- National Safety Council Training Center offering the Defensive Driving Course; and
- Licensed Training Provider of the American Red Cross offering the Emergency Medical Responder Course and other courses.

In addition, we are able to grant EMS continuing education units in New York, New Jersey, Pennsylvania and Texas and through partnerships with the Commission on Accreditation for Prehospital Continuing Education (CAPCE) and the Kentucky Board of Nursing.

We have also implemented a virtual self-paced online training program for company Company policy and procedures training, mandated OSHA Occupational Safety and Health Administration ("OSHA") training courses, hazardous materials awareness, FEMA Incident Command Systems training (100, 200, 700, 800), clinical skills, customer service, diversity, HIPAA regulations, safety and compliance on-site traffic control, and annual documentation training.

Our In addition, our drivers are additionally trained in emergency vehicle operator course (EVOC) and the Coaching the Emergency Vehicle Operator (CEVO) 4 driver training, vehicle maintenance incident reporting, transport risk assessment, critical care transport orientation, and fatigue abatement. Our Ambulance course.

We also use a management system is utilized for credential tracking and Continuous Quality Improvement so to help ensure that our staff maintains all required credentials relevant to their positions with our company.

Employees the Company. Through this system, employees and their supervisors are automatically notified at designated times of recertification deadlines. Course completion, assignments and other compliance requirements are tracked in this system as well. Verification monitoring ensures that all employees meet current state requirements. This tool verifies Office of Inspector General ("OIG") of the U.S. Department of Health and Human Services ("HHS") exclusions at the state and federal levels and performs sanction screening for licensed personnel and 24/7 monitoring of state board licenses.

Our comprehensive training programs utilize a full range of resources, including print materials, training modules, webinars, seminars and videos provided by the Centers for Disease Control and Prevention and federal, state and local entities, medical institutions and public health agencies.

In December 2021, we launched DocGo EMS Academy, a full-service program dedicated to recruiting and training EMS emergency medical services (“EMS”) clinicians. Combining classroom education with practical hands-on learning, the programs are program is designed to help existing healthcare professionals advance their careers and provide aspiring entry-level workers with the opportunity to enter the healthcare industry. DocGo EMS Academy is tailored to EMS workers, from EMTs to paramedics. This comprehensive training program is available in select states and offers free tuition for students who continue their employment with DocGo, which we anticipate could assist us in our recruiting efforts.

The Business Combination

Merger with Motion Acquisition Corp.

On November 5, 2021 (the “Closing Date”), DocGo Inc., a Delaware corporation (formerly the Company (then known as Motion Acquisition Corp. “Motion” prior to the Closing Date and after the Closing Date, “DocGo”), consummated the previously announced a business combination (the “Closing”) pursuant to that certain Agreement and Plan of Merger dated March 8, 2021 (the “Merger Agreement”), by and among Motion, the Company, Motion Merger Sub Corp., a Delaware corporation and a direct wholly owned subsidiary of Motion the Company (“Merger Sub”), and Ambulnz, Inc., a Delaware corporation (“Ambulnz”). The transactions contemplated by the Merger Agreement are referred to herein as the “Business Combination.” In connection with the Closing, closing of the registrant Business Combination, the Company changed its name from Motion Acquisition Corp. to DocGo Inc. As contemplated by

Pursuant to the Merger Agreement and as described in Motion's the Company's definitive proxy statement/consent solicitation/prospectus filed with the U.S. Securities and Exchange Commission (the “SEC”) on October 14, 2021 (the “Prospectus”), Merger Sub was merged with and into Ambulnz, with Ambulnz continuing as the surviving corporation (the “Merger” and, together with the other transactions contemplated by the Merger Agreement, the “Business Combination”). corporation. As a result of the Merger, Business Combination, Ambulnz is became a wholly-owned subsidiary of DocGo the Company, and each share of Series A preferred stock of Ambulnz, no par value, (“Ambulnz Preferred Stock”), Class A common stock of Ambulnz, no par value, (“Ambulnz Class A Common Stock”), and Class B common stock of Ambulnz, no par value, (“Ambulnz Class B Common Stock”, together with Ambulnz Class A Common Stock, “Ambulnz Common Stock”) was cancelled and converted into the right to receive a portion of merger consideration issuable as common stock of DocGo, par value \$0.0001 (“Common Stock”), Stock, pursuant to the terms and conditions set forth in the Merger Agreement.

In connection with the Business Combination, the Company raised \$158.0 million, net of transaction costs of \$20.0 million. This amount was comprised of (i) \$43.4 million of cash held in Motion's the Company's trust account from established in connection with its initial public offering, net of DocGo's the Company's transaction costs and underwriters' fees of \$9.6 million, and (ii) \$114.6 million of cash in connection with from the concurrent PIPE private placement sale of shares of common stock Common Stock to certain investors at a price of \$10.00 per share in a private placement that closed concurrently with the Business Combination (the “PIPE “PIPE Financing”), net of \$10.4 million in transaction costs, costs incurred in connection with the PIPE Financing. These transaction costs consisted of banking, legal and other professional fees, which were recorded as a reduction to additional paid-in capital.

Competition

Competition

The U.S. healthcare industry is highly competitive, and we compete with a broad and diverse set of companies spanning both of our business segments. The competitive landscape is highly fragmented for both medical mobility services and “last-mile” technology-enabled mobile healthcare solutions and medical transportation services, ranging in each case from small, locally owned and operated providers to large national organizations. While we do not believe that any single competitor offers our full vertically integrated suite of mobility solutions Mobile Health Services and “last-mile” healthcare services, Transportation Services, numerous companies offer components of medical mobility transportation mobile health and/or telehealth transportation services that compete with our solutions.

Success in the medical transportation industry is based primarily on the ability to improve customer service, such as on-time performance and efficient call intake; to provide comprehensive clinical care; and to recruit, train and motivate employees, particularly ambulance crews who have direct contact with patients and healthcare personnel. Pricing, billing and reimbursement expertise are also critical. Competitors within the industry vary considerably in type and identity by market, with our primary competitors being small, locally owned operators as well as local fire departments and other local government providers. Larger private provider competitors include Rural/Metro Corporation, Falck, American Medical Response (AMR), Southwest Ambulance, Paramedics Plus and Acadian Ambulance.

Competition in the mobile health industry is primarily based on scale; ease of use, convenience and accessibility; brand recognition; breadth, depth and efficacy of telehealth and mobile health services; technology; clinical quality; customer support; cost; reputation; and customer satisfaction and value. The major Major competitors (in each case relative to only some of our products or services) include much larger, national or regional telehealth or in-home healthcare service providers such as Dispatch DispatchHealth, Modivcare, Addus HomeCare, Option Care Health, Teladoc, Amwell, Signify Health (acquired by CVS in March 2023), MedArrive, Biofourmis and One Medical (acquired by Amazon in February 2023) that generally provide telehealth on behalf of self-insured employers and insurance plans. These competitors, however, generally do not provide direct patient care or “last-mile” care on behalf of the provider organization. We also believe there are several smaller, private organizations providing in-home or on-site care utilizing different, higher cost healthcare providers. Non-traditional providers and others such as payors may enter the space and/or develop innovative technologies or business activities that could disrupt the industry. Competition could also increase from large technology companies, such as Apple, Amazon, Facebook, Verizon or Microsoft, who may develop their own telehealth or mobile health solutions or acquire existing industry participants, such as Amazon's acquisition of One Medical in February 2023, as well as from large retailers like Walmart, CVS and others. Despite the significant growth of telehealth services in recent years, we believe the market is still in its infancy and new competitors with similar and novel models will enter the market as it matures.

Success in the medical transportation industry is based primarily on the ability to improve customer service, such as on-time performance and efficient call intake; provide comprehensive clinical care; and recruit, train and motivate employees, particularly ambulance crews who have direct contact with patients and healthcare personnel. Pricing, billing and reimbursement expertise are also critical. Competitors within the industry vary considerably in type and identity by market, with our primary competitors being small, locally owned operators as well as local fire departments and other local government providers. Larger private provider competitors include Modivcare, Falck, Global Medical Response, Southwest Ambulance, Paramedics Plus and Acadian Ambulance.

Intellectual Property

We own and use trademarks and service marks on or in connection with our services, including both unregistered common law marks and registered trademarks. We have registered “Ambulnz” and our corporate logo in the United States and the United Kingdom. We have registered the “DocGo” word mark and design in the both the United States, and the United Kingdom and are in the process of registering both in the EU. We are also the registered holder of a variety of domain names that include “Ambulnz”, “Ambulnz,” “DocGo” and similar variations.

Our proprietary platform, mobile application and associated software code and firmware are protected as trade secrets and our confidential information, as appropriate. We also license the use of certain technology and other intellectual property rights owned and controlled by others. We believe that our intellectual property is a valuable asset to our business that affords us a competitive advantage in the markets in which we operate. We maintain our intellectual property and confidential business information in a number of ways. For instance, we have a policy requiring all companies we work with to execute confidentiality agreements upon commencement of any a business relationship with us, us where appropriate. Our agreements with customers who are privy to confidential or proprietary information also include confidentiality and non-disclosure provisions, as well.

We In addition, we require our employees, independent contractors and consultants to execute confidentiality and proprietary agreements in connection with their employment or consulting relationships engagement with us and to assign to us inventions conceived during the term of their employment or engagement while using our property or which relate to our business.

Upon discovery of potential infringement of our intellectual property, we assess and, when necessary, take action to protect our rights as appropriate.

Regulation

Regulation

Our operations are subject to comprehensive United States federal, state and local rules and regulations and comparable multiple levels of international regulation in the jurisdictions in which we do business. The laws and regulations governing our business and interpretations of those laws and regulations continue to expand, are subject to frequent change and may become more restrictive. Our ability to operate profitably will depend in part upon our ability, and that of our healthcare provider partners, to maintain all necessary licenses and to operate in compliance with applicable laws and regulations. We therefore devote significant resources to monitoring developments in healthcare regulation. As the applicable laws and regulations change, we may be required to make conforming modifications in our business processes from time to time. In many jurisdictions where we operate, neither our current nor our anticipated business model, in particular with respect to our Mobile Health related services, Services, has been the subject of judicial or administrative interpretation. We cannot be assured that a review of our business by courts or regulatory authorities will not result in determinations that could limit or otherwise adversely affect our operations or that the healthcare regulatory environment will not change in a way that restricts our operations.

False Claims Act

The federal False Claims Act is a means of policing false bills or false requests for payment in the healthcare delivery system. Among other things, the federal False Claims Act authorizes the imposition of up to three times the government’s damages and significant per claim civil penalties on any “person” (including an individual, organization or company) who, among other acts:

- knowingly presents or causes to be presented to the federal government a false or fraudulent claim for payment or approval;
 - knowingly makes, uses or causes to be made or used a false record or statement material to a false or fraudulent claim;
 - knowingly makes, uses or causes to be made or used a false record or statement material to an obligation to pay the government, or knowingly conceals;
 - knowingly and improperly avoids or decreases an obligation to pay or transmit money or property to the federal government; or
 - conspires to commit the above acts.
-
- knowingly presents or causes to be presented to the federal government a false or fraudulent claim for payment or approval;
 - knowingly makes, uses or causes to be made or used a false record or statement material to a false or fraudulent claim;
 - knowingly makes, uses or causes to be made or used a false record or statement material to an obligation to pay the government;
 - knowingly conceals or knowingly and improperly avoids or decreases an obligation to pay or transmit money or property to the federal government; or

- conspires to commit the above acts.

In addition, amendments to the federal False Claims Act and Social Security Act impose severe penalties for the knowing and improper retention of overpayments collected from government payors. Under these provisions, within 60 days of identifying and quantifying an overpayment, a provider is required to notify the Centers for Medicare and Medicaid Services (“CMS”), or the Medicare Administrative Contractor of the overpayment and the reason for it and return the overpayment. An overpayment impermissibly retained could subject a party to liability under the federal False Claims Act, exclusion from government healthcare programs, including Medicare and Medicaid, and penalties under the federal Civil Monetary Penalties Law discussed below.

The penalties for a violation of the federal False Claims Act provides for penalties that range from \$5,500 to \$11,000 (adjusted for inflation) for each false claim, plus up to three times the amount of damages caused by each false claim, which can be as much as the amounts received directly or indirectly from the government for each such false claim. On June 19, 2020 February 12, 2024, the U.S. Department of Justice (“DOJ”) issued a final rule announcing adjustments to federal False Claims Act penalties, under which the per claim range increases to a range from \$11,803 \$13,946 to \$23,607 \$27,894 per claim, so long as the underlying conduct occurred after November 2, 2015.

The federal government has used the statute to prosecute a wide variety of alleged false claims and fraud allegedly perpetrated against Medicare and state healthcare programs, including but not limited to coding errors, billing for services not rendered, the submission of false cost or other reports, billing for services at a higher payment rate than appropriate, billing under a comprehensive code as well as under one or more component codes included in the comprehensive code,

billing for care that is not considered medically necessary and false reporting of risk-adjusted diagnostic codes to Medicare Advantage (“MA”) (or Part C) Plans, plans. The Affordable Care Act of 2010 (the “Affordable Care Act”), as currently structured, provides that claims tainted by a violation of the federal Anti-Kickback Statute are false for purposes of the federal False Claims Act. Some courts have held that filing claims or failing to refund amounts collected in violation of the Stark Law can form the basis for liability under the federal False Claims Act. In addition to the provisions of the federal False Claims Act, which provide for civil enforcement through “qui tam” whistleblower lawsuits, the federal government can also use several criminal statutes to prosecute persons who are alleged to have submitted false or fraudulent claims for payment to the federal government.

Federal Fraud and Abuse Laws

The federal Health Insurance Portability and Accountability Act of 1996, as amended by the Health Information Technology for Economic and Clinical Health Act, (“HITECH”), and their implementing regulations and related rules (collectively, “HIPAA”), established several separate criminal penalties for making false or fraudulent claims to insurance companies and other non-governmental payors of healthcare services. Under HIPAA, these two additional federal crimes are: “Healthcare Fraud” and “False Statements Relating to Healthcare Matters.” The Healthcare Fraud statute prohibits knowingly and recklessly executing a scheme or artifice to defraud any healthcare benefit program, including private payors. A violation of this statute is a felony and may result in fines, imprisonment or exclusion from government sponsored programs. The False Statements Relating to Healthcare Matters statute prohibits knowingly and willfully falsifying, concealing or covering up a material fact by any trick, scheme or device or making any materially false, fictitious or fraudulent statement in connection with the delivery of or payment for healthcare benefits, items or services. A violation of this statute is a felony and may result in fines or imprisonment. This statute could be used by the government to assert criminal liability if a healthcare provider knowingly fails to refund an overpayment. These provisions are intended to punish some of the same conduct in the submission of claims to private payors as the federal False Claims Act covers in connection with governmental health programs.

In addition, the Civil Monetary Penalties Law imposes civil administrative sanctions for, among other violations, inappropriate billing of services to federally funded healthcare programs and employing or contracting with individuals or entities who are excluded from participation in federally funded healthcare programs. Moreover, a person who offers or transfers to a Medicare or Medicaid beneficiary any remuneration, including waivers of co-payments and deductible amounts (or any part thereof), that the person knows or should know is likely to influence the beneficiary's selection of a particular provider, practitioner or supplier of Medicare or Medicaid payable items or services may be liable for civil monetary penalties of up to \$20,000 for each wrongful act. Moreover, in certain cases, providers who routinely waive co-payments and deductibles for Medicare and Medicaid beneficiaries can also be held liable under the federal Anti-Kickback Statute and federal False Claims Act, either of which can impose additional penalties associated with the wrongful act. One of the statutory exceptions to the prohibition is non-routine, unadvertised waivers of co-payments or deductible amounts based on individualized determinations of financial need or exhaustion of reasonable collection efforts. The OIG emphasizes, however, that this exception should only be used occasionally to address special financial needs of a particular patient. Although this prohibition applies only to federal healthcare program beneficiaries, the routine waivers of co-payments and deductibles offered to patients covered by commercial payors may implicate applicable state laws related to, among other things, unlawful schemes to defraud, excessive fees for services, tortious interference with patient contracts and statutory or common law fraud.

State Fraud and Abuse Laws

Various states in which we operate have also adopted similar fraud and abuse laws as the federal laws and statutes described above. The scope of these laws and the interpretations thereof vary from state to state and are enforced by state courts and regulatory authorities, each with broad discretion. Some state fraud and abuse laws apply to items or services reimbursed by any payor, including patients and commercial insurers, not just those reimbursed by a federally funded healthcare program. A determination of liability under such state fraud and abuse laws could result in fines and penalties and restrictions on our ability to operate in these jurisdictions.

Health Information Privacy and Security Laws

There are numerous U.S. federal and state laws and regulations related to the privacy and security of personally identifiable information ("PII"), including health information. In particular, HIPAA establishes privacy and security standards that limit the use and disclosure of protected health information ("PHI"), and require the implementation of administrative, physical and technical safeguards to ensure the confidentiality, integrity and availability of individually identifiable health information in electronic form. HIPAA's requirements apply to "covered entities" and to their independent contractors, agents and other "business associates" that create, receive, maintain or transmit PHI in connection with providing services to covered entities. Although we are a covered entity under HIPAA, we are also a business associate of other covered entities when we are working on behalf of our healthcare provider partners.

Violations of HIPAA may result in civil and criminal penalties. For the lowest penalty tier, the civil penalties range from \$119 to \$59,522 per violation, with a cap of \$1.8 million approximately \$2.1 million per year for violations of the same standard during the same calendar year. However, a single breach incident can result in violations of multiple standards. We must also comply with HIPAA's breach notification rule. Under the breach notification rule, covered entities must notify affected individuals without unreasonable delay in the case of a breach of unsecured PHI, which may compromise the privacy, security or integrity of the PHI. In addition, notification must be provided to HHS and the local media in cases where a breach affects more than 500 individuals. Breaches affecting fewer than 500 individuals must be reported to HHS on an annual basis. The regulations also require business associates of covered entities to notify the covered entity of breaches by the business associate.

State attorneys general also have the right to prosecute HIPAA violations committed against residents of their states. While HIPAA does not create a private right of action that would allow individuals to sue in civil court for a HIPAA violation, its standards have been used as the basis for the duty of care in state civil suits, such as those for negligence or recklessness in misusing personal information. In addition, HIPAA mandates that HHS conduct periodic compliance audits of HIPAA-covered entities and their business associates for compliance. It also tasks HHS with establishing a methodology whereby harmed individuals who were the victims of breaches of unsecured PHI may receive a percentage of the fine paid by the violator under the Civil Monetary Penalties Law paid by the violator. Law. In light of recent enforcement activity and statements from HHS, we expect increased federal and state HIPAA privacy and security enforcement efforts.

HIPAA also requires HHS to adopt national standards establishing electronic transaction standards that all healthcare providers must use when submitting or receiving certain healthcare transactions electronically.

Many states in which we operate and in which our customers reside also have laws that protect the privacy and security of sensitive and personal information, including health information. These laws may be similar to or even more protective than HIPAA and other federal privacy laws. For example, the laws of the State of California, in which we operate, are more restrictive than HIPAA. Where state laws are more protective than HIPAA, we must comply with the state laws we are subject to, in addition to HIPAA. In certain cases, it may be necessary to modify our systems or planned operations to comply with these more stringent state laws. Not only may some of these state laws impose fines and penalties upon violators, but also some, unlike HIPAA, may afford private rights of action to individuals who believe their personal information has been misused. In addition, state laws are changing rapidly, and there is discussion of a new federal privacy law or federal breach notification law, to which we may be subject.

In recent years, there have been a number of well-publicized data breaches involving the improper use and disclosure of PII and PHI. Many states have responded to these incidents by enacting laws requiring holders of personal information to maintain safeguards and to take certain actions in response to a data breach, such as providing prompt notification of the breach to affected individuals and state officials. In addition, under HIPAA and pursuant to the related contracts that we enter into with our healthcare provider partners and other third parties, we must report breaches of unsecured PHI to our contractual partners following discovery of the breach. Notification must also be made in certain circumstances to affected individuals, federal authorities and others.

In addition to HIPAA, state health information privacy and state health information privacy laws, we may be subject to other state and federal privacy laws, including laws that prohibit unfair privacy and security practices and deceptive statements about privacy and security and laws that place specific requirements on certain types of activities, such as data security and texting.

Anti-Kickback Statute

The federal Anti-Kickback Statute is a broadly worded prohibition on the knowing and willful offer, payment, solicitation or receipt of any form of remuneration in return for, or to induce, (i) the referral of a person covered by Medicare, Medicaid or other governmental programs, (ii) the furnishing or arranging for the furnishing of items or services reimbursable under Medicare, Medicaid or other governmental programs or (iii) the purchasing, leasing or ordering or arranging or recommending purchasing, leasing or ordering of any item or service reimbursable under Medicare, Medicaid or other governmental programs. Certain federal courts have held that the Anti-Kickback Statute can be violated if “one purpose” of a payment is to induce referrals. In addition, a person or entity does not need to have actual knowledge of this statute or specific intent to violate it to have committed a violation, making it easier for the government to prove that a defendant had the requisite state of mind or “scienter” required for a violation. Moreover, the government may assert that a claim including items or services resulting from a violation of the Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the federal False Claims Act. Violations of the Anti-Kickback Statute can result in exclusion from Medicare, Medicaid or other governmental programs as well as civil and criminal penalties, including fines of **\$104,330** **\$120,816** per violation, plus up to three times the amount of the unlawful remuneration, and imprisonment of up to ten years. Civil penalties for such conduct can further be assessed under the federal False Claims Act. In addition to a few statutory exceptions, the OIG has published safe harbor regulations that outline categories of activities that are deemed protected from prosecution under the Anti-Kickback Statute provided all applicable criteria are met. The failure of a financial relationship to meet all of the applicable safe harbor criteria does not necessarily mean that the particular arrangement violates the Anti-Kickback Statute. However, conduct and business arrangements that do not fully satisfy each applicable safe harbor may result in increased scrutiny by government enforcement authorities, such as the OIG.

Federal Stark Law

Section 1877 of the Social Security Act, also known as the physician self-referral law and commonly referred to as the Stark Law, prohibits a physician who has a financial relationship, or who has an immediate family member who has a financial relationship, with entities providing certain designated health services from referring Medicare patients to such entities for the furnishing of designated health services, unless an exception applies. Although uncertainty exists, federal agencies and at least one court have taken the position that the Stark Law also applies to Medicaid. Designated health services are defined to include, among others, clinical laboratory services, physical therapy services, occupational therapy services, radiology services including ultrasound services, durable medical equipment and supplies, parenteral and enteral nutrients, equipment and supplies, home health services, outpatient prescription drugs, inpatient and outpatient hospital services and outpatient speech-language pathology services. The types of financial arrangements between a physician and an entity providing designated health services that trigger the self-referral prohibitions of the Stark Law are broad and include direct and indirect ownership and investment interests and compensation arrangements. The Stark Law prohibits any entity providing designated health services that has received a prohibited referral from presenting, or causing to be presented, a claim or billing for the services arising out of the prohibited referral. Similarly, the Stark Law prohibits an entity from “furnishing” a designated health service to another entity in which it has a financial relationship when that entity bills for the service. The Stark Law also prohibits self-referrals within an organization by its own physicians, although broad exceptions exist. The prohibition applies regardless of the reasons for the financial relationship and the referral. Unlike the federal Anti-Kickback Statute discussed above, the Stark Law is a strict liability statute, which means proof of specific intent to violate the law is not required.

If the Stark Law is implicated, the financial relationship must fully satisfy a Stark Law exception. If an exception is not satisfied, then the parties to the arrangement could be subject to sanctions, including denial of payment for claims for services provided in violation of the statute, mandatory refunds of amounts collected for such services, civil penalties of up to **\$25,820** **\$29,899** for each violation and twice the dollar value of each such service as well as possible exclusion from future participation in the federally funded healthcare programs, including Medicare and Medicaid. A person who engages in a scheme to circumvent the Stark Law’s prohibitions may be fined up to **\$172,137** **\$199,338** for each applicable arrangement or scheme. Amounts collected on claims related to prohibited referrals must be reported and refunded generally within 60 days after the date on which the overpayment was identified. In addition, the government and some courts have taken the position that claims presented in violation of the various statutes, including the Stark Law, and failure to return overpayments in a timely manner can form the basis for liability under the federal False Claims Act discussed **below** **above** based on the contention that a provider impliedly certifies compliance with all applicable laws, regulations and other rules when submitting claims for reimbursement.

U.S. Corporate Practice of Medicine; Fee Splitting

The laws and regulations relating to our operations vary from state to state and many states prohibit general business corporations, such as us, from practicing medicine, controlling physicians’ medical decisions or engaging in some practices such as splitting professional fees with physicians. We contract with healthcare providers, physicians or physician-owned professional associations and professional corporations as part of our business. An important aspect of our strategy is to form contractual relationships with different third-party providers pursuant to which we provide them or their patients with medical transportation and/or **telehealth** **mobile health** services and they pay us for those services out of the fees they collect from patients and third-party payors. In certain instances, we also share a portion of our revenues with our partners. These contractual relationships are subject to various state laws that prohibit fee splitting or the practice of medicine by lay entities or persons and are intended to prevent unlicensed persons from interfering with or influencing the physician’s professional judgment. In addition, various state laws also generally prohibit the sharing of professional services income with nonprofessional or business interests. Activities other than those directly related to the delivery of healthcare may be considered an element of the practice of medicine in many states. Under the corporate practice of medicine restrictions of certain states, decisions and activities such as scheduling, contracting, setting rates and the hiring and management of non-clinical personnel may implicate the restrictions on the corporate practice of medicine.

State corporate practice of medicine and fee-splitting laws vary from state to state and are not always consistent. In addition, these requirements are subject to broad powers of interpretation and enforcement by state regulators. Regulatory authorities or other parties may assert that, despite these arrangements, we are engaged in the corporate practice of medicine or that our contractual arrangements with affiliated third parties constitute unlawful fee splitting. In this event, failure to comply could lead to adverse judicial or administrative action against us and/or our healthcare provider partners, civil or criminal penalties, receipt of cease-and-desist orders from state regulators, loss of licenses and the need to make changes to the terms of engagement with our provider partners that interfere with our business.

International Regulation

We expect to continue to expand our operations internationally through both organic growth and acquisitions. Our international operations are subject to different, and sometimes more stringent, legal and regulatory requirements, which vary widely by jurisdiction, including anti-corruption laws such as the Foreign Corrupt Practices Act (“FCPA”), of 1977, as amended, and corresponding foreign laws, including the U.K. Bribery Act 2010; regulation by the U.S. Treasury’s Office of Foreign Assets Control (“OFAC”) and economic sanctions laws; various privacy, insurance, tax, tariff and trade laws and regulations; corporate governance, privacy, data protection, data mining, data transfer, labor and employment, intellectual property, consumer protection and investment laws and regulations; discriminatory licensing procedures; required localization of records and funds; and limitations on dividends and repatriation of capital.

Other Regulations

Our operations are subject to various state hazardous waste and non-hazardous medical waste disposal laws. These laws do not classify as hazardous most of the waste produced from healthcare services. Occupational Safety and Health Administration OSHA regulations require employers to provide workers who are occupationally subject to blood or other potentially infectious materials with prescribed protections. These regulatory requirements apply to all healthcare facilities, including primary care centers, and require employers to make a determination as to which employees may be exposed to blood or other potentially infectious materials and to have in effect a written exposure control plan. In addition, employers are required to provide or deploy hepatitis B vaccinations, personal protective equipment and other safety devices, infection control training, post-exposure evaluation and follow-up, waste disposal techniques and procedures and work practice controls. Employers are also required to comply with various record-keeping requirements.

Some of our operations may be subject to compliance with certain provisions of the federal Fair Debt Collection Practices Act and comparable statutes in many states. Under the Fair Debt Collection Practices Act, a third-party collection company is restricted in the methods it uses to contact consumer debtors and elicit payments with respect to placed accounts. Requirements under state collection agency statutes vary, with most requiring compliance similar to that required under the Fair Debt Collection Practices Act. Many of the states in which we operate have comparable state statutes as well.

See the section of this Annual Report on Form 10-K titled “Risk Factors — Risks Related to DocGo’s Legal and Regulatory Environment.”

Available Information

We file or furnish electronically with the SEC our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and amendments to those reports. We make copies of these reports and amendments thereto available on our website at www.DocGo.com, under “Investors,” free of charge copies of these reports, and amendments thereto, as soon as reasonably practicable after filing or furnishing these reports with the SEC.

Item 1A. Risk Factors.

Risks Related to DocGo’s Business Strategy

DocGo’s failure to successfully implement its business strategy could adversely affect its business.

DocGo’s future financial performance and success is dependent in large part upon its ability to implement its business strategy successfully. DocGo’s business strategy includes several initiatives, including developing contractual relationships with new healthcare provider partners and expanding its business with existing partners; capitalizing on organic growth opportunities such as growing complementary and integrated service offerings, particularly with respect to its mobile health solutions; pursuing selective acquisitions to expand its geographic presence, among other things; and enhancing operational efficiencies and productivity. DocGo may not be able to implement its business strategy successfully or achieve the anticipated benefits of its business plan, which could adversely affect its long-term growth, profitability and ability to service its debt obligations. Even if DocGo is able to implement some or all of the initiatives of its business plan, one or more initiatives may not be successful or if successful, may not achieve the anticipated goals, results or outcomes, and DocGo’s operating results may not improve to the extent it anticipates, or at all, or it could be adversely affected.

Implementation of DocGo’s business strategy could also be negatively impacted by a number of factors beyond its control, including increased competition, competition; government regulation, regulation; general macroeconomic conditions, including an inflationary environment, environment; rising interest rates and recessionary fears, fears; the geopolitical environment, including the war in Ukraine, conflict in Israel and surrounding areas and rising tensions in the Taiwan Strait, and Strait; pandemic or endemics, including COVID-19, endemics; and increased operating costs, including costs of labor or other expenses. In particular, DocGo’s future success is contingent on DocGo’s ability to both penetrate new markets and to further penetrate existing markets, which is subject to a number of uncertainties, including our DocGo’s ability to obtain necessary licenses in new markets, to establish and grow new customer relationships and our ability to attract and retain skilled personnel, many of which are beyond DocGo’s control. personnel. Expanding service offerings such as DocGo’s mobile health solutions also carries unique risks, including lack of market acceptance or the potential inability to realize an appropriate return, if any, on the capital invested. Government regulations in both DocGo’s domestic and international markets can could also delay or prevent expansion or the introduction of new service offerings or require changes to some of DocGo’s current service offerings, which could negatively impact the success of DocGo’s strategies and financial results. In addition, to the extent DocGo has misjudged the nature or extent of industry trends or its competition, it may have difficulty in identifying new provider partners, achieving any geographic expansion, introducing new service offerings or achieving DocGo’s other strategic objectives. As such, due to these and other known and unknown risks, DocGo cannot assure you that its business strategy will be successful, and any failure to effectively

implement its business strategy and otherwise grow the business could have a material adverse effect on DocGo's business, financial condition and results of operations.

DocGo relies on its contractual relationships with its healthcare provider partners and other strategic partners.

DocGo significantly relies on its contractual relationships with its healthcare provider partners and other strategic partners and alliances to generate revenues, expand into new markets and further penetrate existing markets. In recent years, DocGo has entered into strategic business relationships with, among others, healthcare providers and hospital systems to take advantage of commercial opportunities across its operations, but particularly in its medical transportation services Transportation Services segment. The structure of DocGo's relationships with its healthcare provider partners is a novel model in DocGo's industry and because there is little precedent for this approach, there can be no assurances that it will be operationally or financially successful in the long term.

DocGo's contractual relationships with its healthcare provider partners and its reliance on revenues generated pursuant to these arrangements carry commercial and other risks and uncertainties that are different from those underlying DocGo's other revenue streams, including the opportunity cost of not pursuing other ventures independently or with other partners. For example, strategic partners may have business or economic interests that are inconsistent with those of DocGo and may take actions contrary to DocGo's interests. While DocGo typically manages the day-to-day operations, DocGo's partners have certain consent rights, including certain decisions such as the annual budget and the hiring and firing of key management personnel for the venture, and they may not agree with decisions that DocGo believes are appropriate or are otherwise in the venture's or its best interests. This structure can also lead to disputes with partners, which could require DocGo's management to commit additional time and resources to resolve any disagreements or, in some instances, may lead to arbitration or litigation. Contractual relationships like these typically carry termination rights and one or more of DocGo's partners may choose to exit the relationship prematurely and, in certain arrangements, the partner may have the option to sell its interest in the venture to DocGo or acquire DocGo's stake at a predetermined price, even if the venture is beneficial to DocGo and in DocGo's interest to continue the venture. If one of DocGo's ventures or any of its strategic partners is subject to a regulatory investigation or legal dispute or is otherwise the subject of any negative publicity, DocGo may be associated with the matter and be similarly harmed, regardless of whether the specific partnership or DocGo itself had any connection to the underlying matters. In addition, DocGo may, in certain circumstances, be liable for the actions of its partners. Contractual relationships such as these can also raise fraud and abuse issues. For example, the Office of Inspector General (the "OIG") of the U.S. Department of Health and Human Services ("HHS") OIG has taken the position that certain contractual relationships between a party which that makes referrals and a party which that receives referrals for a specific type of service may violate the federal Anti-Kickback Statute if not appropriately structured. Any of the foregoing risks or other risks related to DocGo's reliance on its strategic partners and other relationships could have a material adverse effect on DocGo's business, financial condition and results of operations.

DocGo incurs significant up-front costs in its client relationships and any inability to maintain and grow these client relationships over time or to recover these costs could adversely affect its business.

DocGo's business strategy depends heavily on achieving economies of scale because its initial up-front investment is costly and the associated revenue is recognized on a ratable basis. DocGo devotes significant resources to establish relationships with its clients and implement its solutions. DocGo typically incurs higher variable costs for labor and medical and other supplies in the initial stages of a project, as the focus at that stage is on ensuring that the projects are staffed and stocked properly, even at the risk of temporarily overstaffing the project until revenue achieves the anticipated scale. These risks are heightened when the client is a large enterprise, such as DocGo's healthcare provider or government partners. See **"—Risks Related to DocGo's Business and Industry—DocGo's reliance on government contracts could adversely affect its business" below.** Accordingly, DocGo's results of operations depend, in substantial part, on its ability to maintain and grow its relationships with customers over time, allowing DocGo to build economies of scale and recoup up-front costs. Additionally, as DocGo's business grows, its client acquisition costs could outpace its build-up of recurring revenue, and DocGo may be unable to successfully manage its total operating costs to achieve profitability, or if achieved, to maintain profitability. If DocGo fails to achieve appropriate economies of scale or if it fails to manage or anticipate demand, its business, financial condition and results of operations could be materially adversely affected.

The growth of DocGo's business depends, in part, on its ability to execute on its acquisition strategy.

A significant portion of DocGo's historical growth has occurred through acquisitions, such as its **acquisitions in 2022** acquisition of Government Medical Services, LLC, Ryan Brothers Ambulance Fort Atkinson, LLC, Exceptional Ambulance Medical Transportation, LLC and Community Ambulance Services, Service Ltd in 2022 and **it anticipates continued growth** Cardiac RMS, LLC in 2023, and DocGo may continue to grow through acquisitions in the future. DocGo's growth strategy is primarily focused on geographic expansion, often as part of growing its relationship with an existing healthcare provider partner, and **acquisitions may help** DocGo **expects acquisitions to be its primary means of obtaining** **obtain** the infrastructure, licenses or other resources necessary to enter new markets in the future. DocGo evaluates, and expects to continue to evaluate, **on a regular basis,** a variety of possible acquisition **transactions.** **opportunities as they arise.**

DocGo cannot predict the timing of any contemplated transactions, and there can be no assurances that DocGo will **be able to** identify suitable acquisition opportunities in the geographies into which it expects to grow or, if it does, that any transaction can be consummated on terms acceptable to it, if at all. DocGo also competes for acquisitions with other potential acquirers, some of which may have greater financial or operational resources than DocGo. A significant change in DocGo's business; macroeconomic factors, including inflationary pressures, rising interest rates and recessionary fears; unexpected decreases in cash **flows, flows;** tightening of the capital **markets markets;** or any restrictions imposed by DocGo's debt obligations may limit its ability to obtain the necessary capital for acquisitions or otherwise impede its ability to complete an acquisition. Certain proposed acquisitions or dispositions may also trigger regulatory review by governmental agencies, including the U.S. Department of Justice **(the "DOJ")** and the U.S. Federal Trade Commission, **(the "FTC"),** under their respective regulatory authority. Any delay, prohibition or modification required by regulatory authorities for competitive purposes or otherwise could adversely affect the terms of a proposed acquisition or could require DocGo to modify or abandon an otherwise attractive acquisition opportunity. The failure to identify suitable transaction partners and to consummate transactions on acceptable terms, or at all, could adversely affect DocGo's business, financial condition and results of operations.

DocGo's acquisition strategy exposes it to significant risks and additional costs.

Acquisitions involve risks that the businesses acquired will not perform as expected or provide sufficient infrastructure and other resources necessary to operate in a given geography, and DocGo's judgments regarding the values, strengths and weaknesses and profitability of acquired businesses may prove to be wrong. DocGo may be held liable for certain unforeseen pre-acquisition liabilities of an acquired business, including, among others, tax liabilities, environmental liabilities, liabilities for regulatory violations and liabilities for employment practices, and these liabilities could be significant. In addition, an acquisition could result in the impairment of client relationships and other acquired assets, such as goodwill. DocGo may also incur costs and experience inefficiencies to the extent an acquisition expands the services, markets or geographies in which it operates. Acquisitions may require that DocGo incur additional debt to finance the transaction, which could be substantial and limit its operating flexibility or, alternatively, acquisitions may require that DocGo issue shares of its Common Stock as consideration, which could dilute share ownership. Acquisitions can also involve post-transaction disputes regarding a number of matters, including a purchase price or working capital adjustment, earn-out or other contingent payments, environmental liabilities or other obligations. DocGo's recent growth and its acquisition strategy have placed, and **will may** continue to place, significant demands on management's time, which may divert their attention from DocGo's day-to-day business operations and may lead to significant due diligence and other expenses regardless of whether DocGo pursues or consummates any potential acquisition. DocGo also may not be able to manage its growth resulting from acquisitions due to the number, diversity and geographic disparity of the businesses it may acquire or for other reasons. These and other risks related to acquisitions could adversely affect DocGo's business, financial condition and results of operations.

Any inability to successfully integrate acquisitions or realize their anticipated benefits could adversely affect DocGo's business.

Acquisitions require that DocGo integrate separate companies that have historically operated independently or as part of another, larger organization, and that have different systems, processes and cultures. DocGo may not be able to successfully integrate any business it has acquired or may acquire, or may not be able to do so in a timely, efficient or cost-effective manner. Risks related to the successful integration of an acquired business include:

- diverting the attention of DocGo's management and that of the acquired business;
- merging or linking different accounting and financial reporting systems and systems of internal controls and, in some instances, implementing new controls and procedures;
- diverting the attention of DocGo's management and that of the acquired business;
- merging computer, technology and other information networks and systems, including enterprise resource planning systems and billing systems;
- assimilating personnel, human resources, billing and collections and other administrative departments and potentially contrasting corporate cultures;
- merging or linking different accounting and financial reporting systems and systems of internal controls and, in some instances, implementing new controls and procedures;
- disrupting relationships with or losses of key clients and suppliers of DocGo's business or the acquired business;
- interfering with, or loss of momentum in, DocGo's ongoing business or that of the acquired company;
- merging computer, technology and other information networks and systems, including enterprise resource planning systems and billing systems;
- failure to retain DocGo's key personnel or that of the acquired company; and
- delays or cost-overruns in the integration process.
- assimilating personnel, human resources, billing and collections, and other administrative departments and potentially contrasting corporate cultures;
- disrupting relationships with or losses of key clients and suppliers of DocGo's business or the acquired business;
- interfering with, or loss of momentum in, DocGo's ongoing business or that of the acquired company;
- failure to retain DocGo's key personnel or that of the acquired company; and
- delays or cost-overruns in the integration process.

DocGo's inability to manage its growth through acquisitions, including its inability to manage the integration process, and to realize the anticipated benefits of an acquisition could have a material adverse effect on its business, financial condition and results of operations.

Risks Related to DocGo's Business and Industry

The COVID-19 pandemic has materially impacted DocGo's business.

The COVID-19 pandemic and related direct and indirect impacts have adversely affected, and may continue to adversely affect, the DocGo healthcare transportation segment, and has also heightened various risks related to DocGo's business.

For example, should there be an outbreak of COVID-19 among DocGo's employees in one or more of its markets, in response, DocGo may need to significantly reduce or cease operations in that market. DocGo's cost structure has also been adversely impacted by the pandemic. A number of DocGo's suppliers have been negatively impacted by the COVID-19 pandemic and there have been significant disruptions in its supply chains, particularly with respect to the personal protective equipment, or PPE, that DocGo's healthcare professionals require to do their jobs. At times, sufficient levels of PPE have not been available and these shortages have limited DocGo's ability to meet demand and provide its services to customers in a timely manner. Further, the demand for PPE in the healthcare industry and the public at large caused by the pandemic has significantly increased the cost of PPE and DocGo may not be able to recover these increased costs in the rates it charges for its services, which could adversely affect DocGo's profitability. Limitations on the availability or increases in the price of PPE have and could in the future continue to adversely affect DocGo's business and results of operations.

However, the pandemic also significantly increased the demand for DocGo's remote and mobile testing and vaccination services during the second half of 2020 and throughout 2021 and the first half of 2022 and many of these contracts were on a short-term basis, often spanning only a number of weeks or months. Much of DocGo's revenue, employee and operations growth has occurred during recent years, which has been partially driven by significant COVID-related impacts. For example, the Company estimates that mass COVID testing relating revenue for 2022 was approximately \$75 million. DocGo's ability to forecast its future operating results is limited and subject to a number of uncertainties, including its ability to predict revenue and expense levels, and plan for and model future growth. Moreover, at least with respect to COVID-19-related testing and vaccination, particularly as the pandemic reaches endemic stages and demand subsides, there can be no assurances that DocGo will be able to find alternative revenue streams to compensate for the loss. We have witnessed a significant reduction in COVID testing activity since the second half of 2022 and expect that this activity will continue to decline.

The pandemic has adversely affected many industries as well as the economies and financial markets of many countries, including the United States, causing a significant deceleration of economic activity. This slowdown has reduced production, decreased demand for a broad variety of goods and services, diminished trade levels, and led to widespread corporate downsizing, causing a sharp increase in unemployment. There has also been disruption to and extreme volatility in the global capital markets, which could increase the cost of, or entirely restrict access to, capital. The long-term impact of this pandemic on the U.S. and world economies remains uncertain, and even at times when the pandemic is largely contained, these adverse impacts could worsen, impacting all segments of the global economy, and result in a significant recession or worse.

The degree to which COVID-19 impacts DocGo's business operations, strategy, financial condition and results of operations will depend on future developments, which are highly uncertain, continuously evolving and unpredictable, including, but not limited to, the severity of any new outbreaks, resurgences and variants, actions taken to contain resurgences or variants or to address their impact, and other effects. As the COVID-19 pandemic reaches endemic stages, the future impacts to DocGo of COVID-19 remain uncertain, but such impacts could have a material adverse impact on our business, strategy and financial condition.

The high level of competition in DocGo's industry could adversely affect its business.

The medical transportation industry is highly competitive. In its **healthcare transportation** **Transportation Services** segment, DocGo competes with governmental entities, including cities and fire districts, hospitals, local and volunteer private providers as well as and other regional and local private companies. The industry also includes several large national and regional providers such as Rural/Metro Corporation, Falck, American Global Medical Response, (AMR), Southwest SeniorCare EMS, Priority Ambulance, Paramedics Plus PatientCare EMS Solutions and Acadian Ambulance. Key competitive factors in the medical transportation services industry include the ability to improve customer service, such as on-time performance and efficient call intake; to provide comprehensive clinical care; and to recruit, train and motivate employees, particularly ambulance crews who have direct contact with patients and healthcare personnel. Pricing, billing and reimbursement expertise are also very important.

While the mobile health/telehealth market is in an early stage of development, it is also competitive and DocGo expects it to become increasingly competitive in the future, which could make it difficult for DocGo to succeed. The major Major competitors in the industry (in each case relative to only some of DocGo's products or services) include much larger, national or regional telehealth or in-home healthcare service providers such as Dispatch DispatchHealth, Modivcare, Addus HomeCare, Option Care Health, Teladoc, Amwell, Signify Health (acquired by CVS in March 2023), MedArrive, Biofourmis and One Medical (acquired by Amazon in February 2023) that generally provide telehealth on behalf of self-insured employers and insurance plans. These competitors, however, generally do not provide direct patient care or last-mile care on behalf of the provider organization. DocGo also believes there are several smaller, private organizations providing in-home or in-site on-site care utilizing different, higher cost healthcare providers. Non-traditional providers and others such as large health systems or payors, some of which may be DocGo customers or partners, may enter the space using consumer-grade video conferencing platforms such as Zoom and Twilio or develop innovative technologies or business activities that could be disruptive to the industry. Competition could also increase from large technology companies such as Apple, Amazon, Facebook, Verizon or Microsoft, who may develop their own telehealth or mobile health solutions or acquire existing industry participants, such as Amazon's acquisition of One Medical in February 2023, as well as from large retailers like Walmart, which see an opportunity CVS and others. Competition in the surge in interest in telehealth in connection with the COVID-19 pandemic. Competition in the mobile health and telehealth industry is primarily based on scale; ease of use, convenience and accessibility; brand recognition; breadth, depth and efficacy of telehealth and mobile health services; technology; clinical quality; customer support; cost; reputation; and customer satisfaction and value.

DocGo may not be successful in maintaining or growing its competitive position in one or more of its existing markets or in those into which it may expand. Some of DocGo's competitors may have access to greater financial or other resources than it does, which may afford them greater power, efficiency, financial flexibility, geographical reach or capital resources for growth. In addition, some of DocGo's competitors are vertically integrated and can leverage this structure to their advantage. DocGo may fail to identify optimal service or geographic markets, focus its attention on suboptimal service or geographic markets or fail to execute an appropriate business model in certain service or geographic markets. DocGo's competitors may develop new services or technologies that are superior to DocGo's, develop more efficient or effective methods of providing services or adapt more quickly, efficiently or effectively than DocGo to new technologies and opportunities. DocGo's competitors may be positioned to provide better services or influence customer requirements, or more quickly respond to changing customer requirements, and thereby establish stronger customer relationships. DocGo's competitors may offer their services at lower prices because, among other things, they may possess the ability to provide similar services more efficiently, as part of a bundle with other services or generally at a lower cost. These pricing pressures could require DocGo to lower its prices to at or below its costs, requiring DocGo to sacrifice margins or incur losses. Alternatively, DocGo may choose to forgo entering certain markets or exit other markets, which could limit its growth and competitive reach. Any failure by DocGo to compete or to generally maintain and improve its competitive position could adversely affect its business, financial condition and results of operations.

Negative media coverage could damage DocGo's reputation and harm its ability to bid for and win government and other contracts.

DocGo's revenue reputation has been, and could in the future be, adversely affected by unfavorable publicity regarding, for example, the Company, its products or services, its management team and board of directors, its government contracts and its financial performance, regardless of whether such claims are accurate. For example, DocGo has been the subject of media coverage regarding certain of its contracts with New York City. Any such negative publicity could have an adverse effect on DocGo's relationships with its customers, and accordingly, harm its ability to bid for and win government and other contracts. As a result, DocGo's business, financial condition and results of operations may be adversely affected.

DocGo's revenues could be adversely affected if it loses some or all of its business under existing contracts.

A significant portion of DocGo's revenue growth has historically resulted from increases in the business and related fees it collects under existing contracts and the addition of new contracts. DocGo's contracts with healthcare providers and other customers generally have terms of one to three years (in some cases automatically renewing), and most some of its contracts are terminable by either of the parties upon notice of as little as 30 days. Even if DocGo has an existing contract with a healthcare provider, the contract does not create any exclusive relationship, and even if DocGo is given preferred status, the customer often still does conducts business with one or more of DocGo's competitors. For example, execution under DocGo's medical transportation services contracts requires that an ambulance or other necessary fleet vehicle be available and within a certain proximity and at the time of need and, if one is not available, the customer can and will seek alternative options. Furthermore, certain of DocGo's contracts will expire during each fiscal period, and DocGo may be required to seek renewal of these contracts through a formal bidding process. Even if DocGo is successful in renewing the contract, the contract may contain terms that are not as favorable to DocGo as its current contracts. There can be no assurances that DocGo will successfully retain its existing contracts and any loss of contracts or reduction in services provided thereunder or under any renewal could have a material adverse effect on DocGo's business, financial condition and results of operations.

DocGo's reliance on government contracts could adversely affect its business.

In recent years, DocGo's government contract work has represented a substantial portion of its overall revenue, representing approximately 73%, 64% and 65% of DocGo's revenue revenues for the years ended December 31, 2022, December 31, 2023, 2022 and 2021, respectively, and maintaining and continuing to grow this revenue revenues stream is an important part of DocGo's growth strategy. However, government contract work is subject to significant risks and uncertainties. For example, only eligible parties can bid on and service most government contracts, which requires DocGo to comply with various statutes, rules, regulations and other governmental policies, including those related to wages, benefits, overtime, working conditions, equal employment opportunity, affirmative action and drug testing. If DocGo fails to comply with any of these requirements, it may be suspended or barred from government work or subject to various administrative sanctions and civil and criminal penalties and fines. Government contract work subjects DocGo to government audits, investigations and proceedings, which could also lead to DocGo being barred from government work or subjected to fines if it is determined that a statute, rule, regulation, policy or contractual provision has been violated. Audits can also lead to adjustments to the amount of contract costs DocGo believes are reimbursable or to the ultimate amount DocGo may be paid under the agreement.

Responding to audits can be costly, time-consuming and a significant distraction to management as well.

In addition, government contracts typically include strict provisions relating to service level agreements (“SLAs”), involving specific operating performance metrics with which the provider must comply. Failure to comply with these SLAs could result in DocGo receiving reduced revenues from these contracts, DocGo being removed from the project in favor of another provider or DocGo’s programs ceasing entirely.

Additionally, governments are typically under no obligation to maintain funding at any specific level, and funds for government programs can be eliminated with little or no notice. Given the currently uncertain general economic outlook, whereby a recession could lead to a reduction in a government’s tax revenues, as well as potential changes in the controlling political party in these municipalities, who might be less favorably inclined toward government spending on **health care** **healthcare** and other social services, **particularly as these services are provided to recent migrants**, the long-term outlook for funding for certain government programs is uncertain. As a result, contracts with government agencies may only be partially funded or may be terminated, and DocGo may not realize all of the potential revenue from those contracts. Government contracts typically can be paused or canceled entirely at any time, in whole or in part, at the government’s convenience or the government can default with little or no prior notice. Under these circumstances, the contractor typically receives payment only for the lesser of the work completed or the amount authorized under the contract, but not the anticipated revenue and profit that could have been earned had the contract been completed. A temporary stoppage or delay or the complete cancellation of a project can create inefficiencies, such as leaving portions of DocGo’s fleet idle for a significant period of time, cause DocGo to lose some or all of its investment in the project or result in financial and other damages that DocGo may not be able to recover from the government. The timing of project awards, including expansions of existing projects, is also unpredictable and can involve complex and lengthy negotiations and competitive bidding processes.

Federal, state and local governments may also from time to time adopt, implement or modify certain policies or directives that may adversely affect DocGo’s business. For example, governments may in the future review their use of for-profit service providers such as DocGo and may cancel or decide not to renew existing contracts or opt not to enter new contracts with such providers. Changes in government policy or the political landscape relating to immigration or population health programs may also result in a decrease in DocGo’s government contract work and related revenues.

Other risks associated with government contracting include more extended collection cycles, **due in part to the sometimes prolonged contract registration process**, and heightened or unlimited indemnification obligations. Any failure to maintain and grow DocGo’s government contract revenues for one or more of these or any other reasons could adversely affect DocGo’s business, financial condition and results of operations.

A significant portion of DocGo’s recent revenue growth is derived from a small number of large customers.

A significant portion of DocGo’s revenues and income growth in **2022 2023** was derived from a from a limited number of customers. For the year ended **December 31, 2022** **December 31, 2023**, one customer accounted for approximately **35% 40%** of total **sales, revenues**, while **no other another** customer accounted for as much as **10%** **approximately 21%** of total **revenue. This revenues. DocGo’s largest** customer is a public benefit corporation, operating and provisioning services on behalf of a variety of municipal agencies. DocGo’s services for this customer are provided under several different contracts, spanning a variety of projects. These contracts are not guaranteed and are terminable at will by the **customer, customer, in some cases in as little as 15 days’ notice.** However, termination of any one of those particular contracts does not necessarily indicate a greater likelihood of termination of any of the customer’s other contracts, as these contracts are awarded on a per project basis, with each project running independently of the others. **DocGo’s second largest customer is a municipal agency, and therefore contracts with this customer are subject to the risks described above in the risk factor titled “—DocGo’s reliance on government contracts could adversely affect its business.”** DocGo cannot assure you that **this customer** these customers or other large customers will continue to do business with **it DocGo** on terms or at rates currently in effect, if at all, or will not elect to do business with DocGo’s competitors or otherwise perform their own services themselves. The loss of one of DocGo’s top customers, if not offset by revenues from new or other existing customers, could have a material adverse effect on DocGo’s business, financial condition and results of operations.

DocGo’s participation in partnerships based value-based reimbursement models may have a material adverse effect on its business, financial condition and results of operations.

Part of DocGo’s strategy is to enter into partnerships with health plans based on value-based reimbursement models that involve risk-sharing. These payment models are specifically designed to improve patient health outcomes while reducing overall costs, as reimbursement is tied to quality of care and effectively managing total cost of care. However, there can be no assurance that such models will be profitable to DocGo. Under these arrangements, DocGo may agree to assume partial or full risk for monthly deficits in funds established to provide care to patients in exchange for receiving the benefit of any surpluses. If DocGo is unable to accurately predict, price for and manage costs, such partnerships may not be profitable, and DocGo’s results of operations could be materially and adversely affected.

In addition, DocGo intends to enter these partnerships as pilot programs, and there is no assurance that they will continue or be renewed. Further, many states do not have a well-developed body of law or regulatory guidance for these models. As a result, new and existing laws, regulations or regulatory guidance could subject DocGo to the risk of restructuring or terminating these partnerships, as well as regulatory enforcement, penalties and sanctions if state or federal government enforcement agencies disagree with DocGo’s interpretation of applicable laws. These and other risks related to DocGo’s participation in partnerships based

on value-based reimbursement models may have a material adverse effect on its business, financial condition and results of operations.

DocGo may enter into a large-scale deployment of resources in response to a national emergency as a subcontractor to FEMA or other similar entities, which may adversely affect DocGo's business.

DocGo does not believe that a FEMA deployment would adversely affect its ability to service its customers, and DocGo is not contractually obligated to respond to FEMA requests. However, if management elects to participate in response to a national emergency, any significant FEMA deployment would require significant management attention and could reduce DocGo's ability to pursue other opportunities, including to pursue its geographic expansion and its growth strategies, which could have an adverse effect on DocGo's business, financial condition and results of operations.

The COVID-19 pandemic has had, and a future health crisis may have, a material impact on DocGo's business.

The COVID-19 pandemic and related direct and indirect impacts adversely affected, and a future health crisis may adversely affect, DocGo's Transportation Services segment. COVID-19 also heightened, and a future health crisis may heighten, various risks related to DocGo's business.

For example, should there be a health crisis among DocGo's employees in one or more of its markets, DocGo may need to significantly reduce or cease operations in that market. DocGo's cost structure may also be adversely impacted by a health crisis. A number of DocGo's suppliers were negatively impacted by the COVID-19 pandemic, and there were significant disruptions in its supply chains, particularly with respect to the personal protective equipment ("PPE") that DocGo's healthcare professionals require to do their jobs. Shortages in the availability of PPE have limited, and in the future may limit, DocGo's ability to meet demand and provide its services to customers in a timely manner. Limitations on the availability or increases in the price of PPE have and could in the future continue to adversely affect DocGo's business and results of operations.

A health crisis may adversely affect many industries as well as the economies and financial markets of many countries, including the United States, potentially causing a significant deceleration of economic activity. Such a slowdown could reduce production, decrease demand for a broad variety of goods and services, diminish trade levels and lead to widespread corporate downsizing, causing a sharp increase in unemployment. A health crisis may also disrupt and cause extreme volatility in the global capital markets, which may increase the cost of capital. The long-term impact of a health crisis, such as COVID-19, on the U.S. and world economies is uncertain.

The degree to which a health crisis impacts DocGo's business operations, strategy, financial condition and results of operations depends on future developments, which are highly uncertain, continuously evolving and unpredictable, including, but not limited to, the severity of any new outbreaks, resurgences and variants, actions taken to contain resurgences or variants or to address their impact, and other effects. Such impacts could have a material adverse impact on DocGo's business, strategy and financial condition.

Risks Related to DocGo's Limited Operating History

DocGo's limited operating history may make it difficult to evaluate its business, which may be unsuccessful.

DocGo has a limited operating history since its inception in 2015. history. As such, there is limited information on which to base an evaluation of its business and prospects. DocGo's operations are subject to all of the risks inherent in the establishment of a recently formed business, including adding management personnel, managing general expenditures and managing the timing of payments to vendors and cash receipts from customers, and its success may be limited by unexpected expenses, difficulties, inefficiencies, complications and delays, including the need for additional financing, challenges with the successful commercialization of its services and its geographic expansion, market and customer acceptance of its services and technologies, unexpected issues with federal or state regulatory authorities, competition from larger operations, uncertain intellectual property protection, fluctuations in expenses and dependence on corporate partners and collaborators. Any failure to successfully address these and other risks and uncertainties commonly associated with early-stage companies could seriously harm DocGo's business and prospects, and it may not succeed given the challenges it faces in the markets in which it operates or may choose to expand into in the future. Additionally, DocGo's strategy of providing healthcare transportation services with significant reliance on a mobile platform is novel, the mobile health and telehealth industry is nascent and still evolving, and there are no well-established companies offering the "last-mile" telehealth mobile health solutions that DocGo offers, all of which carry its their own unique risks, including market and consumer acceptance and adoption. Any evaluation of DocGo's business and its prospects must be considered in light of these factors and the other risks and uncertainties frequently encountered by companies in this early stage of development. No assurance can be given that DocGo will be able to successfully navigate these issues or implement any of its growth strategies in a timely or effective manner, which could negatively impact DocGo's business, financial condition and results of operations.

Much of DocGo's revenue, employee and operations growth has occurred during the past three recent years, which has been partially driven by significant COVID-related impacts. The Company estimates that COVID testing related revenue for 2021 was approximately \$110 million and \$75 million in 2022. However, as the COVID-19 pandemic has reached endemic levels and the public health emergency declaration has ended, demand for COVID-related products has subsided, DocGo's COVID testing-related revenues have declined, and at the end of 2022 in 2023 such revenues represented an insignificant proportion of the Company's overall revenues. DocGo's future growth will be driven by its ability to continue to replace these COVID-testing-related revenues with other revenue streams. DocGo's ability to forecast its future operating results is limited and subject to a number of uncertainties, including its ability to predict revenue and expense levels and plan for and model future growth.

DocGo has a history of losses, expects its operating expenses to increase significantly in the foreseeable future and may not achieve or sustain profitability.

From inception Prior to 2021, DocGo the Business Combination, Ambulnz recorded a net loss each fiscal year. Fiscal year 2021 was the first year from its inception in which DocGo recorded net income, and DocGo recorded net income of \$22.8 million in fiscal year 2022. Prior 2015 to 2021, when DocGo recorded \$19.2 million in net income, DocGo had experienced a net loss in each year since inception, including a net loss of \$14.8 million \$14.8 million for the fiscal year ended December 31, 2020. As of December 31, 2022 December 31, 2023, DocGo had an accumulated deficit of \$36.6 million, approximately \$21.4 million. While DocGo has recently historically been able to generate revenues and believes its business strategy provides for predictable revenue streams in future periods, its revenues may not increase in future periods, and it may resume incurring net losses for some time as it continues to grow. Even if DocGo generates net income in a given year, there remains the likelihood that the Company it could incur net losses in any given quarter, given the fluctuating nature of revenues and expenses, particularly given the significant costs that are incurred during the beginning stages of new projects, coupled with marketing and personnel costs incurred for developing potential new business lines. It is difficult for DocGo to predict its future results of operations, and it expects its operating expenses to increase significantly over the next several years as it continues to expand its operations and infrastructure, acquire additional vehicles, hire additional personnel, make and integrate future acquisitions and invest in technology and research and development. In addition to the costs to grow its business, DocGo also expects to incur significant additional legal, accounting and other expenses as a public company. If DocGo fails to increase its revenue to offset the increases in its operating expenses, DocGo may not achieve or sustain profitability in the future.

If DocGo is unable to effectively manage its growth, its financial performance and future prospects will be adversely affected.

Since DocGo's inception, in 2015, it has experienced rapid growth in the United States and more recently, internationally in the United Kingdom, and it expects to continue to grow in the future. For example, DocGo's prior to the Business Combination, the revenues have grown from \$30.9 million in of Ambulnz were approximately \$30.9 million for the year ended December 31, 2017 to \$440.5 million in, and the revenues of DocGo were approximately \$624.3 million for the year ended December 31, 2022, and December 31, 2023. In addition, DocGo's employee base has grown to nearly 3,000 over 4,000 employees (exclusive of independent contractors and agency employees) in just over seven years, as of December 31, 2023. This growth has placed, and may continue to place, significant strain on DocGo's management, its operational and financial infrastructure and its controls and procedures, which may not be adequate to support this growth or sustain further expansion in the future.

DocGo's ability to effectively manage its growth has required, and will continue to require, it to expand and improve its operational and financial infrastructure, including its controls and procedures, and to retain, attract, train, motivate and manage employees, including qualified medical professionals, operations personnel and financial and accounting staff. Additionally, DocGo has needed to, and will continue to need to, integrate new technologies and acquisitions into its existing business and establish consistent policies across regions and functions. Achieving these goals has required DocGo to commit substantial financial, operational and technical resources, and DocGo expects these demands to persist, and very likely to increase, as it continues to grow in the future.

The expansion and increasing complexity of DocGo's business has placed significant strain on its operations, personnel and systems and further growth in the future could restrict DocGo's ability to develop and improve its operational, financial and management controls and enhance its reporting systems and procedures. If DocGo is not able to effectively manage this expansion in its operations and attract, train and retain additional qualified personnel in an efficient manner, DocGo's operations and services will be adversely affected and its customers may choose one or more of its competitors. Additionally, DocGo's failure to maintain or upgrade its technology infrastructure effectively to support its growth or otherwise maintain its technological competitive advantage could result in unanticipated system disruptions, slow response times or an unsatisfactory customer experience, any of which could cause DocGo to no longer be in compliance with the minimum service levels required by certain customer contracts. An inability to maintain effective management, financial and reporting systems, controls and procedures could adversely affect DocGo's ability to provide timely and accurate financial information or result in a misstatement of account balances or disclosures. If DocGo is unable to effectively manage its recent or future growth, its operations, business, financial condition and results of operations could be adversely affected.

DocGo is currently an "emerging growth company" and it cannot be certain if the reduced disclosure requirements applicable to emerging growth companies will make the Common Stock less attractive to investors.

DocGo is currently an "emerging growth company" as defined in the JOBS Act. As an emerging growth company, DocGo is only required to provide two years of audited financial statements and only two years of related selected financial data and management discussion and analysis of financial condition and results of operations disclosure. In addition, DocGo is not required to obtain auditor attestation of its reporting on internal control over financial reporting, has reduced disclosure obligations regarding executive compensation and is not required to hold non-binding advisory votes on executive compensation. In addition, the JOBS Act provides that an emerging growth company can take advantage of an extended transition period to comply with new or revised accounting standards. This allows an emerging growth company to delay the adoption of these accounting standards until they would otherwise apply to private companies. DocGo has elected to take advantage of such extended transition period. DocGo cannot predict whether investors will find its Common Stock to be

less attractive as a result of its reliance on these exemptions. If some investors find its Common Stock to be less attractive as a result, there may be a less active trading market for the Common Stock and the price of the Common Stock may be more volatile than the historical trading market.

DocGo will remain an emerging growth company until the earliest of: (i) the end of the fiscal year in which DocGo has total annual gross revenue of \$1.07 billion; (ii) the last day of DocGo's fiscal year following the fifth anniversary of the Initial Public Offering (or December 31, 2025); (iii) the date on which DocGo issues more than \$1.0 billion in non-convertible debt during the preceding three-year period; or (iv) the end of the fiscal year in which the market value of the Common Stock held by non-affiliates exceeds \$700 million as of the last business day of its most recently completed second fiscal quarter.

Further, there is no guarantee that the exemptions available under the JOBS Act will result in significantly lower compliance costs. To the extent that DocGo chooses not to use exemptions from various reporting requirements under the JOBS Act, or if it is no longer an emerging growth company, it will incur additional compliance costs, which may impact DocGo's financial condition.

DocGo relies on data center providers, Amazon Web Services (“AWS”), Internet infrastructure, bandwidth providers, third-party computer hardware and software, other third parties and DocGo’s own systems for providing services to DocGo’s clients and consumers, and any failure or interruption in the services provided by these third parties or DocGo’s own systems could expose DocGo to disputes, litigation and negatively impact DocGo’s relationships with clients, adversely affecting DocGo’s brand and DocGo’s business. Such disputes and litigation could cause DocGo to incur significant additional legal and other expenses.

DocGo serves its clients and consumers from relies on two geographically dispersed data centers, one in the United States and one in the United Kingdom, as well as AWS to serve its clients and consumers. While DocGo controls and has virtual access to its data center servers, DocGo does not control the operation of these facilities, facilities or AWS. The owners of DocGo’s data center facilities and AWS have no obligation to renew their agreements with DocGo on commercially reasonable terms, or at all. If DocGo is unable to renew these agreements on commercially reasonable terms, or if there is a change of control of one of DocGo’s data center operators is acquired, or AWS, DocGo may be required to transfer its servers and other infrastructure to new data center facilities, and DocGo may incur significant costs and possible service interruption in connection with doing so. Problems faced by DocGo’s third-party data center locations or AWS with the telecommunication network providers with whom DocGo or they contract, or with the systems by which DocGo’s telecommunications providers allocate capacity among their clients, including us, DocGo, could adversely affect the experience of our DocGo’s clients and consumers. DocGo’s third-party data center operators or AWS could also decide to close their facilities without adequate notice. In addition, any financial difficulties, such as bankruptcy, faced by DocGo’s third-party data center operators, AWS or any of the service providers with whom DocGo they or they DocGo contract may have negative effects on our DocGo’s business, the nature and extent of which are difficult to predict.

Additionally, if DocGo’s data centers are or AWS is unable to keep up with meet DocGo’s growing needs for capacity, this could have an adverse effect on DocGo’s business. For example, a rapid expansion of DocGo’s business could affect the service levels at DocGo’s data centers or cause such data centers and systems to fail. Any changes in third-party service levels at DocGo’s data centers or AWS or any disruptions or other performance problems with DocGo’s solution could adversely affect DocGo’s reputation and may damage DocGo’s clients’ and consumers’ stored files or result in lengthy interruptions in DocGo’s services. Interruptions in DocGo’s services may reduce DocGo’s revenue, cause us it to issue refunds to clients for prepaid and unused subscriptions, as well as result in penalties related to service level credits and uptime, subject DocGo to potential liability or adversely affect client renewal rates.

In addition, our DocGo’s ability to deliver DocGo’s its Internet-based services depends on the development and maintenance of the infrastructure of the Internet by third parties. This includes maintenance of a reliable network backbone with the necessary speed, data capacity, bandwidth capacity and security. Our DocGo’s services are designed to operate without interruption in accordance with DocGo’s service level commitments. However, DocGo has experienced, including during the period immediately following the beginning of the COVID-19 pandemic, and expect that DocGo may experience in the future, interruptions and delays in services and availability from time to time. In the event of a catastrophic event with respect to one or more of DocGo’s systems, DocGo may experience an extended period of system unavailability, which could negatively impact DocGo’s relationship with clients and customers. To operate without interruption, both DocGo and its service providers must guard against:

- damage from fire, power loss, natural disasters and other force majeure events outside DocGo’s control;
 - communications failures;
 - software and hardware errors, failures and crashes;
 - security breaches, computer viruses, hacking, denial-of-service attacks, and similar disruptive problems; and
 - other potential interruptions.
-
- damage from fire, power loss, natural disasters and other force majeure events outside DocGo’s control;
 - communications failures;
 - software and hardware errors, failures and crashes;
 - security breaches, computer viruses, hacking, denial-of-service attacks and similar disruptive problems; and
 - other potential interruptions.

DocGo also relies on computer hardware purchased and software licensed from third parties in order to offer its services. These licenses are generally commercially available on varying terms. However, it is possible that this hardware and software may not continue to be available on commercially reasonable terms, or at all. Any loss of the right to use any of this hardware or software could result in delays in the provisions of

DocGo's services until equivalent technology is either developed by DocGo or, if available from third parties, is identified, obtained and integrated.

DocGo exercises limited control over third-party vendors, including AWS, which increases DocGo's vulnerability to problems with technology and information services they such vendors provide. Interruptions in DocGo's network access and services may in connection with related to third-party technology and information services may reduce DocGo's revenues, cause DocGo to issue refunds to clients, subject DocGo to potential liability and adversely affect client renewal rates. Although DocGo maintains a security and privacy damages insurance policy, the coverage under DocGo's policies may not be adequate to compensate DocGo for all losses that may occur related to the services provided by DocGo's third-party vendors. In addition, DocGo may not be able to continue to obtain maintain adequate insurance coverage at an acceptable cost, if at all.

DocGo's ability to rely on these services of third-party vendors, including AWS, could be impaired as a result of the failure of such providers to comply with applicable laws, regulations and contractual covenants, or as a result of events affecting such providers, such as power loss, telecommunication failures, software or hardware errors, computer viruses, cyber incidents and similar disruptive problems, fire, flood and natural disasters. Any such failure or event could adversely affect DocGo's relationships with its clients and damage its reputation. This could materially and adversely impact DocGo's business, financial condition and operating results.

DocGo's proprietary software may not operate properly, which could damage DocGo's reputation, give rise to claims against DocGo or divert application of DocGo's resources from other purpose, purposes, any of which could harm DocGo's business, financial condition and results of operations.

DocGo's platform provides consumers the ability to, among other things, register for DocGo's services; complete, view and edit medical history; request a visit (either scheduled or on demand); and conduct a visit (via video or phone). Proprietary software development is time-consuming, expensive and complex, and may involve unforeseen difficulties. DocGo encounters technical obstacles from time to time, and it is possible that DocGo may discover additional problems that prevent its proprietary applications from operating properly or in accordance with its contractual obligations to its customers. If DocGo's solution does not function reliably or fails to achieve client expectations in terms of performance, clients could assert claims against DocGo or attempt to cancel their contracts with DocGo. This could damage DocGo's reputation, lead to a loss of revenues and impair its ability to attract or maintain clients.

Moreover, data services are complex and those DocGo offers have in the past contained, and may in the future develop or contain, undetected defects or errors. Material performance problems, defects or errors in DocGo's existing or new software-based products and services may arise in the future and may result from interface of our DocGo's solution with systems and data that DocGo did not develop and the function of which is outside of DocGo's control or undetected in our its testing. These defects and errors, and any failure by DocGo to identify and address them, could result in loss of revenue or market share, diversion of development resources, harm to DocGo's reputation and increased service and maintenance costs. Defects or errors may discourage existing or potential clients from purchasing our solution from DocGo, DocGo's solution. Correction of defects or errors could prove to be impossible or impracticable. The costs incurred in correcting any defects or errors may be substantial and could have a material adverse effect on DocGo's financial condition and results of operations.

DocGo invested in and implemented upgraded information systems and processes in 2022, 2023. While DocGo expects these investments to provide incremental advantages, DocGo cannot assure you that all enhancements will be completed in a timely manner within and DocGo's budget or that such enhancements will be sufficient to meet the expectations of DocGo's current and prospective customers.

If DocGo cannot implement its solution for clients or resolve any technical issues in a timely manner, DocGo may lose clients and its reputation may be harmed.

DocGo's clients utilize a variety of data formats, applications and information systems, and our DocGo's solution must support clients' data formats and integrate with complex enterprise applications and information systems. If DocGo's enterprise software does not currently support a client's required data format or appropriate appropriately integrate with a client's applications and information systems, then DocGo must configure its enterprise software to do so, which increases DocGo's expenses. Additionally, DocGo does not control its clients' implementation schedules. As a result, if DocGo's clients do not allocate the internal resources necessary to meet their implementation responsibilities, or if DocGo faces unanticipated implementation difficulties, the implementation may be delayed. If the client implementation process is not executed successfully or if execution is delayed, DocGo could incur significant costs, clients could become dissatisfied and decide not to increase utilization of DocGo's solution or not to implement DocGo's solution beyond an initial term of commitment or, in some cases, revenue recognition could be delayed. In addition, competitors with more efficient operating models with lower implementation costs could jeopardize DocGo's client relationships.

DocGo's clients depend on DocGo's support services to resolve any technical issues relating to DocGo's solution and services, and DocGo may be unable to respond quickly enough to accommodate short-term increases in member demand for support services, particularly as DocGo increases the size of its client, member and patient bases. DocGo may also be unable to modify the format of its support services to compete with changes in support services provided by competitors. It is difficult to predict member demand for technical support services, and if member demand increases significantly, DocGo may be unable to provide satisfactory support services to its consumers. Further, if DocGo is unable to address consumers' needs in a timely fashion or further develop and enhance its solution, or if a client or member is not satisfied with the quality of work performed by DocGo or with the technical support services rendered, then DocGo could incur additional costs to address the situation or be required to issue credits or refunds for amounts related to unused services, and DocGo's profitability may be impaired and impaired. In addition, clients' dissatisfaction with DocGo's solution could damage its ability to expand the number of software-based products and services purchased by such clients. These clients may not renew their contracts, seek to terminate their relationship with DocGo or renew on less favorable terms. Moreover, negative publicity related to DocGo's client relationships, regardless of its accuracy, may further damage its DocGo's business by affecting its reputation or ability to compete for new business with current or prospective clients. If any of these were to occur, DocGo's revenue may decline and its business, financial condition and results of operations could be adversely affected.

DocGo's reliance on third-party software could adversely affect its business.

DocGo's success depends in part on its integrations and relationships with third-party software providers, particularly with the development and expansion of DocGo's offerings and technologies. DocGo also relies on third-party encryption and authentication technologies licensed from third parties that are designed to securely transmit electronic medical records and other personal patient information. DocGo uses third-party software internally as well, including for communication purposes. If these third parties cease to provide access to the software that DocGo uses, if it the software is not available on terms that DocGo believes to be reasonable, or if the software is not available in the most current version, DocGo may be required to seek comparable software from other sources, which may be more expensive or inferior, or may not be available at all. Some of DocGo's technology partners may also take actions which that disrupt the utility of the software to DocGo or the interoperability of DocGo's platform with their its own products or services, or exert strong business influence on DocGo's ability to operate and distribute its platform or the terms on which it operates and distributes its platform, does so. Additionally, third-party services and products are constantly evolving, and DocGo may not be able to modify its operations or platform to assure its compatibility with that of other third parties following development changes. DocGo's third-party licenses are typically non-exclusive and its competitors may obtain the right to use any of the technology covered by these licenses to compete directly with it. If any of DocGo's technology partners limits access or modifies their products, standards or terms of use in a manner that degrades the functionality or performance of DocGo's platform, that is otherwise unsatisfactory or adverse to DocGo, or that gives preferential treatment to competitive products or services, DocGo's business, financial condition and results of operations could be adversely affected.

Some of DocGo's software and systems contain open-source software, which may pose particular risks to DocGo's proprietary software, technologies, products and services in a manner that could harm its business.

DocGo uses software licensed to DocGo by third-party developers under "open source" licenses in connection with the development or deployment of its proprietary software and expects to continue to use open-source software in the future. Some open-source licenses contain express requirements, which may be triggered under certain circumstances, that licensees make available source code for modifications or derivative works created or prohibit such modifications or derivative works from being licensed for a fee. Although DocGo monitors its use of any open-source software to avoid subjecting its platform to such requirements, the terms of many open-source licenses have not been interpreted by U.S. or foreign courts, and there is a risk that these licenses could be construed in a way that could impose unanticipated conditions or restrictions on DocGo's ability to develop or use its proprietary software. DocGo may face claims from third parties demanding the release or license of the open-source software or derivative works that DocGo developed from such software (which could include its proprietary source code) or otherwise seeking to enforce the terms of applicable open-source licenses. These claims could result in litigation and could require DocGo to publicly release portions of its proprietary source code or cease distributing or otherwise using the implicated solutions unless and until DocGo can re-engineer them.

In addition, DocGo's use of open-source software may present greater risks than use of other third-party commercial software, as open-source licensors generally do not provide support, warranties, indemnification or other contractual protections regarding infringement claims or the quality of the code. To the extent that DocGo's platform depends upon the successful operation of open-source software, any undetected errors or defects in open-source software that DocGo uses could prevent the deployment or impair the functionality of its systems and injure its reputation. In addition, the public availability of such software may make it easier for others to compromise its platform. Any of these risks could be difficult to eliminate or manage and, if not addressed, could have an adverse effect on DocGo's business, financial condition and results of operations.

Security breaches, loss of data and other disruptions or cybersecurity incidents could compromise sensitive business, customer or patient information or prevent DocGo from accessing critical information and expose it to liability, which could adversely affect DocGo's business.

DocGo is highly dependent on information technology networks and systems, including on-site systems, managed data center systems and cloud-based computing center systems, to securely process, transmit and store sensitive data and information, such as protected health information ("PHI") PHI and other types of personal data or personally identifiable information ("PII") PII relating to its employees, customers, patients and other confidential or proprietary business information. Computer malware, viruses, spamming and phishing attacks and attempts to gain unauthorized access have become more prevalent, have occurred on DocGo's systems in the past and may occur on DocGo's systems in the future. Various other factors may also cause system failures, including power outages, catastrophic events, inadequate or ineffective redundancy, issues with upgrading or creating new systems or platforms, flaws in third-party software or services, errors or intentional acts by DocGo's employees or third-party service providers, or breaches in the security of these systems or platforms, platforms or other cybersecurity incidents. These and other issues can create system disruptions, shutdowns or unauthorized access to, or disclosure, exfiltration, manipulation, corruption, loss or modifications of, such sensitive data or information, including PHI or PII. DocGo also utilizes third-party service providers for important aspects of the collection, storage, processing and transmission of this sensitive information and therefore is dependent on these third parties to similarly manage cybersecurity risks.

Because of the sensitivity of PHI, other PII and other sensitive information that DocGo and its service providers collect, store, transmit, and otherwise process, the security of DocGo's technology platform and other aspects of its services, including those provided or facilitated by DocGo's third-party service providers, are important to DocGo's operations and business strategy. DocGo takes certain administrative, physical and technological safeguards to address these risks, such as by requiring contractors and other third-party service providers who handle this PHI, other PII and other sensitive information to enter into agreements that contractually obligate them to use reasonable efforts to safeguard such PHI, other PII, and other sensitive information. DocGo attained ISO 27001 certification for its subsidiary Dara Technologies, LLC ("Dara") in November 2021 and is also in the process of upgrading its the entire Company's systems to be ISO 27001 and Service Organization Controls (SOC) ("SOC") 2 compliant. Measures taken to protect DocGo's systems, those of its contractors or third-party service providers, or the PHI, other PII, or other sensitive information DocGo or its contractors or third-party service providers process or maintain, may not adequately protect DocGo from the risks associated with the collection, storage, processing and transmission of such sensitive information. Additionally, updates or upgrades to systems, including those currently underway with respect to ISO 27001 and SOC 2 compliance, are time-consuming and costly, and they may not be effective in preventing data breaches or operate as designed and they could create new inefficiencies or vulnerabilities. DocGo may also be required to expend significant capital and other resources to address problems caused by security breaches, breaches or other cybersecurity incidents. Despite DocGo's implementation of security measures, cyberattacks are becoming more sophisticated and frequent. As a result, DocGo or its third-party service providers may be unable to anticipate these techniques or to implement adequate protective measures. If DocGo is unable to earn and/or maintain necessary certifications, including ISO 27001 certification for Dara and SOC 2 compliance for the entire Company, it could result in reputational harm and customer churn and adversely affect DocGo's ability to provide its services.

As a result, DocGo's revenue may decline and its business, financial condition and results of operations may be adversely affected.

A security breach or privacy violation that leads to disclosure or unauthorized use or modification of, or that prevents access to or otherwise impacts the confidentiality, security, or integrity of, patient information, including PHI, or other PII or other sensitive information that DocGo or its contractors or third-party service providers maintain or otherwise process, could harm DocGo's reputation, reputation; compel it to comply with breach notification laws, laws; cause it to incur significant costs for remediation, fines, penalties, notification to individuals or measures intended to repair or replace systems or technology and to prevent future occurrences, occurrences; cause potential increases in insurance premiums, premiums; and require DocGo to verify the accuracy of database contents, resulting in increased costs or loss of revenue. If DocGo is unable to prevent or mitigate such security breaches or privacy violations or implement satisfactory remedial measures, or if it is perceived that DocGo has been unable to do so, its operations or the functionality of its innovative technology could be disrupted; it may be unable to provide access to its systems; it could lose customers; it could see negative repercussions to its reputation, adverse impacts on customers, loss of customer and investor confidence, and financial loss; and it could be subject to governmental investigations or other actions, regulatory or contractual penalties, and other claims and liabilities. In addition, security breaches and other inappropriate access to, or acquisition or processing of, information can be difficult to detect, and any delay in identifying such incidents or in providing any notification of such incidents may lead to increased harms.

Further, disclosure or media reports of actual or perceived security vulnerabilities to DocGo's systems or those of its third-party service providers, even if no breach has been attempted or occurred, could lead to reputational harm, loss of customers and revenue, or increased regulatory actions, oversight, and scrutiny.

Any such breach cybersecurity incident or interruption of DocGo's systems or those of any of its third-party service providers could compromise DocGo's networks or data security processes, and sensitive information could be made inaccessible or could be accessed by unauthorized parties, publicly disclosed, lost or stolen. Any such cybersecurity incident, interruption in access, improper access, disclosure or other loss of information could result in legal claims or proceedings, liability under laws and regulations that protect the privacy of member information or other personal information, such as the Health Insurance Portability and Accountability Act of 1996, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009 ("HITECH"), and their implementing regulations and related rules (collectively, "HIPAA"), HIPAA, and regulatory penalties. Unauthorized A cybersecurity incident, unauthorized access, loss or dissemination could also disrupt DocGo's operations, including its ability to perform its services, services; access customer and patient health information, information; collect, process, and prepare company financial information, information; and provide information about DocGo's current and future services. Any such breach cybersecurity incident could also compromise DocGo's trade secrets and other proprietary information, which could adversely affect DocGo's business and competitive position. While DocGo maintains insurance covering certain data security and privacy damages and claim expenses, it such insurance coverage may not carry insurance or maintain coverage be sufficient to compensate for all costs and liabilities, and even if covered, it would not address the reputational damage that could result from a security incident.

As of the date of this filing, DocGo has not been materially impacted by any security breaches to its technology platform, including its on-site systems, managed data center systems and cloud-based computing center systems.

Risks Related to DocGo's Operations

DocGo's success depends on its key management personnel.

DocGo's success depends to a significant degree upon the contributions of certain key management personnel. The loss of any of DocGo's key personnel could affect its ability to run its business effectively. DocGo's success will depend on its ability to retain its current management and to develop, attract and retain qualified personnel in the future. Competition for senior management personnel is intense with increasingly aggressive compensation

packages, and DocGo cannot assure you that it can retain its key personnel or that its succession planning will prove effective. The loss of a member of senior management requires the remaining executive officers and the Board of Directors of DocGo (the “Board”) to divert immediate and substantial attention to seeking a replacement. The inability to fill vacancies in DocGo’s key personnel positions, including executive positions, on a timely basis could adversely affect its ability to implement its business strategy, which would negatively impact its results of operations.

DocGo’s labor costs are significant and any inability to control those costs could adversely affect its business.

Labor expenses (which includes both directly employed personnel as well as subcontracted labor) are DocGo’s largest cost, representing approximately 73%, 69% and 60% of its 2023, 2022 and 2021 revenues, respectively. DocGo competes with other healthcare providers in a highly competitive labor market with other healthcare providers to attract healthcare professionals, including EMTs, paramedics and nurses, to support its operations. In some markets in which DocGo operates, the lack of availability of clinical personnel has become a significant operating issue that all healthcare providers face. This labor shortage has required, and could continue in the future to require, DocGo to increase wages and benefits to recruit and retain qualified personnel or to identify and contract with more expensive temporary personnel. DocGo also depends on the available labor pool of technology-skilled workers in certain of the markets in which it operates.

If DocGo’s labor costs increase, and it is may be unable to raise rates to offset these increased costs, DocGo’s results of operations and cash flows will likely be adversely affected. costs. In particular, because a significant percentage of DocGo’s revenue consists of fixed, prospective payments, its ability to pass along increased labor costs is limited. If labor costs rise at an annual rate greater than its revenues, DocGo’s results of operations and cash flows will likely be adversely affected.

Any union activity that may occur within DocGo’s workforce in the future could contribute to increased labor costs. Certain proposed changes in federal labor laws and the National Labor Relations Board’s modification of its election procedures could increase the likelihood of employee unionization attempts. Although none of DocGo’s employees are currently represented by a collective bargaining agreement, to the extent a significant portion of its employee base unionizes, it is possible DocGo’s labor costs could increase materially. DocGo’s failure to recruit and retain qualified healthcare professionals, or to control labor costs, could have a material adverse effect on DocGo’s business, financial condition and results of operations.

DocGo’s inability to successfully recruit, train and retain qualified healthcare professionals could adversely affect its business.

The pool of qualified healthcare professionals, including EMTs, paramedics, LPNs and other nurses, available to staff DocGo’s broad spectrum of contracts and customer needs is limited, and DocGo invests significant resources to attract, train and retain these professionals. There is a relatively high rate of turnover in healthcare professional positions and, with DocGo’s expansion, its requirements in these positions have increased significantly. A significant number of employees have joined DocGo in recent years as it has grown, and DocGo’s success is dependent on its ability to maintain and instill its culture, align its talent with its business needs, engage its employees and inspire them to be open to change, to innovate and to maintain a customer-driven focus when delivering its DocGo’s services. As such, DocGo’s ability to recruit, train and retain a sufficient number of qualified healthcare professionals has a direct impact on its operations.

DocGo has, from time to time experienced, and it expects to continue to experience, difficulty in hiring and retaining healthcare professionals with appropriate qualifications, a difficulty that is amplified by the scope of the geographic and demographic diversity of the markets in which DocGo operates or may expand into in the future. In the U.S., United States, this difficulty is exacerbated by the currently tight labor market. Moreover, DocGo's customers, including the healthcare providers with which it partners, have increasingly demanded a greater degree of specialized skills, training and experience in the healthcare professionals providing services under their contracts, which also decreases the number of healthcare professionals who may be qualified to staff certain of DocGo's contracts. DocGo competes with other companies to recruit and retain these qualified healthcare professionals, including DocGo's direct competitors, government and private emergency and first responders as well as healthcare providers, including DocGo's partners and customers. Competition to fill these positions can be even greater in certain geographic regions, including more rural or economically depressed areas. In addition, the COVID-19 pandemic has significantly increased the demand for healthcare professionals in all regards, which makes it more difficult for DocGo to attract and retain the necessary qualified professionals. If DocGo is unable to attract, train and retain highly qualified healthcare professions, professionals, or if turnover rates are higher than it anticipates, it could have an adverse effect on DocGo's business, financial condition and results of operations.

DocGo's employees may work in challenging environments.

DocGo operates environments, which could result in a liability or other costs that could adversely affect DocGo's business.

DocGo's employees may work in challenging environments that are highly regulated, environment with and DocGo is subject to constantly evolving legal and regulatory frameworks. Consequently, the Company DocGo is subject to heightened risk of legal claims or other regulatory enforcement actions. Although the Company DocGo has implemented policies and procedures designed to ensure compliance with existing laws and regulations, there can be no assurance that our its team members, contractors or agents will not violate our its policies and procedures. Moreover, a failure to maintain effective control processes could lead to violations, unintentional or otherwise, of laws and regulations and may put our DocGo's employees and others in close proximity to potentially harmful environments or situations. These potentially harmful environments or situations may result in injuries to DocGo's employees, which could result in liability to DocGo or delay the completion or commencement of DocGo's services.

Unsafe work sites also have the potential to lead to claims, litigation or other liability, or increase employee turnover, increase costs, damage DocGo's reputation and brand and raise its operating and insurance costs. Any of the foregoing could result in, among other things, financial losses, litigation or other liability or reputational harm, which could have a material adverse effect on DocGo's business, financial condition and results of operations.

DocGo's inability to collect on its customer receivables or unfavorable shifts in payor mix could adversely affect its business.

The general practice in DocGo's industry is to provide healthcare services in advance of payment and, in many cases, prior to any assessment of the patient's insurance coverage and his or her ability to pay in the event insurance coverage is not available. DocGo ultimately bills a number of different payors, including private insurance, Medicare and Medicaid, the healthcare provider or facility and self-pay patients. These different payors typically have different billing, coding, documentation and other compliance requirements that DocGo must satisfy and any procedural deficiencies or incorrect or incomplete information could result in delays or partial or complete non-payment for the services DocGo has rendered. Changes in payor mix, particularly those that increase the percentage of patients covered by lower paying government programs as compared to private insurance or that increase the percentage of self-pay patients, can reduce the amount DocGo receives for its services and adversely affect DocGo's ability to collect on its receivables. The ability to bill and collect on certain accounts may also be limited by statutory, regulatory and investigatory initiatives, such as restrictions on charges for out-of-network services or by private lawsuits, including those directed at healthcare charges and collection practices for uninsured and underinsured patients.

In addition, DocGo's ability to collect on its receivables from government customers has been, and in the future may be, adversely impacted by government contract registration, invoicing and payment processes as well as audits. As a result of these factors, payments from government customers typically lag significantly behind the timing of DocGo's payment obligations to vendors engaged to provide services to such customers.

Other factors that can adversely affect DocGo's billing and collection efforts include general macroeconomic conditions, disputes between payors as to which party is responsible for payment, variation in coverage for similar services among various payors and the ability of individual patients to pay. These and other risks and uncertainties that impact DocGo's ability to timely bill and collect on its receivables or the amount DocGo can charge for its services could adversely affect DocGo's business, financial condition or results of operations.

DocGo may not accurately assess the costs it will incur under new revenue opportunities.

DocGo must accurately assess the costs it will incur in providing its services in order to realize adequate profit margins and otherwise meet its financial and strategic objectives, particularly with respect to the expansion of its mobile health business. However, increasing pressures from healthcare payors to restrict or reduce reimbursement rates at a time when the costs of providing medical services continue to increase, in particular due to labor shortages and other factors, make assessing it more difficult to assess the costs associated with the pricing of new contracts, maintenance of existing contracts and pricing new services that DocGo has not previously offered, more difficult. offered. Starting new contracts and service offerings has typically resulted in a temporary negative impact to cash flow as DocGo absorbed various expenses before it was able to bill and collect revenue associated with the new contracts or services. In addition, integrating new contracts, particularly those in new geographic locations, could prove more costly and could require more management time than DocGo anticipates. Any failure to accurately predict costs or the timing of payments from customers or to negotiate an adequate profit margin could have a material adverse effect on DocGo's business, financial condition and results of operations.

If DocGo is unable to successfully develop new offerings and technologies or adapt to rapidly changing technology and industry standards or changes to regulatory requirements, DocGo's business could be adversely affected.

Technology, including the mobile technologies DocGo utilizes on its innovative platform, is characterized by rapid change, changing consume consumer requirements, short product lifecycles, and evolving industry standards and changing regulatory requirements. DocGo's continued success and growth depend in part upon its ability to enhance its solutions with next-generation technologies and to develop or to acquire and market new services to access new consumer populations. As DocGo's operations grow, DocGo must continuously improve and upgrade its systems and infrastructure while maintaining or improving the reliability and integrity of its infrastructure as the cost of technology increases. DocGo's future success also depends on its ability to adapt its systems and infrastructure to meet rapidly evolving consumer trends and demands while continuing to improve the performance, features and reliability of its solutions in response to competitive services and offerings. DocGo may not be able to maintain its existing systems or replace or introduce new technologies and systems as quickly as DocGo would like or in a cost-effective manner.

There is no guarantee that DocGo will possess the resources, either financial or personnel, for the research, design and development of new applications or services, or that DocGo will be able to utilize these resources successfully and avoid technological or market obsolescence. Further, there can be no assurance that technological advances by one or more of DocGo's competitors or future competitors will not resolute result in DocGo's present or future applications and services becoming uncompetitive or obsolete. If DocGo is unable to enhance its offerings and network capabilities to keep pace with rapid technological and regulatory change, or if new technologies emerge that are able to deliver competitive offerings at lower prices, more efficiently, more conveniently, or more securely than DocGo's offerings, its business, financial condition and results of operations could be adversely affected.

DocGo's success will also depend on the availability of its mobile apps in app stores and in "super-app" environments, and the creations, maintenance and development of relationships with key participants in related industries, some of which may also be DocGo's competitors. In addition, if accessibility of various apps is limited by government actions, the full functionality of devices may not be available to its members. Moreover, third-party platforms, services and offerings are constantly evolving, and DocGo may not be able to modify its platform to assures ensure its compatibility with those third parties. If DocGo loses such interoperability, DocGo experiences difficulties or increased costs in integrating its offerings into alternative devices or systems, or manufacturers or operating systems elect not to include DocGo's offerings, make changes that degrade the functionality of its offerings or give preferential treatment to competitive products, the growth of DocGo's business, financial condition and results of operations could be materially adversely affected. This risk may be exacerbated by the frequency with which individuals change or upgrade their devices. In the event individuals choose devices that do not already include or supports DocGo's platform or do not install DocGo's mobile apps when they change or upgrade their devices, member engagement may be harmed.

DocGo's marketing efforts to help grow its business including its recent rebrand, may not be effective.

Promoting awareness of DocGo's brand, innovative technology and services is important to its ability to grow its business, to attract and retain customers and to gain market acceptance of its products and services, and these efforts can be costly. DocGo believes that much of the growth in its business is in part attributable to its marketing initiatives. DocGo's marketing initiatives may become increasingly expensive and generating a meaningful return on those initiatives may be difficult. Even if DocGo successfully increases revenue as a result of its paid marketing efforts, it may not offset the additional marketing expenses it incurs. Any factor that diminishes DocGo's reputation or that of its brands, including adverse publicity or failing to meet the expectations of customers, could make it substantially more difficult for DocGo to attract new customers. If these marketing efforts are not successful, DocGo's business, financial condition and results of operations could be adversely affected.

DocGo's insurance coverage, including the reserves DocGo establishes with respect to its insurable losses, could adversely affect its business.

DocGo self-insures against certain losses. In connection with DocGo's insurance self-insurance programs, management establishes reserves for losses and related expenses within its self-insured retention limits, which represent estimates involving actuarial and statistical projections, at a given point in time, of DocGo's expectations of the ultimate resolution and administration costs of losses it has incurred in respect of its liability risks. Insurance reserves are inherently are subject to uncertainty. DocGo's reserves are based on historical claims, demographic factors, industry trends, severity and exposure factors and other actuarial assumptions. DocGo uses these actuarial estimates to determine appropriate reserves, and DocGo's reserves could be significantly affected if current and future occurrences differ from historical claim trends and expectations. While DocGo monitors claims closely when it estimates reserves, the complexity of the claims and the wide range of potential outcomes may hamper timely adjustments to the assumptions DocGo uses in these estimates. Actual losses and related expenses may deviate, individually and in the aggregate, from the reserve estimates reflected in DocGo's Consolidated Financial Statements. If DocGo determines that its estimated reserves are inadequate, it would be required to increase reserves at the time of the determination, which would reduce DocGo's earnings in the period in which the deficiency is determined and could have a material adverse effect on DocGo's business, financial condition and results of operations.

Some of DocGo's DocGo also maintains certain insurance coverage is through third-party insurers. To the extent DocGo holds policies to cover certain groups of claims or relies on insurance coverage obtained by third parties to cover such claims, DocGo may still be responsible for losses. This could occur for a variety of reasons, including if DocGo or such third parties did not obtain sufficient insurance limits, did not buy an extended reporting period policy, where applicable, or the issuing insurance company is unable or unwilling to pay such claims. Furthermore, for DocGo's losses that are insured or reinsured through commercial insurance companies, it is subject to the "credit risk" of those insurance companies. In addition, professional liability insurance is expensive and insurance premiums may increase significantly in the future, particularly as DocGo expands the geographies in which it does business. As a result, adequate professional liability insurance may not be available to it in the future at acceptable costs or at all. While DocGo believes its commercial insurance company providers are creditworthy, there can be no assurance that such insurance companies will remain so in the future, and any failure of DocGo's insurance coverage to adequately cover any losses could have a material adverse effect on DocGo's business, financial condition and results of operations.

DocGo is required to make capital expenditures in order to remain competitive.

DocGo's capital expenditure requirements primarily relate to maintaining, growing and upgrading its vehicle fleet and medical equipment to serve its customers and remain competitive. The aging of DocGo's ambulance fleet requires DocGo to make regular capital expenditures, including to lease newer replacement ambulances to maintain its current level of service. DocGo's net capital expenditures totaled \$3.2 million \$6.8 million, \$3.2 million and \$4.7 million \$4.7 million in the years ended December 31, 2022 December 31, 2023, 2022 and 2021, respectively, representing acquisitions of property and equipment, less the proceeds from disposals of property and equipment. In addition, changing competitive conditions or the emergence of any significant advances in medical technology could require DocGo to invest significant capital in additional equipment or capacity in order to remain competitive. DocGo may also commit significant capital to acquiring new infrastructure to expand into new geographies. If DocGo is unable to fund any such investment, due to macroeconomic factors such as rising inflation, lack of access to the capital markets, rising interest rates or otherwise, or otherwise fails to invest in new ambulances, medical equipment or other infrastructure, its business, financial condition or results of operations could be materially and adversely affected.

DocGo's international operations subject it to additional risks that could adversely affect its business.

DocGo currently provides healthcare transportation services in the United Kingdom and intends to may further expand its operations and services internationally, which subjects DocGo to regulatory, macroeconomic, geopolitical and other events and uncertainties in these foreign jurisdictions. internationally. In addition to the risks discussed elsewhere herein that are common to DocGo's operations more generally, DocGo faces additional risks specific to its international U.K. operations, including but not limited to:

- geopolitical, social, macroeconomic and financial instability, including wars, civil unrest, acts of terrorism and other conflicts, such as the war in Ukraine, conflict in Israel and rising tensions in the Taiwan Strait; pandemics and endemics; and an inflationary environment, rising interest rates and recessionary fears;
- difficulties and increased costs in developing, staffing and simultaneously managing foreign operations, including as a result of distance, cultural differences and labor shortages and expenses;
- restrictions and limitations on the transfer or repatriation of funds;
 - geopolitical, social, macroeconomic and financial instability, including wars, civil unrest, acts of terrorism and other conflicts, such as the war in Ukraine and rising tensions in the Taiwan Strait; pandemics and endemics; and an inflationary environment, rising interest rates and recessionary fears;
- fluctuations in currency exchange rates;
- costs and challenges associated with complying with varying legal and regulatory environments in the U.K., including privacy laws such as the U.K. General Data Protection Regulation and tax laws;
 - difficulties and increased costs in developing, staffing and simultaneously managing a large number of varying foreign operations, including as a result of distance, language, cultural differences and labor shortages and expenses;
- laws and business practices that favor local competitors or prohibit foreign ownership of certain businesses;
- potential for privatization and other confiscatory actions; and
 - restrictions and limitations on the transfer or repatriation of funds;
- other dynamics in the U.K., any of which could result in substantial additional legal or compliance costs, liabilities or obligations for DocGo or could require it to significantly modify its current business practices or even exit the market.
 - fluctuations in currency exchange rates;
 - costs and challenges associated with complying with varying legal and regulatory environments in multiple foreign jurisdictions, including privacy laws such as the E.U. General Data Protection Regulation;
 - laws and business practices that favor local competitors or prohibit foreign ownership of certain businesses;
 - potential for privatization and other confiscatory actions; and
 - other dynamics in international jurisdictions, any of which could result in substantial additional legal or compliance costs, liabilities or obligations for DocGo or could require it to significantly modify its current business practices or even exit a given market.

Foreign operations bring increased complexity, and the costs of managing or overseeing foreign operations, including adapting and localizing services or systems to specific regions and countries, can be material. Further, international operations carry inherent uncertainties regarding the effect of local or domestic actions, such as the unpredictable impact of the United Kingdom's exit from the European Union (Brexit) and the uncertainty regarding how the agreements reached will operate, any of which could be material. International operations also carry financial risks such as those related to fluctuations in foreign currency exchange rates and disparate tax laws. These and other risks related to DocGo's existing or future foreign operations, or the associated costs or liabilities, could have a material adverse effect on DocGo's business, financial condition and results of operations.

DocGo's business could be materially and adversely affected by natural disasters, other catastrophic events, acts of war or terrorism, cybersecurity incidents and/or other acts by third parties.

DocGo and its customers depend on the ability of its business to run smoothly, including the ability of its fleet of ambulances, which are often needed in times of emergency, to transport patients. Any material disruption caused by natural disasters, including, fires, floods, hurricanes, volcanoes and earthquakes (in each case, including due to climate change or otherwise); power loss or shortages; environmental disasters; telecommunications or business information systems failures; acts of war or terrorism; viral outbreaks and other similar epidemics; cybersecurity incidents; and other actions by third parties and other similar disruptions could cause DocGo to lose critical data and services and otherwise adversely affect DocGo's ability to conduct business. Even with disaster recovery arrangements, DocGo's services could be interrupted and DocGo's insurance coverage may not compensate it for losses that may occur in the wake of such events. If any disruption results in the destruction of some or all of DocGo's fleet, **causes** significant disruption to DocGo's business, contributes to a general decrease in local, regional or global macroeconomic activity or otherwise impairs DocGo's ability to meet customer demands, or if DocGo is not able to develop or execute on an adequate recovery plan in such circumstances, DocGo's business, financial condition and results of operations could be materially adversely affected.

Rising inflation may negatively impact DocGo's business and financial results.

The inflation rate in the **U.S., United States**, as measured by the Consumer Price Index, **(CPI)** has generally trended up since early 2021. This data is reported monthly, showing year-over-year changes in prices across a basket of goods and services. For 2021, **Though the inflation increased from the 1.4%-2.6% range in the first quarter, rate declined to 4.2% in April, and was in the 5.0%-6.0% range through the end of the third quarter of 2021, before increasing to the 6.0%-7.0% range in the fourth quarter. For 4.1% for the full year the 2023 from 8.0% in 2022, it remains above historical averages. The increased inflation rate was 4.7% has had an impact on DocGo's expenses in 2021, several areas, including wages, fuel and medical and other supplies. This has had the highest annual rate since effect of compressing gross profit margins, as DocGo is generally unable to pass these higher costs on to its customers, particularly in the 5.4% rate recorded in 1990. The inflation rate short term. In a continued to increase in early 2022, reaching approximately 9.1% in June 2022, 8.2% in September 2022, and declining to 6.5% in December 2022. In an attempt to dampen inflation, the U.S. Federal Reserve implemented seven four interest rate increases hikes in 2022, 2023, raising its benchmark rate (the "federal funds rate") from near 0.00% at the beginning of the year to a current level of 4.25% to 4.50% as of the end of December 2022, and 5.25-5.50% as of the date of the filing of this Annual Report, it has so far implemented one interest rate increase in 2023, to the current level of 4.50% - 4.75%. Report. Looking into 2023, 2024, DocGo anticipates a continued moderation of the inflation rate as a result of these the recent federal funds rate increases, but DocGo expects that inflation will remain well above the levels seen with an annual rate similar to those witnessed in the previous 10 years, 2010-2020 period, when the annual inflation rate ranged from 0.1% to 2.4% 3.2%. If However, if inflation is above the levels that the Company DocGo anticipates, gross margins could be below plan and plan. Efforts by the U.S. Federal Reserve to combat inflation by raising the federal funds rate could also impact DocGo's financing costs for borrowings bearing interest at rates based on SOFR. As a result, DocGo's business, operating results and cash flows may be adversely affected.**

Risks Related to DocGo's Intellectual Property

DocGo's failure to protect or enforce its intellectual property rights could impair our its ability to protect our its technology and our brand.

DocGo's success depends in part on its ability to enforce and protect its intellectual property rights and technology, including its code, information, data, processes and other forms of information, know-how and technology. DocGo relies on a combination of copyrights, trademarks, service marks, trade secret laws and contractual restrictions to establish and protect its intellectual property and other proprietary rights. DocGo also enters into confidentiality and invention assignment agreements with **certain of** its employees and consultants and enters into confidentiality agreements with certain of its third-party providers and strategic partners. These laws, procedures and restrictions provide only limited protection, and any of **our DocGo's** intellectual property rights may be challenged, invalidated, circumvented, infringed or misappropriated.

Some of DocGo's intellectual property protections do not prevent competitors or others from independently developing technologies that are substantially equivalent or superior to DocGo's offerings. Further, it may still be possible for competitors and other unauthorized third parties to copy DocGo's technology and use its proprietary information to create or enhance competing platforms, solutions and services. DocGo also enters into strategic relationships, joint development and other similar agreements with third parties where intellectual property arising from such relationships may be jointly owned or may be transferred or licensed to the counterparty. These arrangements may limit DocGo's ability to protect, maintain, enforce or commercialize such intellectual property rights, including requiring agreement with or payment to the joint development partners before protecting, maintaining, licensing or initiating enforcement of such intellectual property rights, and may allow such joint development partners to register, maintain, enforce or license such intellectual property rights in a manner that may affect the value of the jointly owned intellectual property or DocGo's ability to compete in the market. As DocGo expands its international activities, its exposure to unauthorized use, copying, transfer and disclosure of proprietary information will likely increase as the laws of some countries do not provide the same level of intellectual property protection as do the laws of the United States, and effective intellectual property protections may not be available or may be limited and harder to enforce in some jurisdictions.

DocGo may be required to spend significant resources in order to establish, monitor and protect its intellectual property rights. DocGo may not always detect infringement of its intellectual property rights, and defending or enforcing its intellectual property rights, even if successfully detected, prosecuted, enjoined or remedied, could result in the expenditure of significant financial and managerial resources. Any enforcement efforts, and litigation in particular, could be costly, time-consuming and distracting to management and could result in the impairment or loss of portions of DocGo's intellectual property. DocGo's efforts to enforce its intellectual property rights may also be met with defenses, counterclaims and countersuits attacking the validity and enforceability of its intellectual property rights. An adverse determination of any litigation proceedings could put DocGo's **patents intellectual property** at risk of being invalidated or interpreted narrowly and could put DocGo's related pending patent applications at risk of not issuing. DocGo's inability to protect its proprietary technology against unauthorized copying or use, as well as any costly litigation or extensive enforcement activities, could impair the functionality of DocGo's platform, delay introductions of enhancements to the platform, result in DocGo's substituting inferior or more costly technologies, harm DocGo's reputation or brand and otherwise have a material adverse effect on its business, financial condition and results of operations.

Claims by others that DocGo infringed their proprietary technology or other intellectual property rights could adversely affect DocGo's business.

In recent years, there has been significant litigation in the United States involving patents and other intellectual property rights. Companies in the internet and technology industries are increasingly bringing and becoming subject to suits alleging infringement of proprietary rights, particularly patent rights, and **our DocGo's** competitors and other third parties may hold or have pending patent applications, which could be related to **our DocGo's** business. These risks have been amplified by the increase in third parties, which DocGo refers to as non-practicing entities, whose sole primary business is to assert such claims. Regardless of the merits of any other intellectual property litigation, DocGo may be required to expend significant management time and financial resources on the defense of such claims, and any adverse outcome of any such claim could have a material adverse effect on DocGo's business, financial condition and results of operations.

Given the competitive landscape and pervasiveness of litigation in DocGo's industry, from time to time, third parties may assert claims of infringement of intellectual property rights against DocGo. In addition, third parties have previously sent DocGo correspondence regarding various allegations of intellectual property infringement. DocGo

incorporates technology from third parties into its platform and, as such, it cannot be certain that these licensors are not infringing the intellectual property rights of others or that the suppliers and licensors have sufficient rights to the technology in all jurisdictions in which DocGo may operate. As DocGo gains an increasingly higher public profile, DocGo expects the possibility of these and other types of intellectual property rights claims against it will grow. Although DocGo believes that it has meritorious defenses, there can be no assurance that DocGo will be successful in defending against these and future allegations or in reaching a business resolution that is acceptable to DocGo.

Many potential litigants, including some of DocGo's competitors and non-practicing entities, have the ability to dedicate substantial resources to assert their intellectual property rights. Any claim of infringement by a third party, even those without merit, could be costly, time-consuming and a significant distraction to management. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, DocGo could risk compromising its confidential information during this type of litigation. In addition, in some instances, DocGo may agree to indemnify **our its** clients against certain third-party claims, which may include claims that DocGo's solutions infringe the intellectual property rights of such third parties. DocGo's business could be adversely affected by any significant disputes between DocGo and its clients as to the applicability or scope of DocGo's indemnification obligations to them. With respect to any intellectual property rights litigation or indemnification obligation, DocGo may need to negotiate a license to continue operations if found to be in violation of a third party's rights, and these licenses may not be available on favorable or commercially reasonable terms, or at all. DocGo may be required to pay substantial damages, royalties or other fees in connection with a claimant securing a judgment against it, DocGo may be subject to an injunction or other restrictions that prevent it from using the relevant intellectual property, or DocGo may determine it is prudent to agree to a settlement that restricts DocGo's operations or its use of certain intellectual property, any of which could adversely affect DocGo's business, financial condition and results of operations.

Risks Related to DocGo's Legal and Regulatory Environment

DocGo could be subject to lawsuits for which it does not have sufficient reserves, which could have a material adverse effect on DocGo's business, financial condition and results of operations.

Healthcare providers and other participants in the healthcare industry have become subject to an increasing number of lawsuits alleging medical malpractice and related legal theories such as negligent hiring, supervision and credentialing. Similarly, healthcare transportation services can result in lawsuits related to vehicle collisions and personal injuries, patient care incidents or mistreatment and employee job-related injuries. Moreover, in the normal course of DocGo's business, it has been and may continue to be involved in lawsuits, claims, audits and investigations, including those arising out of its billing practices, employment disputes, contractual claims and other business disputes for which DocGo may have no insurance coverage, and which are not subject to actuarial estimates. Some of these lawsuits may involve large claim amounts and substantial defense costs.

As a public company, DocGo has also been named a defendant in a lawsuit involving its securities, and may continue to be involved in lawsuits, claims, audits and investigations related to its securities.

Adverse outcomes with respect to litigation or any of these legal proceedings may result in significant settlement costs or judgments, penalties and fines, which may or may not be covered by DocGo's existing insurance or may require DocGo to modify its services or **require it to** stop serving certain customers or geographies, all of which could negatively impact its existing business and **its** ability to grow. DocGo may also become subject to periodic audits, which would likely increase its regulatory compliance costs and may require it to change its business practices or the scope of its operations. Managing legal proceedings, litigation and audits, even if DocGo achieves favorable outcomes, is time-consuming and diverts management's attention from DocGo's day-to-day business. The outcome of these matters or future claims and disputes are difficult to predict and determining reserves for pending litigation and other legal, regulatory and audit matters requires significant judgment. There can be no assurance that DocGo's expectations will prove correct, and even if these matters are resolved in its favor or without significant cash settlements, these matters, and the time and resources necessary to litigate or resolve them, could have a material effect on DocGo's results of operations in the period when it identifies the matter, and could have a material adverse effect on DocGo's business, financial condition and results of operations.

DocGo is subject to a variety of federal, state and local laws and regulatory regimes, including a variety of labor laws and regulations and **SEC rules and regulations**, and changes to or the failure to comply with these laws and regulations could adversely affect DocGo's business.

DocGo is subject to various federal, state, and local laws and regulations including the Employee Retirement Income Security Act of 1974 ("**ERISA**") and regulations promulgated by the Internal Revenue Service ("IRS"), the U.S. Department

of Labor and **the Occupational Safety and Health Administration, OSHA**. DocGo is also subject to a variety of federal and state employment and labor laws and regulations, including the Americans with Disabilities Act, the federal Fair Labor Standards Act, the Worker Adjustment and Retraining Notification Act and other regulations related to working conditions, wage-hour pay, overtime pay, family leave, employee benefits, antidiscrimination, termination of employment, safety standards and other workplace regulations. **In addition, as a public company, DocGo is subject to SEC rules and regulations.**

Compliance with these and other applicable laws and regulations can be time-consuming and costly. Failure to properly adhere to these and other applicable laws and regulations could result in investigations, the imposition of penalties or adverse legal judgments by public or private plaintiffs. Changes to these laws and regulations can also increase costs and require DocGo to commit additional resources to comply with these laws. For example, the raising of the federal minimum wage or the minimum wage within a state where DocGo has significant operations, which has been and continues to be a subject of ongoing discussions in Washington, D.C. and other U.S. state capitals, could significantly increase DocGo's selling, general and administrative expenses. Changes to or any failure to comply with applicable laws and regulations could also have a material adverse effect on DocGo's business, financial condition and results of operations.

DocGo's ability to utilize its net operating loss carryforwards and certain other tax attributes may be limited.

As of December 31, 2022, December 31, 2023, 2022 and 2021, DocGo had aggregate federal net operating loss carryforwards of approximately \$53.6 million, \$0, \$35.3 million and \$56.6 million, respectively. As of December 31, 2022, December 31, 2023, 2022 and 2021, the Company had state net operating loss carryforwards of approximately \$74.2 million, \$36 million, \$2.6 million and \$67.2 million, respectively. As of December 31, 2022, December 31, 2023, 2022 and 2021, DocGo had approximately \$903, \$10.7 million, \$1.5 million and \$202,965, \$203 thousand, respectively, of foreign net operating loss carryforwards. The federal net operating loss carryforwards generated after December 31, 2017, (including by Ambulnz prior to the Business Combination) of approximately \$62.2 million, \$35.3 million carry forward indefinitely, while the remaining federal net carryforwards of approximately \$11.7 million, \$0 begin to expire in 2037. State and foreign net operating loss carryforwards generated in the tax years from 2017 to 2020 will begin to expire, if not utilized, by 2039. DocGo's unused losses generally carry forward to offset future taxable income, if any, until such unused losses expire. DocGo may be unable to use these losses to offset income before such unused losses expire. However, U.S. federal net operating losses generated in 2019 and forward are not subject to expiration and, if not utilized by fiscal 2021, are only available to offset 80% of taxable income each year due to changes in tax law attributable to the passage of Tax Cuts and Jobs Act of 2017. In addition, if DocGo undergoes an "ownership change" — generally under Section 382 of the Internal Revenue Code of 1986, as amended (generally defined as a greater than 50% cumulative change in the equity ownership of certain shareholders over a rolling three-year period — under Section 382 of the Internal Revenue Code, period), DocGo's ability to use its pre-change net operating loss carryforwards and other pre-change tax attributes to offset future taxable income or taxes may be limited. Although the Merger Business Combination did not constitute such an ownership change, DocGo may experience ownership changes in the future as a result of changes in its stock ownership, some of which may not be within DocGo's control, which could materially reduce or eliminate DocGo's ability to use these losses or tax attributes to offset future taxable income or tax and have an adverse effect on its business, financial condition and results of operations.

Changes in tax laws or unanticipated tax liabilities could adversely affect DocGo's effective income tax rate and profitability.

DocGo is subject to income taxes in the United States (federal and state) and various foreign jurisdictions. DocGo's effective income tax rate could be adversely affected in the future by a number of factors, including changes in the valuation of deferred tax assets and liabilities, changes in tax laws and regulations or their interpretations and application, and the outcome of income tax audits in various jurisdictions around the world. In particular, the Biden administration has proposed increases to the U.S. corporate income tax rate from 21% to 28% and made other proposals. If any of these (or similar) proposals are ultimately enacted into law, in whole or in part, they could have a negative impact on DocGo's effective tax rate. DocGo cannot predict the likelihood, timing or substance of U.S. tax proposals and will continue to monitor the progress of such proposals, as well as other global tax reform initiatives.

DocGo continues to monitor changes in tax laws in the U.S. and the impact of proposed and enacted legislation in the various foreign jurisdictions in which it operates. In August 2022, the Inflation Reduction Act of 2022 was enacted, which, among other things, includes a new 15% alternative minimum tax on the adjusted financial statement income of certain large corporations for tax years beginning after December 31, 2022. President Biden has also provided informal guidance on tax law changes he may support. Among other things, proposed changes would raise the rate on both domestic and foreign income. If any of these proposals are ultimately enacted into legislation, they could materially impact DocGo's tax provision, cash tax liability and effective tax rate.

Changes in accounting rules, assumptions or judgments could materially and adversely affect DocGo.

Accounting rules and interpretations for certain aspects of DocGo's financial reporting are highly complex and involve significant assumptions and judgment. These complexities could lead to a delay in the preparation and dissemination of DocGo's financial statements. Furthermore, changes in accounting rules and interpretations or in DocGo's accounting assumptions or judgments, such as asset impairments and contingencies, are likely to significantly impact its financial statements. In some cases, DocGo could be required to apply a new or revised standard retroactively, resulting in restating financial statements from prior period(s). Any of these circumstances could have a material adverse effect on DocGo's business, financial condition and results of operations. For additional information, see the financial statements of DocGo Consolidated Financial Statements and related footnotes the accompanying notes included elsewhere in this Annual Report on Form 10-K.

Report.

DocGo's internal control over financial reporting may not be effective, and its independent registered public accounting firm may not be able to certify as to their effectiveness, which could adversely affect DocGo's business.

As a public company, DocGo has significant requirements for enhanced financial reporting and internal controls, including the SEC's rules implementing Sections 302 and 404 of the Sarbanes-Oxley Act of 2002 (the "Sarbanes-Oxley Act"), which require management to certify financial and other information in its quarterly and annual reports and provide an annual management report on the effectiveness of internal control over financial reporting. DocGo has made, and will continue to make, changes to its internal controls and procedures for financial reporting and accounting systems to meet its reporting obligations as a public company. The process of designing and implementing effective internal controls is a continuous effort that requires DocGo to anticipate and react to changes in its business and the economic and regulatory environments and to expend significant resources to maintain a system of internal controls that is adequate to satisfy its reporting obligations as a public company. The measures DocGo takes may not be sufficient to satisfy its obligations as a public company, and if DocGo is unable to establish or maintain appropriate internal financial reporting controls and procedures, it could cause DocGo to fail to meet its reporting obligations on a timely basis, result in material misstatements in its Consolidated Financial Statements and harm its results of operations. As of December 31, 2023, DocGo is no longer an emerging growth company, and, as such, a result, its independent registered public accounting firm will not be required to formally attest to the effectiveness of its internal control over financial reporting pursuant to Section 404 until the date DocGo is no longer an emerging growth company. At such time, DocGo's independent registered public accounting firm and may issue a report that is adverse in the event that it is not satisfied with the level at which DocGo's controls are documented, designed or operating, or it may not issue an unqualified report.

To comply with the requirements of being a public company, DocGo may need to undertake various actions, such as implementing additional internal controls and procedures and hiring additional accounting or internal audit staff. The rules governing the standards that must be met for DocGo's management to assess its internal control over financial reporting are complex and require significant documentation, testing and possible remediation. Testing and maintaining internal controls can divert management's attention from other matters that are important to the operation of DocGo's business. In connection with the implementation of the necessary procedures and practices related to internal control over financial reporting, DocGo may identify deficiencies that it may not be able to remediate in time to meet the deadline imposed by the Sarbanes-Oxley Act for compliance with the requirements of Section 404. DocGo's testing, or the subsequent testing (if required) by its independent registered public accounting firm, may reveal deficiencies in its internal controls over financial reporting that are deemed to be material weaknesses. Any material weaknesses could result in a material misstatement of DocGo's annual or quarterly Consolidated Financial Statements or disclosures that may not be prevented or detected. If DocGo identifies material weaknesses in its internal control over financial reporting or is unable to comply with the requirements of Section 404 or assert that its internal control over financial reporting is effective, or if DocGo's independent registered public accounting firm is unable to express an opinion as to the effectiveness of its internal control over financial reporting, when such disclosure is required, investors may lose confidence in the accuracy and completeness of DocGo's financial reports and the market price of its common stock Common Stock could be negatively affected, and DocGo could become subject to investigations by the SEC or other regulatory authorities, any of which could have an adverse effect on DocGo's business, financial condition and results of operations.

DocGo conducts business in the heavily regulated healthcare industry, and any failure to comply with these laws and government regulations could require DocGo to make significant changes to its operations and could have a material adverse effect on its business, financial condition and results of operations.

The U.S. healthcare industry is heavily regulated and closely scrutinized by federal and state governments. Comprehensive statutes and regulations govern the manner in which DocGo provides and bills for its services and collects reimbursement from governmental programs and private payors, its relationship with its providers, vendors and clients, its marketing activities and other aspects of its operations. Of particular importance are:

- the federal False Claims Act that imposes civil and criminal liability on individuals or entities that knowingly submit false or fraudulent claims for payment to the government or knowingly make, or cause to be made, a false statement in order to have a false claim paid, including qui tam or whistleblower suits;
- the federal Civil Monetary Penalties Law, which prohibits, among other things, the offering or transfer of remuneration to a Medicare or state healthcare program beneficiary if the person knows or should know it is likely to influence the beneficiary's selection of a particular provider, practitioner or supplier of services reimbursable by Medicare or a state healthcare program, unless an exception applies;
- the federal False Claims Act that imposes civil and criminal liability on individuals or entities that knowingly submit false or fraudulent claims for payment to the government or knowingly make, or cause to be made, a false statement in order to have a false claim paid, including qui tam or whistleblower suits;
 - reassignment of payment rules that prohibit certain types of billing and collection practices in connection with claims payable by the Medicare or Medicaid programs;
 - a provision of the Social Security Act that imposes criminal penalties on healthcare providers who fail to disclose or refund known overpayments;
 - federal and state laws that prohibit providers from billing and receiving payment from Medicare and Medicaid for services unless the services are medically necessary, adequately and accurately documented, and billed using codes that accurately reflect the type and level of services rendered;
 - the criminal healthcare fraud provisions of HIPAA that prohibit knowingly and willfully executing a scheme or artifice to defraud any healthcare benefit program or falsifying, concealing or covering up a material fact or making any materially false, fictitious or fraudulent statement in connection with the delivery of or payment for healthcare benefits, items or services. HIPAA also imposes certain regulatory and contractual requirements regarding the privacy, security and transmission of PHI. Similar to the federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it to have committed a violation;
 - federal and state laws and policies that require healthcare providers to maintain licensure, certification or accreditation to provide professional healthcare services, to enroll and participate in the Medicare and Medicaid programs, to report certain changes in their operations to the agencies that administer these programs, as well as state insurance laws;
 - the federal Anti-Kickback Statute that prohibits the knowing and willful offer, payment, solicitation or receipt of any bribe, kickback, rebate or other remuneration for referring an individual, in return for ordering, leasing, purchasing or recommending or arranging for or to induce the referral of an individual or the ordering, purchasing or leasing of items or services covered, in whole or in part, by any federal healthcare program, such as Medicare and Medicaid. Remuneration has been interpreted broadly to be anything of value, and could include compensation, discounts or free marketing services. A person or entity does not need to have actual knowledge of the statute or specific intent to violate it to have committed a violation. In addition, the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the False Claims Act;
 - similar state law provisions pertaining to false claims, self-referral and anti-kickback issues, some of which may apply to items or services reimbursed by any third-party payor, including commercial insurers or services paid out-of-pocket by patients;
 -
- the federal Civil Monetary Penalties Law, which prohibits, among other things, the offering or transfer of remuneration to a Medicare or state healthcare program beneficiary if the person knows or should know it is likely to influence the beneficiary's selection of a particular provider, practitioner or supplier of services reimbursable by Medicare or a state healthcare program, unless an exception applies;
- reassignment of payment rules that prohibit certain types of billing and collection practices in connection with claims payable by the Medicare or Medicaid programs;
- a provision of the Social Security Act that imposes criminal penalties on healthcare providers who fail to disclose or refund known overpayments;
- federal and state laws that prohibit providers from billing and receiving payment from Medicare and Medicaid for services unless the services are medically necessary, adequately and accurately documented, and billed using codes that accurately reflect the type and level of services rendered;

- the criminal healthcare fraud provisions of HIPAA that prohibit knowingly and willfully executing a scheme or artifice to defraud any healthcare benefit program or falsifying, concealing or covering up a material fact or making any materially false, fictitious or fraudulent statement in connection with the delivery of or payment for healthcare benefits, items or services. HIPAA also imposes certain regulatory and contractual requirements regarding the privacy, security and transmission of PHI. Similar to the federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it to have committed a violation;
 - federal and state laws and policies that require healthcare providers to maintain licensure, certification or accreditation to provide professional healthcare services, to enroll and participate in the Medicare and Medicaid programs, to report certain changes in their operations to the agencies that administer these programs, as well as state insurance laws;
 - the federal Anti-Kickback Statute that prohibits the knowing and willful offer, payment, solicitation or receipt of any bribe, kickback, rebate or other remuneration for referring an individual, in return for ordering, leasing, purchasing or recommending or arranging for or to induce the referral of an individual or the ordering, purchasing or leasing of items or services covered, in whole or in part, by any federal healthcare program, such as Medicare and Medicaid. Remuneration has been interpreted broadly to be anything of value, and could include compensation, discounts or free marketing services. A person or entity does not need to have actual knowledge of the statute or specific intent to violate it to have committed a violation. In addition, the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the False Claims Act;
 - similar state law provisions pertaining to false claims, self-referral and anti-kickback issues, some of which may apply to items or services reimbursed by any third-party payor, including commercial insurers or services paid out-of-pocket by patients;
 - the federal physician self-referral law under Section 1877 of the Social Security Act, commonly referred to as the Stark Law, that, unless one of the statutory or regulatory exceptions applies, prohibits physicians from referring Medicare or Medicaid patients to an entity for the provision of certain “designated health services” if the physician or a member of such physician’s immediate family has a direct or indirect financial relationship (including an ownership interest or a compensation arrangement) with the entity, and prohibits the entity from billing Medicare or Medicaid for such designated health services. Failure to refund amounts received as a result of a prohibited referral on a timely basis may constitute a false or fraudulent claim and may result in civil penalties and additional penalties under the federal False Claims Act noted below;
 - state laws that prohibit general business corporations, such as DocGo, from practicing medicine, controlling physicians’ medical decisions or engaging in some practices such as splitting fees with physicians;
 - the Federal Trade Commission Act and federal and state consumer protection, advertisement and unfair competition laws, which broadly regulate marketplace activities and activities that could potentially harm consumers; and
 - laws that regulate debt collection practices.
-
- state laws that prohibit general business corporations, such as DocGo, from practicing medicine, controlling physicians’ medical decisions or engaging in some practices such as splitting fees with physicians;
 - the Federal Trade Commission Act and federal and state consumer protection, advertisement and unfair competition laws, which broadly regulate marketplace activities and activities that could potentially harm consumers; and
 - laws that regulate debt collection practices.

DocGo’s ability to provide its services internationally is subject to the similar laws and regulations in those jurisdictions, and the interpretation of these laws is evolving and varies significantly from country to country. As in the United States, many of these laws and regulations are enforced by governmental, judicial and regulatory authorities with broad discretion. Although similar to their U.S. counterparts in the subject matters addressed, these foreign laws may be very different in what is required of the business and how they regulate the underlying activities. DocGo cannot be certain that its interpretation of such laws and regulations are correct in how it structures its operations, its arrangements with its healthcare provider partners, services agreements and customer arrangements.

Many of these laws and regulations are complex, broad in scope and have few or narrowly structured exceptions and safe harbors. Often DocGo is required to fit certain activities within one of the statutory exceptions and safe harbors available, and it is possible that some of DocGo’s current or future business activities could be subject to challenge under one or more of such laws. Achieving and sustaining compliance with these laws can be time-consuming, requires the commitment of significant resources and may prove costly. The risk of DocGo being found in violation of these laws and regulations is increased by the fact that many of these laws and regulations have not been fully interpreted by the regulatory authorities or the courts, and their provisions are sometimes open to a variety of interpretations. DocGo’s failure to accurately anticipate the application of these laws and regulations to its current or future business or any other failure or alleged failure to comply with legal or regulatory requirements could create liability for DocGo and negatively affect its business. Any action against DocGo for violation of these laws or regulations, even if DocGo successfully defends against it, could cause DocGo to incur significant legal expenses, divert management’s attention from the operation of the business and result in adverse publicity.

Enforcement officials have a number of mechanisms to combat regulatory compliance, fraud and abuse, and if DocGo fails to comply with applicable laws and regulations, it could be liable for civil or criminal penalties, including fines, damages, recoupment of overpayments, loss of licenses needed to operate, loss of enrollment status and approvals necessary to participate in Medicare, Medicaid and other government and private third-party healthcare and payor programs, and exclusion from participation in Medicare, Medicaid and other government healthcare programs. Investors, officers and managing employees associated with entities found to have committed healthcare fraud may also be excluded from participation in government healthcare programs. In addition, because of the potential for large monetary exposure, criminal liability and negative publicity, healthcare providers often resolve allegations without admissions of liability for significant and material amounts to avoid the uncertainty of damages that may be awarded in litigation proceedings. Such settlements often contain additional compliance and reporting requirements as part of a consent decree, settlement agreement or corporate integrity agreement.

DocGo believes that its business operations materially comply with applicable healthcare laws and regulations. However, some of the healthcare laws and regulations applicable to DocGo are subject to limited or evolving interpretations, and a review of DocGo's business or operations by a court, law enforcement or a regulatory authority might result in a determination of non-compliance. Any failure to comply with applicable legal and regulatory requirements and the consequences of such non-compliance, including those discussed above, could have a significant adverse effect on DocGo's business, financial condition and results of operations.

DocGo is required to comply with laws governing the transmission, security and privacy of health information and personally identifiable information.

Numerous state and federal laws and regulations govern the collection, dissemination, use, privacy, confidentiality, security, availability, integrity and other processing of **personal health information ("PHI")** PHI and **personal identifiable information ("PII")**, PII, including HIPAA. HIPAA establishes a set of national privacy and security standards for the protection of PHI by health plans, healthcare clearinghouses and certain healthcare providers, referred to as "covered entities," and the business associates with whom such covered entities contract for services. HIPAA requires covered entities such as DocGo and their business associates to develop and maintain policies and procedures with respect to PHI that is used or disclosed, including the adoption of administrative, physical and technical safeguards to protect this information. HIPAA also implemented the use of standard transaction code sets and standard identifiers that covered entities must use when submitting or receiving certain electronic healthcare transactions, including activities associated with the billing and collection of healthcare claims.

HIPAA also authorizes state attorneys general to file suit on behalf of their residents. Courts may award damages, costs and attorneys' fees related to violations of HIPAA in these cases. While HIPAA does not create a private right of action allowing individuals to sue DocGo in civil court for violations of HIPAA, its standards have been used as the basis for duty of care in state civil suits such as those for negligence or recklessness in the misuse or breach of PHI. In addition, HIPAA mandates that the Secretary of **the U.S. Department of Health and Human Services ("HHS")** HHS conduct periodic compliance audits of covered entities and business associates for compliance with the HIPAA privacy and security requirements. HIPAA also tasks HHS with establishing a methodology whereby harmed individuals who were the victims of breaches of unsecured PHI may receive a percentage of the fine paid by the violator under the Civil Monetary Penalties Law.

HIPAA further requires that patients be notified of any unauthorized acquisition, access, use or disclosure of their unsecured PHI that compromises the privacy or security of such information, with certain exceptions related to unintentional or inadvertent use or disclosure by employees or authorized individuals. HIPAA specifies that such notifications must be made “without unreasonable delay and in no case later than 60 calendar days after discovery of the breach.” If a breach affects 500 patients or more, it must be reported to HHS without unreasonable delay, and HHS will post the name of the breaching entity on its public web site. Breaches affecting 500 patients or more in the same state or jurisdiction must also be reported to a prominent media outlet serving the state or jurisdiction in which the breach occurred. If a breach involves fewer than 500 people, the covered entity must record it in a log and notify HHS within 60 days after the end of the calendar year during which the breach was discovered.

In addition to HIPAA, numerous other federal and state laws and regulations protect the confidentiality, privacy, availability, integrity and security of PHI and other types of PII. State statutes and regulations vary from state to state, and these laws and regulations in many cases are more restrictive than, and may not be preempted by, HIPAA. These laws and regulations are often uncertain, contradictory and subject to change or differing interpretations, and DocGo expects new laws, rules and regulations regarding privacy, data protection and information security to be proposed and enacted in the future. By way of example, the California Consumer Privacy Act (CCPA) (“CCPA”), which went into effect on January 1, 2020 and was amended by the California Privacy Rights Act (CPRA) (“CPRA”), a ballot measure approved by California voters in November 2020 that went into effect January 1, 2023, has had a profound impact on the privacy and data security landscape. As the first comprehensive consumer privacy legislation in the U.S., the CCPA created new consumer rights where applicable (some information may be exempt from most of CCPA’s/CPRA’s requirements if subject to HIPAA, for example), which were further expanded by the CPRA. Other A number of other states including Colorado, Connecticut and Utah, have followed suit, with some of those laws already in effect and others may in the future, coming into effect between 2024 and 2026, creating a patchwork of overlapping but different state laws and thus complicating compliance efforts.

As existing data security laws evolve and new ones are implemented, DocGo may not be able to comply with such requirements in a timely manner, or such requirements may not be compatible with its current processes. Changing DocGo’s processes could be time-consuming and expensive, and failure to implement required changes within the applicable timeframe could subject DocGo to liability for non-compliance. Some states may afford private rights of action to individuals who believe their PII has been misused. This complex, dynamic legal landscape regarding privacy, data protection and information security creates significant compliance issues for DocGo and potentially restricts its ability to collect, use and disclose data and can expose it to additional expense, adverse publicity and liability.

There is ongoing concern from privacy advocates, regulators and others regarding data protection and privacy issues, and the number of jurisdictions with data protection and privacy laws has been increasing. In addition, the scope of protection afforded to data subjects by many of these data protection and privacy laws has been increasing. There are also ongoing public policy discussions regarding whether the standards for deidentified, anonymous or pseudonymized health information are sufficient, and whether the risk of re-identification is sufficiently small to adequately protect patient privacy. These trends may lead to further restrictions on the use of this and similar categories of information. These initiatives or future initiatives could compromise DocGo’s ability to access and use data or to develop or market current or future services.

While DocGo has implemented data privacy and security measures in an effort to comply with applicable laws and regulations relating to privacy and data protection, some PHI and other PII or confidential information is transmitted to or from DocGo by third parties, who may not implement adequate security and privacy measures, and it is possible that laws, rules and regulations relating to privacy, data protection or information security may be interpreted and applied in a manner that is inconsistent with DocGo’s practices or those of third parties who transmit PHI and other PII or confidential information to DocGo. Additionally, as a business associate under HIPAA, DocGo may also be liable for privacy and security breaches of PHI and certain similar failures of DocGo’s subcontractors. Even though DocGo contractually requires its subcontractors to safeguard protected health information PHI as required by law, DocGo has limited control over their actions and practices. If DocGo or these third parties are found to have violated such laws, rules or regulations, it could result in government-imposed fines, orders requiring that DocGo or these third parties change its or their practices, or criminal charges, which could adversely affect DocGo’s business. Complying with these various laws and regulations could cause DocGo to incur substantial costs or require it to change its business practices, systems and compliance procedures in a manner adverse to its business.

DocGo publishes statements to its patients and partners that describe how it handles and protects PHI. If federal or state regulatory authorities or private litigants consider any portion of these statements to be untrue, DocGo may be subject to claims of deceptive practices, which could lead to significant liabilities and consequences, including, without limitation, costs of responding to investigations, defending against litigation, settling claims and complying with regulatory or court orders.

DocGo also sends short message service, or SMS, text messages to potential end users who are eligible to use its service through certain customers and partners. While DocGo obtains consent from or on behalf of these individuals to send text messages, federal or state regulatory authorities or private litigants may claim that the notices and disclosures DocGo provides, form of consents it obtains or its SMS texting practices, are not adequate. These SMS texting campaigns are potential sources of risk for class action lawsuits and liability for DocGo. An increased number of class action suits under federal and state laws have been filed in the past year against companies who conduct SMS texting programs, which have resulted in or may result in multimillion-dollar settlements to the plaintiffs. Any future such litigation against DocGo could be costly and time-consuming to defend.

Any failure to comply with HIPAA or similar laws and regulations and the consequences of such non-compliance could have a material adverse impact on DocGo’s business, financial condition and results of operations.

If DocGo does not effectively adapt to changes in the healthcare industry, including changes to laws and regulations regarding telehealth, DocGo's business may be harmed.

The unpredictability of the healthcare regulatory landscape means that sudden changes in laws, rules, regulations and policy are possible. Federal, state and local legislative bodies frequently pass legislation and promulgate regulations that affect the healthcare industry. As has been the trend in the past decade with healthcare reform, it is reasonable to assume that there will continue to be increased government oversight and regulation of the healthcare industry in the future, particularly in times of changing political, regulatory and other influences. DocGo cannot provide any assurances regarding the ultimate content, timing or effect of any new healthcare legislation or regulations, nor is it possible at this time to estimate the impact of potential new legislation or regulations on its business. It is possible that future legislation enacted by Congress or state legislatures, or regulations promulgated by regulatory authorities at the federal or state level, could adversely affect DocGo's current or future business. The extent to which a jurisdiction considers particular actions or relationships to comply with the applicable legal requirements is also subject to evolving interpretations by medical boards and state attorneys general, among others, each with broad discretion. It is possible that the changes to the Medicare, Medicaid or other governmental healthcare program reimbursements may serve as precedent to possible changes in other payors' reimbursement policies in a manner adverse to DocGo. Similarly, changes in private payor reimbursements could lead to adverse changes in Medicare, Medicaid and other governmental healthcare programs.

As one example, the telehealth industry is still relatively young, and DocGo's ability to provide its telehealth solutions is directly dependent upon the development and interpretation of the laws governing remote healthcare, the practice of medicine and healthcare delivery in the applicable jurisdictions and more broadly. A few states have imposed different, and, in some cases, additional, standards regarding the provision of services via telehealth. State medical boards have also established new rules or interpreted existing rules in their respective states in a manner that has limited the way telehealth services can be provided. Although the Covid-19 pandemic has led to the relaxation of certain Medicare, Medicaid and state licensure restrictions on the delivery of telehealth services and many of these relaxed policies were either made permanent or extended through December 31, 2024 (the "Extension"), it is uncertain how long some of the relaxed policies will remain in effect, particularly with the Public Health Emergency ("PHE") expected to end on May 11, 2023, effect. There can be no guarantee that upon expiration of the PHE Extension such restrictions will not be reinstated or changed in a way that adversely affects DocGo's current or future telehealth offerings.

Accordingly, DocGo must monitor its compliance with law in every jurisdiction in which it operates, on a regular basis. While DocGo believes that it has structured its contracts and operations in material compliance with applicable healthcare laws and regulations, the healthcare laws and regulations applicable to DocGo may be amended or interpreted in new or different ways that are adverse to DocGo, and new laws and regulations adverse to DocGo's current or future business may be adopted in the future. There can be no assurance that DocGo will be able to successfully address changes in the current regulatory environment or new laws and regulations that may be implemented in the future, or that practices which are compliant now will continue to be so in the future. Any failure to comply with any changes to or new developments in the healthcare regulatory environment could have a material adverse effect on DocGo's business, financial condition and results of operations.

DocGo must be properly enrolled in governmental healthcare programs before it can receive reimbursement for services, and there may be delays in the enrollment process.

Each time DocGo expands into a new market, whether organically or by way of acquisition, DocGo must enroll the new operations under DocGo's applicable group identification number for Medicare and Medicaid programs and for certain managed care and private insurance programs before DocGo is eligible to receive reimbursement for services rendered to beneficiaries of those programs. The estimated time to receive approval for the enrollment is sometimes difficult to predict.

With respect to Medicare, providers can retrospectively bill Medicare for services provided 30 days prior to the effective date of the enrollment. In addition, the enrollment rules provide that the effective date of the enrollment will be the later of the date on which the enrollment application was filed and approved by the Medicare contractor, or the date on which the provider began providing services. If DocGo is unable to complete the enrollment process within the 30 days after the commencement of services, DocGo will be precluded from billing Medicare for any services which were provided to a Medicare beneficiary more than 30 days prior to the effective date of the enrollment. With respect to Medicaid, new enrollment rules and whether a state will allow providers to retrospectively bill Medicaid for services provided prior to submitting an enrollment application varies by state. Failure to timely enroll could reduce DocGo's total revenues and have a material adverse effect on the business, financial condition or results of operations.

The Affordable Care Act, as currently structured, added additional enrollment requirements for Medicare and Medicaid, which have been further enhanced through implementing regulations and increased enforcement scrutiny. Every enrolled provider must revalidate its enrollment at regular intervals and must update the Medicare contractors and many state Medicaid programs with significant changes on a timely basis. If DocGo fails to provide sufficient documentation as required to maintain its enrollment, Medicare and Medicaid could deny continued future enrollment or revoke DocGo's enrollment and billing privileges.

The requirements for enrollment, licensure, certification and accreditation may include notification or approval in the event of a transfer or change of ownership or certain other changes. Other agencies or payors with which DocGo has contracts may have similar requirements, and some of these processes may be complex. Failure to provide required notifications or obtain necessary approvals may result in the delay or inability to complete an acquisition or transfer, loss of licensure, lapses in reimbursement or other penalties. While DocGo makes reasonable efforts to substantially comply with these requirements, it cannot assure you that the agencies that administer these programs or have awarded DocGo contracts will not find that DocGo has failed to comply in some material respects. A finding of non-compliance and any resulting payment delays, refund demands or other sanctions could have a material adverse effect on DocGo's business, financial condition or results of operations.

Reductions in Medicare reimbursement rates or changes in the rules governing the Medicare program could have a material adverse effect on DocGo.

DocGo generates a significant amount of revenues from Medicare, either directly or through Medicare Advantage (“MA”) MA plans, particularly in its healthcare transportation segment. Medicare revenues represent approximately 6.6% 7.7%, 7.6% and 7.6% 6.6% of DocGo’s revenues for the years ended December 31, 2021 December 31, 2023, 2022 and 2022, 2021, respectively. In addition, many private payors base their reimbursement rates on the published Medicare rates or are themselves reimbursed by Medicare for the services DocGo provides. As a result, DocGo’s results of operations are, in part, dependent on government funding levels for Medicare programs and any changes that limit or reduce MA or general Medicare reimbursement levels, such as reductions in or limitations of reimbursement amounts or rates under programs, reductions in funding of programs, expansion of benefits without adequate funding or elimination of coverage for certain benefits or for certain individuals, could have a material adverse effect on DocGo’s business, financial condition and results of operations.

The Medicare program and its reimbursement rates and rules are subject to frequent change. These include statutory and regulatory changes, rate adjustments (including retroactive adjustments), administrative or executive orders and government funding restrictions, all of which may materially adversely affect the rates at which Medicare reimburses DocGo for its services. Budget pressures often cause the federal government to reduce or place limits on reimbursement rates under Medicare. Implementation of these and other types of measures could result in substantial reductions in DocGo’s revenues and operating margins. For example, due to the federal sequestration, an automatic 2% reduction in Medicare spending took effect beginning in April 2013. Although temporarily paused/reduced from May 1, 2020 through June 30, 2022 due to The Cares Act, which was signed into law on March 27, 2020, and designed to provide financial support and resources to individuals and business affected by the COVID-19 pandemic, the 2% reduction was reimposed as of July 1, 2022, and is still currently in effect as of the date of this filing.

Each year, the Centers for Medicare and Medicaid Services (“CMS”) CMS issues a final rule to establish the MA benchmark payment rates for the following calendar year. Reductions to MA rates impacting DocGo may be greater than the industry average rate and the final impact of the MA rates can vary from any estimate DocGo may have. In addition, CMS may change the rules governing the Medicare program, including those governing reimbursement. Reductions in reimbursement rates or the scope of services being reimbursed could have a material adverse effect on DocGo’s business, financial condition and results of operations.

State and federal efforts to reduce Medicaid spending could adversely affect DocGo.

Certain of DocGo’s customers who are individuals are dual-eligible, meaning their coverage comes from both Medicare and Medicaid. As a result, a small portion of DocGo’s revenue comes from Medicaid, accounting for approximately 1.1% 1.4%, 1.8% and 1.8% 1.1% of revenue for the years ended December 31, 2021 December 31, 2023, 2022 and 2022, 2021, respectively. Medicaid is a joint federal-state program purchasing healthcare services for the low income and indigent as well as certain higher income individuals with significant health needs. Under broad federal criteria, states establish rules for eligibility, services and payment. Medicaid is a state-administered program financed by both state funds and matching federal funds. Medicaid spending has increased rapidly in recent years, becoming a significant component of state budgets. This, combined with slower state revenue growth, has led both the federal government and many states to institute measures aimed at controlling the growth of Medicaid spending, and in some instances reducing aggregate Medicaid spending.

For example, a number of states have adopted or are considering legislation designed to reduce their Medicaid expenditures, such as financial arrangements commonly referred to as provider taxes. Under provider tax arrangements, states collect taxes from healthcare providers and then use the revenue to pay the providers as a Medicaid expenditure, which allows the states to then claim additional federal matching funds on the additional reimbursements. Current federal law provides for a cap on the maximum allowable provider tax as a percentage of the provider’s total revenue. There can be no assurance that federal law will continue to provide matching federal funds on state Medicaid expenditures funded through provider taxes, or that the current caps on provider taxes will not be reduced. Any discontinuance or reduction in federal matching of provider tax-related Medicaid expenditures could have a significant and adverse effect on states’ Medicaid expenditures, and as a result could have an adverse effect on DocGo’s business, financial condition and results of operations.

Also, as part of the movement to repeal, replace or modify the Affordable Care Act and the Health Care Reform Law and Education Reconciliation Act of 2010, and as a means to reduce the federal budget deficit, there are renewed congressional efforts to move Medicaid from an open-ended program with coverage and benefits set by the federal government to one in which states receive a fixed amount of federal funds, either through block grants or per capita caps, and have more flexibility to determine benefits, eligibility or provider payments. If those changes are implemented, DocGo cannot predict whether the amount of fixed federal funding to the states will be based on current payment amounts, or if it will be based on lower payment amounts, which would negatively impact those states that expanded their Medicaid programs in response to the Health Affordable Care Reform Law Act.

DocGo expects these state and federal efforts to continue for the foreseeable future. The Medicaid program and its reimbursement rates and rules are subject to frequent change at both the federal and state level. These include statutory and regulatory changes, rate adjustments (including retroactive adjustments), administrative or executive orders and government funding restrictions, all of which may materially adversely affect the rates at which DocGo’s services are reimbursed by state Medicaid plans.

DocGo could become has been the subject of federal, state and state municipal investigations, audits and compliance reviews. reviews and may be subject to additional investigations, audits and reviews in the future.

Companies in the broader healthcare industry are subject to a high level of scrutiny by various governmental agencies and their agents. Both federal and state government agencies have heightened and coordinated civil and criminal enforcement efforts as part of numerous ongoing investigations of healthcare companies, as well as their executives and managers. These investigations relate to a wide variety of topics, including referral and billing practices. For example, to enforce compliance with the federal laws, the U.S. Department of Justice and the Office of Inspector General OIG have established national enforcement initiatives that focus on specific billing practices or other suspected areas of abuse. Given the significant size of actual and potential settlements, it is expected that the government will continue to devote substantial resources to investigating healthcare providers' compliance, including compliance with the healthcare reimbursement rules and fraud and abuse laws. DocGo is also required to conduct periodic internal audits in connection with its third-party relationships and, in the ordinary course of business receives repayment demands from third-party payors based on allegations that its services were not medically necessary, were billed at an improper level or otherwise violated applicable billing requirements that require investigation. Further, DocGo periodically conducts internal reviews of its regulatory compliance. **To date no investigation or audit**

DocGo has been the subject of DocGo, its executives or its managers has occurred, whether investigations, audits and reviews and may in the future be subject to additional investigations, audits and reviews by the government and its agents, a third-party or DocGo itself. However, should such an investigation or audit occur, it Such investigations, audits and reviews could result in significant expense to DocGo in addition to adverse publicity and diversion of the management's attention from DocGo's business regardless of the outcome. Any adverse findings against DocGo could result in significant fines, penalties and other sanctions, any of which could have a material adverse effect on DocGo's business, financial condition and results of operations.

DocGo's business practices may be found to constitute illegal fee-splitting or corporate practice of medicine, which may lead to penalties and could adversely affect DocGo's business.

Many states have laws that prohibit business corporations such as DocGo from practicing medicine, employing physicians, exercising control over medical judgments or decisions of physicians or other health care healthcare professionals (such as EMTs and nurses), or engaging in certain business arrangements such as fee-splitting, with each of the foregoing activities collectively referred to as the "corporate practice of medicine." In some states these prohibitions are expressly stated in a statute or regulation, while in other states the prohibition is a matter of judicial or regulatory interpretation. Many of the states in which DocGo currently operates generally prohibit the corporate practice of medicine, and other states may as well, including those into which DocGo may expand in the future.

The state laws and regulations and administrative and judicial decisions that enumerate the specific corporate practice of medicine rules vary considerably from state to state and have been subject to limited judicial or regulatory interpretations. These laws and regulations are enforced by both the courts and government agencies, each with broad discretion. Courts, government agencies or other parties, including physicians, may assert that DocGo is engaged in the unlawful corporate practice of medicine. While penalties for violations of the corporate practice of medicine vary from state to state, as a result of such allegations, DocGo could be subject to civil and criminal penalties, its contracts could be found legally invalid and unenforceable, in whole or in part, or DocGo could be required to restructure its contractual arrangements entirely. If found to be engaged in the corporate practice of medicine, DocGo may not be able to restructure its operations or its contractual arrangements on favorable terms or at all. Any failure to comply with these laws and regulations regarding the corporate practice of medicine and the consequences of such non-compliance could have a material adverse impact on DocGo's business, financial condition and results of operations.

DocGo believes its business is structured to comply with the applicable regulations governing fee-splitting and the corporate practice of medicine in the states where it generates revenue; however, in many cases and as noted above, these laws and regulations applicable to DocGo are subject to limited or evolving interpretations, and there can be no assurances that a review of DocGo's business or operations by a court, law enforcement or a regulatory authority might result in a determination of non-compliance.

Risks Related to DocGo's Indebtedness

DocGo's future indebtedness could require that it dedicate a portion of its cash flows to debt service obligations and reduce the funds that would otherwise be available for other general corporate purposes and other business opportunities, which could adversely affect DocGo's operating performance, growth, profitability and financial condition, which in turn could make it more difficult for it to generate cash flow sufficient to satisfy all of its obligations under its future indebtedness.

As of December 31, 2022, December 31, 2023, DocGo did not have any amounts had \$25 million outstanding under a credit agreement, (the "Credit Agreement"), dated as of November 1, 2022, among DocGo, the lender parties thereto, and Citibank, N.A., as administrative agent (the "Agent"), and the other parties thereto (the "Credit Agreement"). The Credit Agreement provides for a revolving credit facility in the initial aggregate principal amount of \$90 million (the "Revolving Facility"). The borrowings under the Revolving Facility were used for general corporate purposes, including the funding of working capital needs. DocGo repaid all amounts outstanding under the Revolving Facility in February 2024, and no amounts are outstanding under the Revolving Facility as of the date of this Annual Report. Borrowings under the Revolving Facility bear interest at a per annum rate equal to: (i) at DocGo's option, the (x) the base rate or (y) the adjusted term SOFR rate, plus (ii) the applicable margin. DocGo is also required to pay a commitment fee to the lenders under the Revolving Facility in respect of any unutilized commitments thereunder. DocGo's future indebtedness, including Any future borrowings under the Credit Agreement or similar future arrangements could require that it DocGo dedicate a portion of its cash flows to debt service payments.

DocGo's As a result, any such future indebtedness could reduce the funds that would otherwise be available for operations and future business opportunities, and payments of its future such debt obligations and could limit its DocGo's ability to:

- obtain additional financing, if necessary, for working capital and operations, or such financing may not be available on favorable terms;
- obtain additional financing, if necessary, for working capital and operations, or such financing may not be available on favorable terms;
- pay dividends and make other distributions on, or redeem or repurchase, capital stock;
- make needed capital expenditures;
- make needed capital expenditures;
- make strategic acquisitions or investments or enter into joint ventures;
- make strategic acquisitions or investments or enter into joint ventures;
- react to changes or withstand a future downturn in its business, the industry or the economy in general;
- react to changes or withstand a future downturn in its business, the industry or the economy in general;
- meet expected demand growth, budget targets and forecasts of future results;
- meet expected demand growth, budget targets and forecasts of future results;
- engage in business activities, including future opportunities that may be in its interest; and
- engage in business activities, including future opportunities that may be in its interest; and
- react to competitive pressures or compete with competitors with less debt.
- react to competitive pressures or compete with competitors with less debt.

These limitations could adversely affect its DocGo's operating performance, growth, profitability and financial condition, which would make it more difficult for it to generate cash flow sufficient to satisfy its obligations under its future indebtedness.

DocGo's future ability to make scheduled payments on its future debt obligations also depends on its then-current financial condition, results of operations and capital resources, which are subject to, among other things: the business, financial, economic, industry, competitive, regulatory and other factors discussed in these risk factors, and on other factors, some of which are beyond its control, including: the level of capital expenditures it makes, including those for acquisitions, if any; its debt service requirements; fluctuations in its working capital needs; its ability to borrow funds and access capital markets; and restrictions on debt service payments and its ability to make working capital borrowings for future debt service payments contained in the Credit Agreement.

If DocGo is unable to generate sufficient cash flow to permit it to meet its future debt obligations under the Credit Agreement or any future arrangements, then it would be in default and, in the case of the Credit Agreement, the Agent could accelerate repayment of all amounts outstanding under the Credit Agreement. If its future indebtedness were to be accelerated, there can be no assurance that DocGo would have, or be able to obtain, sufficient funds to repay such future indebtedness in full. In addition, under the Credit Agreement, in the event of a default, the Agent could seek foreclosure of the Agent's lien on the assets of DocGo and its subsidiary guarantors and exercise other customary secured creditor rights.

DocGo might incur future debt, which could further increase the risks to its financial condition described above.

DocGo may incur significant additional indebtedness in the future, including off-balance sheet financings, trade credit, contractual obligations and general and commercial liabilities. Although the Credit Agreement contains certain restrictions on the incurrence of additional indebtedness, these restrictions are subject to a number of qualifications and exceptions, and the additional indebtedness incurred in compliance with these restrictions could be substantial. These restrictions also would not prevent DocGo from incurring obligations that do not constitute indebtedness, and additionally it has its borrowing capacity under the Revolving Facility, which as of December 31, 2022 December 31, 2023, did not have any borrowings had \$25 million outstanding and had an available borrowing capacity of approximately \$90 million \$65 million (which is subject to customary borrowing conditions). In February 2024, DocGo repaid all amounts outstanding under the Revolving Facility, and no amounts are outstanding under the Revolving Facility as of the date of this Annual Report. DocGo may be able to increase the commitments under the Revolving Facility by an additional aggregate principal amount of up to \$50 million. DocGo's future debt levels could further exacerbate the related risks to DocGo's financial condition that it now faces.

If DocGo is unable to generate sufficient cash to service its future indebtedness, it may be forced to take other actions to fund the satisfaction of its obligations under its future indebtedness, which may not be successful.

If DocGo's cash flow is insufficient to fund its future debt service obligations, it could face substantial liquidity problems and could be forced to reduce or delay investments and capital expenditures or to dispose of material assets or operations, raise additional debt or equity capital or restructure or refinance its future indebtedness. DocGo may not be able to implement any such alternative measures on commercially reasonable terms or at all and, even if successful, those alternative actions may not allow DocGo to meet its future debt service obligations. Even if new financing were available, it may be on terms that are less attractive to DocGo than its then-existing indebtedness or it may not be on terms that are acceptable to DocGo. In addition, the Credit Agreement restricts DocGo's ability to dispose of assets and use the proceeds from those dispositions. Thus, DocGo may not be able to consummate those dispositions or to obtain proceeds in an amount sufficient to meet any debt service obligations then due.

If DocGo cannot generate sufficient cash flow to permit it to meet future payment requirements on its debt, then, under the Credit Agreement, it would be in default and the Agent could accelerate repayment of all amounts outstanding under the Credit Agreement. If DocGo's future indebtedness were to be accelerated, there can be no assurance that it would have, or be able to obtain, sufficient funds to repay such future indebtedness in full. In addition, in the case of the Credit Agreement, in the event of a default, the Agent could seek foreclosure of the Agent's lien on the assets of DocGo and its subsidiary guarantors and exercise other customary secured creditor rights, and DocGo could be forced into bankruptcy or liquidation.

The terms of DocGo's the Credit Agreement and potential future debt arrangements could restrict its current and future operations, particularly its ability to respond to changes or to take certain actions.

The Credit Agreement imposes significant operating and financial restrictions on DocGo and may limit its ability to engage in acts that may be in its best interest, including restrictions on DocGo's ability to:

- incur or guarantee additional indebtedness;
 - pay dividends and make other distributions on, or redeem or repurchase, capital stock;
 - make certain investments;
 - incur certain liens;
 - enter into transactions with affiliates;
 - merge or consolidate; and
 - transfer or sell assets.
-
- incur or guarantee additional indebtedness;
 - pay dividends and make other distributions on, or redeem or repurchase, capital stock;
 - make certain investments;
 - incur certain liens;
 - enter into transactions with affiliates;
 - merge or consolidate; and
 - transfer or sell assets.

Additionally, the Credit Agreement also requires DocGo to maintain a certain interest coverage ratio and a net leverage ratio. DocGo's ability to comply with the covenants and restrictions contained in the Credit Agreement may be affected by events beyond its control. If market or other macroeconomic conditions deteriorate, its ability to comply with these covenants and restrictions may be impaired.

A breach of the covenants could result in an event of default under the Credit Agreement, which, if not cured or waived, could have a material adverse effect on DocGo's business, results of operations and financial condition, including the acceleration of payments as described above. If DocGo's then-existing indebtedness were to be accelerated, there can be no assurance that it would have, or be able to obtain, sufficient funds to repay such indebtedness in full. In addition, in the event of a default, the Agent could seek foreclosure of the Agent's lien on the assets of DocGo and its subsidiary guarantors and exercise other customary secured creditor rights, and DocGo could be forced into bankruptcy or liquidation. Any future debt arrangements that DocGo may enter into could also impose similar restrictions.

DocGo's variable rate indebtedness could subject it to interest rate risk, which could cause its debt service obligations to increase significantly.

Borrowings under the Revolving Facility are at variable rates of interest and DocGo's future borrowings under the Revolving Facility could expose DocGo to interest rate risk. If interest rates increase, DocGo's debt service obligations on its future variable rate indebtedness could increase even though the amount borrowed will remain the same, and DocGo's net income and operating cash flows, including cash available for servicing its indebtedness, would correspondingly decrease.

If the financial institutions that are lenders under the Revolving Facility fail to extend credit under the facility, DocGo's liquidity and results of operations may be adversely affected.

Each financial institution that is a lender under the Revolving Facility is responsible on a several but not joint basis for providing a portion of the loans to be made under the facility. If any participant or group of participants with a significant portion of the commitments under the Revolving Facility fails to satisfy its or their respective obligations to extend credit under the facility and DocGo is unable to find a replacement for such participant or participants on a timely basis (if at all), DocGo's liquidity may be adversely affected. In addition, the lenders under the Revolving Facility may terminate or reduce the Revolving Facility in certain circumstances, which could adversely impact DocGo's liquidity and results of operations.

Risks **Relating** **Related** to Ownership of Common Stock

Nasdaq may delist DocGo's securities from trading on its exchange, which could limit investors' ability to make transactions in its securities and subject DocGo to additional trading restrictions.

DocGo's **The** Common Stock is listed on Nasdaq under the symbol "DCGO." DocGo is required to meet continued listing requirements for its securities to continue to be listed on Nasdaq, including having a minimum number of public securities holders and a minimum stock price. DocGo cannot assure you that it will continue to meet those listing requirements in the future.

If Nasdaq delists DocGo's securities from trading on its exchange and DocGo is not able to list its securities on another national securities exchange, DocGo expects its securities could be quoted on an over-the-counter market. If this were to occur, it could face significant material adverse consequences, including:

- a limited availability of market quotations for its securities;
 - reduced liquidity for its securities;
 - a determination that the Common Stock is a "penny stock" which will require brokers trading in Common Stock to adhere to more stringent rules and possibly result in a reduced level of trading activity in the secondary trading market for its securities;
 - a limited amount of news and analyst coverage; and
 - a decreased ability to issue additional securities or obtain additional financing in the future.
-
- a limited availability of market quotations for its securities;
 - reduced liquidity for its securities;
 - a determination that the Common Stock is a "penny stock" which will require brokers trading in Common Stock to adhere to more stringent rules and possibly result in a reduced level of trading activity in the secondary trading market for its securities;
 - a limited amount of news and analyst coverage; and
 - a decreased ability to issue additional securities or obtain additional financing in the future.

Because there are no current plans to pay cash dividends on Common Stock for the foreseeable future, you may not receive any return on investment unless you sell your Common Stock for a price greater than that which you paid for it.

DocGo intends to retain future earnings, if any, for future operations, expansion and debt repayment and there are no current plans to pay any cash dividends for the foreseeable future. The declaration, amount and payment of any future dividends on shares of Common Stock will be at the sole discretion of the Board. The Board may take into account general and economic conditions, DocGo's financial condition and results of operations, DocGo's available cash and current and anticipated cash needs, capital requirements, contractual, legal, tax, and regulatory restrictions, implications on the payment of dividends by DocGo to its stockholders or by its subsidiaries to it and such other factors as the Board may deem relevant. In addition, DocGo's ability to pay dividends is limited by covenants of DocGo's existing and outstanding indebtedness and may be limited by covenants of any future indebtedness DocGo incurs. As a result, you may not receive any return on an investment in Common Stock unless you sell Common Stock for a price greater than that which you paid for it.

If securities analysts do not publish research or reports about DocGo's business or if they downgrade the Common Stock or DocGo's sector, DocGo's stock price and trading volume could decline.

The trading market for Common Stock relies in part on the research and reports that industry or financial analysts publish about DocGo or its business. DocGo does not control these analysts. In addition, some financial analysts may have limited expertise with DocGo's model and operations. Furthermore, if one or more of the analysts who do cover DocGo downgrade its stock or industry, or the stock of any of its competitors, or publish inaccurate or unfavorable research about its business, the price of Common Stock could decline. If Furthermore, if one or more of these analysts cease coverage of DocGo or fail to publish reports on it regularly, DocGo could lose visibility in the market, which in turn could cause its stock price or trading volume to decline.

Future sales, or the perception of future sales, by DocGo or its stockholders in the public market could cause the market price for Common Stock to decline.

The sale of shares of Common Stock in the public market, or the perception that such sales could occur, by senior executives, directors and significant stockholders could harm the prevailing market price of shares of Common Stock. These sales, or the possibility that these sales may occur, also might make it more difficult for DocGo to sell equity securities in the future at a time and at a price that it deems appropriate.

In addition, the shares of Common Stock reserved for future issuance under DocGo's equity incentive plans will become eligible for sale in the public market once those shares are issued, subject to provisions relating to various vesting agreements and, in some cases, limitations on volume and manner of sale applicable to affiliates under Rule 144 under the Securities Act, as applicable. The number of shares of Common Stock reserved for future issuance under its equity incentive plans including Substitute Options, represents approximately 11.5% 10.13% of outstanding Common Stock as of December 31, 2022 December 31, 2023. The compensation committee of the Board may determine the exact number of shares to be reserved for future issuance under its equity incentive plans at its discretion. DocGo has filed a Form S-8 under the Securities Act to register shares of Common Stock and securities convertible into or exchangeable for shares of Common Stock issued pursuant to DocGo's equity incentive plan and may file additional registration statements on Form S-8 in the future. Any such Form S-8 registration statements will automatically become effective upon filing. Accordingly, shares registered under such registration statements will be available for sale in the open market.

In the future, DocGo may also issue its securities in connection with investments or acquisitions. The amount number of shares of Common Stock issued in connection with an investment or acquisition could constitute a material portion of DocGo's then-outstanding shares of Common Stock. Any issuance of additional securities in connection with investments or acquisitions may result in additional dilution to DocGo's stockholders.

DocGo's share repurchase program may subject it to certain risks.
risks, and DocGo cannot provide any guarantees that it will repurchase Common Stock pursuant to its share repurchase program.

DocGo has adopted a share repurchase program to repurchase shares of its Common Stock; however, any future decisions to reduce or discontinue repurchasing its common stock pursuant to its share repurchase program could cause the market price for its Common Stock to decline.

Stock. Although the Board has authorized the share repurchase program, the timing, manner, price and amount of any determination to execute its share repurchase program Common Stock repurchases will be subject to, among other things, determined by the Company in its financial position discretion and results will depend on a variety of operations, available cash factors, including legal requirements, price and cash flow, capital requirements economic and other factors, as well as its board of director's continuing determination that the repurchase program is in the best interests of its stockholders and is in compliance with all laws and agreements applicable to the repurchase program. market conditions. DocGo's share repurchase program does not obligate it to acquire any common stock. Common Stock., and DocGo may discontinue the program at any time. If it DocGo fails to meet any expectations related to share repurchases, the market price of its Common Stock could decline, and it could have a material adverse impact on investor confidence. confidence and the market price of the Common Stock could decline. Additionally, price volatility of its the Common Stock over a given period may cause the average price at which DocGo repurchases its Common Stock to exceed the stock's market price at a given point in time.

DocGo may further increase or decrease the amount of repurchases of its Common Stock in the future. Any reduction or discontinuance by DocGo of repurchases of its Common Stock pursuant to its current share repurchase program could cause the market price of its Common Stock to decline. Moreover, in the event DocGo's repurchases of DocGo's common stock its Common Stock are reduced or discontinued, its failure or inability to resume repurchasing Common Stock at historical levels could result in a lower market valuation of its Common Stock.

Anti-takeover provisions in DocGo's organizational documents could delay or prevent a change of control.

Certain provisions of the Certificate DocGo's certificate of Incorporation incorporation (as the same may be amended and/or restated from time to time) and the Bylaws bylaws (as the same may be amended and/or restated from time to time) may have an anti-takeover effect and may delay, defer or prevent a merger, acquisition, tender offer, takeover attempt or other change of control transaction that a stockholder might consider in its best interest, including those attempts that might result in a premium over the market price for the shares held by DocGo's stockholders.

These provisions provide for, among other things:

- a classified board of directors;
- the ability of the Board to issue one or more series of preferred stock;
- A classified board of directors;
- advance notice for nominations of directors by stockholders and for stockholders to include matters to be considered at DocGo's annual meetings;
- certain limitations on convening special stockholder meetings;
- the ability of the Board to issue one or more series of preferred stock;
- limiting the ability of stockholders to act by written consent;
- supermajority provisions to amend the bylaws and certain sections of the certificate of incorporation; and
- advance notice for nominations of directors by stockholders and for stockholders to include matters to be considered at DocGo's annual meetings;
- providing the Board with express authority to make, alter or repeal the bylaws.
- certain limitations on convening special stockholder meetings;
- limiting the ability of stockholders to act by written consent;
- supermajority provisions to amend the bylaws and certain sections of the certificate of incorporation; and
- the Board with express authority to make, alter or repeal the Bylaws.

These anti-takeover provisions could make it more difficult for a third party to acquire DocGo, even if the third party's offer may be considered beneficial by many of DocGo's stockholders. As a result, DocGo's stockholders may be limited in their ability to obtain a premium for their shares. These provisions could also discourage proxy contests and make it more difficult for you and other stockholders to elect directors of your choosing and to cause DocGo to take other corporate actions you desire. See "Description of Securities."

The DocGo's certificate of incorporation designates, subject to limited exceptions, the Court of Chancery of the State of Delaware as the sole and exclusive forum for certain types of actions and proceedings that may be initiated by stockholders and the federal district courts as the sole and exclusive forum for

Securities Act claims, which could limit stockholders' ability to obtain a favorable judicial forum for disputes with DocGo or its directors, officers, employees or stockholders.

The DocGo's certificate of incorporation provides that, unless DocGo, in writing, selects or consents to the selection of an alternative forum: (a) the sole and exclusive forum for any complaint asserting any internal corporate claims, to the fullest extent permitted by law, and subject to applicable jurisdictional requirements, is the Court of Chancery of the State of Delaware (or, if the Court of Chancery does not have, or declines to accept, jurisdiction, another state court or a federal court located within the State of Delaware) and (b) the sole and exclusive forum for any complaint asserting a cause of action arising under the Securities Act, to the fullest extent permitted by law, shall be the federal district courts of the U.S.; provided however, these provisions of the certificate of incorporation will not apply to suits brought to enforce a duty or liability created by the Exchange Act (as explained below).

As a result, any (1) derivative action or proceeding brought on behalf of DocGo, (2) action asserting a claim of breach of a fiduciary duty owed by any director, officer, stockholder or employee to DocGo or its stockholders, (3) action asserting a claim arising pursuant to any provision of the DGCL, Delaware General Corporation Law or the DocGo's certificate of incorporation or the Bylaws, bylaws, or (4) action asserting a claim governed by the internal affairs doctrine shall, to the fullest extent permitted by law, be exclusively brought in the Court of Chancery of the State of Delaware (or, if the Court of Chancery does not have, or declines to accept, jurisdiction, another state court or a federal court located within the State of Delaware). Any person or entity purchasing or otherwise acquiring any interest in shares of DocGo's capital stock shall be deemed to have notice of and to have consented to the provisions of the certificate of incorporation described above. This choice of forum provision may limit a stockholder's ability to bring a claim in a judicial forum that it finds favorable for disputes with DocGo or its directors, officers or other employees, which may discourage such lawsuits against DocGo and its directors, officers and employees. Alternatively, if a court were to find these provisions of the DocGo's certificate of incorporation inapplicable to, or unenforceable in respect of, one or more of the specified types of actions or proceedings,

DocGo may incur additional costs associated with resolving such matters in other jurisdictions, which could adversely affect DocGo's business and financial condition.

The DocGo's certificate of incorporation provides that the exclusive forum provision is applicable to the fullest extent permitted by applicable law, subject to certain exceptions. Section 27 of the Exchange Act creates exclusive federal jurisdiction over all suits brought to enforce any duty or liability created by the Exchange Act or the rules and regulations thereunder. As a result, the exclusive forum provision does not apply to suits brought to enforce any duty or liability created by the Exchange Act or any other claim for which the federal courts have exclusive jurisdiction.

The market price and trading volume of Common Stock may be volatile.
volatile, and the value of Common Stock has declined and could continue to decline.

Stock markets, including Nasdaq, have from time-to-time experienced significant price and volume fluctuations. The market price of DocGo's the Common Stock has been and may continue to be volatile and has declined could continue to decline significantly, whether such price changes are related due to matters specific to DocGo or due to general market conditions. In addition, the trading volume in Common Stock may fluctuate and cause significant price variations to occur. If the market price of the Common Stock declines significantly, you may be unable to resell your shares of Common Stock at or above the market price of Common Stock. DocGo cannot assure you that the market price of Common Stock will not fluctuate widely or decline significantly in the future in response to a number of factors, including, among others, the following:

- the realization of any of the risk factors presented in this Annual Report;
- actual or anticipated differences in DocGo's estimates, or in the estimates of analysts, for DocGo's revenues, results of operations, level of indebtedness, liquidity or financial condition;
- the realization of any of the risk factors presented in this Annual Report;
 - additions and departures of key personnel;
 - failure to comply with the requirements of the Nasdaq;
 - failure to comply with the Sarbanes-Oxley Act or other laws or regulations;
 - future issuances, sales or resales, or anticipated issuances, sales or resales, of

Common
Stock;

- DocGo's inability to execute its share repurchase program as planned, including failure to meet internal or external expectations around the timing or price of share repurchases, and any reductions or discontinuances of repurchases thereunder;
- perceptions of the investment opportunity associated with Common Stock relative to other investment alternatives;
- the performance and market valuations of other similar companies;
- future announcements concerning DocGo's business or its competitors' businesses;
- broad disruptions in the financial markets, including sudden disruptions in the credit markets;
- speculation in the press or investment community;

- negative publicity regarding DocGo's business;
 - actual, potential or perceived control, accounting or reporting problems;
 - changes in accounting principles, policies and guidelines; and
 - general macroeconomic and geopolitical conditions, such as the effects of health crises; recessionary fears, rising interest rates and inflationary environment; local and national elections; fuel prices; international currency fluctuations; corruption political instability, including the conflicts in Ukraine and Israel and rising tensions in the Taiwan Strait; and acts of war or terrorism.
- actual or anticipated differences in DocGo's estimates, or in the estimates of analysts, for DocGo's revenues, results of operations, level of indebtedness, liquidity or financial condition;
 - additions and departures of key personnel;
 - failure to comply with the requirements of the Nasdaq;
 - failure to comply with the Sarbanes-Oxley Act or other laws or regulations;
 - future issuances, sales or resales, or anticipated issuances, sales or resales, of Common Stock;
 - DocGo's inability to execute its stock repurchase program as planned, including failure to meet internal or external expectations around the timing or price of stock repurchases, and any reductions or discontinuances of repurchases thereunder;

- perceptions of the investment opportunity associated with Common Stock relative to other investment alternatives;
- the performance and market valuations of other similar companies;
- future announcements concerning DocGo's business or its competitors' businesses;
- broad disruptions in the financial markets, including sudden disruptions in the credit markets;
- speculation in the press or investment community;
- actual, potential or perceived control, accounting or reporting problems;
- changes in accounting principles, policies and guidelines; and
- general macroeconomic and geopolitical conditions, such as the effects of the COVID-19 or other pandemic outbreaks, recessionary fears, rising interest rates, and inflationary environment local and national elections, fuel prices, international currency fluctuations, corruption, political instability, including the conflict in Ukraine and rising tensions in the Taiwan Strait and acts of war or terrorism.

In the past, securities class-action litigation has often been instituted against companies following periods of volatility in the market price of their securities. DocGo is subject to, and may in the future be subject to, such litigation. This type of litigation could result in substantial costs and divert DocGo's management's attention and resources, which could have a material adverse effect on DocGo.

Future issuances of debt securities and equity securities may adversely affect DocGo, including the market price of Common Stock and may be dilutive to existing stockholders.

There is no assurance that DocGo will not incur debt or issue equity ranking senior to Common Stock. Those securities will generally have priority upon liquidation. Such securities also may be governed by an indenture or other instrument containing covenants restricting its DocGo's operating flexibility. Additionally, any convertible or exchangeable securities that DocGo issues in the future may have rights, preferences and privileges more favorable than those of Common Stock. Separately, additional financing may not be available on favorable terms, or at all. Because DocGo's decision to issue debt or equity in the future will depend on market conditions and other factors, it cannot predict or estimate the amount, timing, nature or success of DocGo's future capital raising efforts. As a result, future capital raising efforts may reduce the market price of Common Stock and be dilutive to existing stockholders.

The JOBS Act permits "emerging growth companies" like DocGo to take advantage of certain exemptions from various reporting requirements applicable to other public companies that are not emerging growth companies.

DocGo qualifies as an "emerging growth company" as defined in Section 2(a)(19) of the Securities Act, as modified by the JOBS Act. As such, DocGo can take advantage of certain exemptions from various reporting requirements for as long as it continues to be an emerging growth company, including (i) the exemption from the auditor attestation requirements with respect to internal control over financial reporting under Section 404 of the Sarbanes-Oxley Act, (ii) the exemptions from say-on-pay, say-on-frequency and say-on-golden parachute voting requirements and (iii) reduced disclosure obligations regarding executive compensation in DocGo's periodic reports and proxy statements. As a result, DocGo's stockholders may not have access to certain information they deem important. DocGo will remain an emerging growth company until the earliest of (i) the last day of the fiscal year (a) following the fifth anniversary of its Initial Public Offering, (b) in which DocGo has a total annual gross revenue of at least \$1.07 billion or (c) in which DocGo is deemed to be a large accelerated filer, which means the market value of the Common Stock held by non-affiliates exceeds \$700 million as of the last business day of its second fiscal quarter, and (ii) the date on which DocGo has issued more than \$1.0 billion in non-convertible debt during the prior three-year period.

In addition, Section 107 of the JOBS Act also provides that an emerging growth company can take advantage of the exemption from complying with new or revised accounting standards provided in Section 7(a)(2)(B) of the Securities Act as long as it is an emerging growth company. An emerging growth company can therefore delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies, but any such election to opt out is irrevocable. DocGo has elected to avail itself of such extended transition period, which means that when a standard is issued or revised and it has different application dates for public or private companies, DocGo, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of DocGo's financial statements with another public company that is neither an emerging growth company nor an emerging growth company that has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used.

DocGo cannot predict if investors will find its Common Stock less attractive because it relies on these exemptions. If some investors find the Common Stock less attractive as a result, there may be a less active trading market for the Common Stock and more stock price volatility.

Item 1B. Unresolved Staff Comments.

None.

None.

Item 1C. Cybersecurity.

Risk Management and Strategy

In the ordinary course of our business, we collect, use, store and transmit digitally large amounts of confidential, sensitive, proprietary, personal and health-related information. The secure maintenance of this information and our information technology systems is important to our operations and business strategy, and we consider cybersecurity, along with other significant risks that we face, within our overall enterprise risk management framework. To this end, we have implemented processes designed to assess, identify and manage risks from potential unauthorized occurrences on or through our information technology systems that may result in adverse effects on the confidentiality, integrity and availability of these systems and the data residing therein.

These processes are managed and monitored by a dedicated information technology team, which is led by our Chief Technology Officer ("CTO"), and include mechanisms, controls, technologies, systems and other processes designed to prevent or mitigate data loss, theft, misuse or other security incidents or vulnerabilities affecting the data and maintain a stable information technology environment. For example, we conduct penetration and vulnerability testing, data recovery testing, security audits and ongoing risk assessments, including due diligence on and audits of our key technology vendors and other contractors and suppliers. We also conduct regular employee trainings on cyber and information security, among other topics. In addition, we consult with outside advisors and experts, when appropriate, to assist with assessing, identifying, and managing cybersecurity risks, including to anticipate future threats and trends and their impact on the Company's risk environment. We also rely on information technology and third party vendors to support our operations, including our secure processing of personal, confidential, sensitive, proprietary and other types of information.

With respect to incident response, we have adopted a Cybersecurity Incident Response Plan that applies in the event of a cybersecurity threat or incident (the "IRP") to provide a standardized framework for responding to security incidents. The IRP sets out a coordinated approach to investigating, containing, documenting and mitigating incidents, including reporting findings and keeping senior management and other key stakeholders informed and involved as appropriate. In general, our incident response process follows the National Institute of Standards and Technology framework and focuses on four phases:

- preparation and prevention;
- detection and analysis;
- containment, eradication and recovery; and
- post-incident remediation.

The IRP applies to all Company personnel (including third-party contractors, vendors and partners) that perform functions or services that require access to secure Company information, and to all devices and network services that are owned or managed by the Company.

Despite ongoing efforts to continually improve our and our vendors' ability to protect against cyber incidents, we may not be able to protect all information systems, and such incidents may lead to reputational harm, revenue and client loss, legal actions and statutory penalties, among other consequences. To date, risks from cybersecurity threats, including as a result of any previous cybersecurity incidents, have not materially affected us, including our business strategy, results of operations or financial condition, and we do not believe that such risks are reasonably likely to have such an effect over the long term. However, there can be no guarantee that we will not be the subject of future successful cybersecurity attacks, threats or incidents that materially affect our business strategy, results of operations or financial condition. Additional information on cybersecurity risks we face is discussed in Part I, Item 1A, "Risk Factors," under the heading "Risks Related to Information Technology."

Governance

Our CTO, who reports directly to our Chief Executive Officer, is responsible for assessing and managing cybersecurity risks. Our CTO has gained substantial information technology and cybersecurity knowledge from over 25 years of work experience at the Company and elsewhere. Our CTO receives reports on cybersecurity threats from our dedicated information technology team on an ongoing basis and, in conjunction with management, regularly review risk management measures implemented by the Company to identify and mitigate data protection and cybersecurity risks. Our CTO also works closely with our legal and compliance departments to oversee compliance with legal, regulatory and contractual security requirements.

The Board, as a whole and at the committee level, has oversight for the most significant risks facing us and for our processes to identify, prioritize, assess, manage and mitigate those risks. The Board's Audit and Compliance Committee, which is comprised solely of independent directors, has been designated by our Board to oversee cybersecurity risks. The Audit and Compliance Committee receives regular updates on cybersecurity and information technology matters and related risk exposures from our CTO, which address a wide range of topics including recent developments, evolving standards, vulnerability assessments, third-party and independent reviews, the threat environment, technological trends and information security considerations arising with respect to our peers and third parties. The Board also receives updates from management and the Audit and Compliance Committee on cybersecurity risks on at least an annual basis. In addition, we have protocols by which certain cybersecurity incidents are escalated within the Company and, where appropriate, reported promptly to the Board and Audit and Compliance Committee.

Item 2. Properties.

Facilities

Facilities

Our principal executive offices are located in New York City, where we occupy approximately 6,000 27,000 square feet under a lease that expires in 2026. We use this facility for administration, sales and marketing and general corporate activities, activities for our Corporate segment. In addition to our headquarters, to support our local operations, as of December 31, 2022 December 31, 2023, we owned or leased 30 45 office locations elsewhere in the United States (seven (twelve in New York, York; seven in Wisconsin; six in Wisconsin, four in New Jersey, Jersey; three in Texas, each of Delaware, Michigan and Pennsylvania; two in each in California, of Colorado and Delaware, Texas; and one in each in of Alabama, Arizona, California, Connecticut, New Mexico, Pennsylvania South Carolina and Tennessee, Tennessee). These local facilities are used principally for ambulance basing, garaging and maintenance, as well as for administrative activities and general oversight, oversight for our Mobile Health Services and Transportation Services segments. Outside of the United States, we currently lease seven fourteen facilities in England. These facilities are used for administrative functions and ambulance basing, basing for our Transportation Services segment. Our leases for our local U.S. facilities expire at various dates through 2029, 2029, and our leases for our U.K. facilities expire at various dates through 2032. We believe our existing facilities are adequate to meet our current requirements, and we anticipate that suitable space will be readily available if needed. We intend to procure additional, similar facilities as we expand geographically.

Vehicle Fleet

As of December 31, 2022 December 31, 2023, we operated 643 580 vehicles in the United States, including 384 350 ambulances, 88 54 wheelchair vans and 171 176 basic transportation or support vehicles. Approximately 47% 44% of our fleet is leased and 53% 56% is owned. We replace ambulances based upon age and usage, generally every eight five to ten eight years. The average age of our existing active ambulance fleet is approximately four years. We generally prefer to lease vehicles, but we have purchased vehicles in the past when deemed appropriate. Most of our owned vehicles were acquired in connection with business acquisitions.

As of December 31, 2022 December 31, 2023, we operated another 395 294 vehicles in the United Kingdom, including 18 First Response Ambulances, 22 first response ambulances, 11 Mental Health Transport mental health transport vehicles, 52 High Dependency Units, 288 Patient Transport 27

high dependency units, 200 patient transport vehicles and 26 34 support vehicles. Approximately 67% 75% of our U.K. fleet is owned and 33% 25% is leased.

We use a combination of commercial and in-house maintenance services to maintain our fleet. In those geographies where quality external commercial maintenance services are able to meet our quality standards, we will utilize those commercial maintenance services. We continue to explore ways to decrease our overall maintenance expenditures for vehicles, including major refurbishing and overhaul of our vehicles to extend their useful life.

Item 3. Legal Proceedings.

We are subject to legal proceedings, claims and litigation arising in the ordinary course of our business. The information Descriptions of certain legal proceedings to which we are a party are set forth in Note 20 of the Notes to the Consolidated Financial Statements is and are incorporated herein by reference.

From In addition, from time to time, in the ordinary course of our business we, and like others in our industry, we receive requests for information from government agencies in connection with their regulatory or investigational authority. These requests can include subpoenas or demand letters for documents to assist the government in audits or investigations. We review such requests and notices and take what we believe to be appropriate action. We have been subject to certain requests for information and investigations in the past and could be subject to such requests for information and investigations in the future.

Item 4. Mine Safety Disclosures.

Not applicable.

PART II

PART II

Item 5. Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.

Market Information

Our Common Stock is currently traded on The Nasdaq Capital Market under the trading symbol "DCGO."

Holders of Record

As of March 14, 2023 February 26, 2024, there were 103 64 holders of record of our Common Stock.

Because many of our shares of Common Stock are held by brokers and other institutions on behalf of stockholders, we are unable to estimate the total number of stockholders represented by these record holders.

Dividend Policy

We have not declared or paid any cash dividends on our Common Stock to date, and we do not currently intend to pay cash dividends in the foreseeable future. The payment of cash dividends in the future will depend on a number of factors, including our future revenues and earnings, if any, capital requirements and general financial condition. Any future determination relating to our dividend policy will be made at the discretion of our Board. Our ability to declare dividends may be limited by restrictive covenants we may agree to in connection with our indebtedness.


Recent Sales of Unregistered Securities

None.

Performance Graph

This performance graph shall not be deemed "soliciting material" or to be "filed" with the SEC for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities under that Section, and shall not be deemed to be incorporated by reference into any filing of the Company under the Securities Act or the Exchange Act, except as shall be expressly set forth by specific reference to such filing.

The following performance graph shows the cumulative total return on our Common Stock as compared to the Russell 2000 Index, S&P 500 Index and S&P 500 Health Care Sector Index from November 8, 2021 (the day our Common Stock began trading as DocGo Inc. following the Business Combination) through December 29, 2023 (the last trading day at year end). The graph assumes an investment of \$100 on November 8, 2021 and reinvestment of dividends, as applicable. The graph is based on historical data and is not intended to be a forecast or indication of future performance of our Common Stock.



None.

Repurchases of Equity Securities

On May 24, 2022 There were no repurchases made during the year ended December 31, 2023. Subsequent to the end of fiscal 2023, on January 30, 2024, our the Board approved a share repurchase program to purchase up to \$40 million \$36 million of our the Common Stock (the “Program” “Repurchase Program”). The Repurchase Program does not obligate us DocGo to acquire any specific number of shares and will expire on November 24, 2023 July 30, 2024, and the Repurchase Program may be suspended, extended, modified or discontinued at any time. Under the terms of the Repurchase Program, repurchases can be made using DocGo may purchase shares of Common Stock on a variety of methods, which may include discretionary basis from time to time through open market purchases, block trades, repurchases or privately negotiated transactions and/or a non-discretionary through other means, including by entering into Rule 10b5-1 trading plan, all plans or accelerated share repurchase programs, in compliance with the rules of the SEC each case, during an “open window” and other applicable legal requirements, when DocGo does not possess material non-public information. The timing, manner, price and amount of any common stock repurchases under the Repurchase Program are determined by us DocGo in our its discretion and depend on a variety of factors, including legal stock price, trading volume, market conditions, corporate and regulatory requirements price and economic other general business considerations. Repurchases under the Repurchase Program may be funded from the Company’s existing cash and market conditions. During the twelve months ended December 31, 2022, the Company repurchased 536,839 shares. As cash equivalents, future cash flow or proceeds of December 31, 2022, approximately \$36.2 million remained available for share repurchases pursuant to the Program.

borrowings or debt offerings.

Month	Total Number of Shares Purchased	Average Price Paid per Share	Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs	Approximate Dollar Value of Shares That May Yet Be Purchased Under the Plans or Programs
October 1 through 31, 2022	-	\$ -	-	\$ 39,502,000
November 1 through 30, 2022	193,927	6.88	193,927	\$ 38,168,568
December 1 through 31, 2022	272,912	7.10	272,912	\$ 36,231,296
	466,839	\$ 6.98	466,839	\$ 36,231,296

Item 6. Reserved.

Reserved

Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our Consolidated financial statements Financial Statements and the accompanying notes included elsewhere in this Annual Report on Form 10-K. Report. The discussion and analysis below contain certain forward-looking statements about our business and operations that are subject to the risks, uncertainties and other factors described in the section entitled “Risk Factors,” included in Part I, Item 1A, and other factors included elsewhere in this Annual Report on Form 10-K. Report. These risks, uncertainties and other factors could cause our actual results to differ materially from those expressed in, or implied by, the forward-looking statements. Please refer to the section entitled “Cautionary Note Regarding Forward-Looking Statements.”

Unless the context requires otherwise, references to “DocGo,” “we,” “us,” “our” and “the Company” Certain figures included in this section, are to the business and operations of DocGo and its consolidated subsidiaries, including those periods prior to the Business Combination. Certain figures, such as interest rates and other percentages, included in this section have been rounded for ease of presentation. Percentage figures included in this section have, in some cases, been calculated on the basis of such rounded figures. For this reason, percentage amounts in this section may vary slightly from those obtained by performing the same calculations using the figures in DocGo’s our Consolidated Financial Statements or in the associated text. Certain other amounts that appear in this section may similarly not sum due to rounding.

Overview

Overview

DocGo, which was originally formed in 2015, is a mobile healthcare transportation and mobile services company that uses proprietary dispatch and communication technology to help provide quality healthcare transportation and mobile, services in-person medical treatment directly to patients in the comfort of their homes, workplaces and other non-traditional locations, locations; and medical transportation in major metropolitan cities in the United States and the United Kingdom.

The Company derives revenue primarily from its two operating segments:

- **Mobile Health Services:** The services offered by this segment include a wide variety of healthcare services performed at homes, offices and other locations and event services such as on-site healthcare support at sporting events and concerts. This segment also provides total care management solutions to large, typically underserved population groups, primarily through arrangements with municipalities, which include healthcare services as well as ancillary services, such as shelter.
- **Transportation Services:** The services offered by this segment encompass both emergency response and non-emergency transport services. Non-emergency transport services include ambulance transports and wheelchair transports. Net revenue from Transportation Services is derived from the transportation of patients based on billings to third party payors and Mobile Health Services.
 - **Transportation Services:** The services offered by this segment encompass both emergency response and non-emergency transport services. Non-emergency transport services include ambulance transports and wheelchair transports. Net revenue from Transportation Services is derived from the transportation of patients based on billings to third party payors and healthcare facilities.
 - **Mobile Health Services:** The services offered by this segment include a wide variety of healthcare services performed at home and offices, testing, vaccinations and event services which include on-site healthcare support at sporting events and concerts.

See Item 1.1, “Business” in this Annual Report on Form 10-K for additional information regarding DocGo’s business.

For the year ended December 31, 2022 December 31, 2023 the Company recorded net income of \$30.7 million \$10.0 million, compared to net income of \$30.7 million and \$19.2 million in the year years ended December 31, 2021.

COVID-19

The spread of COVID-19 December 31, 2022 and the related shutdowns and restrictions had a mixed impact on our business. In the Transportation Services segment, which comprises primarily of non-emergency medical transport, the Company saw a decline in volumes from historical and expected levels, as elective surgeries and other non-emergency surgical procedures were postponed. In addition, in the Mobile Health segment, the Company experienced lost revenue associated with sporting, concerts and other events, as those events were cancelled or had a significantly restricted (or entirely eliminated) number of permitted attendees. Ambulance transports and event-related revenues have both since recovered to pre-COVID levels or higher.

There are two areas where the Company experienced positive business impacts from COVID-19. In April and May 2020, the Company participated in an emergency project with Federal Emergency Management Agency in the New York City area. This engagement resulted in incremental transportation revenue that partially offset some of the lost non-emergency transport revenues. In addition, in response to the need for widespread COVID-19 testing and available EMTs and paramedics, the Company expanded its operations to include Rapid Reliable Testing (“RRT”), with the goal of performing COVID-19 tests at nursing homes, municipal sites, businesses, schools and other venues. RRT is part of the Mobile Health business line. Mobile Health generated approximately \$325.9 million in revenue in the year ended December 31, 2022, as compared to \$234.4 million in 2021, and \$30.9 million in 2020. While COVID-19 testing has become a minor part of this segment’s business, as of the second half of 2022, the Mobile Health segment has continued to grow. We have expanded our service offerings in this segment to offer a wider range of testing, vaccination and other services to a broader customer group.

During 2020 and the early part of 2021, the Company continued to operate with several back-office employees working remotely. During that time, the Company did not witness any significant reduction in productivity from these employees, nearly all of whom returned to their respective offices and other locations by early 2021 and our operations have proceeded without major interruption. DocGo also utilized several government programs in 2020 related to the pandemic, receiving approximately \$1.0 million in payments through the Public Health and Social Services Emergency Fund authorized under the Coronavirus Aid, Relief and Economic Security Act and related legislation as well as various state and local programs. DocGo also received accelerated Medicare payments of approximately \$2.4 million that were repaid in 2022.

As the COVID-19 pandemic reaches endemic stages, the future impacts of it or other pandemics on DocGo remain highly uncertain and subject to numerous factors, including the severity of any new outbreaks, resurgences and variants, actions taken to contain resurgences or variants or to address their impact, and other effects, and its related impact on medical transportation levels remain uncertain. However, trip volumes in most of our markets returned to more normal historical levels in 2021, and this trend continued throughout 2022. The Company generated, during 2021, COVID-19 testing revenue, included in its Mobile Health services segment, above the levels projected, and this persisted through the second quarter of 2022. However, as expected, COVID-19 testing revenues declined in the third quarter of 2022 and declined further in the fourth quarter, to the point where, as of the date of the filing of this Annual Report on Form 10-K, they account for an insignificant proportion of total revenues. Given the nature of the Company’s contracts with most of its customers, which include multiple procedures for which the Company is paid per hours worked, per vehicles and related equipment utilized and on a per-procedure basis (such procedures including both testing and several other procedures), it is difficult to determine the revenues that are directly attributable to COVID-19 testing. However, the Company estimates that COVID-19 testing revenue will continue to account for an insignificant proportion of Mobile Health segment and overall consolidated revenues in 2023 and beyond, as COVID-19 enters the endemic phase. In a broader, strategic sense, the consumer focus on Mobile Health services and the formation of RRT, and its emergence as a significant contributor to overall revenues, have accelerated the diversification in the Company’s business by more rapid expansion of the Mobile Health segment, which has now become our larger operating segment, both in terms of revenues and personnel.

The Company’s current business plan assumes an increased demand for Mobile Health services, a demand that was accelerated by the pandemic, but which we believe is also being driven by longer-term secular factors, such as the increasing desire on the part of patients to receive treatments outside of traditional settings, such as doctor’s offices and hospitals. In the Transportation segment, volumes are expected to continue to rise, reflecting an aging population in the U.S. and U.K., which tends to drive demand for the non-emergent medical transportation services provided by the Company.

respectively.

Factors Affecting Our Results of Operations

Our operating results and financial performance are influenced by a variety of factors, including, among others, our ability to obtain or establish, maintain operating licenses; and grow customer relationships; our ability to execute projects to the success/satisfaction of our acquisition strategy; customers; conditions in the healthcare transportation and mobile health services markets; changes in government spending on healthcare and other social services; availability of healthcare professionals and other personnel; changes in the cost of labor; our competitive environment; overall macroeconomic and geopolitical conditions, including rising interest rates, the inflationary environment, the potential recessionary environment, regional conflict and tensions; availability tensions, financial institution instability and the prospect of healthcare professionals; changes in a shutdown of the cost of labor; and U.S. federal government; production schedules of our suppliers. suppliers; our ability to obtain or maintain operating licenses; and the success of our acquisition strategy. Some of these important key factors are briefly discussed below. Future revenue growth and improvement in operating results will be largely contingent on DocGo's our ability to penetrate new markets and further penetrate existing markets, which is subject to a number of uncertainties, many of which are beyond DocGo's our control.

Healthcare Services Market

The COVID-19 pandemic also significantly impacted DocGo's business. Mobile Health Services market is dependent on several factors, including increased patient acceptance of services that are provided outside of traditional healthcare facilities, such as discussed above. While the direct impact in homes, businesses or other designated locations; healthcare coverage of the pandemic itself has waned, various Mobile Health Services; and continued desire on the part of government and municipal entities to fund programs to assist currently underserved patient segments via "population health" programs. These programs increased in number, scale and scope since the beginning of the COVID-19 pandemic. While COVID-19 testing and vaccination programs have been dramatically scaled back from their levels at the pandemic's peak, there have been expansions of these population health programs into other impacts, areas, such as supply chain disruptions the provision of healthcare and the cost related services to recent migrants and availability of labor are expected to persist.

asylum seekers.

Operating Licenses

DocGo has historically pursued a strategy to apply for ambulance operating licenses in the states, counties and cities, identified for future new market entry. The approval of a new operating license may take an extended period of time. DocGo reduces this risk through its acquisition strategy by identifying businesses and/or underlying licenses in these new markets that may be for sale.

Acquisitions

Historically DocGo pursued an acquisition strategy to obtain ambulance operating licenses from small operators. Future acquisitions may also include larger companies that may help drive revenue, profitability, cash flow and stockholder value, in both the Mobile Health and the Transportation segments. During the twelve months ended December 31, 2022, DocGo completed five acquisitions, for a purchase price of \$69.1 million.

On July 6, 2022, the Company acquired Government Medical Services LLC ("GMS") in exchange for \$20.3 million in cash and up to a total of \$3.0 million in future contingent consideration upon GMS meeting certain performance conditions. GMS is in the business of providing licensed healthcare clinicians. We believe this acquisition will allow us to increase our presence in that market, while giving us improved access to municipal contracts.

On July 13, 2022, the Company acquired Exceptional Medical Transportation, LLC ("Exceptional") in exchange for \$7.7 million in cash (and a total of \$6.0 million deferred consideration). The Company also agreed to pay an estimated \$1.1 million contingent consideration upon Exceptional meeting certain performance conditions. Exceptional is in the business of providing medical transportation services in New Jersey. We believe this acquisition will allow us to increase our presence in that market.

On August 9, 2022, the Company acquired Ryan Brothers Ambulance Inc. ("RB"), in exchange for \$7.4 million of cash (and a total of \$4 million in future contingent consideration). Ryan Brothers is in the business of providing medical transportation services in Wisconsin. We believe this acquisition will allow us to increase our presence in that market.

On October 12, 2022, the Company acquired Community Ambulance Services LTD ("CAS") in exchange for approximately \$5.5 million in cash. CAS is located in the U.K. and is engaged in providing emergency and non-emergency transport services, including high dependency, urgent care, mental health and blue light transport services and diagnostics testing. We believe that this acquisition will help allow us to continue to grow our presence in the U.K. market.

On December 9, 2022, Ambulnz U.K. Ltd., a wholly owned subsidiary of the Company acquired Location Medical Services, LLC ("LMS") for a total of \$11.6 million in cash (of which \$11.3 million is deferred consideration) and \$2.5 million in future contingent consideration. LMS, based in Shepperton, U.K., provides professional medical support services, including staff and equipment, for events (festivals, equestrian, cycling, etc.), as well as for the film and television production industry. LMS has a staff of over 250 medical professionals. We believe that this acquisition will allow us to increase our share of the events business in the U.K. market.

During the twelve months ended December 31, 2021, DocGo completed one acquisition, for a purchase price of \$2.3 million.

Healthcare Services Market

The transportation services market is highly dependent on patients requiring transportation after surgeries and other medical procedures and treatments. During The Company primarily focuses on the pandemic, DocGo experienced a decrease non-emergency medical transport market, which includes services that are provided to patients who need assistance getting to and from medical appointments. Key drivers of this market are the increase in transportation volumes as a result chronic conditions and the number of fewer elective surgeries. However, since 2021, the Company has seen increased demand and trip volumes in nearly all of its Transportation services markets, as elective surgeries resumed as well as the ongoing aging of the population, as older

demographics tend to be much more frequent consumers of medical transportation services. The market will also grow if hospitals and other healthcare facilities continue to outsource more of their transportation needs to independent providers, such as the Company, expanded its customer base.

allowing these facilities to concentrate their efforts on their core competencies.

Overall Economic Conditions in the Markets in which we Which We Operate

Economic changes, both nationally and locally, in our markets impact our financial performance. Unfavorable changes in demographics, health care healthcare coverage of transportation Mobile Health Services and mobile health services, Transportation Services, interest rates, inflation rates, ambulance manufacturing, a weakening of the national economy or of any regional or local economy in which we operate and other factors beyond our control could adversely affect our business.

Our Ability to Control Expenses

We pay close attention to the management of our working capital and operating expenses. Some of our most significant operating expenses are labor costs, medical supplies and vehicle-related costs, such as fuel, maintenance, repair and insurance. Insurance costs include premiums paid for coverage as well as reserves for estimated losses within the Company's insurance policy deductibles. We employ our proprietary technology to help drive improvements in productivity per transport and per shift. We regularly analyze our workforce productivity to help achieve the optimum, cost-efficient labor mix for our locations. This involves managing the mix of Company-employed labor and subcontracted labor as well as full-time and part-time employees.

Inflation

The inflation rate in the United States, as measured by the Consumer Price Index, has generally trended up since early 2021. This data is reported monthly, showing year-over-year changes in prices across a basket of goods and services. Though the annual inflation rate declined to 4.1% for the full year 2023 from 8.0% in 2022, it remains above historical averages. The increased inflation rate has had an impact on the Company's expenses in several areas, including wages, fuel and medical and other supplies. This has had the effect of compressing gross profit margins, as the Company is generally unable to pass these higher costs on to its customers, particularly in the short term. In a continued attempt to dampen inflation, the U.S. Federal Reserve implemented four interest rate hikes in 2023, raising its benchmark rate to the current level of 5.25-5.50% as of the date of this Annual Report. Looking into 2024, we anticipate a continued moderation of the inflation rate as a result of these recent interest rate increases, with an annual rate similar to those witnessed in the 2010-2020 period, when the annual inflation rate ranged from 0.1% to 3.2%. If inflation is above the levels that the Company anticipates, gross margins could be below plan and our business, operating results and cash flows may be adversely affected.

Trip Volumes and Average Trip Price

A "trip" is defined as an instance where the Company completes the transport transportation of a patient to a specific destination, for which we are able to charge a fee. This metric does not include instances where a trip is ordered and subsequently either canceled (by the customer) or declined (by the Company). As trip volume represents the most basic unit of transportation service provided by the Company, the Company believes it is the best a good measure of the level of demand for the Company's Transportation services, Services and is used by management to monitor and manage the scale of the business.

The average trip price is calculated by dividing the aggregate revenue from completed transports ("trips") the total number of trips by the total number of transports, trips and is an important indicator of the effective rate at which the Company is being compensated for its provision of Transportation services, Services.

Revenues generated from programs under which DocGo the Company is paid a fixed hourly or daily rate for the use of a fully staffed and equipped ambulance do not factor in the trip counts or average trip prices mentioned above. We anticipate that expect these fixed rate, "leased hour" programs will to continue to account for an increasing proportion of the Transportation Services segment's revenues in the future.

Acquisitions

Historically, we have pursued an acquisition strategy to obtain enhanced capabilities or licenses to offer Mobile Health Services or Transportation Services. Future acquisitions may also include companies that may help drive revenue, profitability, cash flow and stockholder value.

During the year ended December 31, 2023, we completed three acquisitions for an aggregate purchase price of \$34.2 million. During the year ended December 31, 2022, we completed five acquisitions for a purchase price of \$69.1 million. During the year ended December 31, 2021,

we completed one acquisition for a purchase price of \$2.3 million.

Our Ability to Control Expenses

We pay close attention to managing our working capital and operating expenses. Some of our most significant operating expenses are labor costs, medical supplies and vehicle-related costs, such as fuel, maintenance, repair and insurance. Insurance costs include premiums paid for coverage as well as reserves for estimated losses within the Company's insurance policy deductibles. We aim to employ our proprietary technology to drive improvements in productivity per transport. We regularly analyze our workforce productivity with a goal of balancing the optimum, cost-efficient labor mix for our locations.

Inflation

Beginning in March 2021, the inflation rate in the US, as measured by the Consumer Price Index (CPI) has generally trended higher. This data is reported monthly, showing year-over-year changes in prices across a basket of goods and services. The monthly 12-month inflation rate was 2.6% in March 2021, and increased steadily over the rest of 2021 and into 2022, with the inflation rate hitting 9.1% in June 2022. The inflation rate has seemingly moderated since that point, declining to 6.4% in January 2023, but remains well above historical averages. On an annual basis, in 2019, the inflation rate was approximately 1.8%, while it dropped to approximately 1.2% in 2020, rising to 4.7% in 2021 and 8.0% in 2022. The increased inflation rate has had an impact on the Company's expenses in several areas, including wages, fuel and medical and other supplies. This has had the impact of compressing gross profit margins, as the Company is generally unable to pass these higher costs on to its customers, particularly in the short term. In an attempt to dampen inflation, the U.S. Federal Reserve implemented seven interest rate hikes in 2022, and another hike to date in 2023, raising its benchmark rate (the "federal funds rate") from near 0.00% at the beginning of 2022 to the current level of 4.50%-4.75% as of the date of the filing of this Annual Report on Form 10-K. The federal funds rate was raised in March, May, June, July, September, November and December of 2022 and in February of 2023. The rate of the increase in the federal funds rate has declined, however, with the December 2022 increase coming in at 0.50% and the February 2023 rate increase of 0.25%, compared with rate hikes at 0.75% each in June, July, September and November of 2022. Looking to 2023, we anticipate a continued moderation of the inflation rate when compared to the levels seen in 2022, as a result of these recent rate hikes, but expect that inflation will remain well above the levels seen in the previous 10 years, when the annual inflation rate ranged from 0.1% to 2.4%. If inflation is above the levels that the Company anticipates, gross margins could be below plan and our business, operating results and cash flows may be adversely affected.

Investing in R&D and Enhancing our Customer Experience

Our performance is dependent on the investments we make in research and development ("R&D"), including our ability to attract and retain highly skilled research and development R&D personnel. We must continually intend to develop and introduce innovative new software services, integrate integrations with third-party products and services, mobile applications and other new offerings. If we fail to innovate and enhance our brand and our products, our market position and revenue will likely may be adversely affected.

Regulatory Environment

DocGo The Company is subject to federal, state and local regulations, including healthcare and emergency medical services laws and regulations and tax laws and regulations. The Company's current business plan assumes no material change in these laws and regulations. In the event that any such change occurs, compliance with new laws and regulations might may significantly affect its the Company's operations and cost of doing business.

COVID-19

The spread of COVID-19 and the related shutdowns and restrictions had a mixed impact on the Company's business. In the ambulance transportation business, which predominantly comprises non-emergency medical transportation, the Company initially saw a decline in volumes from historical and expected levels, as elective surgeries and other procedures were postponed. In some of the Company's larger markets, such as New York and California, there were declines in trip volume. In addition, the Company experienced lost revenues associated with sporting, concerts and other events, as those events were cancelled or significantly restricted (or entirely eliminated) the number of permitted attendees. Ambulance transports and event-related revenues have both since recovered to pre-COVID levels or higher.

There were two areas in which the Company initially experienced positive business impacts from COVID-19. In April and May 2020, the Company participated in an emergency project with FEMA in the New York City area. This engagement resulted in incremental transportation revenue. In addition, in response to the need for widespread COVID-19 testing, EMTs and paramedics, the Company formed a new subsidiary, Rapid Reliable Testing, LLC ("RRT"), with the goal of performing COVID-19 tests at nursing homes, municipal sites, businesses, schools and other venues. RRT is part of the Mobile Health Services segment. As COVID-19 testing activity slowed and accounted for a more minor portion of the Company's revenues, RRT expanded its services beyond COVID-19 testing to a wide variety of tests, vaccinations and other procedures. The Company estimates that during 2023, its revenue from COVID-19 related services accounted for less than 1% of total revenues, compared to about 17% in 2022 and nearly 35% in 2021.

The Company's current business plan assumes increased demand for Mobile Health Services, a demand that was accelerated by the pandemic, but which is also being driven by longer-term factors, such as the increasing desire on the part of patients to receive treatments outside of traditional settings, such as doctor's offices and hospitals.

Components of Results of Operations

Our business consists of **two** three reportable segments — **Transportation services and Mobile Health services**. Services, Transportation Services and Corporate. All revenue and cost of goods sold are contained within the Mobile Health Services and Transportation Services segments. Accordingly, revenues and cost of goods sold are discussed below on a consolidated level and are also broken down between Mobile Health Services and Transportation Services. Operating expenses are discussed on a consolidated level and broken down among all three segments. The Company evaluates the performance of **both** each of its segments based primarily on its results of **its** operations. Accordingly, other income and expenses not included in results **from** of operations are only included in the discussion of consolidated results of operations.

Revenue

Revenue

The Company's revenue consists of services provided by its **Transportation Mobile Health Services** segment and its **Mobile Health Transportation Services** segment.

Cost of Revenues

Cost of revenues consists primarily of revenue generating wages paid to employees, **fees to paid to subcontractors, medical supplies**, vehicle insurance costs (including insurance premiums and costs incurred under the insurance deductibles), maintenance, fuel **laboratory fees, and facility rent, medical supplies and subcontractors, rent**. We expect cost of **revenue revenues** to continue to rise **in proportion to the expected increase in revenue**. **as we grow our business**.

Operating expenses Expenses

General and Administrative Expenses

General and administrative expenses consist primarily of salaries, bad debt expense, insurance expense, consultant fees and professional fees for accounting services. We expect our general and administrative **expense expenses** to increase as we **continue to scale up headcount with the growth of** our business **and grow headcount** and as a result of operating as a public company, including **our** compliance with SEC rules and regulations, audit **activities**, additional insurance expenses, investor relations activities and other administrative and professional services.

Depreciation and Amortization

DocGo The Company depreciates its assets using the straight-line method over the estimated useful lives of the respective assets. Amortization of intangibles consists of amortization of definite-lived intangible assets over their respective useful lives.

Legal and Regulatory Expenses

Legal and regulatory expenses include legal fees, consulting fees related to healthcare compliance **claims processing fees** and legal settlements.

Technology and Development Expenses

Technology and development Expenses

Technology and development expense, net of capitalization, **expenses** consists primarily of costs incurred in the design and development of **DocGo's the Company's** proprietary technology, third-party software and technologies. We expect technology and development **expense expenses** to increase in future periods to support our growth, including **as we invest our intent to continue investing** in the optimization, accuracy and reliability of our **dispatch and communication platform to help** and drive efficiency in our operations. These expenses may vary from period to period as a percentage of **revenue, revenues**, depending primarily upon when we choose to make more significant investments, **which is in turn, dependent on numerous factors, including particularly** when **we plan to enter into entering** new business lines or customer sales channels.

Sales, Advertising and Marketing Expenses

Our sales, **advertising** and marketing expenses consist of costs directly associated with our sales and marketing activities, which primarily include sales commissions, marketing programs, trade shows, **promotional materials and promotional materials, general branding**. We expect **that** our sales, **advertising** and marketing expenses **will** to continue to increase over time as we increase our marketing activities, grow our domestic and international operations and continue to build brand awareness. **As the Company expands its sales efforts to include the direct-to-consumer channel, marketing expenses are likely to increase as a percentage of revenues, given the marketing-intensive nature of that sales channel**.

Interest Expense

Interest expense consists primarily of interest on our outstanding borrowings under our outstanding notes payable **credit line** and financing **obligations**. **obligations, including our Revolving Facility**.

Results of Operations

Comparison of Fiscal 2023 with Fiscal 2022

\$ in Millions	Year Ended December 31,				Change \$	Change %
	2023		2022			
	Actual Results	% of Total Revenue	Actual Results	% of Total Revenue		
Revenues, net	\$ 624.3	100.0 %	\$ 440.5	100.0 %	\$ 183.8	41.7 %
Cost of revenues	428.9	68.7 %	285.8	64.9 %	143.1	50.1 %
Operating expenses:						
General and administrative	137.2	22.0 %	103.4	23.5 %	33.8	32.7 %
Depreciation and amortization	16.4	2.6 %	10.6	2.4 %	5.8	54.7 %
Legal and regulatory	13.1	2.1 %	8.8	2.0 %	4.3	48.9 %
Technology and development	10.9	1.7 %	5.4	1.2 %	5.5	101.9 %
Sales, advertising and marketing	2.8	0.4 %	4.7	1.1 %	(1.9)	(40.4 %)
Total expenses	609.2	97.6 %	418.7	95.1 %	190.5	45.5 %
Income from operations	15.1	2.4 %	21.8	4.9 %	(6.7)	
Other income:						
Interest income (expense), net	1.7	0.3 %	0.8	0.2 %	0.9	112.5 %
Gain on remeasurement of warrant liabilities	—	— %	1.1	0.3 %	(1.1)	
Change in fair value of contingent liability	1.4	0.2 %	—	— %	1.4	
(Loss) on equity method investments	(0.3)	(0.1)%	—	— %	(0.3)	
Gain on remeasurement of finance leases	—	— %	1.4	0.3 %	(1.4)	
Gain on bargain purchase	—	— %	1.6	0.4 %	(1.6)	
Loss on disposal of fixed assets	(0.9)	(0.1)%	—	— %	(0.9)	
Goodwill impairment	—	— %	(2.9)	(0.7)%	2.9	
Other expense	(0.7)	(0.1)%	(1.0)	(0.2)%	0.3	
Total other income	1.2	0.2 %	1.0	0.2 %	0.2	20.0 %
Net income before (provision for) benefit from income tax	16.3	2.6 %	22.8	5.2 %	(6.5)	

(Provision for) benefit from income taxes	(6.2)	(1.0)%	7.9	1.8 %	(14.1)	
Net income	10.0	1.6 %	30.7	7.0 %	(20.7)	
Net income (loss) attributable to noncontrolling interests	3.2	0.5 %	(3.9)	(0.9)%	7.1	182.1 %
Net income attributable to stockholders of DocGo Inc. and Subsidiaries	\$ 6.9	1.1 %	\$ 34.6	7.9 %	\$ (27.7)	

Revenues

Consolidated

For the year ended December 31, 2023, total revenues were \$624.3 million, an increase of \$183.8 million, or 41.7%, from the total revenues recorded for the year ended December 31, 2022.

Mobile Health Services

For the year ended December 31, 2023, Mobile Health Services revenues were \$442.8 million, an increase of \$116.9 million, or 35.9%, as compared with the year ended December 31, 2022. The increase in revenues was primarily due to an expansion in services offered by the Mobile Health Services segment, particularly in the government customer sector. This expansion accelerated during the year ended December 31, 2023 as the Company extended several large customer contracts and introduced a broader range of services.

Transportation Services

For the year ended December 31, 2023, Transportation Services revenues were \$181.5 million, an increase of \$66.9 million, or 58.3%, as compared with the year ended December 31, 2022. This increase was due to a 15.8% increase in trip volumes, from 216,009 trips for the year ended December 31, 2022 to 250,114 trips for the year ended December 31, 2023. The increase in trip volumes was due to a combination of growth in the Company's customer base in certain core markets and acquisitions made during the second half of 2022. Our average trip price increased from \$380 in the year ended December 31, 2022 to \$407 in the year ended December 31, 2023. The increase in the average trip price in 2023 reflected a shift in mix toward higher-priced transports with existing customers, as well as the acquisition of licenses to provide higher acuity transports resulting in higher prices per trip. The average trip price also benefited from an 8.7% increase in the average Medicare reimbursement rate for ambulance transports. The Medicare ambulance fee schedule has increased by a further 2.4%, effective January 1, 2024.

Cost of Revenues

For the year ended December 31, 2023, total cost of revenues (exclusive of depreciation and amortization) increased by 50.1% compared to the year ended December 31, 2022, while revenues increased by approximately 41.7%. Cost of revenues as a percentage of revenues increased to 68.7% in the year ended December 31, 2023 from 64.9% in the year ended December 31, 2022.

Total cost of revenues in the year ended December 31, 2023 increased by \$143.1 million compared to the same period in 2022. This increase was primarily attributable to a \$44.0 million increase in total compensation, due to higher headcount for both the Transportation Services and Mobile Health Services segments; an \$80.2 million increase in subcontracted labor costs, primarily driven by new projects in the Mobile Health Services segment that required a greater number of personnel and certain more highly specialized personnel than the Company was able to initially provide through its existing staff; a \$19.6 million increase in medical and related supplies; a \$2.1 million increase in travel costs for field personnel and other clinicians who traveled out of their home regions to provide Mobile Health Services; and a \$1.6 million net increase in other cost of revenues categories. These items were partially offset by a \$2.3 million decline in vehicle costs, as the Company exited certain rental agreements, and a \$2.1 million reduction in lab fees, as COVID testing services declined to an immaterial amount in 2023.

For the Mobile Health Services segment, cost of revenues (exclusive of depreciation and amortization) in the year ended December 31, 2023 amounted to \$306.2 million, up 53.7% from \$199.2 million in the year ended December 31, 2022. Cost of revenues as a percentage of revenues increased to 69.1% from 61.1% in the prior year period, despite a significant increase in revenues, reflecting higher compensation expenses as a result of headcount growth, significantly higher subcontracted labor costs and increased costs for medical supplies.

For the Transportation Services segment, cost of revenues (exclusive of depreciation and amortization) in the year ended December 31, 2023 amounted to \$122.7 million, up 41.8% from \$86.5 million in the year ended December 31, 2022. Cost of revenues as a percentage of revenues decreased to 67.6% from 75.5% in the prior year, reflecting the impact of higher per-trip prices, increased revenues from standby contracts (for which we are paid a daily or hourly rate) and the overall increase in revenues, as well as a decline in the average fuel price.

Operating Expenses

For the year ended December 31, 2023, operating expenses were \$180.3 million compared to \$132.9 million for the year ended December 31, 2022, an increase of \$47.4 million, or 35.7%. As a percentage of revenues, operating expenses decreased from 30.2% in 2022 to 28.9% in 2023, even as the Company added to its management infrastructure and total compensation increased, due to the significant increase in overall revenues described above. The increase of \$47.4 million related primarily to a \$27.1 million increase in total compensation, which included costs for both directly employed and subcontracted staff due to investments in and expansion of corporate infrastructure to support the revenue growth, as well as an increase in stock-based compensation expense; a \$5.7 million increase in depreciation and amortization due to an increase in assets to support revenue growth and capitalized software amortization, as well as recently acquired companies; a \$4.9 million increase in IT infrastructure, driven by the Company's business and headcount expansion; a \$2.5 million increase in insurance costs, reflecting higher headcount, a larger vehicle fleet and expanded operations; a \$1.3 million increase in rent and utilities relating to the Company's ongoing geographic expansion; and a \$5.9 million net increase across a variety of expense categories.

For the Mobile Health Services segment, operating expenses in the year ended December 31, 2023 were \$56.3 million, up from \$33.9 million in the year ended December 31, 2022. Operating expenses as a percentage of revenues increased to 12.7% from 10.4% in 2022, despite the increase in Mobile Health Services revenues, reflecting significant expenditures that were made in 2023 related to the expansion of services and geographic areas of operation, as well as the continued buildout of the Mobile Health Services management infrastructure and the costs of developing the Company's "on-demand" direct-to-consumer offering.

For the Transportation Services segment, operating expenses in the year ended December 31, 2023 were \$55.2 million, compared to \$43.0 million in the year ended December 31, 2022. The increase in operating expenses for this segment, in absolute dollar terms, was driven primarily by higher compensation expense and depreciation charges, reflecting the expansion of the business, including recent acquisitions. Operating expenses as a percentage of revenues decreased to 30.4% for the year ended December 31, 2023 from 37.5% in the year ended December 31, 2022.

For the Corporate segment, which represents primarily shared services that are not contained within the entities included in either the Mobile Health Services or Transportation Services segments, operating expenses in the year ended December 31, 2023 were \$68.8 million, compared to \$55.1 million in the year ended December 31, 2022. The increase in operating expenses for this segment, in absolute dollar terms, was primarily driven by higher compensation expenses, reflecting the ongoing build-out of the Company's corporate human resources infrastructure. Corporate expenses amounted to approximately 11.0% of total consolidated revenues in 2023, compared to 12.5% in 2022, reflecting the significant increase in total consolidated revenues.

Interest Income, Net

For the year ended December 31, 2023, the Company recorded approximately \$1.7 million of interest income, net compared to \$0.8 million of interest income, net in the year ended December 31, 2022. This increase was primarily due to higher rates of interest earned on balances in the Company's interest-bearing accounts in the year ended December 31, 2023, which reflected significantly higher market interest rates. The higher rates of interest earned outweighed the impact of the lower average cash balances in 2023.

Gain on Remeasurement of Warrant Liabilities

During the year ended December 31, 2023, there were no gains or losses recorded relating to remeasurement of warrant liabilities, as all warrants were redeemed during the third quarter of 2022. During the year ended December 31, 2022, the Company recorded a gain of approximately \$1.1 million from the remeasurement of warrant liabilities. The warrants were marked-to-market in each reporting period, and this gain reflected the decline in the Company's stock price relative to the beginning of the period.

Change in Fair Value of Contingent Liability

During the year ended December 31, 2023, the Company recorded a change in fair value of contingent liability of approximately \$1.4 million, reflecting a decline in the anticipated payments to be made for a recent acquisition, based upon performance compared to certain targets. There was no related change in fair value recorded in the year ended December 31, 2022.

(Loss) Gain on Equity Method Investments

During the year ended December 31, 2023, the Company recorded a loss on equity method investments of approximately \$0.3 million representing its share of the losses incurred by an entity in which the Company has a minority interest. During the year ended December 31, 2022, the Company recorded a gain on equity method investments of \$8,919.

Gain on Remeasurement of Finance Leases

During the year ended December 31, 2023, there were no gains or losses recorded relating to remeasurement of finance leases. During the year ended December 31, 2022, the Company recorded a gain on remeasurement of finance leases of \$1.4 million.

Gain on Bargain Purchase

During the year ended December 31, 2023, the Company recorded no gain or loss on bargain purchase. During the year ended December 31, 2022, the Company recorded a gain on bargain purchase of \$1.6 million.

Loss on Disposal of Fixed Assets

During the year ended December 31, 2023, the Company recorded a loss on disposal of fixed assets of \$0.9 million, compared to a loss on disposal of fixed assets of \$21,000 during the year ended December 31, 2022.

Goodwill Impairment

During the year ended December 31, 2023, the Company did not record any impairment to goodwill. During the year ended December 31, 2022, the Company recorded a goodwill impairment of \$2.9 million, relating to the Company's exit from the medical transportation market in California.

(Provision for) Benefit from Income Taxes

During the year ended December 31, 2023, the Company recorded a provision for income taxes of \$6.2 million compared to an income tax benefit of \$7.9 million in the year ended December 31, 2022. The tax benefit in 2022 was due to the release of the valuation allowance recorded in previous years for net operating losses, as the Company determined that it was more likely than not that it would be able to realize its net operating loss carryforwards in the future.

Net Income (Loss) Attributable to Noncontrolling Interests

For the year ended December 31, 2023, the Company had net income attributable to noncontrolling interests of approximately \$3.2 million compared to a net loss attributable to noncontrolling interests of \$3.9 million for the year ended December 31, 2022. The income compared to the prior year period loss reflected improved performance in the Company's joint venture markets in the year ended December 31, 2023.

Comparison of Fiscal 2022 with Fiscal 2021

\$ in Millions	Year Ended December 31,				Change \$	Change %
	2022		2021			
	Actual Results	% of Total Revenue	Actual Results	% of Total Revenue		
Revenues, net	\$ 440.5	100.0 %	\$ 318.7	100.0 %	\$ 121.8	38.2 %
Cost of revenues	285.8	64.9 %	209.0	65.6 %	\$ 76.8	36.8 %
Operating expenses:						
General and administrative	103.4	23.5 %	74.9	23.5 %	\$ 28.5	38.1 %
Depreciation and amortization	10.6	2.4 %	7.5	2.4 %	\$ 3.1	40.7 %
Legal and regulatory	8.8	2.0 %	3.9	1.2 %	\$ 4.9	125.6 %
Technology and development	5.4	1.2 %	3.3	1.0 %	\$ 2.1	63.6 %
Sales, advertising and marketing	4.7	1.1 %	4.8	1.5 %	\$ (0.1)	(2.4 %)
Total expenses	418.7	95.1 %	303.4	95.2 %	\$ 115.3	38.0 %
Income from operations	21.8	4.9 %	15.4	4.8 %	\$ 6.5	
Other income:						
Interest income (expense), net	0.8	0.2 %	(0.8)	(0.2)%	\$ 1.6	200.0 %
Gain on remeasurement of warrant liabilities	1.1	0.3 %	5.2	1.6 %	\$ (4.1)	
Change in fair value of contingent liability	—	— %	—	— %	\$ —	
(Loss) on equity method investments	—	— %	(0.1)	— %	\$ 0.1	
Gain on remeasurement of finance leases	1.4	0.3 %	—	— %	\$ 1.4	
Gain on bargain purchase	1.6	0.4 %	—	— %	\$ 1.6	
Gain from PPP loan forgiveness	—	— %	0.1	— %	\$ (0.1)	
(Loss) on disposal of fixed assets	—	— %	—	— %	\$ —	
Goodwill impairment	(2.9)	(0.7)%	—	— %	\$ (2.9)	
Other expense	(1.0)	(0.2)%	—	— %	\$ (1.0)	
Total other income	1.0	0.2 %	4.4	1.4 %	\$ (3.4)	(77.3 %)
Net income before benefit from (provision for) income tax	22.8	5.2 %	19.8	6.2 %	\$ 3.0	
Benefit from (provision for) income tax	7.9	1.8 %	(0.6)	(0.2)%	\$ 8.5	
Net income	30.7	7.0 %	19.2	6.0 %	\$ 11.5	
Net (loss) attributable to noncontrolling interests	(3.9)	(0.9)%	(4.5)	(1.4)%	\$ 0.6	13.3 %

Net income attributable to stockholders of DocGo Inc. and Subsidiaries						
	\$	34.6	7.9 %	\$	23.7	
				7.4 %	\$	10.9

Revenues

\$ in Millions	Years Ended December 31,		Change	Change
	2022	2021	\$	%
Revenue, net	\$ 440.5	\$ 318.7	\$ 121.8	38 %
Cost of revenues	285.8	209.0	76.8	37 %
Operating expenses:				
General and administrative	103.4	74.9	28.5	38 %
Depreciation and amortization	10.6	7.5	3.1	41 %
Legal and regulatory	8.8	3.9	4.9	126 %
Technology and development	5.4	3.3	2.1	64 %
Sales, advertising and marketing	4.7	4.8	(0.1)	(2) %
Total expenses	418.7	303.4	115.3	38 %
Income (loss) from operations	21.8	15.4	6.5	
Other income (expenses):				
Interest income (expense), net	0.8	(0.8)	1.6	200 %
Gain (loss) from Payroll Protection Program ("PPP") loan forgiveness	-	0.1	(0.1)	
Gain on remeasurement of warrant liabilities	1.1	5.2	(4.1)	
Gain (loss) on equity method investment	-	(0.1)	0.1	
Gain on remeasurement of finance leases	1.4	-	1.4	
Loss on disposal of fixed assets	-	-	-	
Gain on bargain purchase	1.6	-	1.6	
Other income (loss)	(3.9)	-	(3.9)	
Total other income (expense)	1.0	4.4	(3.4)	(77) %
Net income (loss) before income tax benefit (expense)	22.8	19.8	3.3	
Benefit (provision) for income tax	7.9	(0.6)	8.5	
Net income (loss)	30.7	19.2	11.5	60 %
Net loss attributable to noncontrolling interests and Subsidiaries	(3.9)	(4.5)	0.6	13 %
	\$ 34.6	\$ 23.7	10.9	

Consolidated

Consolidated

For the year ended December 31, 2022, total revenues were \$440.5 million, an increase of \$121.8 million, or 38%, from the total revenues recorded in the year ended December 31, 2021.

Mobile Health

Services

For the year ended December 31, 2022, Mobile Health revenue was \$325.9 million, an increase of \$91.4 million, or 39%, as compared with the year ended December 31, 2021. This increase was primarily due to the expansion of the services offered by this segment, particularly with respect to testing, vaccination and other healthcare services revenues. This expansion accelerated through 2021 and into 2022 as the Company increased its customer base, primarily in the municipal customer segment, and its geographic reach, while extending the terms of and/or expanding the scope of several large customer contracts and introducing a broader range of services. Compared to the prior year, 2022 featured significantly lower COVID-19 testing revenue,

which was outweighed by the substantial increase in other Mobile Health **services, Services**, as the Mobile Health **Services** segment transitioned away from its dependence on COVID-19 related revenue. COVID-19 testing continued to be a significant driver of Mobile Health **Services** revenues in the first half of 2022, but dropped sharply in the third quarter of the year, and represented an insignificant proportion of total revenues in the fourth quarter.

Transportation Services

For the year ended December 31, 2022, Transportation Services **revenue was revenues were** \$114.6 million, an increase of \$30.3 million, or 36%, as compared with the year ended December 31, 2021. This increase was due to a 20% increase in **transportation** trip volumes, from 180,753 trips for the year ended December 31, 2021 to 216,009 trips for the year ended December 31, 2022. The increase in trip volumes was due to a combination of growth in the customer base in certain core markets, entry into new markets in 2021 and early 2022 and acquisitions made during the second half of 2022. Our average trip price increased from \$301 in the year ended December 31, 2021, to \$380 in the year ended December 31, 2022. The increase in the average trip price in 2022 reflected a shift in mix toward higher-priced transports with existing customers, as well as the acquisition of licenses to provide higher acuity transports resulting in higher prices per trip. The average trip price also benefited from a 5.1% increase in the average Medicare reimbursement rate for ambulance transports. **In October 2022, the Centers for Medicare and Medicaid Services (CMS) announced that the Medicare ambulance fee schedule would be increasing by a further 8.7%, effective January 1, 2023.**

Cost of Revenue **Revenues**

For the year ended December 31, 2022, total cost of **revenue revenues** (exclusive of depreciation and amortization) increased by 37%, as compared to the year ended December 31, 2021, while **revenue revenues** increased by approximately 38%. Cost of **revenue revenues** as a percentage of **revenue revenues** decreased to 64.9% in 2022 from 65.5% in 2021.

In absolute dollar terms, cost of **revenue revenues** in the year ended December 31, 2022 increased by \$76.8 million from the levels of the year ended December 31, 2021. This was primarily attributable to a \$64.9 million increase in total compensation, due to higher headcount for both the Transportation Services and Mobile Health **Services** segments; a \$16.0 million increase in subcontracted labor, driven mostly by the Mobile Health **Services** segment, where the Company did not have sufficient personnel to staff the initial phases of large new projects; \$13.6 million increase in vehicle costs, driven by a continued increase in the Company's vehicle fleet and higher fuel and maintenance costs, as well as costs incurred to rent vehicles to provide Mobile Health **services; Services**; a \$2.1 million increase in travel costs, due to field personnel and other clinicians who traveled out of their home regions to provide Mobile Health **services; Services**; a \$0.4 million increase in facilities and related costs; and approximately \$2.6 million in increases across a variety of other cost of **revenue revenues** categories relating to the Company's increased scale and geographic presence. These items were partially offset by a \$21.1 million decrease in lab fees related to COVID-19 testing activity, reflecting sharply lower COVID-19 testing activity in the second half of 2022, lower per-test lab fees and a shift toward rapid tests; and a \$1.8 million decline in medical supplies, reflecting a decline in COVID-19 testing activity and improved sourcing of various supplies.

For the Mobile Health **Services** segment, cost of revenues (exclusive of depreciation and amortization) in the year ended December 31, 2022 amounted to \$199.2 million, compared to \$145.2 million in the year ended December 31, 2021. Cost of revenues as a percentage of revenues decreased slightly to 61.1% from 61.9%, due to the increase in revenues and the continued shift away from higher-cost subcontracted labor toward Company personnel during 2022, which was partially offset by higher compensation costs associated with some of the Company's newer projects.

For the Transportation **services Services** segment, cost of revenues (exclusive of depreciation and amortization) in the year ended December 31, 2022 was \$86.5 million, an increase of \$23.1 million, or 36%, from the year ended December 31, 2021. Cost of revenues as a percentage of revenues were essentially unchanged, at 75.5% in 2022 compared to 75.3% in 2021. Increased volumes and higher average trip prices, as described above, combined with lower average hourly wages, as recent market wage pressures began to subside and **as** the Company more effectively managed its staff to reduce overtime hours for field employees, to offset the effects of increased fuel costs. Fuel prices moderated somewhat during the third quarter and in the fourth quarters of 2022, but the full-year average fuel price for 2022 was approximately 29% above the full-year average for 2021. We **anticipate anticipated** that fuel prices **will would** remain at elevated levels for 2023, but we **expect expected** that the full-year average for 2023 **will would** be lower than it was in 2022.

Operating expenses **Expenses**

For the year ended December 31, 2022, operating expenses were \$132.9 million compared to \$94.4 million for the year ended December 31, 2021, an increase of 41%. As a percentage of **revenue, revenues**, operating expenses increased slightly, from 29.6% in 2021 to 30.2% in 2022, despite the significant increase in overall revenues described above, as the Company continued to add to its management infrastructure and incurred a full year's worth of expenses relating to its status as a public company. The increase of \$38.3 million related primarily to a \$20.1 million increase in total compensation, which includes salaries, benefits, bonuses and commissions for both direct and subcontracted labor, reflecting higher headcount driven by the Company's overall growth and expansion; a \$7.1 million increase in legal, accounting and other professional fees related to increased **revenue revenues** and related contract generation and SEC filing-related costs; a \$2.8 million increase in insurance costs reflecting the growth and expansion of the Company, as well as the addition of directors and officers (D&O) insurance in 2022; a \$3.2 million increase in depreciation and amortization charges due to an increase in assets to support revenue growth and capitalized software amortization, including from recently acquired companies; a \$2.3 million increase in rent utility expenses due to the Company's ongoing growth and geographic expansion; a \$2.9 million increase in IT infrastructure, driven by the Company's business and headcount expansion; and a \$0.6 million increase in marketing expenses, driven in part by expenditures made to develop and expand the Company's direct-to-consumer **(DTC) offering** and other

Mobile Health programs. Services. These items were partially offset by a \$0.7 million decline witnessed across several operating expense categories, such as travel, commissions and general office expenses. The Company anticipates that operating expenses will continue to increase along with the Company's revenue growth and remain in the range of 25%-30% of revenue in the coming quarters.

For the Mobile Health Services segment, operating expenses in the year ended December 31, 2022 were \$58.0 million, up 25% from operating expenses of \$46.3 million in the year ended December 31, 2021. Operating expenses as a percentage of revenues decreased to 17.8% from 19.8% in 2021, due to the increase in Mobile Health Services revenues, which outweighed the effect of the significant expenditures that were made in 2022 in the expansion of services and geographic areas of operation, as well as the continued buildout of the Mobile Health Services management infrastructure and the costs of developing the Company's "on-demand" direct-to-consumer offering.

For the Transportation Services segment, operating expenses in the year ended December 31, 2022 were \$74.0 million, up \$26.6 million, or 56%, from the year ended December 31, 2021. Operating expenses as a percentage of revenues increased to 64.6% from 56.3% in the prior year period, 2021, despite the increase in revenues, primarily due to increases in the Company's corporate overhead expenditures, as described above, as these expenses were allocated to the Transportation Services segment for purposes of segment reporting. Operating expenses for the Transportation Services segment were also driven higher by the inclusion of the acquisitions the Company made in the second half of 2022.

Interest Income (Expense), Net

For the year ended December 31, 2022, the Company recorded \$0.8 million of net interest income, net compared to \$0.8 million of interest expense, net in the year ended December 31, 2021. This was due to a significantly higher amount of interest earned during 2022, resulting from an increase in the Company's cash balances in income-bearing accounts, coupled with higher rates of interest earned on balances in these accounts, which reflected significantly higher market interest rates.

Gain/(loss) Gain on Remeasurement of Warrant Liabilities

During the year ended December 31, 2022, the Company recorded a net gain of approximately \$1.1 million from the remeasurement of warrant liabilities. The warrants are were marked-to-market in each reporting period, and this gain reflected the decrease in DocGo's stock price relative to the beginning of the period. During the year ended December 31, 2021, the Company recorded a net gain of \$5.2 million on the remeasurement of warrant liabilities. On August 15, 2022, the Company announced the redemption of all of its outstanding warrants under the Warrant Agreement, dated as of October 14, 2020, by and between Motion the Company and Continental Stock Transfer & Trust Company, as warrant agent, on the redemption date of September 16, 2022 (the "Redemption Date"). Warrants surrendered for exercise on a cashless basis resulted in the issuance of 1,406,371 shares, shares of Common Stock. A total of 68,514 warrants were not surrendered on the Redemption Date and were redeemed for \$0.10 per warrant.

Gain/(Loss) Gain on Equity Method Investment Investments

During the year ended December 31, 2022, the Company recorded a gain on equity method investment investments of \$8,919, representing its share of the losses incurred by an entity in which the Company has a minority interest, which is accounted for under the equity method. This investment was made in the fourth quarter of 2021, during which period a loss of \$66,818 was recorded in relation to this equity method investment.

Gain on Bargain Purchase

During the year ended December 31, 2022, the Company recorded a gain on bargain purchase of approximately \$1.6 million in relation to an acquisition made during the fourth quarter of the year, wherein the tangible net asset value of the acquired entity exceeded the purchase price. No such gain or loss was recorded during the same period in 2021.

Gain/(Loss) from Gain on Remeasurement of Finance Leases

During the year ended December 31, 2022, the Company recorded a gain from on remeasurement of finance leases of approximately \$1.4 million, resulting from a change in estimated remaining liabilities under the terms of its leases. No such gain or loss was recorded in the same period in 2021.

Gain from PPP Loan Forgiveness

In 2021, the Company recorded a \$0.1 million gain due to the forgiveness of a loan that one of its subsidiaries had obtained via the government's Paycheck Protection Program (PPP) ("PPP") in 2020. No gain from loan forgiveness was recorded during the year ended December 31, 2022.

Benefit From (Provision For) Income Tax Benefit (Expense) Taxes

During the year ended December 31, 2022, the Company recorded **an a benefit from** income **tax benefit taxes** of \$7.9 million compared to **an a provision for income tax expense taxes** of \$0.6 million in the year ended December 31, 2021. The tax benefit in 2022 was due to the release of the valuation allowance recorded in previous years for net operating losses, **(NOLs)**, as the Company determined that it was **now** more likely than not that it would be able to realize its **NOL net operating loss** carryforwards in the future.

*Net Loss Attributable to Noncontrolling **Interest***

Interests

For the year ended December 31, 2022, the Company had a net loss attributable to noncontrolling **interest interests** of approximately \$3.8 million compared to a net loss attributable to noncontrolling **interest interests** of \$4.6 million for the year ended December 31, 2021. For both periods, the loss reflected ongoing investments in new markets that were entered into during 2021 and 2022, partially offset by income generated by those markets.

Since Between the inception DocGo has of DocGo's wholly owned subsidiary Ambulnz and the Business Combination, Ambulnz completed three equity financing transactions as its principal source of liquidity. In November 2021, upon the completion of the Business Combination and the PIPE Financing, the Company received proceeds of approximately \$158.1 million, net of transaction expenses. Generally, the Company has utilized proceeds from the equity raised financing transactions and the Business Combination to finance operations, investments invest in assets, ambulance operating licenses make acquisitions and to fund accounts receivable. The Company has also funded these activities through operating cash flows. In November 2021, upon the completion of the merger between Motion and Ambulnz, the Company received proceeds of approximately \$158.1 million, net of transaction expenses. Despite the fact that the Company generated positive net income in for the year ended December 31, 2022 December 31, 2023, operating cash flows are not always sufficient to meet immediate obligations arising from current operations. For example, as the business has grown, the Company's expenditures for human capital and supplies has expanded accordingly, and the timing of the payments for payroll and to associated vendors, compared to the timing of receipts of cash from customers, frequently results in the need to use existing cash balances to fund these working capital needs. During the year ended December 31, 2023, as a greater proportion of the Company's overall revenues were generated through services provided to municipal customers with long payment cycles, and expenditures made by the Company to allow for the provision of these services were substantial, operating cash flows were not sufficient to meet these demands for working capital, leading to a marked decline in the Company's cash balances. As these invoices are collected, the Company expects cash flows to be sufficient for near term working capital needs.

The Company's future working capital needs depend on many factors, including the overall growth of the Company and the various payment terms that are negotiated with customers and vendors. Future The Company's future capital requirements depend on many factors, including potential acquisitions, DocGo's the Company's level of investment in technology and ongoing technology development, and rate of growth in existing markets and into new markets. Capital requirements might also be affected by factors outside of the Company's control, such as interest rates, rising inflation and other monetary and fiscal policy changes to the manner in which the Company currently operates. Additionally, as the impact of the COVID-19 on the economy and on the Company's market environment and operations evolves, the Company routinely assesses its liquidity needs. If the Company's growth rate is higher than is currently anticipated, resulting in greater-than-anticipated capital requirements, the Company might need to, or choose to, raise additional capital through debt or equity financings.

This last factor was evident during the second half of 2023, leading to a draw down in the Company's credit line during the fourth quarter of 2023 and the first quarter of 2024, as described below.

On November 1, 2022, the Company entered into a revolving loan and security agreement with two banks, with one bank acting as the administrative agent (the "Lenders"), with an Credit Agreement, which provides for the Revolving Facility in the initial maximum commitment aggregate principal amount of \$90,000,000, \$90 million. The revolving facility Revolving Facility includes the ability for the Company to request an increase to the commitment by an additional amount of up to \$50,000,000, \$50 million, though no Lender lender (nor the Lenders lenders collectively) are is obligated to increase their its respective commitments. Borrowings under the revolving facility Revolving Facility bear interest at a per annum rate equal to (i) at the Company's option, the (x) the base rate or (y) the adjusted term SOFR rate, plus (ii) the applicable margin. The applicable margins are based on the Company's consolidated net leverage ratio, adjusted on a quarterly basis. The initial applicable margins are were 1.25% for an adjusted term SOFR loan and 0.25% for a base rate loan and will be are updated based on the Company's consolidated net leverage ratio. The revolving facility Revolving Facility matures on November 1, 2027. The revolving facility and is secured by a first-priority lien on substantially all of the Company's present and future personal assets and intangible assets. The revolving facility Revolving Facility is subject to certain financial covenants, such as a net leverage ratio and interest coverage ratio, as defined in the agreement. As Credit Agreement. On October 19, 2023, the Company drew down \$25 million under the Revolving Facility, which amount remained outstanding as of December 31, 2023. In February 2024, the Company repaid all amounts outstanding under the Revolving Facility, and no amounts are outstanding as of the date of the filing of this Annual Report on Form 10-K, the Company has not made any draws under the facility and there are no amounts outstanding.

Report.

Considering the foregoing, DocGo anticipates that its existing balances of cash and cash equivalents, future expected cash flows generated from its operations and its available line of credit under the revolving facility (as further discussed in Note 9, "Line of Credit" to the Consolidated Financial Statements) Revolving Facility will be sufficient to satisfy operating requirements for at least the next twelve months.

Looking beyond the next twelve months, DocGo anticipates that expected future cash flows, its available line of credit and proceeds from potential additional financings will be sufficient to satisfy any operating and potential investing requirements.

Capital Resources

Comparison Working capital as of December 31, 2023 and December 31, 2022 and December 31, 2021 was as follows:

\$ in Millions	December 31,		Change \$	Change %
	2023	2022		
Working capital				
Current assets	\$ 338.9	\$ 271.1	\$ 67.8	25.0 %
Current liabilities	170.1	100.2	70.0	69.8 %
Total working capital	\$ 168.8	\$ 170.9	\$ (2.2)	(1.2 %)

\$ in Millions	As of December 31,		Change \$	Change %
	2022	2021		
Working capital				
Current assets	\$ 271.1	\$ 256.0	\$ 15.1	6 %
Current liabilities	100.2	57.9	42.3	73 %
Total working capital	\$ 170.9	\$ 198.1	\$ (27.2)	(14 %)

As of December 31, 2022 December 31, 2023, available cash totaled \$157.3 million \$59.3 million, which represented a decrease of \$18.2 million \$98.0 million compared to December 31, 2021 December 31, 2022, as changes to working capital reflecting a significant increase in accounts receivable and cash used for acquisitions in 2022 outweighed made during the positive cash flow generated by operations, year ended December 31, 2023. As of December 31, 2022 December 31, 2023, working capital amounted to \$170.9 million \$168.8 million, which represented a decrease of \$27.2 million \$2.2 million compared to December 31, 2021 December 31, 2022, which reflected the decreased cash balance in 2022, 2023. Increased accounts receivable, which reflected the growth of the business and a shift towards higher credit quality customers who have longer payment terms, cycles in 2022, 2023, were outweighed by the increase in current liabilities, which reflected the growth of the business and amounts due to seller and contingent consideration resulting from acquisitions, acquisitions, as well as the draw down of \$25 million under the terms of the Revolving Credit Facility.

Cash Flows

Cash flows as of the years ended December 31, 2023 and 2022 were as follows:

\$ in Millions	Year Ended December 31,		Change \$	Change %
	2023	2022		
Cash flow summary				
Net cash (used in) provided by operating activities	\$ (64.2)	\$ 28.9	\$ (93.1)	(322.1 %)
Net cash used in investing activities	(29.9)	(38.4)	8.5	(22.1 %)
Net cash provided by (used in) financing activities	1.1	(6.2)	7.3	(117.7 %)
Effect of exchange rate changes	1.1	0.7	0.4	57.1 %
Net decrease in cash	\$ (91.9)	\$ (15.0)	\$ (76.9)	512.7 %

Year

Cash flows as of the years ended December 31, 2022 and 2021

\$ in Millions	As of December 31,		Change \$	Change %
	2022	2021		
Cash flow summary				
Net cash provided by/(used in) operating activities	\$ 28.9	\$ (1.9)	\$ 30.8	1,621 %
Net cash provided by/(used in) investing activities	(38.4)	(8.6)	(29.8)	(347 %)
Net cash provided by/(used in) financing activities	(6.2)	155.2	(161.4)	(104 %)
Effect of exchange rate changes	0.7	-	0.7	100 %

Net (decrease) increase in cash	\$ (15.0)	\$ 144.7	\$ (159.7)	(110 %)
---------------------------------	-----------	----------	------------	---------

were as follows:

\$ in Millions	Year Ended December 31,		Change \$	Change %
	2022	2021		
Cash flow summary				
Net cash provided by (used in) operating activities	\$ 28.9	\$ (1.9)	\$ 30.8	1621.1 %
Net cash used in investing activities	(38.4)	(8.6)	(29.9)	(347.7 %)
Net cash (used in) provided by financing activities	(6.2)	155.2	(161.4)	(104.0 %)
Effect of exchange rate changes	0.7	—	0.7	100.0 %
Net (decrease) increase in cash	\$ (15.0)	\$ 144.7	\$ (159.7)	(110.4 %)

Operating Activities

During the year ended December 31, 2023, cash used by operating activities was \$64.2 million, despite net income of \$10.0 million. Non-cash charges amounted to \$38.9 million, which primarily consisted of \$11.2 million in depreciation of property and equipment and right-of-use assets, \$5.2 million from amortization of intangible assets, \$21.0 million of stock compensation expense, a \$0.9 million loss on the disposal of assets and a loss of \$0.3 million from an investment that is accounted for under the equity method and \$3.6 million in bad debt expense. These were partially offset by \$2.0 million in deferred taxes and a non-cash gain of \$1.4 million resulting from a reduction in the fair value of contingent consideration. Changes in assets and liabilities resulted in approximately \$113.1 million in negative operating cash flow, as a \$160.5 million increase in accounts receivable, reflecting the growth of the business and primarily driven by an increased amount of business with municipalities, which tend to have longer payment cycles; a \$1.8 million decrease in accounts payable; and a \$10.8 million increase in prepaid expenses and other current assets were partially offset by a \$59.0 million increase in accrued liabilities and a \$1.0 million decline in other assets.

Operating activities

During the year ended December 31, 2022, cash provided by operating activities was \$28.9 million, aided by net income of \$30.73 million \$30.7 million. Non-cash charges were \$11.3 million and included \$7.3 million in depreciation of property and equipment and right-of-use assets, \$3.2 million from amortization of intangible assets, \$3.8 million in bad debt expense primarily related to a provision for potential uncollectible accounts receivable, \$8.1 million of stock compensation expense and a non-cash loss of \$2.9 million related to the impairment of a business unit that was discontinued at the end of the year. These charges were partially offset by non-cash gains of \$1.4 million relating to the remeasurement of finance lease liabilities, \$1.1 million from the remeasurement of warrant liabilities, \$1.6 million in a gain on a bargain purchase and \$9.9 million in the realization of a deferred tax asset. Changes in assets and liabilities resulted in an approximately \$13.2 million decrease to operating cash flow, as an \$8.4 million increase in accounts receivable, a \$4.2 million increase in prepaid expenses and a \$6.0 million decrease in accrued liabilities outweighed the effect of a \$1.8 million decrease in other assets and a \$3.6 million increase in accounts payable.

During the year ended December 31, 2021, cash used in operating activities was \$1.9 million, despite net income of \$19.2 million. Non-cash charges amounted to \$7.7 million, as \$5.2 million in depreciation of property and equipment and right-of-use assets, \$1.8 million from amortization of intangible assets, \$4.5 million in bad debt expense primarily related to a provision for potential uncollectible accounts receivable and \$1.4 million of stock compensation expense were partially offset by \$5.2 million in a non-cash gain on the remeasurement of warrant liabilities. Changes in assets and liabilities resulted in an approximately \$28.8 million decrease in operating cash flow and were primarily driven by a \$57.1 million increase in accounts receivable arising from the growth of the business, particularly in the fourth quarter of the year, and the inclusion of larger Mobile Health Services customers with extended credit terms; terms, and a \$3.5 million increase in prepaid expenses and other current assets, partially offset by a \$32.6 million increase in accounts payable and accrued expenses due primarily to the extension of credit and timing of payments, as DocGo attempted to align the timing of payments to vendors with the timing of payments received from customers, where possible, in an attempt to manage cash balances.

Investing Activities

During the year ended December 31, 2023, investing activities

used \$29.9 million of cash and consisted of the acquisition of property and equipment totaling approximately \$7.6 million, the acquisition of intangibles in the amount of \$2.5 million, the acquisition of businesses in the amount of \$20.2 million and an equity method investment in the amount of \$0.3 million, partially offset by \$0.7 million in cash proceeds from the disposal of property and equipment.

During the year ended December 31, 2022, cash used in investing activities was \$38.4 million and consisted of the acquisition of property and equipment totaling approximately \$3.2 million, the acquisition of intangibles in the amount of \$2.3 million and \$33.0 million in the acquisition of businesses in

the amount of \$33.0 million, primarily relating to acquisitions the Company completed in the third and fourth quarters of 2022.

During the year ended December 31, 2021, cash used in investing activities was \$8.6 million, primarily consisting of the acquisition of property and equipment totaling \$4.8 million and the acquisition of businesses and intangibles of totaling \$3.1 million to support the ongoing growth of the business. In addition, the Company made an equity investment amounting to approximately \$0.7 million.

Financing Activities

During the year ended December 31, 2023, cash provided by financing activities

was \$1.1 million, including \$25 million in proceeds from the Company's Revolving Facility and \$1.6 million in proceeds from the exercise of stock options, mostly offset by \$4.3 million in payments under the terms of a finance lease, a \$13.6 million decrease in amounts due to seller, \$5.3 million in earnout payments on contingent liabilities and \$2.3 million in payments for taxes related to shares withheld for employee taxes.

During the year ended December 31, 2022, cash used in financing activities was \$6.2 million, including \$3.7 million in the repurchase of Common Stock, \$3.0 million in payments under the terms of a finance lease, a \$2.5 million decrease in amounts due to seller and \$0.9 million in repayments of notes payable, which were partially offset by \$2.1 million in non-controlling interest contributions and \$2.0 million in proceeds from the exercise of stock options.

During the year ended December 31, 2021, cash provided by financing activities was \$155.2 million, due primarily to \$158.1 million in proceeds from the issuance of common stock Common Stock in connection with the Motion merger, Business Combination, which is net of \$20.0 million in issuance costs. This was slightly offset by \$2.2 million in payments on obligations under the terms of a finance lease and \$0.5 million in expenditures to acquire the remaining 20% of the Company's U.K. subsidiary. During 2021, the Company received \$8.0 million in proceeds from a revolving bank loan, which was repaid during the fourth quarter of 2021.

Future minimum annual maturities of notes payable as of December 31, 2022 December 31, 2023 are as follows:

Amounts in millions	Notes Payable
2023	0.6
2024	0.5
2025	0.4
2026	0.3
Thereafter	0.1
Total maturities	\$ 1.9
Current portion of notes payable	(0.7)
Long-term portion of notes payable	\$ 1.2

follows (in thousands):

	Notes Payable
2024	\$ 28.8
2025	25.8
2026	15.1
Total maturities	69.7
Current portion of notes payable	(28.1)
Long-term portion of notes payable	\$ 41.6

Future minimum lease payments under finance leases as of the year ended December 31, 2022 December 31, 2023 are as follows (in millions):

	Finance Leases
2024	\$ 4.1

2025	3.7
2026	2.9
2027	1.5
2028	0.3
Thereafter	—
Total future minimum lease payments	12.5
Less effects of discounting	(1.1)
Present value of future minimum lease payments	\$ 11.4

Amounts in millions	Finance Leases
2023	\$ 3.2
2024	2.4
2025	2.2
2026	1.4
2027 and thereafter	0.4
Total future minimum lease payments	9.6
Less effects of discounting	(1.0)
Present value of future minimum lease payments	\$ 8.6

Future minimum lease payments under operating leases as of the year ended **December 31, 2022** **December 31, 2023** are as follows (in millions):

	Operating Leases
2024	\$ 3.3
2025	3.3
2026	2.4
2027	1.2
2028	0.6
Thereafter	0.3
Total future minimum lease payments	11.1
Less effects of discounting	(1.1)
Present value of future minimum lease payments	\$ 10.0

Amounts in millions	Operating Leases
2023	\$ 2.8
2024	2.3
2025	2.3
2026	1.7
2027 and thereafter	1.6
Total future minimum lease payments	10.7
Less effects of discounting	(1.3)
Present value of future minimum lease payments	\$ 9.4

Critical Accounting Policies

Basis of Presentation

The Company's Consolidated Financial Statements are presented in conformity with accounting principles generally accepted in the U.S. ("U.S. GAAP") and pursuant to the rules and regulations of the SEC. The Consolidated Financial Statements include the accounts and operations of the Company and

its wholly-owned subsidiaries. All intercompany accounts and transactions are eliminated upon consolidation. Noncontrolling interests (“NCI”) on the Consolidated Balance Sheets represents the portion of consolidated joint ventures and a variable interest entity (“VIE”) in which the Company does not have direct equity ownership. Accounts and transactions between consolidated entities have been eliminated.

Pursuant to the Business Combination the merger between Motion and Ambulnz was accounted for as a reverse recapitalization in accordance with U.S. GAAP (the “Reverse Recapitalization”). Under this method of accounting, Motion the Company was treated as the “acquired” company for financial reporting purposes. Accordingly, for accounting purposes, the Reverse Recapitalization was treated as the equivalent of Ambulnz stock for the net assets of Motion, the Company, accompanied by a recapitalization. The net assets of Motion the Company are stated at historical cost, with no goodwill or other intangible assets recorded. The consolidated assets, liabilities and results of operations prior to the Reverse Recapitalization are those of Ambulnz. The shares of common stock and corresponding capital amounts and earnings per share available for common stockholders, prior to the Business Combination, have been retroactively restated as shares of the Company, reflecting the exchange ratio (645.1452 to 1) established in the Business Combination. Further, Ambulnz was determined to be the accounting acquirer in the transaction, transaction; as such, the acquisition is considered to be a business combination under Accounting Standards Codification (“ASC”), Topic 805, *Business Combinations* (“ASC 805”) and was accounted for using the acquisition method of accounting.

Principles of Consolidation

The In accordance with ASC 810, *Consolidation* (“ASC 810”), the Company holds assesses whether it has a variable interest in an entity legal entities in which contracts it has a financial relationship and, if so, whether or not those entities are VIEs. For those entities that qualify as VIEs, ASC 810 requires the Company to determine if the Company is the primary beneficiary of the VIE, and if so, to consolidate the VIE.

The Company holds variable interests in legal entities that contract with physicians and other health professionals in order to provide services to the Company. MD1 Medical Care P.C. (“MD1”) is These entities are considered a variable interest entity (“VIE”) VIEs since it does they do not have sufficient equity to finance its their activities without additional subordinated financial support. An enterprise having a controlling financial interest in a VIE must consolidate the VIE if it has both power and benefits—that is the primary beneficiary, meaning it has (1) the power to direct the activities of a the VIE that most significantly impacts the VIE’s economic performance (power) and (2) the obligation to absorb losses of the VIE that potentially could be significant to the VIE or the right to receive benefits from the VIE that potentially could be significant to the VIE (benefits). The Company has the power and rights to control all activities of MD1 its VIEs and funds and absorbs all losses of its VIEs. The Company has determined that it is the VIE primary beneficiary of its VIEs and therefore appropriately consolidates MD1.

its VIEs.

Total revenue for the VIE amounted to \$2,857,463 as of December 31, 2022. Net loss for the VIE was Company’s VIEs were \$235,976, \$373,456 as of December 31, 2022, and \$122,982 for the years ended December 31, 2023, 2022 and 2021, respectively. The VIE’s total assets all of which were current, amounted to \$4,364,274 and \$610,553 as of December 31, 2022, on December 31, 2023 and 2022, respectively. Total liabilities all of which were current for the VIE, was \$4,811,857 and \$320,424 as of December 31, 2022, on December 31, 2023 and 2022, respectively. The VIE’s Company’s VIEs total stockholders’ deficit was were \$447,583 and \$290,130 as of December 31, 2022. The Company made payments of \$3,018,119 on December 31, 2023 and \$1,746,736 to MD1 and its affiliates during the years ended December 31, 2022 and 2021, 2022, respectively.

Business Combinations

The Company accounts for its business combinations under the provisions of ASC 805-10, *Business Combinations* (“ASC 805-10”), which requires that the acquisition method of accounting be used for all business combinations. Assets acquired and liabilities assumed, including NCI, noncontrolling interests, are recorded at the date of acquisition at their respective fair values. ASC 805-10 also specifies criteria that intangible assets acquired in a business combination must meet to be recognized and reported apart from goodwill.

Goodwill represents the excess purchase price over the fair value of the tangible net assets and intangible assets acquired in a business combination. If the business combination provides for contingent consideration, the Company records the contingent consideration at fair value at the acquisition date and any changes in fair value after the acquisition date are accounted for as measurement-period adjustments. Changes in fair value of contingent consideration resulting from events after the acquisition date, such as earn-outs, are recognized as follows: 1) if the contingent consideration is classified as equity, the contingent consideration is not re-measured and its subsequent settlement is accounted for within equity, or 2) if the contingent consideration is classified as a liability, the changes in fair value are recognized in earnings. For transactions that are business combinations, the Company evaluates the existence of goodwill or a gain from a bargain purchase. The Company capitalizes acquisition-related costs and fees associated with asset acquisitions and immediately expenses acquisition-related costs and fees associated with business combinations.

The estimated fair value of net assets to be acquired, including the allocation of the fair value to identifiable assets and liabilities, is determined using established valuation techniques. Management uses assumptions on the basis of historical knowledge of the business and projected financial information of the target. These assumptions may vary based on future events, perceptions of different market participants and other factors outside the control of management, and such variations may be significant to estimated values.

Goodwill and Indefinite-Lived Intangible Assets

Goodwill represents the excess of the total purchase consideration over the fair value of the identifiable assets acquired and liabilities assumed in a business combination. Goodwill is not amortized but is tested for impairment at the reporting unit level annually on December 31 or more frequently if events or changes in circumstances indicate that it is more likely than not to be impaired. These events include: (i) severe adverse industry or economic trends; (ii) significant company-specific actions, including exiting an activity in conjunction with restructuring of operations; (iii) current, historical or projected deterioration of our financial performance; or (iv) a sustained decrease in our market capitalization, as indicated by our publicly quoted share price, below our net book value.

On February 3, 2023, Ambulnz Health, LLC (“Health”), commenced an assignment for the benefit of creditors (“ABC”) pursuant to California law. An ABC is a liquidation process governed by state law (California law in this instance) that is an alternative to a bankruptcy case under federal law. Prior to commencing the ABC, Health ceased business operations and all of its employees were terminated and treated in accordance with California law. In the ABC, all of Health’s assets were transferred to an assignee (the “Assignee”) who acts as a fiduciary for creditors and in a capacity equivalent to that of a bankruptcy trustee. The Assignee is responsible for liquidating the assets. Similar to a bankruptcy case, there is a claims process. Creditors of Health will receive received notice of the ABC and a proof of claim form and are were required to submit a proof of claim in order to participate in distribution of net liquidation proceeds by the Assignee.

Based on such filing for Health, the Company impaired the goodwill assigned to that reporting unit as of December 31, 2022 by approximately \$5.1 million.

Revenue Recognition

On January 1, 2019, the Company adopted ASU 2014-09, ASC 606, *Revenue from Contracts with Customers* ("ASC 606"), as amended.

To determine revenue recognition for contractual arrangements that the Company determines are within the scope of ASC 606, the Company performs the following five steps: (1) identify each contract with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to performance obligations in the contract; and (5) recognize revenue when (or as) the relevant performance obligation is satisfied. The Company only applies the five-step model to contracts when it is probable that the Company will collect the consideration it is entitled to in exchange for the goods or services the Company provides to the customer.

The Company generates revenues from the provision of (1) ambulance and medical transportation services ("Transportation Services") Mobile Health Services and (2) Mobile Health services, Transportation Services. The customer simultaneously receives and consumes the benefits provided by the Company as the performance obligations are fulfilled, fulfilled; therefore the Company satisfies performance obligations immediately. The Company has utilized the "right to invoice" expedient, which allows an entity to recognize revenue in the amount of consideration to which the entity has the right to invoice when the amount that the Company has the right to invoice corresponds directly to the value transferred to the customer. Revenues are recorded net of an estimated contractual allowances for claims subject to contracts with responsible paying entities. The Company estimates contractual allowances at the time of billing based on contractual terms, historical collections or other arrangements. All transaction prices are fixed and determinable, which includes a fixed base rate, fixed mileage rate and an evaluation of historical collections by each payor.

Income Taxes

Income taxes are recorded in accordance with ASC 740, *Income Taxes* ("ASC 740"), which provides for deferred taxes using an asset and liability approach. The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or its tax returns. Deferred tax assets and liabilities are determined based on the difference between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Valuation allowances are provided if based upon the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. The Company accounts for uncertain tax positions in accordance with the provisions of ASC 740. When uncertain tax positions exist, the Company recognizes the tax benefit of tax positions to the extent that the benefit would more likely than not be realized assuming examination by the taxing authority. The determination as to whether the tax benefit will more likely than not be realized is based upon the technical merits of the tax position as well as consideration of the available facts and circumstances. The Company recognizes any interest and penalties accrued related to unrecognized tax benefits as income tax expense.

Please see Note 2, "Summary of Significant Accounting Policies" to the Consolidated Financial Statements.

Item 7A. Quantitative and Qualitative Disclosures About Market Risk.

Market Risks

We are exposed to certain market risks, including those relating to changes in interest rates and foreign currency exchange rates. We do not enter into instruments for trading or speculative purposes.

Interest Rate Risk

We are subject to interest rate risk relating to our cash equivalents and borrowings under our Revolving Facility, which bear interest at a smaller reporting company, as defined by Rule 12b-2 per annum rate equal to (i) at our option, (x) the base rate or (y) the adjusted term SOFR rate, plus (ii) the applicable margin. The applicable margins are based on the Company's consolidated net leverage ratio, adjusted on a quarterly basis. As of December 31, 2023, the Company had \$25 million outstanding under the Securities Revolving Facility. In February 2024, the Company repaid all amounts outstanding under the Revolving Facility, and no amounts are outstanding as of the date of this Annual Report. While the applicable interest rate is set for a specific term when amounts are drawn down under the terms of the Revolving Facility, any subsequent draws on the Revolving Facility may be subject to a higher or lower interest rate, depending upon, among other things, the then-prevailing SOFR rate. We have not utilized interest rate hedging or other strategies in an attempt to mitigate our interest rate risk. A hypothetical 10% change in interest rates during the year ended December 31, 2023 would have had a neutral net impact on our Consolidated Financial Statements, as changes in amounts paid for interest expense would have offset changes in interest income earned on cash balances.

Foreign Exchange Act Risk

We operate our business primarily within the United States and currently execute a majority of 1934 our transactions in U.S. dollars. However, we are exposed to limited foreign exchange risk as a result of our U.K. operations. The foreign exchange gain (loss) amounted to \$4,022 to the Company for the year ended December 31, 2023, compared to \$(20,423) and \$(45,826) in the years ended December 31, 2022 and 2021, respectively. We have not utilized hedging or other strategies with respect to such foreign exchange exposure. This limited foreign currency translation risk is not expected to have a material impact on our Consolidated Financial Statements. A hypothetical 10% change in the applicable foreign exchange rate during the year ended December 31, 2023 would have resulted in a change in total revenues of approximately 0.7% and a change in total assets of approximately 0.9%.

Concentrations of Risk

Our financial instruments that are exposed to concentrations of credit risk consist primarily of cash, cash equivalents, restricted cash and accounts receivable.

Although we deposit our cash, cash equivalents and restricted cash with multiple financial institutions in the United States and in Item 10(f)(1) foreign countries, our deposits, at times, may exceed federally insured limits. We do not believe we are exposed to significant credit risk due to the financial strength of Regulation S-K, the depository institutions in which the funds are held.

With respect to accounts receivable, for the year ended December 31, 2023, the Company had one customer that accounted for approximately 40% of revenues and are 42% of net accounts receivable and another customer accounted for approximately 21% of revenues and 40% of net accounts receivable. For the year ended December 31, 2022, the Company had one customer that accounted for 35% of revenues and 45% of net accounts receivable. For the year ended December 31, 2021, the Company had one customer that accounted for approximately 23% of revenues and 26% of net accounts receivable and another customer that accounted for 26% of revenues and 24% of net accounts receivable. We perform ongoing evaluations of customers' financial condition, creditworthiness and payment performance. Based on these evaluations, we consider whether or not required the accounts receivable exposure to provide the information under this item.

any specific customer is within an acceptable range for that customer.

Item 8. Financial Statements and Supplementary Data.

DocGo Inc. and Subsidiaries

Index to the Consolidated Financial Statements

Reports of Independent Registered Public Accounting Firm (PCAOB ID: 1013)1013	F-2 F-2
Consolidated Balance Sheets as of December 31, 2022 December 31, 2023 and 2021 2022	F-3 - F-4 F-5
Consolidated Statements of Operations and Comprehensive Income for the Years Ended December 31, 2022 December 31, 2023, 2022 and 2021 2021	F-5 F-7
Consolidated Statements of Changes in Stockholders' Equity for the Years Ended December 31, 2022 December 31, 2023, 2022 and 2021 2021	F-6 F-8
Consolidated Statements of Cash Flows for the Years Ended December 31, 2022 December 31, 2023, 2022 and 2021 2021	F-7 - F-8 F-10
Notes to Consolidated Financial Statements	F-9 - F-37 F-12

Report of Independent Registered Public Accounting Firm

Opinion on the Consolidated Financial Statements

We have audited the accompanying consolidated balance sheets of DocGo, Inc. and Subsidiaries (the “Company”) as of **December 31, 2022** **December 31, 2023** and **2021**, 2022, the related consolidated statements of operations and comprehensive income, changes in stockholders’ equity, and cash flows for each of the three years **then in the period** ended **December 31, 2023**, and the related notes (collectively referred to as the “consolidated financial statements”). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of **December 31, 2022** at **December 31, 2023** and **2021**, 2022, and the results of its operations and **comprehensive income (loss)** and its cash flows for **each of the three years then in the period** ended **December 31, 2023**, in conformity with accounting principles generally accepted in the United States of America.

We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (“PCAOB”), the Company’s internal control over financial reporting as of December 31, 2023, based on criteria established in *Internal Control – Integrated Framework (2013)* issued by the Committee of Sponsoring Organizations of the Treadway Commission (“COSO”) and our report dated February 28, 2024 expressed an unqualified opinion thereon.

Basis for Opinion

These consolidated financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s consolidated financial statements based on our audits. We are a public accounting firm registered with the **Public Company Accounting Oversight Board (United States) (“PCAOB”)** PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. **The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion.**

Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion.

Critical Audit Matters

The critical audit matters communicated below are matters arising from the current period audit of the consolidated financial statements that were communicated or required to be communicated to the audit committee and that: (1) relates to accounts or disclosures that are material to the consolidated financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matters below, providing separate opinions on the critical audit matters or on the accounts or disclosures to which they relate.

Loss allowance for Accounts Receivable

As described in Note 2 to the consolidated financial statements, the Company recorded consolidated accounts receivable of approximately \$262.1 million net of a loss allowance of approximately \$6.3 million at December 31, 2023. The allowance is management’s estimate of loss allowance on accounts receivable after considering quantitative and qualitative factors, applied for accounts receivables without a significant financing component by using a loss provision. Management makes periodic as well as individual assessments on the recoverability of accounts receivables based on customer historical credit loss experience, and where necessary, adjusted for information based on macroeconomic factors affecting the ability of its customers to settle the accounts receivables. Accounts receivables from customers with known financial difficulties or with significant doubt on collection of receivables are assessed individually for a loss allowance. Management assesses other customers by grouping them based on shared credit risk characteristics including geographical location, service type and payor.

The principal considerations for our determination that performing procedures relating to the loss allowance for accounts receivables is a critical audit matter are the significant judgment by management in determining the loss allowance for accounts receivable as influenced by qualitative factors in particular, which led to a high level of auditor judgment, subjectivity and effort in performing procedures and evaluating audit evidence obtained.

The primary procedures we performed to address this critical audit matter included:

- Testing the effectiveness of controls relating to the loss allowance for trade receivables.
- Testing management's process included (i) evaluating the appropriateness of the methodology and models; (ii) testing the completeness and accuracy of certain data used in the estimate; (iii) evaluating management's process to identify customers with known financial difficulties; and (iv) evaluating the reasonableness of significant assumptions and judgments made by management to estimate the loss allowance for accounts receivable, including the grouping of accounts receivables based on type of service and historical collections.

Revenue Recognition – Transport Services

As described in Note 2 to the consolidated financial statements, the Company recorded transport services revenue of approximately \$181.5 million. Transport revenues are recorded net of an estimated contractual allowances for claims subject to contracts with responsible paying entities. The Company estimates contractual allowances at the time of billing based on contractual terms and historical collections by each payor and geographical location.

The principal considerations for our determination that performing procedures relating to the transport revenue is a critical audit matter are the significant judgement by management in determining the lookback periods of historical collections which led to a high level of auditor judgment, subjectivity, and effort in performing procedures.

The primary procedures we performed to address this critical audit matter included:

- Testing the effectiveness of controls relating to transport services revenue recognition.
- Testing the Company's process included (i) selected a sample of transactions and verified the transport service has been performed (ii) obtained supporting cash collections for a sample of transactions (iii) obtained the Company's historical collections for recent completed services, verified the receipts and recalculated the applied historical rate to the recorded revenue (iv) obtained the Company's historical collections and verified these collections to ensure appropriate reserves for unpaid, open services.

/s/ Urish Popeck & Co., LLC

We have served as the Company's auditor since 2021.

Pittsburgh, PA
March 14, 2023

Pittsburgh, PA

February 28, 2024

Report of Independent Registered Public Accounting Firm

Shareholders and Board of Directors

DocGo, Inc. and Subsidiaries

New York, New York

Opinion on Internal Control over Financial Reporting

We have audited DocGo Inc. and Subsidiaries' (the "Company's") internal control over financial reporting as of December 31, 2023, based on criteria established in *Internal Control – Integrated Framework (2013)* issued by the Committee of Sponsoring Organizations of the Treadway Commission (the "COSO criteria"). In our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of December 31, 2023, based on the COSO criteria.

We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) ("PCAOB"), the consolidated balance sheets of DocGo, Inc. and Subsidiaries (the "Company") as of December 31, 2023 and 2022, the related consolidated statements of operations and comprehensive income, changes in stockholders' equity, and cash flows for each of the three years in the period ended December 31, 2023, and the related notes (collectively referred to as the "consolidated financial statements") and our report dated February 28, 2024 expressed an unqualified opinion thereon.

Basis for Opinion

The Company's management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting, included in the accompanying Item 9A, Management's Report on Internal Control over Financial Reporting. Our responsibility is to express an opinion on the Company's internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audit of internal control over financial reporting in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects. Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. Our audit also included performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.

Definition and Limitations of Internal Control over Financial Reporting

A company's internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements.

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

/s/ Urish Popeck & Co., LLC

Pittsburgh, PA

February 28, 2024

DocGo Inc. and Subsidiaries

CONSOLIDATED BALANCE SHEETS

	December 31,	
	2023	2022
ASSETS		
Current assets:		
Cash and cash equivalents	\$ 59,286,147	\$ 157,335,323
Accounts receivable, net of allowance of \$6,276,454 and \$7,818,702 as of December 31, 2023 and December 31, 2022, respectively	262,083,462	102,995,397
Assets held for sale	—	4,480,344
Prepaid expenses and other current assets	17,499,953	6,269,841
Total current assets	338,869,562	271,080,905
Property and equipment, net	16,835,484	21,258,175
Intangibles, net	37,682,928	22,969,246
Goodwill	47,539,929	38,900,413
Restricted cash	12,931,839	6,773,751
Operating lease right-of-use assets	9,580,535	9,074,277
Finance lease right-of-use assets	12,003,919	9,039,663
Equity method investments	553,573	597,977
Deferred tax assets	11,888,539	9,957,967
Other assets	2,565,649	3,625,254
Total assets	<u>\$ 490,451,957</u>	<u>\$ 393,277,628</u>
LIABILITIES AND STOCKHOLDERS' EQUITY		
Current liabilities:		
Accounts payable	\$ 19,827,258	\$ 21,582,866
Accrued liabilities	91,340,609	31,573,031
Line of credit	25,000,000	—
Notes payable, current	28,131	664,913
Due to seller	7,823,009	26,244,133
Contingent consideration	19,792,982	10,555,540
Operating lease liability, current	2,773,020	2,325,024
Liabilities held for sale	—	4,480,344
Finance lease liability, current	3,534,073	2,732,639
Total current liabilities	170,119,082	100,158,490
Notes payable, non-current	41,586	1,236,601
Operating lease liability, non-current	7,223,941	7,040,982
Finance lease liability, non-current	7,896,392	5,914,164
Total liabilities	<u>185,281,001</u>	<u>114,350,237</u>
Commitments and contingencies		

Stockholders' equity:

Common stock (\$0.0001 par value; 500,000,000 shares authorized as of December 31, 2023 and December 31, 2022; 104,055,168 and 102,411,162 shares issued and outstanding as of December 31, 2023 and December 31, 2022, respectively)

	10,406	10,241
Additional paid-in-capital	320,693,866	301,451,435
Accumulated deficit	(21,394,310)	(28,972,216)

	December 31,	
	2022	2021
ASSETS		
Current assets:		
Cash and cash equivalents	\$ 157,335,323	\$ 175,537,221
Accounts receivable, net of allowance of \$7,818,702 and \$7,377,389 as of December 31, 2022 and December 31, 2021, respectively	102,995,397	78,383,614
Prepaid expenses and other current assets	6,269,841	2,111,656
Assets held for sale	4,480,344	-
Total current assets	271,080,905	256,032,491
Property and equipment, net	21,258,175	12,733,889
Intangibles, net	22,969,246	10,678,049
Goodwill	38,900,413	8,686,966
Restricted cash	6,773,751	3,568,509
Operating lease right-of-use assets	9,074,277	4,195,682
Finance lease right-of-use assets	9,039,663	9,307,113
Equity method investment	597,977	589,058
Deferred tax assets	9,957,967	-
Other assets	3,625,254	3,810,895
Total assets	\$ 393,277,628	\$ 309,602,652
LIABILITIES AND STOCKHOLDERS' EQUITY		
Current liabilities:		
Accounts payable	\$ 21,582,866	\$ 15,833,970
Accrued liabilities	31,573,031	35,110,877
Line of credit	-	25,881
Notes payable, current	664,913	600,449
Due to seller	26,244,133	1,571,419
Contingent consideration	10,555,540	-
Operating lease liability, current	2,325,024	1,461,335
Liabilities held for sale	4,480,344	-
Finance lease liability, current	2,732,639	3,271,990
Total current liabilities	100,158,490	57,875,921
Notes payable, non-current	1,236,601	1,302,839
Operating lease liability, non-current	7,040,982	2,980,946
Finance lease liability, non-current	5,914,164	6,867,420
Warrant liabilities	-	13,518,502
Total liabilities	114,350,237	82,545,628

DocGo Inc. and Subsidiaries**CONSOLIDATED BALANCE SHEETS (CONTINUED)**

	December 31,	
	2023	2022
Accumulated other comprehensive income	1,484,905	741,206
Total stockholders' equity attributable to DocGo Inc. and Subsidiaries	300,794,867	273,230,666
Noncontrolling interests	4,376,089	5,696,725
Total stockholders' equity	305,170,956	278,927,391
Total liabilities and stockholders' equity	\$ 490,451,957	\$ 393,277,628

The accompanying notes are an integral part of these Consolidated Financial Statements.

DocGo Inc. and Subsidiaries

CONSOLIDATED BALANCE SHEETS (CONTINUED)

STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME

	Year Ended December 31,		
	2023	2022	2021
Revenues, net	\$ 624,288,642	\$ 440,515,746	\$ 318,718,580
Expenses:			
Cost of revenues (exclusive of depreciation and amortization, which is shown separately below)	428,906,225	285,794,520	208,971,062
Operating expenses:			
General and administrative	137,152,512	103,403,416	74,892,828
Depreciation and amortization	16,431,892	10,565,578	7,511,579
Legal and regulatory	13,082,569	8,780,590	3,907,660
Technology and development	10,858,724	5,384,853	3,320,183
Sales, advertising and marketing	2,801,740	4,755,161	4,757,970
Total expenses	609,233,662	418,684,118	303,361,282
Income from operations	15,054,980	21,831,628	15,357,298
Other income:			
Interest income (expense), net	1,684,399	762,685	(763,030)
Gain on remeasurement of warrant liabilities	—	1,127,388	5,199,496
Change in fair value of contingent liability	1,437,525	—	—
(Loss) gain on equity method investments	(343,336)	8,919	(66,818)
(Loss) gain on remeasurement of operating and finance leases	(866)	1,388,273	—

Gain on bargain purchase	—	1,593,612	—
Gain from PPP loan forgiveness	—	—	142,667
Loss on disposal of fixed assets	(852,544)	(21,173)	(34,342)
Goodwill impairment	—	(2,921,958)	—
Other expense	(686,865)	(987,482)	(40,086)
Total other income	1,238,313	950,264	4,437,887
Net income before (provision for) benefit from income tax	16,293,293	22,781,892	19,795,185
(Provision for) benefit from income taxes	(6,244,965)	7,961,321	(615,697)
Net income	10,048,328	30,743,213	19,179,488
Net income (loss) attributable to noncontrolling interests	3,189,873	(3,841,285)	(4,564,270)
Net income attributable to stockholders of DocGo Inc. and Subsidiaries	6,858,455	34,584,498	23,743,758
Other comprehensive income			
Foreign currency translation adjustment	743,699	773,707	16,038
Total comprehensive income	\$ 7,602,154	\$ 35,358,205	\$ 23,759,796
Net income per share attributable to DocGo Inc. and Subsidiaries - Basic	\$ 0.07	\$ 0.34	\$ 0.30
Weighted-average shares outstanding - Basic	103,511,299	101,228,369	80,293,959
Net income per share attributable to DocGo Inc. and Subsidiaries - Diluted	\$ 0.06	\$ 0.34	\$ 0.25
Weighted-average shares outstanding - Diluted	105,617,817	102,975,831	94,863,613

	December 31,	
	2022	2021
Commitments and contingencies		
STOCKHOLDERS' EQUITY:		
Class A common stock (\$0.0001 par value; 500,000,000 shares authorized as of December 31, 2022 and December 31, 2021; 102,411,162 and 100,133,953 shares issued and outstanding as of December 31, 2022 and December 31, 2021, respectively)	10,241	10,013
Additional paid-in-capital	301,451,435	283,161,216
Accumulated deficit	(28,972,216)	(63,556,714)
Accumulated other comprehensive income/(loss)	741,206	(32,501)
Total stockholders' equity attributable to DocGo Inc. and Subsidiaries	273,230,666	219,582,014
Noncontrolling interests	5,696,725	7,475,010
Total stockholders' equity	278,927,391	227,057,024
Total liabilities and stockholders' equity	\$ 393,277,628	\$ 309,602,652

The accompanying notes are an integral part of these Consolidated Financial Statements.

DocGo Inc. and Subsidiaries

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME

CHANGES IN STOCKHOLDERS' EQUITY

	Series A Preferred						Accumulated				
	Stock		Class A Common Stock		Class B Common Stock		Additional	Other		Total	
	Shares	Amount	Shares	Amount	Shares	Amount	Paid-in-Capital	Accumulated Deficit	Comprehensive (Loss) Income	Noncontrolling Interests	Stockholders' Equity
Balance - December 31, 2020	28,055	\$ —	35,497	\$ —	55,008	\$ —	\$ 142,346,852	\$ (87,300,472)	\$ (48,539)	\$ 11,949,200	\$ 66,947,041
Effect of reverse acquisition	18,099,548	—	22,900,719	—	35,488,938	—	—	—	—	—	—
Conversion of share due to merger recapitalization	(18,099,548)	—	(22,900,719)	7,649	(35,488,938)	—	—	—	—	—	7,649
Effect of reverse acquisition	—	—	76,489,205	7,649	—	—	142,346,852	(87,300,472)	(48,539)	11,949,200	66,954,690
Share issued for services	—	—	171,608	17	—	—	—	—	—	—	17
Exercise of cashless warrants	—	—	1,817,507	182	—	—	—	—	—	—	182
Issuance of shares net redemption and issuance costs of \$9,566,304	—	—	5,297,097	530	—	—	43,404,558	—	—	—	43,405,088
PIPE, net of issuance costs of \$10,396,554	—	—	12,500,000	1,250	—	—	114,602,318	—	—	—	114,603,568
Exercise of stock options	—	—	1,235,131	123	—	—	628,469	—	—	—	628,592
Stock based compensation	—	—	—	—	—	—	1,376,353	—	—	—	1,376,353
Fair value of Warrants from reverse acquisition	—	—	—	—	—	—	(18,717,998)	—	—	—	(18,717,998)
UK Ltd. Shares purchase	—	—	50,192	5	—	—	(479,336)	—	—	(242,945)	(722,276)
Sponsor Earnout shares	—	—	2,573,213	257	—	—	—	—	—	—	257
Noncontrolling interest contribution	—	—	—	—	—	—	—	—	—	333,025	333,025
Foreign currency translation	—	—	—	—	—	—	—	—	16,038	—	16,038
Net loss attributable to noncontrolling interests	—	—	—	—	—	—	—	—	—	(4,564,270)	(4,564,270)
Net income attributable to stockholders of DocGo Inc. and Subsidiaries	—	—	—	—	—	—	—	23,743,758	—	—	23,743,758
Balance - December 31, 2021	—	\$ —	100,133,953	\$ 10,013	—	\$ —	\$ 283,161,216	\$ (63,556,714)	\$ (32,501)	\$ 7,475,010	\$ 227,057,024
Equity cost	—	—	—	—	—	—	(19,570)	—	—	—	(19,570)
Noncontrolling interest contribution	—	—	—	—	—	—	—	—	—	2,063,000	2,063,000
Common stock repurchased	—	—	(536,839)	(54)	—	—	(3,731,658)	—	—	—	(3,731,712)
Exercise of stock options	—	—	1,053,401	105	—	—	1,980,674	—	—	—	1,980,779
Cashless exercise of options	—	—	354,276	36	—	—	(230)	—	—	—	(194)
Stock based compensation	—	—	—	—	—	—	7,183,992	—	—	—	7,183,992
Restricted stock units	—	—	—	—	—	—	495,579	—	—	—	495,579
Share warrants conversion	—	—	1,406,371	141	—	—	12,381,432	—	—	—	12,381,573
Net loss attributable to noncontrolling interests	—	—	—	—	—	—	—	—	—	(3,841,285)	(3,841,285)
Foreign currency translation	—	—	—	—	—	—	—	—	773,707	—	773,707

Net income attributable to												
stockholders												
of DocGo Inc. and												
Subsidiaries	—	—	—	—	—	—	—	34,584,498	—	—	—	34,584,498
Balance - December 31, 2022	—	\$ —	102,411,162	\$ 10,241	—	\$ —	\$ 301,451,435	\$ (28,972,216)	\$ 741,206	\$ 5,696,725	\$ 278,927,391	
UK Ltd. restricted stock	—	—	—	—	—	—	167,175	—	—	—	—	167,175
Health liquidation	—	—	—	—	—	—	—	70,284	—	—	—	70,284
Acquisition of CRMS	—	—	117,330	12	—	—	1,000,000	—	—	—	—	1,000,012

	Years Ended December 31	
	2022	2021
Revenue, net	\$ 440,515,746	\$ 318,718,580
Expenses:		
Cost of revenues (exclusive of depreciation and amortization, which is shown separately below)	285,794,520	208,971,062
Operating expenses:		
General and administrative	103,403,416	74,892,828
Depreciation and amortization	10,565,578	7,511,579
Legal and regulatory	8,780,590	3,907,660
Technology and development	5,384,853	3,320,183
Sales, advertising and marketing	4,755,161	4,757,970
Total expenses	418,684,118	303,361,282
Income from operations	21,831,628	15,357,298
Other income (expenses):		
Interest income (expense), net	762,685	(763,030)
Gain on remeasurement of warrant liabilities	1,127,388	5,199,496
Gain (loss) on equity method investment	8,919	(66,818)
Gain on remeasurement of finance leases	1,388,273	-
Gain on bargain purchase	1,593,612	-
Gain from PPP loan forgiveness	-	142,667
Loss on disposal of fixed assets	(21,173)	(34,342)
Goodwill impairment	(2,921,958)	-
Other expenses	(987,482)	(40,086)
Total other income	950,264	4,437,887
Net income before income tax benefit (expense)	22,781,892	19,795,185
Benefit (provision) for income tax	7,961,321	(615,697)
Net income	30,743,213	19,179,488
Net loss attributable to noncontrolling interests	(3,841,285)	(4,564,270)
Net income attributable to stockholders of DocGo Inc. and Subsidiaries	34,584,498	23,743,758
Other comprehensive income		
Foreign currency translation adjustment	773,707	16,038
Total comprehensive income	\$ 35,358,205	\$ 23,759,796
Net income per share attributable to DocGo Inc. and Subsidiaries – Basic	\$ 0.34	\$ 0.30
Weighted-average shares outstanding – Basic	101,228,369	80,293,959
Net income per share attributable to DocGo Inc. and Subsidiaries – Diluted	\$ 0.34	\$ 0.25
Weighted-average shares outstanding – Diluted	102,975,831	94,863,613

DocGo Inc. and Subsidiaries

CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (CONTINUED)

Acquisition of FMC NA	—	—	360,145	36	—	—	(1,432,963)	649,167	—	(3,213,956)	(3,997,716)
Acquisition of Healthworx	—	—	—	—	—	—	—	—	—	(1,296,553)	(1,296,553)
Exercise of stock options	—	—	465,429	46	—	—	1,413,962	—	—	—	1,414,008
Cashless exercise of options	—	—	6,374	1	—	—	(1)	—	—	—	—
Shares withheld for taxes	—	—	(280,654)	(27)	—	—	(2,308,927)	—	—	—	(2,308,954)
Stock-based compensation	—	—	975,382	97	—	—	20,403,185	—	—	—	20,403,282
Net loss attributable to noncontrolling interests	—	—	—	—	—	—	—	—	—	3,189,873	3,189,873
Foreign currency translation	—	—	—	—	—	—	—	—	743,699	—	743,699
Net income attributable to stockholders of DocGo Inc. and Subsidiaries	—	—	—	—	—	—	—	6,858,455	—	—	6,858,455
Balance - December 31, 2023	—	\$ —	104,055,168	\$ 10,406	—	\$ —	\$ 320,693,866	\$ (21,394,310)	\$ 1,484,905	\$ 4,376,089	\$ 305,170,956

The accompanying notes are an integral part of these Consolidated Financial Statements.

DocGo Inc. and Subsidiaries CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY

	Series A Preferred Stock		Class A Common Stock		Class B Common Stock		Additional Paid-in- Capital	Accumulated Deficit	Accumulated Other Comprehensive Income	Noncontrolling Interests	Total Stockholders' Equity
	Shares	Amount	Shares	Amount	Shares	Amount					
Balance – December 31, 2020	28,055	\$ -	35,497	\$ -	55,008	\$ -	\$ 142,346,852	\$ (87,300,472)	\$ (48,539)	\$ 11,949,200	\$ 66,947,041
Effect of reverse acquisition	18,099,548	-	22,900,719	-	35,488,938	-	-	-	-	-	-
Conversion of share due to merger recapitalization	(18,099,548)	-	(22,900,719)	7,649	(35,488,938)	-	-	-	-	-	7,649
Effect of reverse acquisition	-	-	76,489,205	7,649	-	-	142,346,852	(87,300,472)	(48,539)	11,949,200	66,954,690
Share issued for services	-	-	171,608	17	-	-	-	-	-	-	17
Exercise of cashless warrants	-	-	1,817,507	182	-	-	-	-	-	-	182
Issuance of shares net redemption and issuance costs of \$9,566,304	-	-	5,297,097	530	-	-	43,404,558	-	-	-	43,405,088

PIPE, net of issuance costs of \$10,396,554	-	-	12,500,000	1,250	-	-	114,602,318	-	-	-	114,603,568
Exercise of stock options	-	-	1,235,131	123	-	-	628,469	-	-	-	628,592
Stock based compensation	-	-	-	-	-	-	1,376,353	-	-	-	1,376,353
Fair value of Warrants from reverse acquisition	-	-	-	-	-	-	(18,717,998)	-	-	-	(18,717,998)
U.K. Ltd. Shares purchase (Note 4)	-	-	50,192	5	-	-	(479,336)	-	-	(242,945)	(722,276)
Sponsor Earnout shares	-	-	2,573,213	257	-	-	-	-	-	-	257
Noncontrolling interest contribution	-	-	-	-	-	-	-	-	-	333,025	333,025
Foreign currency translation	-	-	-	-	-	-	-	-	16,038	-	16,038
Net loss attributable to Noncontrolling interests	-	-	-	-	-	-	-	-	-	(4,564,270)	(4,564,270)
Net income attributable to stockholders of DocGo Inc. and Subsidiaries	-	-	-	-	-	-	-	23,743,758	-	-	23,743,758
Balance – December 31, 2021	-	\$ -	100,133,953	\$ 10,013	-	\$ -	\$ 283,161,216	\$ (63,556,714)	\$ (32,501)	\$ 7,475,010	\$ 227,057,024
Equity cost	-	-	-	-	-	-	(19,570)	-	-	-	(19,570)
Noncontrolling interest contribution	-	-	-	-	-	-	-	-	-	2,063,000	2,063,000
Common stock repurchased	-	-	(536,839)	(54)	-	-	(3,731,658)	-	-	-	(3,731,712)
Exercise of stock options	-	-	1,053,401	105	-	-	1,980,674	-	-	-	1,980,779
Cashless exercise of options	-	-	354,276	36	-	-	(230)	-	-	-	(194)
Stock based compensation	-	-	-	-	-	-	7,183,992	-	-	-	7,183,992
Restricted stock units	-	-	-	-	-	-	495,579	-	-	-	495,579
Share warrants conversion	-	-	1,406,371	141	-	-	12,381,432	-	-	-	12,381,573
Net loss attributable to Noncontrolling interests	-	-	-	-	-	-	-	-	-	(3,841,285)	(3,841,285)
Foreign currency translation	-	-	-	-	-	-	-	-	773,707	-	773,707
Net income attributable to stockholders of DocGo Inc. and Subsidiaries	-	-	-	-	-	-	-	34,584,498	-	-	34,584,498

Balance – December 31, 2022	-	\$	-	102,411,162	\$ 10,241	-	\$	-	\$ 301,451,435	\$ (28,972,216)	\$ 741,206	\$ 5,696,725	\$ 278,927,391
-----------------------------------	---	----	---	-------------	-----------	---	----	---	----------------	------------------	------------	--------------	----------------

The accompanying notes are an integral part of these Consolidated Financial Statements.

CONSOLIDATED STATEMENTS OF CASH FLOWS

	Year Ended December 31,		
	2023	2022	2021
CASH FLOWS FROM OPERATING ACTIVITIES:			
Net income	\$ 10,048,328	\$ 30,743,213	\$ 19,179,488
Adjustments to reconcile net income to net cash (used in) provided by operating activities:			
Depreciation of property and equipment	4,829,780	4,114,346	2,312,437
Amortization of intangible assets	5,249,358	3,214,814	1,845,193
Amortization of finance lease right-of-use assets	6,352,754	3,236,418	2,913,925
Loss on disposal of assets	852,544	21,173	34,342
Deferred income tax	(1,981,519)	(9,957,967)	—
Gain from PPP loan forgiveness	—	—	(142,667)
Loss (gain) on equity method investments	343,336	(8,919)	66,818
Bad debt expense	3,601,520	3,815,187	4,467,956
Stock-based compensation	20,969,174	8,054,571	1,376,353
Loss on remeasurement of operating and finance leases	866	(1,388,273)	—
Loss on liquidation of business	70,284	—	—
Gain on remeasurement of warrant liabilities	—	(1,127,388)	(5,199,496)
Gain on bargain purchase	—	(1,593,612)	—
Goodwill impairment	—	2,921,958	—
Change in fair value of contingent consideration	(1,437,525)	—	—
Changes in operating assets and liabilities:			
Accounts receivable	(160,524,934)	(8,415,793)	(57,996,613)
Asset held for sale	—	190,312	—
Prepaid expenses and other current assets	(10,843,890)	(4,181,035)	(961,165)
Other assets	1,059,605	1,557,655	(2,490,564)
Accounts payable	(1,780,403)	3,637,305	11,879,850
Accrued liabilities	58,968,844	(5,964,064)	20,766,723
Net cash (used in) provided by operating activities	(64,221,878)	28,869,901	(1,947,420)
CASH FLOWS FROM INVESTING ACTIVITIES:			
Acquisition of property and equipment	(7,584,561)	(3,198,234)	(4,808,409)
Acquisition of intangibles	(2,541,661)	(2,299,558)	(1,849,136)
Acquisition of businesses	(20,203,464)	(32,953,179)	(1,300,000)
Equity method investments	(298,932)	—	(655,876)
Proceeds from disposal of property and equipment	747,088	3,000	74,740

Acquisition of leased assets	—	—	(50,504)
Net cash used in investing activities	(29,881,530)	(38,447,971)	(8,589,185)
CASH FLOWS FROM FINANCING ACTIVITIES:			
Proceeds from revolving credit line	25,000,000	—	8,000,000
Repayments of revolving credit line	—	(25,881)	(8,000,000)
Repayments of notes payable	(25,926)	(925,151)	(604,826)
Due to seller	(13,590,382)	(2,535,521)	(595,528)
Earnout payments on contingent liabilities	(5,266,681)	—	—
Noncontrolling interest contributions	—	2,063,000	333,025
Proceeds from exercise of stock options	1,581,183	1,980,585	628,592
Acquisition of UK Ltd remaining 20% shares	—	—	(479,331)

	Years Ended December 31,	
	2022	2021
CASH FLOWS FROM OPERATING ACTIVITIES:		
Net income	\$ 30,743,213	\$ 19,179,488
Adjustments to reconcile net income to net cash provided by operating activities:		
Depreciation of property and equipment	4,114,346	2,312,437
Amortization of intangible assets	3,214,814	1,845,193
Amortization of finance lease right-of-use assets	3,236,418	2,913,925
Loss on disposal of assets	21,173	34,342
Deferred tax asset	(9,957,967)	-
Gain from PPP loan forgiveness	-	(142,667)
(Loss) gain on equity method investment	(8,919)	66,818
Bad debt expense	3,815,187	4,467,956
Stock based compensation	8,054,571	1,376,353
Gain on remeasurement of finance leases	(1,388,273)	-
Gain on remeasurement of warrant liabilities	(1,127,388)	(5,199,496)
Gain on bargain purchase	(1,593,612)	-
Goodwill impairment	2,921,958	-
Changes in operating assets and liabilities:		
Accounts receivable	(8,415,793)	(57,996,613)
Cash held for sale	190,312	-
Prepaid expenses and other current assets	(4,181,035)	(961,165)
Other assets	1,557,655	(2,490,564)
Accounts payable	3,637,305	11,879,850
Accrued liabilities	(5,964,064)	20,766,723
Net cash provided by (used in) operating activities	28,869,901	(1,947,420)
CASH FLOWS FROM INVESTING ACTIVITIES:		
Acquisition of property and equipment	(3,198,234)	(4,808,409)
Acquisition of intangibles	(2,299,558)	(1,849,136)
Acquisition of businesses	(32,953,179)	(1,300,000)
Proceeds from disposal of property and equipment	3,000	74,740
Acquisition of leased assets	-	(50,504)
Investments in equity method investment	-	(655,876)
Net cash used in investing activities	(38,447,971)	(8,589,185)
CASH FLOWS FROM FINANCING ACTIVITIES:		
Proceeds from revolving line of credit	-	8,000,000
Repayments of revolving line of credit	(25,881)	(8,000,000)
Proceeds from FMC loan	1,000,000	-
Repayments of FMC loan	(1,000,000)	-

Right-of-use assets obtained in exchange for lease liabilities	\$ 7,621,538	\$ 5,035,201	\$ 5,271,662
Fixed assets acquired in exchange for notes payable	\$ —	\$ 923,377	\$ 1,113,102
Gain from PPP loan forgiveness	\$ —	\$ —	\$ 142,667
Due to seller non-cash	\$ —	\$ —	\$ 434,494
Acquisition of remaining FMC NA through due to seller and issuance of stock	\$ 7,000,000	\$ —	\$ —
Acquisition of CRMS through issuance of stock	\$ 1,000,000	\$ —	\$ —
Receivable exchanged for trade credits	\$ 1,500,000	\$ —	\$ —
Reconciliation of cash and restricted cash			
Cash	\$ 59,286,147	\$ 157,335,323	\$ 175,537,221
Restricted cash	12,931,839	6,773,751	3,568,509
Total cash and restricted cash shown in statement of cash flows	\$ 72,217,986	\$ 164,109,074	\$ 179,105,730

The accompanying notes are an integral part of these Consolidated Financial Statements.

DocGo Inc. and Subsidiaries
CONSOLIDATED STATEMENTS OF CASH FLOWS (CONTINUED)

	Years Ended December 31,	
	2022	2021
Supplemental disclosure of cash and non-cash transactions:		
Cash paid for interest	\$ 197,005	\$ 315,272
Cash paid for interest on finance lease liabilities	\$ 559,596	\$ 525,476
Cash paid for income taxes	\$ 1,505,235	\$ 615,697
Right-of-use assets obtained in exchange for lease liabilities	\$ 5,035,201	\$ 5,271,662
Fixed assets acquired in exchange for notes payable	\$ 923,377	\$ 1,113,102
Gain from PPP loan forgiveness	\$ -	\$ 142,667
Due to Seller non cash	\$ -	\$ 434,494

Reconciliation of cash and restricted cash

Cash	\$ 157,335,323	\$ 175,537,221
Restricted Cash	<u>6,773,751</u>	<u>3,568,509</u>
Total cash and restricted cash shown in Consolidated Statements of Cash Flows	<u>\$ 164,109,074</u>	<u>\$ 179,105,730</u>
Non-cash investing activities Acquisition of business funded by acquisition payable	46,324,909	1,028,942

The accompanying notes are an integral part of these Consolidated Financial Statements.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

1. Description of Organization and Business Operations

On November 5, 2021 (the “Closing Date”), DocGo Inc., a Delaware corporation, (formerly then known as Motion Acquisition Corp) (prior to Corp. (collectively with its subsidiaries, the Closing Date, “Motion” and after the Closing Date, “DocGo” “Company”), consummated the previously announced a business combination (the “Closing”) pursuant to that certain Agreement and Plan of Merger, dated March 8, 2021 (the “Merger Agreement”), by and among Motion Acquisition Corp., a Delaware corporation (“Motion”), the Company, Motion Merger Sub Corp., a Delaware corporation and a direct wholly owned subsidiary of Motion the Company (“Merger Sub”), and Ambulnz, Inc., a Delaware corporation (“Ambulnz”). The transactions contemplated by the Merger Agreement are referred to herein as the “Business Combination.” In connection with the Closing, closing of the registrant Business Combination, the Company changed its name from Motion Acquisition Corp. to DocGo Inc.

As contemplated by the Merger Agreement and as described in Motion’s the Company’s definitive proxy statement/consent solicitation/prospectus filed with the U.S. Securities and Exchange Commission (the “SEC”) on October 14, 2021 (the “Prospectus”), Merger Sub was merged with and into Ambulnz, with Ambulnz continuing as the surviving corporation (the “Merger” and, together with the other transactions contemplated by the Merger Agreement, the “Business Combination”). corporation. As a result of the Merger, Business Combination, Ambulnz is became a wholly-owned wholly owned subsidiary of DocGo the Company and each share of Series A preferred stock of Ambulnz, no par value, (“Ambulnz Preferred Stock”), Class A common stock of Ambulnz, no par value, (“Ambulnz Class A Common Stock”), and Class B common stock of Ambulnz, no par value, (“Ambulnz Class B Common Stock,” together with Ambulnz Class A Common Stock, “Ambulnz Common Stock”) was cancelled and converted into the right to receive a portion of the merger consideration issuable as common stock of DocGo, the Company, par value \$0.0001 (“Common Stock”), pursuant to the terms and conditions set forth in the Merger Agreement.

In connection with the Business Combination, the Company raised \$158.0 million \$158,000,000 of net proceeds. This amount was comprised consisted of \$43.4 million (i) \$43,400,000 of cash held in Motion’s the Company’s trust account from established in connection with its initial public offering, net of DocGo’s the Company’s transaction costs and underwriters’ fees of \$9.6 million, \$9,600,000, and \$114.6 million (ii) \$114,600,000 of cash in connection with from the concurrent PIPE private placement sale of shares of common stock Common Stock to certain investors at a price of \$10.00 per share in a private placement that closed concurrently with the Business Combination (the “PIPE Financing” Financing”), net of \$10.4 million \$10,400,000 in transaction costs, costs in connection with the PIPE Financing. These transaction costs consisted of banking, legal, and other professional fees, which were recorded as a reduction to additional paid-in capital.

The Business

DocGo Inc. and Subsidiaries (collectively, the “Company”) The Company is a mobile healthcare transportation and Mobile Health services company (“Mobile Health”) that uses proprietary dispatch and communication technology to help provide quality healthcare transportation and healthcare services in major metropolitan cities in the United States and the United Kingdom. Mobile Health performs mobile, in-person care medical treatment directly to patients in the comfort of their homes, workplaces and other non-traditional locations.

locations and healthcare transportation in major metropolitan cities in the United States (“U.S.”) and the United Kingdom (“U.K.”).

Ambulnz LLC was originally formed in Delaware on June 17, 2015, as Ambulnz, LLC, a limited liability company. On November 1, 2017, with an effective date of January 1, 2017, Ambulnz converted its legal structure from a limited liability company to a C-corporation and changed its name to Ambulnz, Inc. Ambulnz is the sole owner of Ambulnz Holdings, LLC (“Holdings”), which was formed in the state of Delaware on August 5, 2015, as a limited liability company. Holdings is the owner of multiple operating entities incorporated in various states in the United States U.S. as well as within England and Wales, United Kingdom. U.K.

The Company conducts business in three operating segments: Mobile Health Services, Transportation Services and Corporate. Mobile Health Services include a wide variety of healthcare services performed at homes, offices and other locations and event services such as on-site healthcare support at sporting events and concerts. This segment also provides total care management solutions to large, typically underserved, population groups primarily through arrangements with municipalities, which include healthcare services as well as ancillary services, such as shelter. Transportation Services encompass both emergency response and non-emergency transport services. Non-emergency transport services include ambulance transports and wheelchair transports. Net revenue from Transportation Services is derived from the transportation of patients based on billings to third party payors and healthcare facilities. The Company’s Corporate segment primarily represents shared services and personnel that support both the Transportation Services and Mobile Health Services segments. It contains operating expenses such as information technology costs, certain insurance costs and the compensation costs of senior and executive leadership. None of the Company’s revenues or cost of revenues are reported within the Corporate segment.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)

2. Summary of Significant Accounting Policies

Basis of Presentation

The accompanying Consolidated Financial Statements are presented have been prepared in conformity accordance with generally accepted accounting principles generally accepted in the United States of America U.S. ("U.S. GAAP") and pursuant to the applicable rules and regulations of the Securities and Exchange Commission ("SEC"). SEC.

Principles of Consolidation

The Consolidated Financial Statements include the accounts and operations of the Company DocGo Inc. and its wholly owned subsidiaries. All intercompany accounts and transactions are eliminated upon consolidation. Noncontrolling interests ("NCI") on the Consolidated Balance Sheets represents the Financial Statements represent a portion of consolidated joint ventures and a variable interest entity in which the Company does not have direct equity ownership. Accounts Certain amounts in the prior years' consolidated statements of changes in stockholders' equity and transactions between consolidated entities statements of cash flows have been eliminated.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)

Pursuant reclassified to conform to the current year presentation.

The Business Combination the merger between Motion and Ambulnz, Inc. was accounted for as a reverse recapitalization in accordance with U.S. GAAP (the "Reverse Recapitalization"). Under this method of accounting, Motion the Company was treated as the "acquired" company for financial reporting purposes. Accordingly, for accounting purposes, the Reverse Recapitalization was treated as the equivalent of Ambulnz Inc. stock for the net assets of Motion, the Company, accompanied by a recapitalization. The net assets of Motion the Company are stated at historical cost, with no goodwill or other intangible assets recorded. The consolidated assets, liabilities and results of operations prior to the Reverse Recapitalization are those of Ambulnz, Inc. Ambulnz. The shares and corresponding capital amounts and earnings per share available for common stockholders prior to the Business Combination have been retroactively restated as shares reflecting the exchange ratio (645.1452 to 1) established in the Business Combination. Further, Ambulnz Inc. was determined to be the accounting acquirer in the transaction, and as such, the acquisition is considered a business combination under Accounting Standards Codification ("ASC"), Topic 805, *Business Combinations* ("ASC 805") and was accounted for using the acquisition method of accounting.

Principles

In accordance with ASC 810, Consolidation ("ASC 810"), the Company assesses whether it has a variable interest in legal entities in which it has a financial relationship and, if so, whether or not those entities are variable interest entities ("VIEs"). For those entities that qualify as VIEs, ASC 810 requires the Company to determine if the Company is the primary beneficiary of Consolidation

the VIE, and if so, to consolidate the VIE.

The accompanying Consolidated Financial Statements include the accounts of DocGo Inc. and its subsidiaries. All significant intercompany transactions and balances have been eliminated in these Consolidated Financial Statements.

The Company holds a variable interest interests in legal entities, which contracts contract with physicians and other health professionals in order to provide services to the Company. MD1 Medical Care P.C. ("MD1") is These entities are considered a variable interest entity ("VIE") VIEs since it does they do not have sufficient equity to finance its their activities without additional subordinated financial support. An enterprise having a controlling financial interest in a VIE must consolidate the VIE if it has both power and benefits—that is the primary beneficiary, meaning it has (1) the power to direct the activities of a the VIE that most significantly impacts the VIE's economic performance (power) and (2) the obligation to absorb losses of the VIE that potentially could be significant to the VIE or the right to receive benefits from the VIE that potentially could be significant to the VIE (benefits). The Company has the power and rights to control all activities of MD1 its VIEs and funds and absorbs all losses of its VIEs. The Company has determined that it is the VIE primary beneficiary of its VIEs and therefore appropriately consolidates MD1. its VIEs.

Total revenue for the VIE amounted to \$2,857,463 as of December 31, 2022. Net loss for the VIE was Company's VIEs were \$235,976, \$373,456 as of December 31, 2022, and \$122,982 for the years ended December 31, 2023, 2022 and 2021, respectively. The VIE's total assets all of which were current, amounted to \$4,364,274 and \$610,553 on December 31, 2022, December 31, 2023 and 2022, respectively. Total liabilities all of which were current for the VIE, was \$4,811,857 and \$320,424 on December 31, 2022, December 31, 2023 and 2022, respectively. The VIE's Company's VIEs total stockholders' deficit was were \$447,583 and \$290,130 on December 31, 2022. The Company made payments of \$3,018,119 December 31, 2023 and \$1,746,736 to MD1 and its affiliates during the years ended December 31, 2022 and 2021, 2022, respectively.

Foreign Currency

The Company's functional currency is the U.S. dollar. The functional currency of our foreign operation is the respective local currency. British pound. Assets and liabilities of foreign operations denominated in local currencies are translated at the spot rate in effect at the applicable reporting date, except for equity accounts which are translated at historical rates. The Consolidated Statements of Operations and Comprehensive Income are translated at the weighted average rate of exchange during the applicable period. The resulting unrealized cumulative translation adjustment for the year of years ended December 31, 2023, 2022 was \$773,707. For the same period of and 2021 it was not material to the financial statements. were \$743,699, \$773,707, and \$16,038, respectively.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)

Use of Estimates

The preparation of financial statements requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities and expenses and the disclosure of contingent assets and liabilities in its financial statements and the reported amounts of expenses during the reporting period. The most significant estimates in the Company's financial statements relate to revenue recognition related to the allowance for doubtful accounts, **stock based stock-based** compensation, calculations related to the incremental borrowing rate for the Company's lease agreements, estimates related to ongoing lease terms, software development costs, impairment of long-lived assets, goodwill and indefinite-lived intangible assets, business combinations, reserve for losses within the Company's insurance deductibles, income taxes, and deferred income tax. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources.

*Actual results may differ materially and adversely from these estimates. To the extent there are material differences between the estimates and actual results, the Company's future results of operations **will** could be **adversely** affected.*

Self-Insurance Reserves

The Company self-insures a number of risks, including, but not limited to, workers' compensation, general liability, auto liability and certain employee-related healthcare benefits. Standard actuarial procedures and data analysis are used to estimate the liabilities associated with these risks on an undiscounted basis. The recorded liabilities reflect the ultimate cost for claims incurred but not paid and any estimable administrative run-out expenses related to the processing of these outstanding claim payments. On a regular basis, the liabilities are evaluated for appropriateness with claims reserve valuations. To limit exposure to some risks, the Company maintains insurance coverage with varying limits and retentions, including stop-loss insurance coverage for workers' compensation, general liability and auto liability.

Concentration of Credit Risk and Off-Balance Sheet Risk

The Company is potentially subject to concentration of credit risk with respect to its cash, cash equivalents and restricted cash, which the Company attempts to minimize by maintaining cash, cash equivalents and restricted cash with institutions of sound financial quality. At times, cash balances may exceed limits federally insured by the Federal Deposit Insurance Corporation ("FDIC"). The Company believes it is not exposed to significant credit risk due to the financial strength of the depository institutions in which the funds are held. The Company has no financial instruments with off-balance sheet risk of loss.

DocGo Inc. and Subsidiaries
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)

Major Customers

The Company had one customer that accounted for approximately 40% of revenues and 42% of net accounts receivable and another customer that accounted for 21% of revenues and 40% of net accounts receivable for the year ended December 31, 2023.

The Company had one customer that accounted for approximately 35% of sales revenues and 45% of net accounts receivable for the year ended December 31, 2022.

The Company had one customer that accounted for approximately 23% of revenues and 26% of net accounts receivable and another customer that accounted for 26% of revenues and 24% of net accounts receivable for the year ended December 31, 2021.

DocGo Inc. and Subsidiaries
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)

Major Vendor

The Company had one vendor that accounted for approximately 14%, 12% and 11% of total cost for the year years ended December 31, 2022, December 31, 2023, 2022 and 2021, respectively. The Company expects to maintain this relationship with the vendor and believe believes the services provided from this vendor are available from alternatives sources.

Reclassifications

Certain reclassifications of amounts previously reported have been made to the accompanying Consolidated Financial Statements to maintain consistency between periods presented. The Company reclassifications had one vendor that accounted for approximately 11% of total cost for the years ended December 31, 2021.

no impact on previously reported net income or retained earnings.

Emerging Growth Company

The Company is an “emerging growth company,” as defined in Section 2(a) of the Securities Act of 1933, as amended (the “Securities Act”), as modified by the Jumpstart our Business Startups Act of 2012 (the “JOBS Act”), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act of 2002, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved.

Further, Section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that an emerging growth company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but any such an election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company’s financial statements with another public company which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used.

Cash and Cash Equivalents

Cash and cash equivalents include all highly liquid investments with an original maturity of three months or less. The Company maintains most of its cash and cash equivalents with financial institutions in the United States, U.S. The Company’s accounts at financial institutions in the United States U.S. are insured by the Federal Deposit Insurance Corporation (“FDIC”) FDIC and are in excess of FDIC insured limits. The Company had cash balances of approximately \$8,125,966 \$3,699,793 and \$803,000 \$8,125,966 with foreign financial institutions on December 31, 2022 December 31, 2023 and 2021, 2022, respectively.

Restricted Cash

Cash and cash equivalents subject to contractual restrictions and not readily available are classified as restricted cash in the Consolidated Balance Sheets. Restricted cash is classified as either a current or non-current asset depending on the restriction period. The Company is required to pledge or otherwise restrict a portion of cash and cash equivalents as collateral for self-insurance exposures, transportation equipment leases and a standby letter of credit as required by its insurance carrier (see Notes 9 and 15).

The Company utilizes a combination of insurance and self-insurance programs, including a wholly-owned captive insurance entity, to provide for the potential liabilities for certain risks, including workers' compensation, automobile liability, general liability and professional liability. Liabilities associated with the risks that are retained by the Company within its high deductible limits are not discounted and are estimated, in part, by considering claims experience, exposure and severity factors and other actuarial assumptions. The Company has commercial insurance in place for catastrophic claims above its deductible limits.

ARM Insurance, Inc. a Vermont-based wholly-owned captive insurance subsidiary of the Company, charges the operating subsidiaries premiums to insure the retained workers' compensation, automobile liability, general liability and professional liability exposures. Pursuant to Vermont insurance regulations, ARM Insurance, Inc. maintains certain levels of cash and cash equivalents related to its self-insurance exposures.

The Company also maintains certain cash balances related to its insurance programs, which are held in a self-depleting trust and restricted as to withdrawal or use by the Company other than to pay or settle self-insured claims and costs. These amounts are reflected in "Restricted cash" in the accompanying Consolidated Balance Sheets.

Fair Value of Financial Instruments

ASC 820, *Fair Value Measurements*, provides guidance on the development and disclosure of fair value measurements. Under this accounting guidance, fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or a liability.

The accounting guidance classifies fair value measurements in one of the following three categories for disclosure purposes:

Level 1: Quoted prices in active markets for identical assets or liabilities.

Level 2: Inputs other than Level 1 prices for similar assets or liabilities that are directly or indirectly observable in the marketplace.

Level 3: Unobservable inputs which are supported by little or no market activity and values determined using pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments for which the determination of fair value requires significant judgment or estimation.

DocGo Inc. and Subsidiaries

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)

Level 2: Inputs other than Level 1 prices for similar assets or liabilities that are directly or indirectly observable in the marketplace.

Level 3: Unobservable inputs which are supported by little or no market activity and values determined using pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments for which the determination of fair value requires significant judgment or estimation.

Fair value measurements discussed herein are based upon certain market assumptions and pertinent information available to management as of December 31, 2023, December 31, 2022 and December 31, 2021. For certain financial instruments, including cash and cash equivalents, accounts receivable, prepaid expenses and other current assets, restricted cash, accounts payable and accrued expenses, and due to seller, the carrying amounts approximate their fair values as it is short term in nature. The notes payable are presented at their carrying value, which based on borrowing rates currently available to the Company for loans with similar terms, approximates its fair values.

Level 3 instruments are valued based on unobservable inputs that are supported by little or no market activity and reflect the Company's own assumptions in measuring fair value. Future changes in fair value of the contingent financial milestone consideration, as a result of changes in significant inputs such as the discount rate and estimated probabilities of financial milestone achievements, could have a material effect on the Consolidated **Statement of Operations and Comprehensive Income** and Consolidated Balance Sheets in the period of the change.

During the year ended December 31, 2022, the Company recorded \$4,000,000 **Contingent** in contingent consideration in connection with the acquisition by Holdings of Ryan **Brothers Bros. Fort Atkinson, LLC** **business acquisition**, ("Ryan Brothers") to be paid based on the completion of certain performance obligations over a 24-month period. During the year, the Company recorded a change in fair value of contingent consideration in the amount of \$338,956 and made a payment of \$1,840,026. As of December 31, 2023, the remaining contingent liability balance was \$1,821,018 (see Note 4).

In **relation to** connection with the acquisition of Exceptional **Medical Transportation, LLC** ("Exceptional"), the Company also agreed to pay up to \$2,000,000 in contingent consideration upon meeting certain performance conditions within two years of the **Closing Date**, closing date of such acquisition. During the year, the Company recorded a change in fair value of contingent consideration in the amount of \$374,044 and made a payment of \$426,655. The estimated **Contingent** contingent consideration amount for Exceptional was \$279,301 and \$1,080,000 as of December 31, 2023 and December 31, 2022, respectively (see Note 4).

For Location Medical Services, LLC,

During the year ended December 31, 2022, the Company also recorded \$2,475,540 estimated **Contingent** contingent consideration in **relation to** connection with the acquisition by Holdings of Location Medical Services, LLC ("LMS") to be paid upon LMS meeting certain performance conditions in 2023. **For** The Company recorded a change in fair value of contingent consideration in the amount of \$2,000,312 and recorded \$129,599 as a result of foreign exchange movement. The outstanding balance as of December 31, 2023 was \$604,827 (see Note 4).

In connection with the acquisition by Holdings of Government Medical Services, **an amount of** LLC ("GMS"), the Company recorded \$3,000,000 is recorded as **Contingent** in contingent consideration to be paid upon GMS meeting certain performance conditions within a year of the **Closing Date** closing date of such acquisition. During the year, the Company made a \$3,000,000 payment to settle the contingent liability balance as of December 31, 2023. As of December 31, 2022, there was a balance of \$3,000,000 (see Note 4).

In connection with the acquisition by Holdings of Cardiac RMS, LLC ("CRMS"), the Company recorded \$15,822,190 in contingent consideration to be paid out over 36 months for the remaining 49% equity of CRMS, based on CRMS' attainment of full-year EBITDA targets. The Company recorded a change in fair value of contingent consideration in the amount of \$1,265,645 for the year ended December 31, 2023. As of December 31, 2023, there was a remaining contingent liability balance of \$17,087,835 (see Note 4).

DocGo Inc. and Subsidiaries

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)

Accounts Receivable

The Company contracts with hospitals, healthcare facilities, businesses, **State** state and local **Government** government entities, and insurance providers to transport patients and to provide Mobile Health **services** Services and to transport patients at specified rates. These rates are either on a per procedure or per transport basis, or on an hourly or daily basis. Accounts receivable consist of billings for transportation and healthcare services provided to patients. **The billings will** Billings typically are either **be** paid or settled on the patient's behalf by health insurance providers, managed care organizations, treatment facilities, government sponsored programs or businesses, or by patients directly. Accounts receivable are net of insurance provider contractual allowances, which are estimated at the time

DocGo Inc. and Subsidiaries

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)

of billing based on contractual terms or other arrangements. Accounts **receivables** receivable are periodically evaluated for collectability based on past credit history with payors and their current financial condition. Changes in the estimated collectability of **account** accounts receivable are

recorded in the results of operations for the period in which the estimate is revised. Accounts receivable deemed uncollectible are offset against the allowance for uncollectible accounts. The Company generally does not require collateral for accounts receivables.
receivable.

Property and Equipment

Property and equipment are stated at cost, net of accumulated depreciation and amortization. When an item is sold or retired, the costs and related accumulated depreciation or amortization are eliminated, and the resulting gain or loss, if any, is recorded in operating expenses in the Consolidated Statement Statements of Operations, Operations and Comprehensive Income. The Company provides for depreciation and amortization using the straight-line method over the estimated useful lives of the respective assets. A summary of estimated useful lives is as follows:

Asset Category	Estimated Useful LivesLife
Buildings	39 years
Office equipment and furniture	3 years
Vehicles	2-85-8 years
Medical equipment	5 years
Leasehold improvements	Shorter of useful life of asset or lease term

Expenditures for repairs and maintenance are charged to expense as incurred. Expenditures that improve an asset or extend its estimated useful life are capitalized.

Software Development Costs

Costs incurred during the preliminary project stage, maintenance costs and routine updates and enhancements of products are charged to expense expensed as incurred. The Company capitalizes software development costs intended for internal use in accordance with ASC 350-40, Internal-Use Software. Costs incurred in developing the application of its software and costs incurred to upgrade or enhance product functionalities are capitalized when it is probable that the expenses would result in future economic benefits to the Company and the functionalities and enhancements are used for their intended purpose. Capitalized software costs are amortized over its useful life.

Estimated useful lives life of software development activities are reviewed annually or whenever events or changes in circumstances indicate that intangible assets may be impaired and adjusted as appropriate to reflect upcoming development activities that may include significant upgrades or enhancements to the existing functionality.

Business Combinations

The Company accounts for its business combinations under the provisions of ASC 805-10, Business Combinations (“ASC 805-10”), which requires that the acquisition method of accounting be used for all business combinations. Assets acquired and liabilities assumed, including NCI, noncontrolling interests, are recorded at the date of acquisition at their respective fair values. ASC 805-10 also specifies criteria that intangible assets acquired in a business combination must meet to be recognized and reported apart from goodwill.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)

Goodwill represents the excess purchase price over the fair value of the tangible net assets and intangible assets acquired in a business combination. If the business combination provides for Contingent contingent consideration, the Company records the Contingent contingent consideration at fair value at the acquisition date and any changes in fair value after the acquisition date are accounted for as measurement-period adjustments. Changes in fair value of Contingent contingent consideration resulting from events after the acquisition date, such as earn-outs, are recognized as follows: 1) (1) if the Contingent contingent consideration is classified as equity, the Contingent contingent consideration is not re-measured and its subsequent settlement is accounted for within equity, or 2) (2) if the Contingent contingent consideration is classified as a liability, the changes in fair value are recognized in earnings. For transactions that are business combinations, the Company evaluates the existence of goodwill or a gain from a bargain purchase. The Company capitalizes acquisition-related costs and fees associated with asset acquisitions and immediately expenses acquisition-related costs and fees associated with business combinations.

DocGo Inc. and Subsidiaries

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)

The estimated fair value of net assets to be acquired, including the allocation of the fair value to identifiable assets and liabilities, is determined using established valuation techniques. Management uses assumptions based on the basis of historical knowledge of the business and projected financial information of the target. These assumptions may vary based on future events, perceptions of different market participants and other factors outside the control of management, and such variations may be significant to estimated values.

Impairment of Long-Lived Assets

The Company evaluates the recoverability of the recorded amount of long-lived assets, primarily property and equipment and finite-lived intangible assets, whenever events or changes in circumstance indicate that the recorded amount of an asset may not be fully recoverable. An impairment is assessed when the undiscounted expected future cash flows derived from an asset are less than its carrying amount. If an asset is determined to be impaired, the impairment to be recognized is measured as the amount by which the carrying amount of the asset exceeds its fair value. Assets targeted for disposal are reported at the lower of the carrying amount or fair value less cost to sell.

In 2022, the Company reassigned all the assets at Ambulnz Health, LLC ("Health") to Assets held for sale as a result of an assignment for the benefit of creditors ("ABC") transaction. We have also recognized a non-cash charge of \$2,921,958 for its Goodwill impairment for the year ended December 31, 2022 in the Consolidated Statements of Operations.

Goodwill and Indefinite-Lived Intangible Assets

Goodwill represents the excess of the total purchase consideration over the fair value of the identifiable assets acquired and liabilities assumed in a business combination. Goodwill is and indefinite-lived intangible assets are not amortized but is are tested for impairment at the reporting unit level annually on December 31 or more frequently if events or changes in circumstances indicate that it is more likely than not to be impaired. These events include: (i) severe adverse industry or economic trends; (ii) significant company-specific actions, including exiting an activity in conjunction with restructuring of operations; (iii) current, historical or projected deterioration of our the Company's financial performance; or (iv) a sustained decrease in our the Company's market capitalization, as indicated by our its publicly quoted share price, below our its net book value.

In 2022, the Company reassigned all the assets at Ambulnz Health, LLC ("Health") to assets held for sale as a result of an assignment for the benefit of creditors ("ABC") (see Note 5). The Company also recognized a non-cash charge of \$2,921,958 for Goodwill impairment for the year ended December 31, 2022 in the Consolidated Statements of Operations and Comprehensive Income.

Line of Credit

The costs associated with the Company's line of credit are deferred and recognized over the term of the Line line of credit as interest expense.

Derivative Warrant Liabilities

The Company does not use derivative instruments to hedge exposures to interest rate, market or foreign currency risks. The Company evaluates its financial instruments to determine if such instruments contain features that qualify as embedded derivatives.

DocGo Inc. and Subsidiaries
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)

Related Party Transactions

The Company defines related parties as affiliates of the company, entities for which investments are accounted for by the equity method, trusts for the benefit of employees, principal owners (beneficial owners of more than 10% of the voting interest), management, and members of immediate families of principal owners or management, other parties with which the company may deal with if one party controls or can significantly influence management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.

Related party transactions are recorded within operating expenses in the Company's statement Consolidated Statements of operations, Operations and Comprehensive Income. For details regarding the related party transactions that occurred during the periods years ended December 31, 2022 December 31, 2023, 2022 and 2021 refer to Note 17.

Revenue Recognition

On January 1, 2019, the Company adopted ASU 2014-09, ASC 606, Revenue from Contracts with Customers ("ASC 606"), as amended.

DocGo Inc. and Subsidiaries
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)

To determine revenue recognition for contractual arrangements that the Company determines are within the scope of ASC 606, the Company performs the following five steps: (1) identify each contract with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to performance obligations in the contract; and (5) recognize revenue when (or as) the relevant performance obligation is satisfied. The Company only applies the five-step model to contracts when it is probable that the Company will collect the consideration it is entitled to in exchange for the goods or services the Company provides to the customer.

The Company generates revenues from the provision of (1) ambulance and medical transportation services ("Transportation Services") Mobile Health Services and (2) Mobile Health services. The Transportation Services. Since the customer simultaneously receives and consumes the benefits provided by the Company as the performance obligations are fulfilled, therefore the Company satisfies performance obligations immediately. The Company has utilized the "right to invoice" expedient, which allows an entity to recognize revenue in the amount of consideration to which the entity has the right to invoice when the amount that the Company has the right to invoice corresponds directly to the value transferred to the customer. Revenues are recorded net of an estimated contractual allowances for claims subject to contracts with responsible paying entities. The Company estimates contractual allowances at the time of billing based on contractual terms, historical collections or other arrangements. All transaction prices are fixed and determinable, which includes a fixed base rate, fixed mileage rate and an evaluation of historical collections by each payer. payor.

Nature of Our Services

Revenue is primarily derived from:

i. **Mobile Health Services:** **Transportation Services:** These services encompass both emergency response and non-emergency transport services. Non-emergency transport services include ambulance transports and wheelchair transports. Net revenue from transportation services is derived from the transportation of patients based on billings to third party payors and healthcare facilities.

These services include a wide variety of healthcare services performed at homes, offices and other locations and event services such as on-site healthcare support at sporting events and concerts. This segment also provides total care management solutions to large, typically underserved population groups, primarily through arrangements with municipalities, which include healthcare services as well as ancillary services, such as shelter.

ii. Transportation Services: These services include services performed at home and offices, COVID-19 testing, and event services which include on-site healthcare support at sporting events and concerts. These services encompass both emergency response and non-emergency transport services. Non-emergency transport services include ambulance transports and wheelchair transports. Net revenue from Transportation Services is derived from the transportation of patients based on billings to third party payors and healthcare facilities.

For Mobile Health Services, the performance of the services and any related support activities in the majority of the Company's contracts are a single performance obligation under ASC 606. Mobile Health Services are typically billed based on a fixed rate (i.e., time and materials separately or combined) fee structure taking into consideration staff and materials utilized. The Company concluded that Transportation Services and any related support activities are a single performance obligation under ASC 606. The transaction price is determined by the fixed rate usage-based fees or fixed fees which are agreed upon in the Company's executed contracts. For Mobile Health, the performance of the services and any related support activities are a single performance obligation under ASC 606. Mobile Health services are typically billed based on a fixed rate (i.e., time and materials separately or combined) fee structure taking into consideration staff and materials utilized.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)

As the performance associated with such services is known and quantifiable at the end of a period in which the services occurred (i.e., monthly or quarterly), revenues are typically recognized in the respective period performed. The typical billing cycle for Transportation Mobile Health Services and Mobile Health services Transportation Services is same day to five days with payments generally due within 30 days. For large municipal customers in the Mobile Health Services segment, invoices are generally produced on a monthly basis, in arrears, and are generally due within 30-60 days of when they are submitted to the customer. For Transportation Services, the Company estimates the amount of revenues unbilled at month end and recognizes such amounts as revenue, based on available data and customer history. The majority of the Company's Mobile Health Services and Transportation Services and Mobile Health services each represent a single performance obligation. Therefore, allocation is not necessary as the transaction price (fees) for the services provided is standard and explicitly stated in the contractual fee schedule and/or invoice. For contracts with multiple distinct performance obligations, the Company allocates the transaction price based on their agreed-upon price to the individually identified performance obligations in the contract. The Company monitors and evaluate evaluates all contracts on a case-by-case basis to determine if multiple performance obligations are present in a contractual arrangement.

For Transportation Mobile Health Services, the customer also generally simultaneously receives and consumes the benefits provided by the Company as the performance obligations are fulfilled. Therefore, the Company satisfies performance obligations at the same time. For certain Mobile Health Services that have a fixed fee arrangement and are provided over time, revenue is recognized over time as the services are provided to the customer. For Transportation Services, since the customer

DocGo Inc. and Subsidiaries

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)

simultaneously receives and consumes the benefits provided by the Company as the performance obligations are fulfilled, therefore the Company satisfies performance obligations at the same time. For Transportation Services, where the customer pays fixed rate usage-based fees, the actual usage in the period represents the best measure of progress. Generally, for Mobile Health services, the customer simultaneously receives and consumes the benefits provided by the Company as the performance obligations are fulfilled, therefore the Company satisfies performance obligations at the same time. For certain Mobile Health services that have a fixed fee arrangement, and the services are provided over time, revenue is recognized over time as the services are provided to the customer.

Disaggregation of revenue

In the following table, revenue is disaggregated by as follows:

Revenue Breakdown	Years Ended December 31,		
	2022	2021	
Primary Geographical Markets			
United States	\$ 419,578,082	\$ 309,218,594	
United Kingdom	20,937,664	9,499,986	
Total revenue	\$ 440,515,746	\$ 318,718,580	
Major Segments/Service Lines			
Transportation Services	\$ 114,624,306	\$ 84,268,817	
Mobile Health	325,891,440	234,449,763	
Total revenue	\$ 440,515,746	\$ 318,718,580	

Revenue Breakdown	Year ended December 31,		
	2023	2022	2021
Primary Geographical Markets			
United States	\$ 571,887,943	\$ 419,578,082	\$ 309,218,594
United Kingdom	52,400,699	20,937,664	9,499,986
Total revenue	\$ 624,288,642	\$ 440,515,746	\$ 318,718,580
Major Segments/Service Lines			
Mobile Health Services	\$ 442,793,537	\$ 325,891,440	\$ 234,449,763

Transportation Services	181,495,105	114,624,306	84,268,817
Total revenue	\$ 624,288,642	\$ 440,515,746	\$ 318,718,580

Stock Based Compensation

The Company maintained stock incentive plans under which incentive and non-qualified stock options, restricted stock units and performance-based stock units. The Company accounts for stock-based compensation using the provisions of ASC 718, *Stock-Based Compensation*, which requires the recognition of the fair value of stock-based compensation. The Company expenses stock-based compensation over the requisite service period based on the estimated grant-date fair value of the awards. The Company estimates the fair value of stock option grants using the Black-Scholes option pricing model, and the assumptions used in calculating the fair value of stock-based awards represent management's best estimates and involve inherent uncertainties and the application of management's judgment. The Company accounts for forfeitures as they occur. For performance-based awards, expense is recognized over the period from the grant date to the estimated attainment date, which is the derived service period of the award, if the management determines that it is probable that the performance-based vesting conditions will be achieved. All stock-based compensation costs are recorded in operating expenses in the Consolidated Statements of Operations and Comprehensive Income.

Earnings per Share

Earnings per share represents the net income attributable to stockholders divided by the weighted-average number of shares outstanding during the period. Diluted earnings per share reflects the potential dilution that could occur if securities or other contracts to issue common stock Common Stock were exercised or converted into common stock of the Company Common Stock during the reporting periods. Potential dilutive common stock Common Stock equivalents consist of the incremental common stock shares of Common Stock issuable upon conversion exercise of warrants and the incremental shares issuable upon exercise of stock options. In reporting periods in which the Company has a net loss, the effect is considered anti-dilutive and excluded from the diluted earnings per share calculation.

The following table presents the calculation of basic and diluted net income per share to stockholders of DocGo Inc. and Subsidiaries:

	For the years ending December 31,	
	2022	2021
Net income attributable to stockholders of DocGo Inc. and Subsidiaries:	\$ 34,584,498	\$ 23,743,758
Weighted-average shares - basic	101,228,369	80,293,959
Effect of dilutive options	1,747,462	14,569,654
Weighted-average shares - dilutive	102,975,831	94,863,613
Net income share - basic	\$ 0.34	\$ 0.30
Net income share - diluted	\$ 0.34	\$ 0.25
Anti-dilutive employee share-based awards excluded	9,000,750	-

DocGo Inc. and Subsidiaries

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)

	Year Ended December 31,		
	2023	2022	2021
Net income attributable to stockholders of DocGo Inc. and Subsidiaries	6,858,455	34,584,498	23,743,758
Weighted-average shares - basic	103,511,299	101,228,369	80,293,959
Effect of dilutive options	2,106,518	1,747,462	14,569,654
Weighted-average shares - dilutive	105,617,817	102,975,831	94,863,613
Net income per share attributable to DocGo Inc. and Subsidiaries - Basic	0.07	0.34	0.30
Net income per share attributable to DocGo Inc. and Subsidiaries - Diluted	0.06	0.34	0.25
Anti-dilutive employee share-based awards excluded	10,638,371	9,000,750	—

Equity Method Investment

On October 26, 2021, the Company acquired a 50% interest in RND Health Services Inc. ("RND") for \$655,876. The Company uses the equity method to account for investments in which the Company has the ability to exercise significant influence over the operating and financial policies of the investee but does not exercise control. The Company's carrying value in the equity method investee is reflected in the caption "Equity method investment" on the Consolidated Balance Sheets. Changes in value of RND are recorded in "Gain (loss) on equity method investment" on the Consolidated Statements of Operations. The Company's judgment regarding its level of influence over the equity method investee includes considering key factors, such as ownership interest, representation on the board of directors and participation in policy-making decisions.

On November 1, 2021, the Company acquired a 20% interest in National Providers Association, LLC ("NPA") for \$30,000. The Company uses the equity method to account for investments in which the Company has the ability to exercise significant influence over the operating and financial policies of the investee, but does not exercise control. The Company's carrying value in the equity method investee is reflected in the caption "Equity method investment" on the Consolidated Balance Sheets. Changes in value of NPA are recorded in "Gain (loss) on equity method investment" on the Consolidated Statements of Operations. The Company's judgment regarding its level of influence over the equity method investee includes considering key factors, such as ownership interest, representation on the board of directors, and participation in policy-making decisions. Effective December 21, 2021, three members withdrew from NPA resulting in the remaining two members obtaining the remaining ownership percentage. As of December 31, 2021 DocGo owned 50% of NPA.

Under the equity method, the Company's investment is initially measured at cost and subsequently increased or decreased to recognize the Company's share of income and losses of the investee, capital contributions and distributions and impairment losses. The Company performs a qualitative assessment annually and recognizes an impairment if there are sufficient indicators that the fair value of the investment is less than carrying value.

Leases

On October 26, 2021, the Company acquired a 50% interest in RND Health Services Inc. ("RND") for \$655,876. During the year ended December 31, 2023, the Company made an additional investment amounting to \$298,932. The Company's carrying value in RND, an equity method investee, is reflected in the caption "Equity method investments" in the Condensed Consolidated Balance Sheets. Changes in value of RND are recorded in "(Loss) gain on equity method investments" on the accompanying Consolidated Statements of Operations and Comprehensive Income.

On November 1, 2021, the Company acquired a 20% interest in National Providers Association, LLC ("NPA") for \$30,000. Effective December 21, 2021, three members withdrew from NPA, resulting in the remaining two members obtaining the remaining ownership percentage. As of December 31, 2023 and December 31, 2022, the Company owned 50% of NPA. The Company's carrying value in NPA, an equity method investee, is reflected in the caption "Equity method investments" in the accompanying Consolidated Balance Sheets. Changes in value of NPA are recorded in "(Loss) gain on equity method investments" in the Consolidated Statements of Operations and Comprehensive Income.

Leases

The Company categorizes leases at its inception as either operating or finance leases based on the criteria in ASC 842, Leases ("ASC 842"). The Company adopted FASB ASC 842 Leases, ("ASC 842") on January 1, 2019, using the modified retrospective approach, and has established a Right-of-Use ("ROU") Asset right-of-use asset and a current and non-current Lease Liability lease liability for each lease arrangement identified. The lease liability is recorded at the present value of future lease payments discounted using the discount rate that approximates the Company's incremental borrowing rate for the lease established at the commencement date, and the ROU right-of-use asset is measured as the lease liability plus any initial direct costs, less any lease incentives received before commencement. The Company recognizes a single lease cost, so that the remaining cost of the lease is allocated over the remaining lease term on a straight-line basis.

The Company has lease arrangements for vehicles, equipment and facilities. These leases typically have original terms not exceeding 10 years and in some cases contain multi-year renewal options, none of which are reasonably certain of exercise. The Company's lease arrangements may contain both lease and non-lease components. The Company has elected to combine and account for lease and non-lease components as a single lease component. The Company has incorporated residual value obligations in leases for which there is such occurrences. Regarding short-term leases, ASC 842-10-25-2

DocGo Inc. and Subsidiaries

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)

permits and an entity to make a policy election not to apply the recognition requirements of ASC 842 to Short-term short-term leases. The Company has elected not to apply the ASC 842 recognition criteria to any leases that qualify as Short-Term Leases.

short-term leases.

Income Taxes

Income taxes are recorded in accordance with ASC 740, *Income Taxes* (“ASC 740”), which provides for deferred taxes using an asset and liability approach. The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or its tax returns. Deferred tax assets and liabilities are determined based on the difference between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Valuation allowances are provided if based upon the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. The Company accounts for uncertain tax positions in accordance with the provisions of ASC 740. When uncertain tax positions exist, the Company recognizes the tax benefit of tax positions to the extent that the benefit would more likely than not be realized assuming examination by the taxing authority. The determination as to whether the tax benefit will more likely than not be realized is based upon the technical merits of the tax position as well as consideration of the available facts and circumstances. The Company recognizes any interest and penalties accrued related to unrecognized tax benefits as income tax expense.

Recently Issued Accounting Standards

In March 2022, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2022-02, *Financial Instruments – Credit Losses (Topic 326): Troubled Debt Restructurings and Vintage Disclosures* (“ASU 2022-02”), which eliminates accounting guidance for troubled debt restructurings by creditors in Subtopic 310-40, *Receivables—Troubled Debt Restructurings by Creditors*, while enhancing disclosure requirements for certain loan refinancings and restructurings by creditors when a borrower is experiencing financial difficulty. ASU 2022-02 also requires public business entities to disclose current-period gross write-offs by year of origination for financing receivables and net investments in leases within the scope of Subtopic 326-20, *Financial Instruments—Credit Losses—Measured at Amortized Cost*. ASU 2022-02 only affects entities that have already adopted ASU 2016-13, *Financial Instruments—Credit Losses (Topic 326)*, which is effective for fiscal years beginning after December 15, 2022. The Company adopted ASU 2022-02 on January 1, 2023, which did not have a material impact on the Company’s Consolidated Financial Statements.

Recently Issued Accounting Standards Not Yet Adopted

In June 2016, November 2023, the FASB issued ASU 2016-13, which requires measurement 2023-07, *Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosure*. The ASU updates reportable segment disclosure requirements, primarily through requiring enhanced disclosures about significant segment expenses and recognition information used to assess segment performance. The ASU is effective for fiscal years beginning after December 15, 2023, with early adoption permitted. The Company is currently evaluating the impact of expected credit losses for financial assets held. Following adopting this ASU on its disclosures.

In December 2023, the effective date philosophy for all other entities in FASB issued ASU 2019-10, which No. 2023-09, *Income Taxes (Topic 740): Improvements to Income Tax Disclosures*. The ASU includes smaller reporting companies (SRCs) amendments requiring enhanced income tax disclosures, primarily related to standardization and emerging growth companies (EGC), this disaggregation of rate reconciliation categories and income taxes paid by jurisdiction. The guidance is effective for fiscal years beginning after December 15, 2022 including interim periods within those fiscal years. The standard is to December 15, 2024, with early adoption permitted, and should be applied through a cumulative-effect adjustment to retained earnings as of the beginning of the first reporting period in which the guidance is effective, either prospectively or retrospectively. The Company is in the process of currently evaluating the potential impact of adopting this new accounting standard ASU on our Consolidated Financial Statements and related its disclosures.

In March 2022, the FASB issued ASU No. 2022-02, *Financial Instruments—Credit Losses (Topic 326): Troubled Debt Restructurings and Vintage Disclosures*. The guidance is intended to improve the decision usefulness of information provided to investors about certain loan refinancings, restructurings, and write-offs. The standard eliminates the recognition and measurement guidance on TDRs for creditors that have adopted ASC 326, *Financial Instruments — Credit Losses* and requires them to make enhanced disclosures about loan modifications for borrowers experiencing financial difficulty. The new guidance also requires public business entities to present current-period gross write-offs (on a current year-to-date basis for interim-period disclosures) by year of origination in their vintage disclosures. The adoption of this guidance is not expected to have a material impact on the Company’s Consolidated Financial Statements.

In September 2022, the FASB issued ASU No. 2022-04, *Liabilities—Supplier Finance Programs (Subtopic 405-50): Debt Restructurings Disclosure of Supplier Finance Program Obligations*. The guidance requires entities to disclose the key terms of supplier finance programs they use in connection with the purchase of goods and services along with information about their obligations under these programs, including a rollforward of those obligations. The guidance is not applicable to the Company.

In December 2022, the FASB issued ASU No. 2022-06, *Reference Rate Reform (Topic 848): Deferral of the Sunset Date of Topic 848*. ASU No. 2020-04, *Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting* provided optional guidance to ease the potential burden in accounting for (or recognizing the effects of) reference rate reform on financial reporting. The ASU was effective upon issuance and generally could be applied through December 31, 2022. Because the current relief in ASC 848, *Reference Rate Reform* may not cover a period of time during which a significant number of modifications may take place, the amendments in ASU No. 2022-06 defer the sunset date from December 31, 2022 to December 31, 2024, after which entities will no longer be permitted to apply the relief in ASC 848. The ASU is effective upon issuance. The guidance is not applicable to the Company.

DocGo Inc. and Subsidiaries
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)

3. Property and Equipment, net

Property and equipment, net as of December 31, 2022, December 31, 2023 and 2021, respectively, 2022 are as follows:

	December 31, 2022	December 31, 2021
Office equipment and furniture	\$ 2,686,065	\$ 1,977,808
Buildings	527,283	527,284
Land	37,800	37,800
Transportation equipment	20,773,862	13,772,251
Medical equipment	5,177,520	3,949,566
Leasehold improvements	579,658	616,446
	<u>29,782,188</u>	<u>20,881,155</u>
Less: Accumulated depreciation	(8,524,013)	(8,147,266)
Property and equipment, net	<u>\$ 21,258,175</u>	<u>\$ 12,733,889</u>

	December 31, 2023	December 31, 2022
Transportation equipment	\$ 17,438,072	\$ 20,773,862
Medical equipment	7,104,161	5,177,520
Office equipment and furniture	3,701,657	2,686,065
Leasehold improvements	709,619	579,658
Buildings	527,283	527,283
Land	37,800	37,800
	<u>29,518,592</u>	<u>29,782,188</u>
Less: Accumulated depreciation	(12,683,108)	(8,524,013)
Property and equipment, net	<u>\$ 16,835,484</u>	<u>\$ 21,258,175</u>

During the year ended December 31, 2023, the Company disposed of assets with a cost of \$12,343,547 and accumulated depreciation of \$10,743,915 for proceeds of \$747,088. The Company recorded a loss on disposal of assets of \$852,544.

During the year ended December 31, 2022, the Company disposed of assets with a cost of \$50,353 and accumulated depreciation of \$26,180 for proceeds of \$3,000. The Company recorded a loss on disposal of assets of \$21,173.

During the year ended December 31, 2021, the Company disposed of assets with a cost of \$119,026 and accumulated depreciation of \$9,944 for proceeds of \$74,740. The Company recorded a loss on disposal of assets of \$34,342.

The Company recorded depreciation expenses of \$4,829,780, \$4,114,346 and \$2,312,437 as of December 31, 2022, December 31, 2023, 2022 and 2021, respectively.

The total disposal for the years ended December 31, 2022 and 2021 were \$50,353 and \$0, respectively.

4. Acquisitions

Government Medical Services, LLC

On July 6, 2022, Holdings acquired 100% of the outstanding shares of common stock of Government Medical Services, LLC ("GMS"), GMS, a provider of medical services. The aggregate purchase price consisted of \$20,338,789 in cash consideration. Holdings also agreed to pay GMS an additional \$3,000,000 upon GMS meeting certain performance conditions within a year of the Closing Date, closing date of such acquisition. Acquisition costs are included in general and administrative expenses and totaled \$1,001,883 for the twelve months year ended December 31, 2022.

During the year ended December 31, 2023, the Company made a \$3,000,000 payment to settle the contingent liability balance. As of December 31, 2023 and 2022, there was a due to seller balance of \$0 and \$3,000,000, respectively.

Exceptional Medical Transportation, LLC

On July 13, 2022, the Company acquired 100% of the outstanding shares of common stock of Exceptional, Medical Transportation, LLC (“Exceptional”) a provider of medical transportation services, in exchange for \$13,708,333 consisting of \$7,708,333 in cash at closing and \$6,000,000 payable over a 24 month period. Holdings period following the closing date of the acquisition. The Company also agreed to pay an estimated \$1,080,000 Contingent up to \$2,000,000 in contingent consideration upon Exceptional meeting certain performance conditions in 2023. Exceptional is in within two years of the business closing date of providing medical transportation services, such acquisition. Acquisition costs are included in general and administrative expenses totaled \$56,571 for the twelve months year ended December 31, 2022.

During the year ended December 31, 2023, the Company recorded a change in contingent consideration in the amount of \$374,044. During the year ended December 31, 2023, the Company made a payment for the first installment due on the

contingent liability in the amount of \$426,655. The estimated contingent consideration amount payable for Exceptional was \$279,301 and \$1,080,000 as of December 31, 2023 and 2022, respectively. Additionally, the Company paid \$3,000,000 of the \$6,000,000 remaining purchase price payable as of December 31, 2023. As of December 31, 2023 and 2022, there was a due to seller balance of \$3,000,000 and \$6,000,000, respectively.

DocGo Inc. and Subsidiaries

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)

Ryan Brothers Fort Atkinson, LLC

On August 9, 2022, the Company acquired 100% of the outstanding shares of common stock of Ryan Brothers, Fort Atkinson, LLC (“RB”) a provider of medical transportation services, in exchange for an aggregate purchase price of \$11,422,252 consisting of \$7,422,252 in cash at closing and an estimated \$4,000,000 of estimated Contingent in contingent consideration to be paid out over 24 months, commencing on August 1, 2022, based on performance of certain obligations. RB is in the business of providing medical transportation services. Acquisition costs are included in general and administrative expenses and totaled \$230,175 for the twelve months year ended December 31, 2022.

During the year ended December 31, 2023, the Company recorded a change in contingent consideration in the amount of \$338,956. During the year ended December 31, 2023, the Company made a payment for the first installment due on the contingent liability in the amount of \$1,840,026. The estimated contingent consideration amount payable for Ryan Brothers was \$1,821,018 and \$4,000,000 as of December 31, 2023 and 2022, respectively.

Community Ambulance Services LTD

Service Ltd

On October 12, 2022, the Company Holdings, through its indirect wholly owned subsidiary Ambulnz U.K. Ltd. (“UK Ltd.”), acquired Community Ambulance Service Ltd (“CAS”), a company located provider of emergency and non-emergency transport services, including high dependency, urgent care, mental health and blue light transport services, and diagnostics testing in United Kingdom, in exchange for the U.K. The aggregate purchase price consisted of approximately \$5,541,269 in cash. The net assets acquired through the CAS acquisition was \$7,134,881 mainly from the vehicles with high fair market value, which directly lead to a Gain gain on bargain purchase of amounting to \$1,593,612. CAS is engaged in providing emergency and non-emergency transport services, including high dependency, urgent care, mental health and blue light transport services and diagnostics testing. We believe The Company expects this acquisition will allow us to help increase our the Company’s presence in that the U.K. market while giving us and help provide improved access to municipal contracts. Acquisition costs are included in general and administrative expenses totaling \$171,779 for the three and twelve months year ended December 31, 2022, respectively.

DocGo Inc. and Subsidiaries
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)

Location Medical Services, LLC

On December 9, 2022, Holdings, through its indirect wholly owned subsidiary, Ambulnz U.K. UK Ltd., closed acquiring acquired 100% of the outstanding shares of common stock of Location Medical Services, LLC ("LMS"). LMS. The aggregate purchase price consisted of \$302,450 in cash consideration. The Company also agreed to pay LMS an additional \$11,279,201 in deferred consideration and an estimated \$2,475,540 Contingent in contingent consideration upon LMS meeting certain performance conditions in 2023. Acquisition costs are included in general and administrative expenses and totaled \$4,200 for the three year ended December 31, 2022.

During the year ended December 31, 2023, the Company recorded a change in contingent consideration in the amount of \$2,000,312 and twelve recorded \$129,599 in foreign exchange movement. The estimated contingent consideration amount payable for LMS was \$604,827 and \$2,475,540 as of December 31, 2023 and 2022, respectively. Additionally, the Company paid \$11,279,201 of deferred consideration to LMS during the year ended December 31, 2023. As of December 31, 2023 and 2022, there was a due to seller balance of \$0 and \$11,279,201, respectively.

Cardiac RMS, LLC

On March 31, 2023, Holdings acquired 51% of the outstanding shares of common stock of CRMS, a provider of cardiac implantable electronic device remote monitoring and virtual care management services. The closing consideration of \$10,000,000 consisted of \$9,000,000 in cash and \$1,000,000 worth of shares of Common Stock issued in a private placement transaction. A further probable consideration of \$15,822,190 is to be paid out over 36 months following the closing of the transaction for the remaining 49% equity of CRMS, based on CRMS' attainment of full-year EBITDA targets. \$5,000,000 of such further probable consideration is to be paid in cash and the remaining \$10,822,190 is to be paid in shares of Common Stock. Acquisition costs are included in general and administrative expenses and totaled \$229,937 for the year ended December 31, 2022 December 31, 2023.

During the year ended December 31, 2023, respectively.

the Company recorded a change in contingent consideration in the amount of \$1,265,645. As of December 31, 2023, there was a remaining contingent liability balance of \$17,087,835.

Ambulnz-FMC North America LLC

On April 1, 2023, the Company acquired the remaining outstanding shares of common stock of Ambulnz-FMC North America LLC ("FMC NA"), a prominent healthcare company that focuses on providing vital products and services for patients suffering from kidney diseases and renal failure, from its joint venture with Holdings in exchange for \$4,000,000 in cash and \$3,000,000 in Common Stock. Acquisition costs are included in general and administrative expenses totaling approximately \$35,560 for the year ended December 31, 2023.

Healthworx LLC

On May 10, 2023, the Company acquired the remaining outstanding shares of common stock of Healthworx LLC ("Healthworx"), a provider of management, administration and support services to service providers focused on medical testing and diagnostic screening, from its joint venture with Rapid Reliable Testing, LLC ("RRT") in exchange for \$1,385,156 in cash.

The following table presents the assets acquired and liabilities assumed at the date of the acquisitions:

	Location Medical Services	Community Ambulance Service	Ryan Brothers	Exceptional Medical Transport	Government Medical Services	Total
Consideration:						
Cash consideration	\$ 302,450	\$ 5,541,269	\$ 7,422,252	\$ 6,375,000	\$ 20,338,789	\$ 39,979,760
Deferred consideration	11,279,201	-	-	6,000,000	-	17,279,201
Amounts held under an escrow account	-	-	-	1,333,333	-	1,333,333
Contingent consideration	2,475,540	-	4,000,000	1,080,000	3,000,000	10,555,540
Total consideration	14,057,191	5,541,269	11,422,252	14,788,333	23,338,789	69,147,834

Recognized amounts of identifiable assets acquired and liabilities assumed																
Cash	\$	5,404,660	\$	892,218	\$	620,248	\$	299,050	\$	1,005,453	\$	8,221,629				
Accounts receivable		623,635		7,002,325		5,844,494		3,785,490		3,975,160		21,231,104				
Other current assets		134,216		1,167,326		136,157		-		30,734		1,468,433				
Property, plant and equipment		519,391		4,548,956		2,125,134		2,450,900		4,092		9,648,473				
Intangible assets		2,419,600		-		387,550		125,000		10,305,000		13,237,150				
Total identifiable assets acquired		9,101,502		13,610,825		9,113,583		6,660,440		15,320,439		53,806,789				
Accounts payable	\$	40,447	\$	2,036,714	\$	44,911	\$	-	\$	137,239	\$	2,259,311				
Due to seller		-		-		5,844,494		4,084,540		-		9,929,034				
Other current liabilities		1,012,992		4,439,230		286,792		-		562,809		6,301,823				
Total liabilities assumed		1,053,439		6,475,944		6,176,197		4,084,540		700,048		18,490,168				
Goodwill/(Gain on bargain purchase)		6,009,128		(1,593,612)		8,484,866		12,212,433		8,718,398		33,831,213				
Total purchase price	\$	14,057,191	\$	5,541,269	\$	11,422,252	\$	14,788,333	\$	23,338,789	\$	69,147,834				
	FMC NA	CRMS	LMS	CAS	Ryan Brothers	Exceptional	GMS	Total								
Consideration:																
Cash consideration	\$	4,000,000	\$	9,000,000	\$	302,450	\$	5,541,269	\$	7,422,252	\$	6,375,000	\$	20,338,789	\$	52,979,760
Stock consideration		3,000,000		1,000,000												4,000,000
Due to seller		—		—		11,279,201		—		—		6,000,000		—		17,279,201
Amounts held under an escrow account		—		—		—		—		1,333,333		—		—		1,333,333
Contingent liability		—		15,822,190		2,475,540		—		4,000,000		1,080,000		3,000,000		26,377,730
Total consideration	\$	7,000,000	\$	25,822,190	\$	14,057,191	\$	5,541,269	\$	11,422,252	\$	14,788,333	\$	23,338,789	\$	101,970,024
Recognized amounts of identifiable assets acquired and liabilities assumed																
Cash	\$	—	\$	1,574,604	\$	5,404,660	\$	892,218	\$	620,548	\$	299,050	\$	1,005,453	\$	9,796,533
Accounts receivable		—		2,033,533		623,635		7,002,325		5,844,494		3,785,490		3,975,160		23,264,637
Other current assets		—		293,478		134,216		1,167,326		136,157		—		30,734		1,761,911
Property, plant and equipment		—		—		519,391		4,548,956		2,125,134		2,450,900		4,092		9,648,473
Intangible assets		—		15,930,000		2,419,600		—		387,550		125,000		10,305,000		29,167,150
Total identifiable assets acquired		—		19,831,615		9,101,502		13,610,825		9,113,883		6,660,440		15,320,439		73,638,704
Accounts payable		—		28,978		40,447		2,036,714		44,911		—		137,239		2,288,289
Due to seller		—		2,448,460		—		—		5,844,494		4,084,540		—		12,377,494
Other current liabilities		—		174,177		1,012,992		4,439,230		286,792		—		562,809		6,476,000
Total liabilities assumed		—		2,651,615		1,053,439		6,475,944		6,176,197		4,084,540		700,048		21,141,783
Noncontrolling interests		2,567,037		—		—		—		—		—		—		2,567,037
Goodwill		—		8,642,190		6,009,128		(1,593,612)		8,484,566		12,212,433		8,718,398		42,473,103
Additional paid-in-capital		4,432,963		—		—		—		—		—		—		4,432,963

Total purchase price	<u>\$ 7,000,000</u>	<u>\$ 25,822,190</u>	<u>\$ 14,057,191</u>	<u>\$ 5,541,269</u>	<u>\$ 11,422,252</u>	<u>\$ 14,788,333</u>	<u>\$ 23,338,789</u>	<u>\$ 101,970,024</u>
-----------------------------	---------------------	----------------------	----------------------	---------------------	----------------------	----------------------	----------------------	-----------------------

Proforma disclosures

Pro Forma Disclosures

The following unaudited pro forma combined financial information for the fiscal years ended **December 31, 2022**, **December 31, 2023, 2022** and 2021 gives effect to the acquisitions disclosed above as if they had occurred on January 1, 2021. The pro forma information is not necessarily indicative of the results of operations that actually would have occurred under the ownership and management of the Company.

			2022	2021
Revenue			\$ 523,948,302	\$ 451,696,206
Net Income			38,164,837	38,743,940
	2023	2022	2021	
Revenue	\$ 627,402,261	\$ 539,522,587	\$ 461,001,227	
Net Income	11,087,122	46,960,359	43,763,036	

The unaudited pro forma combined financial information presented above includes the accounting effects of the acquisitions, including, to the extent applicable, amortization charges from acquired intangible assets; depreciation of property, plant and equipment that have been revalued; transaction costs; interest expense; and the related tax effects.

DocGo Inc. and Subsidiaries
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)

5. ABC Transaction and Held for Sale

During the year 2022, the Company started discussions regarding the potential liquidation process of Health through an assignment for the benefit of creditors (“ABC”), ABC, with a targeting targeted timeline for the transaction to be fully closed in December 2022, by December 31, 2022. The conversation involved operations, human resources, external legal counsel and the Assignee, Amb, LLC (a California limited liability company, the “Assignee”) company). It was the management’s intention and decision that the ABC transaction will be commenced and completed by year end 2022. Due to operational processes, the filing was extended and finalized on February 3, 2023.

On February 3, 2023, Health commenced the ABC pursuant to California law. An ABC is a liquidation process governed by state law (California law in this instance) that is an alternative to a bankruptcy case under federal law. Prior to commencing the ABC, Health ceased business operations and all of its employees were terminated and treated in accordance with California law. In the ABC, all of Health’s assets were transferred to the Assignee, who acts as a fiduciary for creditors and in a capacity equivalent to that of a bankruptcy trustee. The Assignee is responsible for liquidating the assets. Similar to a bankruptcy case, there is a claims process. Creditors of Health will receive received notice of the ABC and a proof of claim form and are were required to submit a proof of claim in order to participate in distribution of net liquidation proceeds by the Assignee.

As of December 31, 2022, Health met the criteria to be classified as held for sale. As the entity has met this criteria, the Company is required to record the respective assets and liabilities at the lower of carrying value or fair value, less any costs to sell, and present the related assets and liabilities as separate line items in the Consolidated Balance Sheets.

The following table presents information related to the major classes of assets and liabilities that were classified as held for sale in the Company’s Consolidated Balance Sheets as of December 31, 2022 and December 31, 2023:

	December 31, 2022		
	Pre ABC Adjustment	Adjustment	Post ABC Adjustment
ASSETS			
Current assets:			
Cash and cash equivalents	\$ (190,312)	\$ 190,312	\$ -
Accounts receivable, net	1,219,927	(1,219,927)	-
Prepaid expenses and other current assets	22,850	(22,850)	-
Assets held for sale	-	4,480,344	4,480,344
Total current assets	1,052,465	3,427,879	4,480,344
Property and equipment, net	1,107,279	(1,107,279)	-
Intangibles, net	30,697	(30,697)	-
Goodwill	5,085,689	(5,085,689)	-
Operating lease right-of-use assets	29,753	(29,753)	-
Intercompany receivables	17,957,076	-	17,957,076
Other assets	96,419	(96,419)	-
Total assets	\$ 25,359,378	\$ (2,921,958)	\$ 22,437,420
LIABILITIES AND STOCKHOLDERS’ EQUITY			
Current liabilities:			
Accounts payable	\$ 196,122	\$ (196,122)	\$ -
Accrued liabilities	4,250,603	(4,250,603)	-
Intercompany payables	59,404,839	-	59,404,839
Operating lease liability, current	33,619	(33,619)	-
Liabilities held for sale	-	4,480,344	4,480,344
Total current liabilities	63,885,183	-	63,885,183
Total liabilities	\$ 63,885,183	\$ -	\$ 63,885,183
STOCKHOLDERS’ EQUITY:			
Accumulated deficit	\$ (38,525,805)	\$ (2,921,958)	\$ (41,447,763)
Total stockholders’ equity attributable to DocGo Inc. and Subsidiaries	(38,525,805)	(2,921,958)	(41,447,763)

Noncontrolling interests				-	-	-
Total stockholders' equity				\$ (38,525,805)	\$ (2,921,958)	\$ (41,447,763)
Total liabilities and stockholders' equity				\$ 25,359,378	\$ (2,921,958)	\$ 22,437,420
	Pre ABC Adjustment	2022 Adjustments	December 31, 2022	YTD 2023 Adjustments	December 31, 2023	
ASSETS						
Current assets:						
Cash and cash equivalents	\$ (190,312)	\$ 190,312	\$ —	\$ —	\$ —	
Accounts receivable, net	1,219,927	(1,219,927)	—	—	—	
Prepaid expenses and other current assets	22,850	(22,850)	—	—	—	
Total current assets	1,052,465	(1,052,465)	—	—	—	
Property and equipment, net	1,107,279	(1,107,279)	—	—	—	
Intangibles, net	30,697	(30,697)	—	—	—	
Goodwill	5,085,689	(5,085,689)	—	—	—	
Operating lease right-of-use assets	29,753	(29,753)	—	—	—	
Assets held for sale	—	4,480,344	4,480,344	(4,480,344)	—	
Other assets	18,053,495	(96,419)	17,957,076	(17,957,076)	—	
Total assets	\$ 25,359,378	\$ (2,921,958)	\$ 22,437,420	\$ (22,437,420)	\$ —	
LIABILITIES AND STOCKHOLDERS' EQUITY						
Current liabilities:						
Accounts payable	\$ 196,122	\$ (196,122)	\$ —	\$ —	\$ —	
Accrued liabilities	63,655,442	(4,250,603)	59,404,839	(59,404,839)	—	
Operating lease liability, current	33,619	(33,619)	—	—	—	
Liabilities held for sale	—	4,480,344	4,480,344	(4,480,344)	—	
Total current liabilities	63,885,183	—	63,885,183	(63,885,183)	—	
Total liabilities	\$ 63,885,183	\$ —	\$ 63,885,183	\$ (63,885,183)	\$ —	
Stockholders' equity:						
Accumulated deficit	\$ (38,525,805)	\$ (2,921,958)	\$ (41,447,763)	\$ 41,447,763	\$ —	
Total stockholders' equity attributable to DocGo Inc. and Subsidiaries	(38,525,805)	(2,921,958)	(41,447,763)	41,447,763	—	
Noncontrolling interests	—	—	—	—	—	
Total stockholders' equity	\$ (38,525,805)	\$ (2,921,958)	\$ (41,447,763)	\$ 41,447,763	\$ —	
Total liabilities and stockholders' equity	\$ 25,359,378	\$ (2,921,958)	\$ 22,437,420	\$ (22,437,420)	\$ —	

The **Intercompany intercompany** receivables and **Intercompany intercompany** payables are eliminated in the Company's Consolidated Balance Sheets.

DocGo Inc. and Subsidiaries

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)

6. Goodwill

In connection with the ABC, transaction, the Company has evaluated its Goodwill goodwill balances as of December 31, 2022 and has determined that there is was an impairment of Goodwill goodwill related to its Health reporting unit. The impairment is was primarily due to the ABC filing.

As a result of this impairment, the Company has recognized a non-cash charge of \$2,921,958 in the year ended December 31, 2022 in the Consolidated Statements of Operations. Operations and Comprehensive Income. The charge was recorded as part of Other Income other income in the Company's Consolidated Statements of Operations and Comprehensive Income and has no impact on its cash flow, liquidity or compliance with debt covenants.

Additionally, the Company recorded Goodwill an aggregate of \$8,642,190 and \$35,299,136 in goodwill in connection with its acquisitions in the total Goodwill acquired in 2022 was \$35,299,136.

year ended December 31, 2023 and December 31, 2022, respectively.

The Company also updated the carrying value of the Goodwill goodwill in its Condensed Consolidated Balance Sheets to reflect the additional Goodwill and the impairment charge. goodwill. The carrying value of Goodwill amounts \$38,900,413, the goodwill amounted to \$47,539,929 as of December 31, 2023. The changes in the carrying value of Goodwill goodwill for the period year ended December 31, 2022 December 31, 2023 are as noted in the tables table below:

	Carrying Value
Balance as of December 31, 2021	\$ 8,686,966
Goodwill acquired during the period	35,299,136
Impairment recognized during the year	(2,921,958)
Reassignment of Goodwill to Assets held for sale	(2,163,731)
Balance as of December 31, 2022	\$ 38,900,413
Goodwill acquired during the period	8,642,190
Currency translation adjustment and others	(2,674)
Balance as of December 31, 2023	\$ 47,539,929

	Carrying Value
Balance as of December 31, 2020	\$ 6,610,557
Goodwill acquired during the period	2,076,409
Balance as of December 31, 2021	\$ 8,686,966
Goodwill acquired during the period	35,299,136
Impairment during the year	(2,921,958)
Reassignment of Goodwill to Assets held for sale	(2,163,731)
Balance as of December 31, 2022	\$ 38,900,413

7. Intangibles

Intangible assets consisted of the following as of December 31, 2023 and December 31, 2022:

	December 31, 2023				
	Estimated Useful Life (Years)	Gross Carrying Amount	Additions	Accumulated Amortization	Net Carrying Amount
Patents	15 years	\$ 62,823	\$ 20,961	\$ (15,592)	\$ 68,192
Computer software	5 years	247,828	—	(235,967)	11,861
Operating licenses	Indefinite	8,799,004	600,000	—	9,399,004
Internally developed software	4-5 years	8,284,058	1,794,029	(8,821,563)	1,256,524
Material contracts	Indefinite	62,550	—	—	62,550
Customer relationships	8-9 years	12,397,954	15,939,570	(3,334,925)	25,002,599

Trademark	8 years	326,646	17,101	(46,549)	297,198
Non-compete agreements	5 years	—	100,000	(15,000)	85,000
Trade credits	5 years	—	1,500,000	—	1,500,000
		<u>\$ 30,180,863</u>	<u>\$ 19,971,661</u>	<u>\$ (12,469,596)</u>	<u>\$ 37,682,928</u>

December 31, 2022					
	Estimated Useful Life (Years)	Gross Carrying Amount	Additions	Accumulated Amortization	Net Carrying Amount
Patents	15 years	\$ 48,668	\$ 14,155	\$ (10,116)	\$ 52,707
Computer software	5 years	294,147	(46,319)	(224,886)	22,942
Operating licenses	Indefinite	8,375,514	423,490	—	8,799,004
Internally developed software	4-5 years	6,013,513	2,270,545	(6,378,911)	1,905,147
Material contracts	Indefinite	—	62,550	—	62,550
Customer relationships	8-9 years	—	12,397,954	(594,301)	11,803,653
Trademark	8 years	—	326,646	(3,403)	323,243
		<u>\$ 14,731,842</u>	<u>\$ 15,449,021</u>	<u>\$ (7,211,617)</u>	<u>\$ 22,969,246</u>

The intangible assets include an immaterial foreign currency translation adjustment in the amount of \$8,621. Intangible asset balances are translated into U.S. dollars using exchange rates in effect at period end, and adjustments related to foreign currency translation are included in other comprehensive income.

The Company recorded amortization expenses expense of \$5,249,358, \$3,214,814 and \$1,845,193 as of December 31, 2022 for the periods ended December 31, 2023, 2022 and 2021, respectively.

December 31, 2022					
	Estimated Useful Life (Years)	Gross Carrying Amount	Additions	Accumulated Amortization	Net Carrying Amount
Patents	15 years	\$ 48,668	\$ 14,155	\$ (10,116)	\$ 52,707
Computer software	5 years	294,147	(46,319)	(224,886)	22,942
Operating licenses	Indefinite	8,375,514	423,490	-	8,799,004
Internally developed software	4-5 years	6,013,513	2,270,545	(6,378,911)	1,905,147
Material contracts	Indefinite	-	62,550	-	62,550
Customer relationship	8-9 years	-	12,397,954	(594,301)	11,803,653
Trademark	8 years	-	326,646	(3,403)	323,243
		<u>\$ 14,731,842</u>	<u>\$ 15,449,021</u>	<u>\$ (7,211,617)</u>	<u>\$ 22,969,246</u>

Future amortization expense at December 31, 2023 for the next five years and in the aggregate are as follows:

December 31, 2021					
	Estimated Useful Life (Years)	Gross Carrying Amount	Additions	Accumulated Amortization	Net Carrying Amount
Patents	15 years	\$ 19,275	\$ 29,393	\$ (6,367)	\$ 42,301
Computer software	5 years	132,816	161,331	(219,388)	74,759
Operating licenses	Indefinite	8,375,514	-	-	8,375,514
Internally developed software	4-5 years	2,146,501	3,867,012	(3,828,038)	2,185,475
		<u>\$ 10,674,106</u>	<u>\$ 4,057,736</u>	<u>\$ (4,053,793)</u>	<u>\$ 10,678,049</u>

	Amortization Expense
2024	\$ 3,905,132
2025	3,855,130
2026	3,249,936
2027	3,249,222
2028	3,232,758
Thereafter	9,229,196
Total	\$ 26,721,374

DocGo Inc. and Subsidiaries

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)

The estimated future amortization expense of definite life intangible assets as of December 31, 2022 is as follows:

	Amortization Expense
2023	\$ 2,494,148
2024	1,917,338
2025	1,867,861
2026	1,453,827
2027	1,453,109
Thereafter	4,921,409
Total	\$ 14,107,692

8. Accrued Liabilities

Accrued liabilities consisted of the following at the dates indicated:

	December 31, 2023	December 31, 2022
<i>Accrued subcontractors</i>	\$ 37,858,755	\$ 8,101,150
<i>Accrued general expenses</i>	27,001,232	11,436,462
<i>Accrued workers' compensation and other insurance liabilities</i>	12,881,902	3,766,469
<i>Accrued payroll</i>	6,464,192	4,245,838
<i>Accrued bonus</i>	4,784,005	1,500,717
<i>Other current liabilities</i>	2,350,523	2,522,395
Total accrued liabilities	\$ 91,340,609	\$ 31,573,031

	December 31, 2022	December 31, 2021
Accrued bonus	\$ 1,500,717	\$ 7,260,456
Accrued lab fees	584,203	4,885,539
Accrued payroll	4,245,838	3,539,301
Medicare advance	-	975,415
FICA/Medicare liability	555,166	739,629
Accrued general expenses	11,436,462	3,497,418
Accrued subcontractors	8,101,150	9,564,833
Accrued fuel and maintenance	253,243	450,842
Accrued workers compensation and insurance liabilities	3,766,469	2,259,571
Other current liabilities	706,528	736,021
Accrued legal fees	344,417	1,143,629
Credit card payable	78,838	58,223
Total accrued liabilities	\$ 31,573,031	\$ 35,110,877

9. Line of Credit

On December 17, 2021, Ambulnz-FMC North America, LLC ("FMC NA"), entered into a revolving loan and bridge credit and security agreement with a subsidiary of one of its members with a maximum revolving advance amount of \$12,000,000. Each Revolving Advance shall bear interest at a per annum rate equal to the Wall Street Journal Prime Rate (7.75% as of March 10, 2023), as the same may change from time to time, plus one percent (1.00%), but in no event less than five percent (5.00%) per annum, calculated on the basis of a 360-day year for the actual number of days in the applicable period. The agreement is subject to certain financial covenants such as an unused fee, whereas the Company shall pay to the subsidiary of one of its members an unused fee in the amount of 0.5% of the average daily amount by which the Revolving Commitment Amount (\$12,000,000) exceeds the principal balance of the aggregate outstanding advances. All accrued and unpaid interest and unused fee shall be due and payable on the first anniversary of the date of the agreement ("Revolving Credit Maturity Date"). This loan is secured by all assets of entities owned 100% by DocGo Inc. As of December 31, 2021, the outstanding balance of the line of credit was zero. On January 26, 2022, the company drew \$1,000,000 to fund operations and meet short-term obligations. In December 2022, the Company did not renew the agreement, and repaid the outstanding balance.

On November 1, 2022, the Company entered into a revolving loan and security credit agreement (the "Credit Agreement") with two banks, with one bank in the capacity as a lender and the administrative agent (the (collectively with the other lender, the "Lenders"), with . The Credit Agreement provides for a maximum revolving advance credit facility in the initial aggregate principal amount of \$90,000,000. \$90,000,000 (the "Revolving Facility"). The revolving facility Revolving Facility includes the ability for the Company to request an increase to the commitment by an additional amount of up to \$50,000,000, though no Lender (nor the Lenders collectively) are is obligated to increase their its respective commitments. Borrowings under the revolving facility Revolving Facility bear interest at a per annum rate equal to, to: (i) at the Company's option, the (x) the base rate or (y) the adjusted term SOFR rate, plus (ii) the applicable margin. The applicable margins are based on the Company's consolidated net leverage ratio, adjusted on a quarterly basis. The Initial initial applicable margins are 1.25% for an adjusted term SOFR loan and 0.25% for a base rate loan and will be updated based on the Company's consolidated net leverage ratio reported in the compliance certificate. ratio. The revolving facility Revolving Facility matures on the five-year anniversary of the closing date, November 1, 2027. The revolving facility Revolving Facility is secured by a first-priority lien on substantially all of the Company's present and future personal assets and intangible assets. The revolving facility Revolving Facility is subject to certain financial covenants such as a net leverage ratio and interest coverage ratio, as defined in the agreement. The Credit Agreement. On October 19, 2023, the Company has not made any draws drew down \$25,000,000 under the facility and there is no amount outstanding. Revolving Facility. As of December 31, 2022 December 31, 2023, the outstanding balance of the line of credit under the Revolving Facility was \$25,000,000. The unused line of credit under the Revolving Facility was \$65,000,000 as of December 31, 2023. The Company incurred \$359,330 in interest charges relating to its line of credit during 2023, which is \$0.

reflected in interest income (expense) on the Company's Consolidated Statements of Operations and Comprehensive Income.

DocGo Inc. and Subsidiaries

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)

10. Notes Payable

The Company has various loans with finance companies with monthly installments aggregating \$76,546, \$3,784, inclusive of interest ranging from 2.5% through 8% 7.5%. The notes mature at various times through 2027 2026 and are secured by transportation equipment.

The following table summarizes the Company's notes payable:

	December 31, 2022	December 31, 2021
Equipment and financing loans payable, between 2.5% and 8% interest and maturing between January 2022 and October 2027	\$ 1,901,514	\$ 1,903,288
Loan received pursuant to the PPP Term Note	-	-
Total notes payable	1,901,514	1,903,288
Less: current portion of notes payable	\$ 664,913	\$ 600,449
Total non-current portion of notes payable	\$ 1,236,601	\$ 1,302,839
	December 31, 2023	December 31, 2022
Equipment and financing loans payable, between 2.5% and 7.5% interest and maturing between March 2024 and August 2026	\$ 69,717	\$ 1,901,514
Total notes payable	69,717	1,901,514
Less: current portion of notes payable	28,131	664,913
Total non-current portion of notes payable	\$ 41,586	\$ 1,236,601

Interest expenses were \$(201,883), \$117,664 and \$61,324 for the periods ended December 31, 2022 December 31, 2023, 2022 and 2021, respectively.

Future minimum annual maturities of notes payable as of December 31, 2022 December 31, 2023 are as follows:

	Notes Payable
2024	\$ 28,755
2025	25,847
2026	15,115
Total maturities	69,717
Current portion of notes payable	(28,131)
Long-term portion of notes payable	\$ 41,586
	Notes Payable
2023	\$ 563,366
2024	443,416
2025	425,863
2026	345,557
Thereafter	123,312
Total maturities	\$ 1,901,514
Current portion of notes payable	(664,913)
Non-current portion of notes payable	\$ 1,236,601

11. Derivative Warrant Liabilities

For the year ended December 31, 2021, the Company determined the fair value of its Public Warrants, which warrants that were previously publicly traded in active markets ("Public Warrants") using quoted market prices for identical instruments. Accordingly, the Public Warrants were classified as Level 1 financial instruments. As of December 31, 2021, there were 3,833,333 Public Warrants outstanding at a fair value of \$8.1 million. Because the transfer of the Company's warrants that were issued in a private placement simultaneously with the closing of its initial public offering ("Private Warrants" and together with the Public Warrants, the "warrants") to anyone outside of a small group of individuals constituting the sponsors of DocGo the Company would result in the Private Warrants having substantially the same terms as the Public Warrants, management determined that the fair value of each Private Warrant was the same as that of a Public Warrant, with an insignificant adjustment for marketability restrictions. Accordingly, the Private Warrants were classified as Level 1 financial instruments. As of December 31, 2021, 2,533,333 Private Warrants remained outstanding at a fair value of \$5.4 million. Due to fair value changes throughout the year ended December 31, 2021, we recorded a gain on remeasurement of warrant liabilities of \$5.2 million.

As of For the year ended December 31, 2022, the Company recorded a gain of approximately \$1.1 million from the remeasurement of warrant liabilities. The warrants are were marked-to-market in each reporting period, and this loss reflected the increase in DocGo's the Company's stock price relative to the beginning of the period. On August 15, 2022, the Company announced the redemption of all of its outstanding warrants under the Warrant Agreement, dated as of October 14, 2020, by and between Motion Acquisition Corp. ("Motion") the Company and Continental Stock Transfer & Trust Company, as warrant agent, as part of the units sold in Motion's initial public offering, on the redemption date of September 16, 2022 (the "Redemption Date"). Warrants surrendered for exercise on a cashless basis resulted in the issuance of 1,406,371 shares, shares of Common Stock. A total of 68,514 warrants were not surrendered on the Redemption Date and were redeemed for \$0.10 per warrant.

There were no warrants liabilities outstanding for the years ended December 31, 2023 and 2022.

DocGo Inc. and Subsidiaries
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)

12. Business Segment Information

The Company conducts business as two in three operating segments, segments: Mobile Health Services, Transportation Services, and Mobile Health services, Corporate. In accordance with ASC 280, *Segment Reporting*, operating segments are components of an enterprise for which separate financial information is evaluated regularly by the chief operating decision maker, who is the chief executive officer, Company's Chief Executive Officer and Chief Financial Officer, in deciding how to allocate resources and assessing performance. The Company's business operates Prior to 2023, the Company reported in two operating segments because the Company's entities have two main revenue streams, streams. Beginning with the first quarter of 2023, the Company began reporting in three operating segments, adding a Corporate segment to allow for analysis of shared services and personnel that support both the Transportation Services and Mobile Health Services segments. Previously, these costs had been allocated almost entirely to the Transportation Services segment. All of the Company's revenues and costs of revenues continue to be reported within the Transportation Services and Mobile Health Services segments. The Corporate segment contains operating expenses such as information technology costs, certain insurance costs and the compensation costs of senior and executive leadership. The segment reporting for the prior-year period has been adjusted to conform to the new methodology, for the purposes of allowing a clearer analysis of year-over-year performance. The Company's chief operating decision maker evaluates Chief Executive Officer and Chief Financial Officer evaluate the Company's financial information and resources and assesses the performance of these resources by revenue stream. stream and by operating income or loss performance.

The accounting policies of the segments are the same as the accounting policies of the Company as a whole. The Company evaluates the performance of its Transportation services and Mobile Health services Services, Transportation Services, and Corporate segments based primarily on results of operations.

Operating results for the business segments of the Company are as follows:

	Transportation Services	Mobile Health Services	Total	
For the Year Ended December 31, 2022				
Revenues	\$ 114,624,306	\$ 325,891,440	\$ 440,515,746	
Income (loss) from operations	(45,676,221)	67,507,849	21,831,628	
Total assets	276,456,130	116,821,498	393,277,628	
Depreciation and amortization expense	8,787,570	1,778,008	10,565,578	
Stock compensation	2,013,643	6,040,928	8,054,571	
Long-lived assets	32,302,611	50,825,223	83,127,834	
For the Year Ended December 31, 2021				
Revenues	\$ 84,268,817	\$ 234,449,763	\$ 318,718,580	
Income (loss) from operations	(26,365,962)	41,723,260	15,357,298	
Total assets	229,206,964	80,395,688	309,602,652	
Depreciation and amortization expense	5,508,679	2,002,900	7,511,579	
Stock compensation	592,664	783,689	1,376,353	
Long-lived assets	28,814,481	3,284,423	32,098,904	
	Mobile Health Services	Transportation Services	Corporate	Total
Year Ended December 31, 2023				
Revenues	\$ 442,793,537	\$ 181,495,105	\$ —	\$ 624,288,642
Income (loss) from operations	80,362,820	3,541,377	(68,849,217)	15,054,980

Total assets	280,646,925	132,178,214	77,626,818	490,451,957
Depreciation and amortization expense	4,226,657	9,393,895	2,811,340	16,431,892
Stock compensation	1,698,350	1,434,505	17,836,319	20,969,174
Long-lived assets	32,841,680	78,848,587	11,952,528	123,642,795
Capital expenditures	30,163,882	20,254,373	597,283	51,015,538
Year Ended December 31, 2022				
Revenues	\$ 325,891,440	\$ 114,624,306	\$ —	\$ 440,515,746
Income (loss) from operations	92,710,163	(14,546,171)	(56,332,364)	21,831,628
Total assets	116,821,500	118,627,613	157,828,515	393,277,628
Depreciation and amortization expense	1,685,114	6,050,265	2,830,199	10,565,578
Stock compensation	1,425,299	1,415,670	5,213,602	8,054,571
Long-lived assets	33,181,594	65,580,291	2,479,889	101,241,774
Capital expenditures	39,569,802	52,105,196	2,542,854	94,217,852
Year Ended December 31, 2021				
Revenues	\$ 234,449,763	\$ 84,268,817	\$ —	\$ 318,718,580
Income (loss) from operations	59,605,712	(20,983,766)	(23,264,648)	15,357,298
Total assets	61,503,278	59,299,426	188,799,948	309,602,652
Depreciation and amortization expense	(888,355)	6,458,218	1,941,716	7,511,579
Stock compensation	536,910	479,542	359,901	1,376,353
Long-lived assets	4,382,704	38,370,683	2,848,312	45,601,699
Capital expenditures	4,180,004	10,636,454	3,766,289	18,582,747

Long-lived assets include **Property** property and equipment, **Goodwill** goodwill, intangible assets, operating lease right-of-use assets and **Intangible** finance lease right-of-use assets.

Geographic Information

The following table summarizes long-lived assets by geographic location for the years ended December 31, 2023, 2022, and 2021:

F-33

	December 31, 2023	December 31, 2022	December 31, 2021
Primary Geographical Markets			
United States	\$ 103,779,506	\$ 83,145,362	\$ 42,166,999

United Kingdom	19,863,289	18,096,412	3,434,700
Total Long-Lived Assets	\$ 123,642,795	\$ 101,241,774	\$ 45,601,699

Revenues by geographic location are included in Note 2.

13. Equity

Preferred Stock

In November 2021, the Company's Series A preferred stock was cancelled and converted into the right to receive a portion of merger consideration issuable as common stock of DocGo, par value \$0.0001 ("Common Stock"), pursuant to the terms and conditions set forth in the Merger Agreement. The Company's Consolidated Statements of Changes in Stockholders' Equity reflect the 2020 shares as if the merger occurred in 2020.

Prior to the reverse merger, on May 23, 2019, the Series A preferred stock was formed, and 40,000 shares were authorized. Each share of Series A preferred stock was convertible into Class A common stock at a conversion price of \$3,000 per share, subject to adjustment as defined in the articles of incorporation.

Series A preferred stockholders had voting rights equivalent to the number of common stock shares issuable upon conversion. The Series A preferred stockholders were entitled to a non-cumulative dividends equal to 8% of the original issue price as defined in the agreement when declared by the board of directors.

The holders of the Series A preferred stock had preferential liquidation rights and rank senior to the holders of common stock. If a liquidation were to occur, the holders of the Series A preferred stock would have been paid an amount equal to \$3,000 per share, subject to adjustment as defined in the articles of incorporation, plus all accrued and unpaid dividends thereon. After the payment of the Series A preferred stockholders, the common stockholders would have been paid out on a pro-rate basis.

Common Stock

On November 1, 2017, Ambulnz, Inc. converted its legal structure from a limited liability company to a corporation and converted its membership units into shares of common stock at a rate of 1,000 shares per membership unit. The total authorized number of shares of common stock converted was 100,000 shares, comprised of 35,597 shares of Class A common stock and 64,402 shares of Class B common stock.

Prior to the reverse merger, on May 23, 2019, the Ambulnz, Inc amended and restated its articles of incorporation and the total authorized common shares increased to 154,503 shares, comprised of 78,000 shares of Class A common stock and 76,503 shares of Class B common stock. The Class A common stockholders had voting rights equivalent to one vote per share of common stock and the Class B common stockholders have no voting rights. Dividends may be paid to the common stockholders out of funds legally available, when declared by the Board.

Share Repurchase Program

On May 24, 2022, the Company's Board of Directors (the "Board of Directors") authorized a share repurchase program to purchase up to \$40 million of the Company's common stock under a share repurchase program Common Stock (the "Program"). During the second and fourth quarter of 2022, the Company repurchased 536,839 shares of its common stock Common Stock for \$3,731,712. These shares were subsequently cancelled. There were no shares repurchased during the third quarter of 2022. year ended December 31, 2023. The Program does not oblige the Company to acquire any specific number of shares and will expire expired on November 24, 2023. Under the Program, shares may could be repurchased using a variety of methods, including privately negotiated and/or open market transactions, including under plans complying with Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, (the "Exchange Act"), as part of accelerated share repurchases, block trades and other methods. The timing, manner, price and amount of any common stock Common Stock repurchases under the Program are were determined by the Company in its discretion and depend depended on a variety of factors, including legal requirements, price and economic and market conditions.

DocGo Inc. and Subsidiaries
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)

14. Stock Based Compensation

Stock Options

In 2021, the Company established the DocGo Inc. 2021 Equity Incentive Plan (the “Plan”) replacing Ambulnz, Inc.’s 2017 Equity Incentive Plan. The Plan reserved 16,607,894 shares of Class A common stock for issuance under the Plan. The Company’s stock options generally vest on various terms based on continuous services up over periods ranging from three to five years. The stock options are subject to time vesting requirements through 2026 2033 and are nontransferable. Stock options granted have a maximum contractual term of 10 years. On December 31, 2022 As of December 31, 2023, approximately 2.6 million 4.7 million employee stock options had vested.

The fair value of each stock option grant is estimated on the date of grant using the Black-Scholes option-pricing model. Management Before the consummation of the Business Combination, management took the company specific volatility and the average of several publicly traded companies that were representative of the Company’s size and industry in order to estimate its expected stock volatility. Subsequent to the Business Combination, the Company utilized publicly available pricing. The expected term of the options represents represented the period of time the instruments are were expected to be outstanding. The Company bases based the risk-free interest rate on the rate payable on the U.S. Treasury securities corresponding to the expected term of the awards at the date of grant. Expected dividend yield is was zero based on the fact that the Company has had not historically paid and does not intend to pay a dividend in the foreseeable future.

Prior to the merger, the Company utilized contemporaneous valuations in determining the fair value of its shares at the date of option grants. Each valuation utilized both the discounted cash flow and guideline public company methodologies to estimate the fair value of its shares on a non-controlling and marketable basis. The March 11, 2021 valuation report relied solely on the fair value of the Company’s shares implied by the March 8, 2021 Merger Agreement with Motion Acquisition Corp.

For certain stock options issued prior to the Merger, a discount for lack of marketability was applied to the non-controlling and marketable fair value estimates determined above. The determination of an appropriate discount for lack of marketability was based on a review of discounts on the sale of restricted shares of publicly traded companies and put-based quantitative methods. Factors that influenced the size of the discount for lack of marketability include (a) the estimated time it would take for a Company stockholder to achieve marketability, and (b) the volatility of the Company’s business.

Subsequent to the Merger, the Company utilized publicly available pricing.

The following assumptions were used to compute the fair value of the sole stock option grant grants during the period years ended December 31, 2022 December 31, 2023 and 2021:

2022:

	Years Ended December 31	
	2022	2021
Risk-free interest rate	0.71% - 4.31 %	0.12% - 0.67 %
Expected term (in years)	6.25	1-5
Volatility	60% - 69 %	63% - 65 %
Dividend yield	0 %	0 %
	Year Ended December 31,	
	2023	2022
Risk-free interest rate	4.1% - 4.9%	0.71% - 4.3%
Expected term (in years)	6.25	6.25
Volatility	52% - 62%	60% - 69%
Dividend yield	— %	— %

F-34

The following table summarizes the Company’s stock option activity under the Plan for the period years ended December 31, 2022:

and 2023:

	Options Shares	Weighted Average Exercise Price	Weighted Average Remaining Contractual Life in Years	Aggregate Intrinsic Value
Balance as of December 31, 2020	4,635,898	\$ 1.84	7.28	\$ 8,129,671
Granted/ Vested during the year	5,495,095	2.88	9.80	-
Exercised during the year	(1,235,130)	0.50	4.32	-
Cancelled during the year	(472,891)	2.37	7.93	-
Balance as of December 31, 2021	8,422,972	\$ 6.21	8.77	\$ 24,706,020
Granted/ Vested during the year	5,443,368	7.04	-	-
Exercised during the year	(1,699,720)	2.03	-	-
Cancelled during the year	(595,312)	8.28	-	-
Balance as of December 31, 2022	11,571,308	7.11	9.05	\$ 39,389,063
Options vested and exercisable as of December 31, 2022	2,628,288	\$ 6.15	8.02	\$ 6,982,555

	Options Shares	Weighted Average Exercise Price	Weighted Average Remaining Contractual Life in Years	Aggregate Intrinsic Value
Balance as of December 31, 2021	8,422,972	\$ 6.21	8.77	\$ 24,706,020
Granted/vested during the year	5,443,368	7.04	—	—
Exercised during the year	(1,699,720)	2.03	—	—
Cancelled during the year	(595,312)	8.28	—	—
Balance as of December 31, 2022	11,571,308	7.11	9.05	39,389,063
Granted/vested during the year	1,566,010	7.93	—	—
Exercised during the year	(514,065)	3.55	—	—
Cancelled during the year	(680,989)	7.52	—	—
Balance as of December 31, 2023	11,942,264	7.36	8.16	\$ 50,315,593
Options vested and exercisable as of December 31, 2023	4,703,686	\$ 7.02	7.47	\$ 3,199,037

The aggregate intrinsic value in the above table is calculated as the difference between fair value of the **Company's common stock** **Common Stock** price and the exercise price of the stock options. The weighted average grant date fair value per share for stock option grants during the years ended **December 31, 2022** December 31, 2023 and 2022 was \$7.93 and \$7.04, respectively.

On December 31, 2023, 2022 and 2021, the total recorded stock-based compensation related to stock option awards granted was **\$7.04** \$11,795,320, \$6,232,992, and **\$2.88**, \$1,376,353, respectively.

On December 31, 2022 December 31, 2023, 2022 and December 31, 2021, 2021, the total unrecognized compensation related to unvested stock option awards granted was **\$29,058,756**, \$41,666,564 and \$20,792,804, respectively, which the Company expects to recognize over a weighted-average period of approximately **2.16** 1.79 years.

DocGo Inc. and Subsidiaries
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)

Restricted Stock Units

The fair value of restricted stock units (“RSUs”) is determined on the date of grant. The Company records compensation expenses in the Consolidated Statements of Operations and Comprehensive Income on a straight-line basis over the vesting period for RSUs. The vesting period for employees and members of the Board of Directors ranges from one to four years.

Activity under RSUs for the year ended December 31, 2023 was as follows:

	RSUs	Weighted-Average Grant Date Fair Value Per RSU
Balance as of December 31, 2021	50,192	\$ 9.97
Granted	311,637	8.17
Vested during the year	(56,242)	5.86
Balance as of December 31, 2022	305,587	8.35
Vested and unissued as of December 31, 2022	56,242	5.86
Non-vested as of December 31, 2022	305,587	8.35

	RSUs	Weighted-Average Grant Date Fair Value Per RSU
Balance as of December 31, 2022	305,587	\$ 8.35
Granted	3,104,766	6.15
Vested	(986,258)	8.61
Forfeited	—	0
Balance as of December 31, 2023	2,424,095	5.61
Vested and unissued as of December 31, 2023	49,490	5.47
Non-vested as of December 31, 2023	2,424,095	5.61

The total grant-date fair value of RSUs granted during the period year ended December 31, 2022 December 31, 2023 was \$2,547,498. \$19,526,515.

In 2022, For the company entered into agreements year ended December 31, 2023, the Company recorded stock-based compensation expense related to issue \$535,000 RSUs of \$9,101,027, of which \$493,043 is included in aggregate RSUs in 2023. The number of shares to be issued in 2023 will be based on the stock prices at stated dates in these agreements. accrued liabilities.

For the year ended December 31, 2022, the Company recorded stock-based compensation expense related to RSUs of \$870,579. \$1,821,579, of which \$375,000 is included in accrued liabilities.

As of December 31, 2022 On December 31, 2023, and 2022, the Company had \$2,177,713 in total unrecognized compensation cost related to non-vested unvested RSUs granted was \$12,602,662, and \$2,177,713, respectively, which is expected to be recognized over a weighted-average period of approximately 1.7 2.5 years.

Performance-based Stock Units

The fair value of performance-based stock units (“PSUs”) is determined on the date of grant. The Company records compensation expenses in the Consolidated Statements of Operations and Comprehensive Income on a straight-line basis over the vesting period based on the grant date

fair value of the awards and probability of the achievement of the specified performance target. The vesting period for employees and members of the Board of Directors ranges from one to four years.

Activity under PSUs for the year ended December 31, 2023 was as follows:

	PSUs	Weighted-Average Grant Date Fair Value Per PSU
Balance as of December 31, 2022	—	\$ —
Granted	1,085,270	5.16
Vested	—	—
Forfeited	—	—
Balance as of December 31, 2023	1,085,270	5.16
Vested and unissued as of December 31, 2023	—	—
Non-vested as of December 31, 2023	1,085,270	5.16

The total grant-date fair value of PSUs granted during the year ended December 31, 2023 was \$5,599,993.

For the year ended December 31, 2023, the Company recorded stock-based compensation expense related to PSUs of \$72,827 which is included in accrued liabilities.

As of December 31, 2023, the Company had \$5,527,166 in unrecognized compensation cost related to non-vested PSUs, which is expected to be recognized over a weighted-average period of approximately 4.0 years.

15. Leases

Operating Leases

The Company is obligated to make rental payments under non-cancellable operating leases for office, dispatch station space and transportation equipment, expiring at various dates through 2029, 2032. Under the terms of the leases, the Company is also obligated for its proportionate share of real estate taxes, insurance and maintenance costs of the property. The Company is required to hold certain funds in restricted cash and cash equivalents accounts under some of these agreements.

Certain leases for property and transportation equipment contain options to purchase, extend or terminate the lease. Determining the lease term and amount of lease payments to include in the calculation of the right-of-use (ROU) asset and lease obligations for leases containing options requires the use of judgment to determine whether the exercise of an option is reasonably certain and whether the optional period and payments should be included in the calculation of the associated ROU right-of-use asset and lease obligation. In making the determination of such judgment, the Company considers all relevant economic factors that would require whether to exercise or not exercise the option.

The Company's lease agreements generally do not provide an implicit borrowing rate. Therefore, the Company used a benchmark approach to derive an appropriate imputed discount rate. The Company benchmarked itself against other companies of similar credit ratings and comparable quality and derived imputed rates, which were used to discount its real estate lease liabilities. The Company used estimated borrowing rates of 6% on January 1, 2019, for all leases that commenced prior to that date for office spaces and transportation equipment.

DocGo Inc. and Subsidiaries NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)

Lease Costs

The table below comprise comprises lease expenses for the periods years ended December 31, 2022 December 31, 2023, 2022 and 2021, respectively:

Components of total lease cost:	December 31, 2022	December 31, 2021
Operating lease expense	\$ 2,294,636	\$ 1,993,984
Short-term lease expense	1,201,622	1,012,260

Total lease cost			\$ 3,496,258	\$ 3,006,244
	December 31,			
Components of total lease cost:	2023	2022	2021	
Operating lease expense	\$ 3,418,134	\$ 2,294,636	\$ 1,993,984	
Short-term lease expense	1,678,487	1,201,622	1,012,260	
Total lease cost - operating leases	\$ 5,096,621	\$ 3,496,258	\$ 3,006,244	

Lease Position as of December 31, 2022
December 31, 2023

Right-of-use lease assets and lease liabilities for the Company's operating leases were recorded in the Consolidated Balance Sheets as follows:

		December 31,	December 31,
		2022	2021
		<u></u>	<u></u>
Assets			
Lease right-of-use assets		\$ 9,074,277	\$ 4,195,682
Total lease assets		<u>\$ 9,074,277</u>	<u>\$ 4,195,682</u>
Liabilities			
Current liabilities:			
Lease liability – current portion		\$ 2,325,024	\$ 1,461,335
Noncurrent liabilities:			
Lease liability, net of current portion		7,040,982	2,980,946
Total lease liability		<u>\$ 9,366,006</u>	<u>\$ 4,442,281</u>
		December 31,	December 31,
		2023	2022
		<u></u>	<u></u>
Assets			
Lease right-of-use assets		\$ 9,580,535	\$ 9,074,277
Total lease assets		<u>\$ 9,580,535</u>	<u>\$ 9,074,277</u>
Liabilities			
Current liabilities:			
Lease liability - current portion		\$ 2,773,020	\$ 2,325,024
Noncurrent liabilities:			
Lease liability, net of current portion		7,223,941	7,040,982
Total lease liability		<u>\$ 9,996,961</u>	<u>\$ 9,366,006</u>

Lease Terms and Discount Rate

Weighted average remaining lease term (in years) ■ - operating leases	5.57 3.67
Weighted average discount rate ■ - operating leases	5.71 6.00 %

DocGo Inc. and Subsidiaries

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)

Undiscounted Cash Flows

Future minimum lease payments under the operating leases as of December 31, 2022 December 31, 2023 are as follows:

	Operating Leases
2023	\$ 2,788,584
2024	2,346,789
2025	2,345,424
2026	1,716,501
2027 and thereafter	1,440,116
Total future minimum lease payments	10,637,414
Less effects of discounting	\$ (1,271,408)
Present value of future minimum lease payments	\$ 9,366,006

	Operating Leases
2024	\$ 3,271,821
2025	3,305,703
2026	2,429,393
2027	1,219,709
2028	597,566
Thereafter	318,901
Total future minimum lease payments	11,143,093
Less effects of discounting	(1,146,132)
Present value of future minimum lease payments	\$ 9,996,961

Operating lease expenses approximated \$3,418,134, \$2,294,636 and \$1,993,984 for the years ended December 31, 2022, December 31, 2023, 2022 and 2021, respectively.

For the year years ended December 31, 2022, December 31, 2023, 2022, 2021, the Company made \$3,287,125, \$2,294,636, \$1,993,984 of fixed cash payments related to operating leases and \$4,270,553, \$2,985,568, \$2,741,784 related to finance leases, respectively.

Finance Leases

The Company leases vehicles under a non-cancelable finance lease agreements with a liability of \$11,430,465, \$8,646,803 and \$10,139,410 for the periods years ended December 31, 2022, December 31, 2023, 2022 and 2021, respectively (accumulated depreciation of \$11,679,823, \$7,906,966 and \$7,095,242 as of December 31, 2022, December 31, 2023, 2022 and 2021, respectively).

Depreciation expenses for the vehicles under non-cancelable lease agreements amounted to \$6,352,754, \$3,236,418 and \$2,913,925 for the years ended December 31, 2022, December 31, 2023, 2022 and 2021, respectively.

Gain on Lease Remeasurement

In June 2022, the Company reassessed its finance lease estimates relating to vehicle mileage and residual value. As a result, the Company determined to purchase the vehicles at the end of the leases, which resulted in a gain of \$1.4 million recorded as gains from lease accounting on the Consolidated Statements of Operations and Comprehensive Income.

Lease Payments

The table below comprise comprises lease payments for the periods years ended December 31, 2022, December 31, 2023, 2022 and 2021, respectively:

Components of total lease payment:	December 31, 2022	December 31, 2021
Finance lease payment	\$ 2,985,568	\$ 2,741,784
Short-term lease payment	-	-
Total lease payments	\$ 2,985,568	\$ 2,741,784

	Year Ended December 31,		
Components of total lease cost:	2023	2022	2021

Finance lease payment	\$	4,270,553	\$	2,985,568	\$	2,741,784
Short-term lease payment		—		—		—
Total lease payments	\$	4,270,553	\$	2,985,568	\$	2,741,784

DocGo Inc. and Subsidiaries

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)

Lease Position as of December 31, 2022

December 31, 2023

Right-of-use lease assets and lease liabilities for the Company's finance leases were recorded in the Consolidated Balance Sheets as follows:

	December 31, 2022	December 31, 2021
Assets		
Lease right-of-use assets	\$ 9,039,663	\$ 9,307,113
Total lease assets	\$ 9,039,663	\$ 9,307,113
	December 31, 2023	December 31, 2022
Assets		
Lease right-of-use assets	\$ 12,003,919	\$ 9,039,663
Total lease assets	\$ 12,003,919	\$ 9,039,663
Liabilities		
Current liabilities:		
Lease liability - current portion	\$ 3,534,073	\$ 2,732,639
Noncurrent liabilities:		
Lease liability, net of current portion	7,896,392	5,914,164
Total lease liability	\$ 11,430,465	\$ 8,646,803
Liabilities		
Current liabilities:		
Lease liability – current portion	\$ 2,732,639	\$ 3,271,990
Noncurrent liabilities:		
Lease liability, net of current portion	5,914,164	6,867,420
Total lease liability	\$ 8,646,803	\$ 10,139,410

Lease Terms and Discount Rate

The table below presents certain information related to the weighted average remaining lease term and the weighted average discount rate for the Company's finance leases as of December 31, 2022 December 31, 2023:

Weighted average remaining lease term (in years) - finance leases	43.37
Weighted average discount rate - finance leases	5.42 6.0 %

Undiscounted Cash Flows

Future minimum lease payments under the finance leases as of December 31, 2022 December 31, 2023 are as follows:

	Finance Leases
2024	\$ 4,072,021
2025	3,745,030

2026	2,868,368
2027	1,495,766
2028	352,811
Thereafter	—
Total future minimum lease payments	12,533,996
Less effects of discounting	(1,103,531)
Present value of future minimum lease payments	\$ 11,430,465

	Finance Leases
2023	\$ 3,156,298
2024	2,438,224
2025	2,159,661
2026	1,377,432
2027 and thereafter	468,651
Total future minimum lease payments	9,600,266
Less effects of discounting	\$ (953,463)
Present value of future minimum lease payments	\$ 8,646,803

16. Other Income (Loss)

The Company recognized \$1,238,313, \$950,264 and 4,437,887 \$4,437,887 of Other other income for the years ended December 31, 2022 December 31, 2023, 2022 and December 31, 2021, 2021, respectively, as follows:

	Years Ended December 31	
	2022	2021
Other income (expenses):		
Interest income (expense), net	762,685	(763,030)
Gain on remeasurement of warrant liabilities	1,127,388	5,199,496
Gain (loss) on initial equity method investment	8,919	(66,818)
Gain on remeasurement of finance leases	1,388,273	-
Gain on bargain purchase	1,593,612	-
Gain from PPP loan forgiveness	-	142,667
Loss on disposal of fixed assets	(21,173)	(34,342)
Goodwill impairment	(2,921,958)	-
Other expenses	(987,482)	(40,086)
Total other income	950,264	4,437,887

	Year Ended December 31,		
	2023	2022	2021
Other Income			
Interest income (expense), net	\$ 1,684,399	\$ 762,685	\$ (763,030)
Gain on remeasurement of warrant liabilities	—	1,127,388	5,199,496
Change in fair value of contingent liability	1,437,525	—	—
(Loss) gain on equity method investments	(343,336)	8,919	(66,818)
(Loss) gain on remeasurement of operating and finance leases	(866)	1,388,273	—
Gain on bargain purchase	—	1,593,612	—
Gain from PPE loan forgiveness	—	—	142,667
(Loss) on disposal of fixed assets	(852,544)	(21,173)	(34,342)
Goodwill impairment	—	(2,921,958)	—
ABC litigation	(1,000,000)	—	—
Other income (expense)	313,135	(987,482)	(40,086)
Total other income	\$ 1,238,313	\$ 950,264	\$ 4,437,887

DocGo Inc. and Subsidiaries

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)

17. Related Party Transactions

Historically, the Company has been involved in transactions with various related parties.

Legal Services

Ely D. Tendler Strategic & Legal Services PLLC provides legal is compensated for his services for to the Company. Ely D. Tendler Strategic & Legal Services PLLC is owned by the Company as General Counsel of the Company, and therefore is a related party. The Company made legal Secretary through payments to Ely D. Tendler Strategic & Legal Services PLLC totaling ("EDTSLS"), a law firm owned by Mr. Tendler. All payments made to EDTSLS by the Company were for Mr. Tendler's services to the Company as General Counsel and Secretary. No other services were provided by EDTSLS to the Company. The Company's payments to EDTSLS for Mr. Tendler's services totaled \$916,370, \$960,081 and \$702,083 for the years ended December 31, 2022, December 31, 2023, 2022 and 2021, respectively.

Subcontractor Services

PrideStaff provides subcontractor services for the Company. PrideStaff is owned by the a former operations manager of the Company and his spouse, and therefore, a related party. The Company made subcontractor payments to PrideStaff totaling \$0, \$547,500 and \$656,883 for the years ended December 31, 2022, December 31, 2023, 2022 and 2021, respectively.

Transition Services Agreement

On October 11, 2023, the Company and Anthony Capone, who resigned as Chief Executive Officer of the Company on September 15, 2023, entered into a separation and transition services agreement (the "Transition Agreement"). Pursuant to the Transition Agreement, Mr. Capone will continue to serve as a consultant to the Company until March 15, 2024 (such period, the "Consulting Period") to advise on matters relating to business continuity and processes and transition his institutional knowledge with respect to operational and other departmental functions.

As compensation for his services during the Consulting Period, and subject to his compliance with the Transition Agreement, including the execution and non-revocation of a general release of claims in favor of the Company, Mr. Capone will receive a monthly consulting fee of \$45,000 and subsidized premiums for continued group health plan coverage for the duration of the Consulting Period. Mr. Capone will not receive new equity awards or incentive compensation under the Company's equity incentive compensation program during the Consulting Period. The Transition Agreement further acknowledges and affirms that Mr. Capone will be bound by and comply with certain restrictive covenants. The Company made payments to Anthony Capone totaling \$90,000, \$0, and \$0 for the years ended December 31, 2023, 2022, and 2021 respectively.

Included in **Accounts payable** were **\$86,555** **\$45,000** and **\$230,517** **\$86,555** due to related parties as of **December 31, 2022** **December 31, 2023**, and **2021, 2022**, respectively.

18. Income Taxes

A reconciliation of the statutory U.S. federal income tax rate to the Company's effective tax rate **consist** **consists** of the following:

		For the Years Ended December 31,	
		2022	2021
Statutory federal income tax benefit		21.00 %	21.00 %
Permanent items		0.56 %	(2.71) %
State taxes, net of federal tax benefit		7.77 %	5.99 %
Effects of Rates Different from Statutory		0.17 %	(0.06) %
Rate Change		0.01 %	0.00 %
Other		(3.64) %	(0.71) %
Change in valuation allowance		(54.94) %	(20.98) %
Income tax (benefit)/provision		(29.07) %	2.53 %

		Year Ended December 31,		
		2023	2022	2021
Statutory federal income tax benefit	21.00 %	21.00 %	21.00 %	21.00 %
Permanent items	26.18 %	0.56 %	(2.71) %	(2.71) %
State taxes, net of federal tax benefit	20.67 %	7.77 %	5.99 %	5.99 %
Effects of Rates Different from Statutory	(0.04) %	0.17 %	(0.06) %	(0.06) %
Rate Change	0.04 %	0.01 %	— %	— %
Other	(29.54) %	(3.64) %	(0.71) %	(0.71) %
Change in valuation allowance	(1.91) %	(54.94) %	(20.98) %	(20.98) %
Income tax provision (benefit)	36.40 %	(29.07) %	2.53 %	2.53 %

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)

The components of income tax provision expense (benefit) are as follows:

		For the Years Ended December 31,	
		2022	2021
Current:			
Federal	\$	1,493,772	\$ 295,956
State and local		502,872	319,741
Foreign		-	-
	\$	1,996,644	\$ 615,697
Deferred:			
Federal	\$	(7,683,475)	\$ -
State and local		(2,649,791)	-
Foreign		375,301	-
		(9,957,965)	-
Total income tax (benefit) expense	\$	(7,961,321)	\$ 615,697

		For the Years Ended December 31,		
		2023	2022	2021
Current:				
Federal	\$	2,555,164	\$ 1,493,772	\$ 295,956
State and local		5,782,335	502,872	319,741
Foreign		-	-	-
	\$	8,337,499	\$ 1,996,644	\$ 615,697
Deferred:				
Federal	\$	1,650,695	\$ (7,683,475)	\$ -
State and local		(3,256,914)	(2,649,791)	-
Foreign		(375,300)	375,301	-
		(1,981,519)	(9,957,965)	-
Total income tax expense (benefit)	\$	6,355,980	\$ (7,961,321)	\$ 615,697

Deferred income taxes reflect the net tax effects of temporary differences between the carrying value of assets and liabilities for financial reporting purposes and amounts used for income tax purposes. The temporary differences that give rise to deferred tax assets and liabilities are as follows:

		For the Years Ended December 31,	
		2022	2021
Deferred tax assets (liabilities):			
Net operating loss carryforwards	\$	11,523,632	17,153,341
Allowance for doubtful accounts		893,329	874,029
Amortization		(157,839)	(582,284)
Prepaid expenses		(994,644)	(411,798)
Property and equipment		(2,798,988)	(2,245,003)
Research and development expense		303,446	(580,497)
Accrued bonus		(184,724)	1,414,357
Stock compensation		2,780,019	883,317
Other		114,080	197,218
Net deferred tax assets		11,478,311	16,702,680

Valuation allowance		(1,520,345)	(16,702,680)
Deferred tax assets, net of allowance		\$ 9,957,966	\$ -
For the Years Ended			
December 31,			
	2023	2022	
<i>Deferred tax assets:</i>			
Allowance for doubtful accounts	\$ 1,683,119	\$ 893,328	
Accrued expenses	799,295	382,649	
Lease liability	4,674,177	2,359,566	
Stock compensation	5,039,590	2,780,020	
Research and development expense	865,800	303,446	
Net operating loss	4,568,113	11,523,633	
Other	(471,694)	(466,789)	
Total deferred tax asset	\$ 17,158,400	\$ 17,775,853	
Valuation allowance	(1,207,673)	(1,520,345)	
Deferred income tax assets, net of allowance	\$ 15,950,727	\$ 16,255,508	
<i>Deferred tax liabilities:</i>			
Prepaid expenses	\$ (780,767)	\$ (994,644)	
Depreciation	(3,819,069)	(2,798,988)	
Right-of-use asset	(4,544,024)	(2,346,070)	
Amortization	5,081,672	(157,839)	
Total deferred tax liability	\$ (4,062,188)	\$ (6,297,541)	
Deferred tax assets, net of allowance	\$ 11,888,539	\$ 9,957,967	

The Company has determined, based upon available evidence, that it is more likely than not that all of the net deferred tax asset will not be realized and, accordingly, has provided a partial and a full valuation allowance against its net deferred tax asset as of December 31, 2022, December 31, 2023 and 2021, 2022, respectively. Management considers the scheduled reversal of deferred tax liabilities, projected future taxable income, net operating loss carryback potential and tax planning strategies in making these assessments.

As of December 31, 2022, December 31, 2023, 2022 and 2021, the Company had federal net operating loss carryforwards of approximately \$0, \$35,289,184 and \$53,573,046, respectively. As of December 31, 2022, December 31, 2023, 2022 and 2021, the Company had approximately \$10,737,510, \$1,520,345 and \$202,965 of foreign net operating loss carryforwards, respectively. As of December 31, 2022, December 31, 2023, 2022 and 2021, the Company had state net operating loss carryforward of approximately \$36,422,543, \$2,592,560 and \$67,229,895, respectively. The federal net operating loss carryforwards generated after December 31, 2017 of \$35,289,184, \$35,298,184 carry forward infinitely. State and foreign net operating loss carryforwards generated in the tax years from 2017 to 2020 will begin to expire, if not utilized, by 2039. Utilization of the net operating loss carryforwards may be subject to an annual limitation according to Section 382 of the Internal Revenue Code of 1986, as amended (the "Internal Revenue Code"), and similar provisions.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)

The difference between the statutory income taxes on the Company's pre-tax loss and the Company's effective income tax rate during the years ended December 31, 2022, December 31, 2023, and 2021 2022 is primarily due to a recorded valuation allowance. The valuation allowance for deferred tax assets as of December 31, 2022, December 31, 2023, and 2021 2022 was \$1,520,345, \$1,207,673, and \$16,702,680, \$1,520,345, respectively. The net change in the total valuation allowance for the years ended December 31, 2022, December 31, 2023, and 2021 2022 was a decrease of \$312,672 and \$15,182,335, and \$5,328,621, respectively.

In assessing the realizability of the deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Management considers the scheduled reversals of deferred tax liabilities, projected future taxable income and tax planning strategies in making this assessment.

The Company recognizes interest accrued to unrecognized tax benefits and penalties as income tax expense. The Company accrued total no penalties and or interest of \$0 during the years ended December 31, 2022, December 31, 2023, 2022, and 2021 and in total, as of both December 31, 2022 and 2021 has recognized penalties and interest of \$0.

2021.

The Company files tax returns as prescribed by the tax laws of the jurisdictions in which they operate. In the normal course of business, the Company is subject to examination by federal and foreign jurisdictions where applicable based on the statute of limitations that apply in each jurisdiction. As of December 31, 2022, December 31, 2023, open years related to all jurisdictions are 2022, 2021, 2020, and 2019. 2020. The Company has no open tax audits with any taxing authority as of December 31, 2022, December 31, 2023.

19. 401(K) Plan

19. 401(k) Plan

The Company has established a 401(k) plan in January 2022 that qualifies as a deferred compensation arrangement under Section 401 of the Internal Revenue Code. All U.S. employees that complete two months of service with the Company are eligible to participate in the plan. The Company did not make any employer contributions to this plan as of December 31, 2022 except for one subsidiary. Exceptional matched the 401K plan contributions amounting to \$226,260 for the year ended December 31, 2022, December 31, 2023.

20. Legal Proceedings

From time to time, the Company may be involved as a defendant in legal actions that arise in the normal course of its business. In the opinion of management, the Company has adequate legal defense on all legal actions, and the results of any such proceedings would not materially impact the Consolidated Financial Statements of the Company. The Company discloses provides disclosure and records loss contingencies in accordance with the loss contingencies accounting guidance. In accordance with such guidance, the Company establishes accruals for such matters when potential losses become probable and can be reasonably estimated. If the Company determines that a loss is reasonably possible and the loss or range of loss can be estimated, the Company discloses the possible loss in its Consolidated Financial Statements.

As of December 31, 2022 and December 31, 2021, the Company recorded a liability of \$1,000,000, which represented represents an amount for an agreed-upon settlement of various class-based claims, both actual and potential, under California state law, as described in detail below.

Stephanie Zamora, Jascha Dlugatch, et al. v. Ambulnz Health, LLC, et al. was filed in the Los Angeles Superior Court on October 11, 2018, and the complaint alleged wage and hour violations pursuant to California's Private Attorneys' General Act of 2004 ("PAGA"). On February 24, 2020, this case was consolidated with Jascha Dlugatch, et. al. v. Ambulnz Health, LLC (the "Consolidated Complaint"), another lawsuit filed in the Los Angeles Superior Court. On May 6, 2021, the parties attended mediation and settled the claims pled in the Consolidated Complaint on a class-wide and PAGA basis in exchange for a proposed \$1,000,000 payment by the defendant parties, inclusive of administrative costs and fees. On September 9, 2022, the Los Angeles Superior Court preliminarily approved the proposed settlement. A settlement, and on May 2, 2023, the Los Angeles Superior Court issued a final approval hearing is currently scheduled of the proposed settlement, which was paid in July 2023.

In addition, on October 27, 2023, Joe Naclerio, individually and purportedly on behalf of all others similarly situated, filed a putative class action complaint for April 28, 2023.

violation of federal securities laws in the U.S. District Court for the Southern District of New York against the Company, its Chairman, current and former Chief Executive Officers, and current and former Chief Financial Officers. The complaint alleges that the Company violated various securities laws, and seeks class certification, damages, interest, attorneys' fees, and other relief. On January 17, 2024, the Court appointed the Genesee County Employees' Retirement System as lead plaintiff. Due to the early stage of this proceeding, we cannot reasonably estimate the potential range of loss, if any. We dispute the allegations of wrongdoing and intend to defend ourselves vigorously in this matter.

21. Risk and Uncertainties

COVID-19 Risks, Impacts and Uncertainties

The spread of COVID-19 and the related country-wide shutdowns and restrictions had a mixed impact on the Company's business. In the ambulance transportation business, which predominantly comprises of non-emergency medical transportation, the Company saw a decline in volumes from historical and expected levels, as elective surgeries and other procedures were postponed. In some of the Company's larger markets, such as New York and California, there were declines in trip volume. In addition, the Company experienced lost revenues associated with sporting, concerts and other events, as those events were cancelled or had a significantly restricted (or entirely eliminated) the number of permitted attendees. Ambulance transports and event-related revenues have both since recovered to pre-COVID levels or higher.

There are two areas where the Company has experienced positive business impacts from COVID-19. In April and May 2020, the Company participated in an emergency project with Federal Emergency Management Agency ("FEMA") in the New York City area. This engagement resulted in incremental transportation revenue. In addition, in response to the need for widespread COVID-19 testing and available EMT EMTs and Paramedics, paramedics, the Company formed a new subsidiary, Rapid Reliable Testing, LLC ("RRT"), RRT, with the goal to perform COVID-19 tests at nursing homes, municipal sites, businesses, schools and other venues. RRT is part of the Mobile Health Services segment. Since early 2020, As COVID-19 testing activity slowed to account for a minor portion of the Company's revenues, RRT has grown significantly, and expanded its services have expanded beyond COVID-19 testing to a wide variety of tests, vaccinations and other procedures. While COVID-19 testing activity continued to grow throughout 2021 and into early 2022, such activity has slowed considerably over the past several months, as the pandemic has waned, and COVID-19 testing accounted for a relatively small proportion of the Company's overall revenues during the third and fourth quarters of 2022. DocGo anticipates that COVID-19 will continue to account for a shrinking proportion of the Company's revenues in 2023 and beyond.

The Company's current business plan assumes continued recovery of industry-wide transportation volumes to historical levels and beyond, plus an increased demand for mobile health Mobile Health Services. Demand for such services a demand that was accelerated by the pandemic, but which is also being driven by longer-term secular factors, such as the increasing desire on the part of patients to receive treatments outside of traditional settings, such as doctor's offices and hospitals. However, given

22. Subsequent Events**Share Repurchase Program**

On January 31, 2024, the unpredictable, unprecedented, and fluid nature Board of the pandemic and its economic consequences, we are unable to predict the duration and extent Directors authorized a new share repurchase program pursuant to which the pandemic Company may purchase up to \$36,000,000 in shares of Common Stock during a six-month period ending July 30, 2024 (the "Repurchase Program") and its related positive and negative impacts will affect our business, financial condition, and results of operations in future periods. Likewise, we are unable to predict may be suspended, extended, modified or discontinued at any time.

Under the emergence of future, unrelated pandemics, which would have some terms of the same impacts as those experienced with COVID-19.

Medicare Accelerated Payments

Medicare accelerated payments of approximately \$2,397,024 were received by Repurchase Program, the Company may purchase shares of Common Stock on a discretionary basis from time to time through open market repurchases or privately negotiated transactions or through other means, including by entering into Rule 10b5-1 trading plans or accelerated share repurchase programs, in April 2020. Effective October 8, 2020 each case, during an "open window" and when the Company does not possess material non-public information.

The timing, manner, price and amount of shares repurchased under the Repurchase Program will depend on a variety of factors, including stock price, trading volume, market conditions, corporate and regulatory requirements and other general business considerations. The Repurchase Program may be modified, suspended or discontinued at any time without prior notice.

Repurchases under the Repurchase Program may be funded from the Company's existing cash and cash equivalents, future cash flow or proceeds of borrowings or debt offerings.

Line of Credit

On February 8, 2024, CMS is the Company made a draw of \$15,000,000 under its Revolving Facility.

On February 27, 2024, the Company repaid all amounts outstanding under the Revolving Facility, and no longer accepting new applications for accelerated payments. There were no Medicare accelerated payments reflected within accrued liabilities in the Consolidated Balance Sheets amounts are outstanding as of December 31, 2022, compared to \$975,415 as the date of December 31, 2021.

this Annual Report.

DocGo Inc. and Subsidiaries

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)

22. Subsequent Events

On February 3, 2023, Health commenced the ABC pursuant to California law. An ABC is a liquidation process governed by state law (California law in this instance) that is an alternative to a bankruptcy case under federal law. Prior to commencing the ABC, Health ceased business operations and all of its employees were terminated and treated in accordance with California law. In the ABC, all of Health's assets were transferred to the Assignee who acts as a fiduciary for creditors and in a capacity equivalent to that of a bankruptcy trustee. The Assignee is responsible for liquidating the assets. Similar to a bankruptcy case, there is a claims process. Creditors of Health will receive notice of the ABC and a proof of claim form and are required to submit a proof of claim in order to participate in distribution of net liquidation proceeds by the Assignee.

Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure.

None.

None.

Item 9A. Controls and Procedures.

Management's Evaluation of Disclosure Controls and Procedures

Our management, with the participation of our Principal Executive Officer and our Principal Financial Officer, evaluated, as of the end of the period covered by this Annual Report on Form 10-K, the effectiveness of our disclosure controls and procedures. Based on this evaluation of our disclosure controls and procedures as of December 31, 2022, our Principal Executive Officer and Principal Financial Officer concluded that our disclosure controls and procedures as of such date are effective at the reasonable assurance level. The term "disclosure controls and procedures," as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act, of 1934, as amended (the "Exchange Act"), means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act are recorded, processed, summarized and reported within the time periods specified in the SEC's rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by us in the reports we file or submit under the Exchange Act is accumulated and communicated to our management, including our Principal Executive Officer and Principal Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. Management recognizes that any

Our management, with the participation of our Principal Executive Officer and our Principal Financial Officer, evaluated, as of the end of the period covered by this Annual Report, the effectiveness of our disclosure controls and procedures. Based on this evaluation of our disclosure controls and procedures no matter how well designed as of December 31, 2023, our Principal Executive Officer and operated, can provide only Principal Financial Officer concluded that our disclosure controls and procedures as of such date are effective at the reasonable assurance of achieving their objectives and our management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures.

level.

Management's Annual Report on Internal Control Over Financial Reporting

Our management is responsible for establishing and maintaining adequate internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act). Our internal control over financial reporting includes policies and procedures designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external reporting purposes in accordance with generally accepted accounting principles.

As of December 31, 2022 December 31, 2023, our management assessed the effectiveness of our internal control over financial reporting using the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) in Internal Control-Integrated Framework. Based on this assessment, our management concluded that our internal control over financial reporting was effective as of December 31, 2022 December 31, 2023.

Limitations on Effectiveness of Controls and Procedures

In designing and evaluating the disclosure controls and procedures and internal control over financial reporting, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. In addition, the design of disclosure controls and procedures and internal control over financial reporting must reflect the fact that there are resource constraints and that management is required to apply judgment in evaluating the benefits of possible controls and procedures relative to their costs.

Attestation Report of Registered Public Accounting Firm

This Annual Report on Form 10-K does not include an attestation report of our Urish Popeck & Co., LLC, the independent registered public accounting firm because, as an emerging growth company, we are not required to provide that audited the financial statements included in this Annual Report, has issued an attestation report from our independent registered public accounting firm on our internal control over financial reporting. Such report is included in Item 8 of this Annual Report and incorporated by reference herein.

Changes in Internal Control over Financial Reporting

There were no No changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) occurred during the quarter ended December 31, 2022 December 31, 2023 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Item 9B. Other Information.

In the fourth quarter of 2023, other than as disclosed below, none of our directors or officers (as defined in Rule 16a-1 under the Exchange Act) adopted, modified or terminated a “Rule 10b5-1 trading arrangement” or “non-Rule 105b-1 trading arrangement” (as those terms are defined in Item 408 of Regulation S-K).

Name	Title	Date Plan Adopted / Terminated	Original Duration of Plan	Shares to be Purchased or Sold	Intended to Satisfy Rule 10b5-1(c)?
Lee Bienstock	Chief Executive Officer	Adopted May 17, 2023 and terminated November 10, 2023	August 16, 2023 to July 19, 2024	Sell 20,000	Yes

None.

Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections.

Not applicable.

PART III

PART III

Item 10. Directors, Executive Officers and Corporate Governance.

Except as indicated below, the information required under this Item 10 of Form 10-K is incorporated herein by reference to our definitive proxy statement with respect to our 2023 2024 Annual Meeting of Stockholders to be filed with the SEC not later than 120 days after the end of the fiscal year covered by this Annual Report on Form 10-K (the (our “Proxy Statement”).

We have adopted a Code of Business Conduct and Ethics (the “Code of Ethics”) that applies to all of our directors, officers and employees, including our principal executive, principal financial and principal accounting officers, or persons performing similar functions. Our Code of Ethics is posted on our website located at www.DocGo.com. We intend to disclose any future amendments to certain provisions of the Code of Ethics and waivers of the Code of Ethics granted to executive officers and directors on the our website within four business days following the date of the amendment or waiver, as and to the extent required under the SEC and Nasdaq rules.

Item 11. Executive Compensation.

The information required by this Item 11 of Form 10-K will be included in our Proxy Statement and is incorporated herein by reference.

Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.

The information required by this Item 12 of Form 10-K will be included in our Proxy Statement and is incorporated herein by reference.

Item 13. Certain Relationships and Related Transactions and Director Independence.

The information required by this Item 13 of Form 10-K will be included in our Proxy Statement and is incorporated herein by reference.

Item 14. Principal Accountant Fees and Services.

The information required by this Item 14 of Form 10-K will be included in our Proxy Statement and is incorporated herein by reference.

PART IV

PART IV

Item 15. Exhibits and Financial Statement Schedules.

The following documents are filed as part of this Annual Report on Form 10-K:
Report:

1. Financial Statements

The Consolidated Financial Statements filed as part of this Annual Report on Form 10-K are listed on page F-1 in the accompanying index to financial statements on page F-1.
the Consolidated Financial Statements.

2. Financial Statement Schedules

All financial statement schedules are omitted because they are not applicable, or the required information is shown in the Consolidated Financial Statements or notes thereto.

3. Exhibit Index

The following exhibits are filed (or incorporated by reference herein) as part of this Annual Report on Form 10-K:
Report:

Exhibit Number	Description
2.1	Agreement and Plan of Merger, dated as of March 8, 2021, by and among Motion Acquisition Corp.the Company, Motion Merger Sub Corp., and Ambulnz, Inc. (incorporated by reference to Exhibit 2.1 to Motion'sthe Company's Current Report on Form 8-K filed with the SEC on March 9, 2021).
3.1	Second Amended and Restated Certificate of Incorporation of DocGo Inc., dated November 5, 2021 (incorporated(incorporated by reference to Exhibit 3.1 of DocGo'sthe Company's Current Report on Form 8-K, filed with the SEC on November 12, 2021).
3.2	Amended and Restated Bylaws of DocGo Inc. (incorporated(incorporated by reference to Exhibit 3.2 of DocGo'sthe Company's Quarterly Report on Form 8-K,10-Q filed with the SEC on November 12, 2021). November 6, 2023).
4.1	Specimen Common Stock Certificate of DocGo Inc. (incorporated by reference to Exhibit 4.3 of DocGo's the Company's Current Report on Form 8-K filed with the SEC on November 12, 2021).
4.2*	Description of Securities.
10.1#	Form of Indemnification Agreement, by between Motion Acquisition Corp. the Company and its officers and directors (incorporated by reference to Exhibit 10.4 of Motion's the Company's Current Report on Form 8-K filed with the SEC on October 16, 2020).
10.2	Amended and Restated Registration Rights Agreement, dated as of November 5, 2021, by and among Motion Acquisition Corp.the Company, Motion Acquisition LLC and Stan Vashovsky (incorporated by reference to Exhibit 10.4 of DocGo's the Company's Current Report onForm 8-K filed with the SEC on November 12, 2021).
10.3#	DocGo Inc. 2021 Stock Incentive Plan (incorporated by reference to Annex D to Motion'sthe Company's Proxy Statement/Consent Solicitation/Prospectus (File No. 333-257681), filed with the SEC on October 14, 2021).
10.4#	New Executive Employment Agreement, effective November 5, 2021, by and between Motion Acquisition Corp. and Stan Vashovsky (incorporated by reference to Exhibit 10.6 of DocGo's Form 8-K, filed with the SEC on November 12, 2021).Company
10.5#	New Executive Agreement.

effective
November 5,
2021, by and
between
Motion
Acquisition
Corp. and
Andre
Oberholzer
(incorporated
by reference
to Exhibit
10.7 of
DocGo's the
Company's
Current
Report
on Form 8-K
filed with the
SEC on
November
12, 2021).

10.6#10.5#	<u>New Executive Employment Agreement, effective November 5, 2021, by and between Motion Acquisition Corp. the Company and Anthony Capone (incorporated by reference to Exhibit 10.8 of DocGo's the Company's Current Report on Form 8-K filed with the SEC on November 12, 2021).</u>
10.7#10.6#	<u>New Executive Employment Agreement, effective November 5, 2021, by and between Motion Acquisition Corp. the Company and Norman Rosenberg (incorporated by reference to Exhibit 10.9 of DocGo's the Company's Current Report on Form 8-K filed with the SEC on November 12, 2021).</u>
10.7#*	<u>Executive Employment Agreement, dated August 3, 2023, by and between the Company and Stephen Sugrue.</u>
10.8#	<u>Executive Employment Agreement, dated November 2, 2023, by and between the Company and Lee Bienstock (incorporated by reference to Exhibit 10.2 of the Company's Quarterly Report on Form 10-Q filed with the SEC on November 6, 2023).</u>
10.9#	<u>Separation and Transition Services Agreement, dated October 11, 2023, by and between the Company and Anthony Capone (incorporated by reference to Exhibit 10.1 of the Company's Current Report on Form 8-K, filed with the SEC on November 12, 2021 October 13, 2023).</u>
10.8#10.10#	<u>Form of Indemnification Agreement of DocGo Inc. (incorporated by reference to Exhibit 10.10 of DocGo's the Company's Current Report on Form 8-K filed with the SEC on November 12, 2021).</u>
10.910.11	<u>Stock Escrow Agreement, dated as of November 5, 2021, by and among Motion Acquisition Corp. the Company, Motion Acquisition LLC and Continental Stock & Transfer Company (incorporated by reference to Exhibit 10.11 of DocGo's the Company's Current Report on Form 8-K filed with the SEC on November 12, 2021).</u>
10.10*#10.12#	<u>Form of Grant Notice for Restricted Stock Unit Award and Standard Terms and Conditions for Restricted Stock Units under the DocGo Inc. 2021 Stock Incentive Plan (Director Form) (incorporated by reference to Exhibit 10.10 of the Company's Annual Report on Form 10-K filed with the SEC on March 14, 2023).</u>
10.11*#10.13#	<u>Form of Grant Notice for Nonqualified Stock Options and Standard Terms and Conditions for Nonqualified Stock Options under the DocGo Inc. 2021 Stock Incentive Plan. Plan (incorporated by reference to Exhibit 10.11 of the Company's Annual Report on Form 10-K filed with the SEC on March 14, 2023).</u>

10.12*# 10.14#	Form of Grant Notice for Incentive Stock Options and Standard Terms and Conditions for Incentive Stock Options under the DocGo Inc. 2021 Stock Incentive Plan. Plan (incorporated by reference to Exhibit 10.12 of the Company's Annual Report on Form 10-K filed with the SEC on March 14, 2023).
10.13# 10.15#	Form of Restricted Stock Unit Grant Notice and Agreement under the DocGo Inc. 2021 Stock Incentive Plan (incorporated by reference to Exhibit 10.3 of DocGo's the Company's Quarterly Report on Form 10-Q filed with the SEC on May 10, 2022).
10.16#	Form of Grant Notice for Restricted Stock Unit Award and Standard Terms and Conditions for Restricted Stock Units under the DocGo Inc. 2021 Stock Incentive Plan (Employee Form) (incorporated by reference to the Company's Quarterly Report on Form 10-Q filed with the SEC on May 10, 2022 August 8, 2023).
10.14 10.17*#	Form of Performance Stock Unit Grant Notice and Agreement under the DocGo Inc. 2021 Stock Incentive Plan.
10.18	Credit Agreement, dated November 1, 2022, by and among DocGo Inc, the Company, the lender parties thereto and Citibank, N.A., as administrative agent (incorporated by reference to Exhibit 10.1 of DocGo's the Company's Current Report on Form 8-K filed with the SEC on November 2, 2022).
21* 10.19	First Amendment to Credit Agreement, dated January 30, 2024, by and between the Company and Citibank, N.A., as administrative agent (incorporated by reference to Exhibit 10.1 of the Company's Current Report on Form 8-K filed with the SEC on January 31, 2024).
21.1*	Subsidiaries of DocGo Inc.

23.1*	Consent of Independent Registered Public Accounting Firm.
31.1*	Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2*	Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1**	Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
32.2**	Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101.INS*97.1*	DocGo Inc. Compensation Recoupment (Clawback) Policy.
101.INS*	Inline XBRL Instance Document.
101.SCH*	Inline XBRL Taxonomy Extension Schema Document.
101.CAL101.CAL**	Inline XBRL Taxonomy Extension Calculation Linkbase Document.
101.DEF101.DEF**	Inline XBRL Taxonomy Extension Definition Linkbase Document.
101.LAB101.LAB**	Inline XBRL Taxonomy Extension Label Linkbase Document.
101.PRE101.PRE**	Inline XBRL Taxonomy Extension Presentation Linkbase Document.
104	Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).

- * Filed herewith.
- ** Furnished herewith.
- * Filed herewith.
- ** Furnished herewith.
- # Indicates management contract or compensatory plan or arrangement.
- # Indicates management contract or compensatory plan or arrangement.

Item 16. Form 10-K Summary

None.

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized.

DOCGO INC.

Date: March 14, 2023February 28, 2024

By: /s/ Anthony CaponeLee Bienstock

Anthony CaponeLee Bienstock

Chief Executive Officer

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this Report has been signed below by the following persons on behalf of the Registrant in the capacities and on the dates indicated.

Signature	Title	Date
/s/ Anthony CaponeLee Bienstock	Chief Executive Officer	March 14, 2023February 28, 2024
Anthony CaponeLee Bienstock	(principal executive officer)	
		March 14, 2023February 28, 2024

<div>/s/ Norman Rosenberg</div> <div>Norman Rosenberg</div>	Chief Financial Officer (principal financial and accounting officer)	2024
<div>/s/ Stanley Vashovsky</div> <div>Stanley Vashovsky</div>	Chairman	March 14, 2023 February 28, 2024
<div>/s/ Michael Burdiek</div> <div> <div>/s/ Vina Leite</div> <div>Vina Leite</div> </div> <div>Michael Burdiek</div>	Director	March 14, 2023 February 28, 2024
<div>/s/ Steven Katz</div> <div>Steven Katz</div>	Director	February 28, 2024
<div>/s/ Vina Leite</div> <div>Vina Leite</div>	Director	February 28, 2024
<div>/s/ Ira Smedra</div> <div>Ira Smedra</div>	Director	February 28, 2024
<div>/s/ Ely D. Tandler</div> <div>Ely D. Tandler</div>	Director; General Counsel and Secretary	March 14, 2023
<div>/s/ Ira Smedra</div> <div>Ira Smedra</div>	Director	March 14, 2023 February 28, 2024
<div>/s/ Steven Katz</div> <div>Steven Katz</div>	Director	March 14, 2023
<div>/s/ James M. Travers</div> <div>James M. Travers</div>	Director	March 14, 2023 February 28, 2024
<div>/s/ Michael Burdiek</div> <div>Michael Burdiek</div>	Director	March 14, 2023

DESCRIPTION OF SECURITIES

The following sets forth a summary of the material terms of the securities of DocGo Inc.'s ("DocGo") securities, registered pursuant to Section 12 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), including certain provisions of the Delaware General Corporation Law (as the same exists or may hereafter be amended, (the the "DGCL")), the Second Amended and Restated Certificate of Incorporation of DocGo (the "Charter") and the Amended and Restated Bylaws of DocGo (the "Bylaws"). This summary is not intended to be a complete summary of the rights and preferences of such securities and is qualified entirely by reference to the Charter and Bylaws. You should refer to DocGo's the Charter and Bylaws, which are incorporated by reference to DocGo's Annual Report on Form 10-K, for a complete description of the rights and preferences of DocGo's securities. The summary below is also qualified by reference to the provisions of the DGCL, as applicable.

Capital Stock

The Charter authorizes the issuance of 550,000,000 shares of capital stock, consisting of (i) 500,000,000 shares of common stock, par value \$0.0001 per share (the "Common Stock"), and (ii) 50,000,000 shares of preferred stock, par value \$0.0001 per share.

Common Stock

The Charter provides that DocGo has one class of common stock, the Common Stock, par value \$0.0001 per share.

Stock.

Preferred Stock

The Charter provides that shares of preferred stock may be issued from time to time in one or more series. The Board of Directors of DocGo (the "Board") is authorized to fix the voting rights, if any, designations, powers, preferences and relative participating, optional, special and other rights, if any, and any qualifications, limitations and restrictions thereof, applicable to the shares of each series of preferred stock. The Board is able, without stockholder approval, to issue preferred stock with voting and other rights that could adversely affect the voting power and other rights of the holders of Common Stock and could have anti-takeover effects. The ability of the Board to issue preferred stock without stockholder approval could have the effect of delaying, deferring or preventing a change of control of DocGo or the removal of existing management. DocGo has no preferred stock outstanding as of the date hereof. Although DocGo does not currently intend to issue any shares of preferred stock, DocGo cannot assure you that it will not do so in the future.

Dividends

Under the Charter, holders of Common Stock are entitled to receive ratable dividends, if any, as may be declared from time-to-time by DocGo's the Board out of legally available assets or funds. DocGo has no current plans to pay cash dividends on Common Stock for the foreseeable future.

Voting Power

Except as otherwise required by law or as otherwise provided in any certificate of designation for any series of preferred stock, under the Charter, the holders of Common Stock will possess all of the voting power for the election of DocGo's directors and all other matters requiring stockholder action and are entitled to one vote per share on matters to be voted on by stockholders. Subject to certain limited exceptions, the holders of Common Stock shall at all times vote together, as one class, on all matters submitted to a vote of the holders of Common Stock under the Charter.

Preemptive or Other Rights

The Charter does not provide for any preemptive or other similar rights.

Conflicts of Interest; Corporate Opportunity

Delaware law permits corporations to adopt provisions renouncing any interest or expectancy in certain opportunities that are presented to the corporation or its officers, directors, or stockholders. The Charter provides that, to the maximum extent allowed by law, the doctrine of corporate opportunity, or any other analogous doctrine, shall not apply with respect to DocGo or any of its officers or directors, or any of their respective affiliates, in circumstances where the application of any such doctrine would conflict with any fiduciary duties or contractual obligations they may have as of the date of the Charter or in the future, and further provides that DocGo will renounce any expectancy that any of the directors or officers of DocGo will offer any such corporate opportunity of which he or she may become aware to DocGo, except the doctrine of corporate opportunity shall apply with respect to any of the directors or officers of DocGo.

Limitations on Liability and Indemnification of Officers and Directors

The Charter provides that, to the fullest extent permitted by the DGCL, as the same exists or may hereafter be amended, no director of DocGo shall be personally liable to DocGo or its stockholders for monetary damages for breach of fiduciary duty as a director. The Bylaws also provide that no director or officer of DocGo shall be personally liable to DocGo or to any stockholder of DocGo for monetary damages for breach of fiduciary duty as a director or officer, but does not limit liability: (i) for any breach of the director's or the officer's duty of loyalty to DocGo or its stockholders, (ii) for acts or omissions not in good faith or which involve intentional misconduct or a knowing violation of law, (iii) under Section 174 of the DGCL, or (iv) for any transaction from which the director or officer derived an improper personal benefit. DocGo has also entered into indemnification agreements with its directors and officers. The Charter requires DocGo to maintain directors' and officers' liability insurance coverage of at least \$5,000,000 per occurrence, to the fullest extent permitted by law covering, among other things, violations of federal or state securities laws.

These provisions may discourage current or future stockholders from bringing a lawsuit against DocGo's directors for a breach of their fiduciary duty. These provisions also may have the effect of reducing the likelihood of derivative litigation against officers and directors, even though such an action, if successful, might otherwise benefit DocGo or its stockholders. Furthermore, a stockholder's investment may be adversely affected to the extent DocGo pays the costs of settlement and damage awards against officers and directors pursuant to these indemnification provisions.

DocGo believes that these provisions, the directors' and officers' liability insurance and the indemnity agreements are necessary to attract and retain talented and experienced officers and directors.

Certain Anti-Takeover Provisions of the DGCL, DocGo's the Charter and the Bylaws

The Charter, Bylaws and DGCL contain provisions as summarized in the following paragraphs that are intended to enhance the likelihood of continuity and stability in the composition of DocGo's the Board. These provisions are intended to avoid costly takeover battles, reduce DocGo's vulnerability to a hostile change of control and enhance the ability of DocGo's the Board to maximize stockholder value in connection with any unsolicited offer to acquire DocGo. However, these provisions may have an anti-takeover effect and may delay, deter or prevent a merger or acquisition of DocGo by means of a tender offer, a proxy contest or other takeover attempt that stockholders might consider to be in their best interests, including those attempts that might result in a premium over the prevailing market price for the shares of Common Stock held by stockholders.

Forum Selection Clause

The Charter provides that unless DocGo selects or consents, in writing, to the selection of an alternative forum: (a) the sole and exclusive forum for any complaint asserting any internal corporate claims (as defined below), to the fullest extent permitted by law, and subject to applicable jurisdictional requirements, shall be the Court of Chancery of the State of Delaware (or, if the Court of Chancery does not have, or declines to accept, jurisdiction, another state court or a federal court located within the State of Delaware); and (b) the sole and exclusive forum for any complaint asserting a cause of action arising under the Securities Act of 1933, as amended, to the fullest extent permitted by law, shall be the federal district courts of the United States; however, this provision will not apply to suits brought to enforce a duty or liability created by the

Securities Exchange Act of 1934, as amended (the “Exchange Act”). Act. Section 27 of the Exchange Act creates exclusive federal jurisdiction over all suits brought to enforce any duty or liability created by the Exchange Act or the rules and regulations thereunder. As a result, the exclusive forum provision will not apply to suits brought to enforce any duty or liability created by the Exchange Act or any other claim for which the federal courts have exclusive jurisdiction. For purposes of this provision, “internal corporate claims” means claims, including claims in the right of DocGo that are based upon a violation of a duty by a current or former director, officer, employee or stockholder in such capacity, or as to which the DGCL confers jurisdiction upon the Court of Chancery.

Advance Notice of Director Nominations and New Business

The Bylaws state that in order for a stockholder to propose nominations of candidates to be elected as directors or any other proper business to be considered by stockholders at an annual meeting of stockholders, such stockholder must, among other things, provide notice thereof in writing to the Secretary at DocGo’s principal executive offices not later than the close of business on the 90th day nor earlier than the close of business on the 120th day prior to the first anniversary of the preceding year’s annual meeting (provided, however, that if the date of the annual meeting is more than 30 days before or more than 60 days after such anniversary date, or if no annual meeting was held the preceding year, notice must be delivered no earlier than the close of business on the 120th day prior to such annual meeting and not later than the close of business on the later of the 90th day prior to such annual meeting or the 10th day following the date on which public announcement of such meeting is first made by DocGo). Such notice must contain, include, among other things, certain information about the stockholder giving the notice (and the beneficial owner, if any, on whose behalf the nomination or proposal is made as well as certain control persons) and certain consents, representations and information about with respect to any nominee or other proposed business.

No Cumulative Voting

The DGCL provides that a stockholder’s right to vote cumulatively in the election of directors does not exist unless the certificate of incorporation specifically provides otherwise. DocGo’s The Charter does not provide for cumulative voting.

Classified Board of Directors

The Charter provides that the Board shall be divided into three classes of directors, designated Class I, Class II and Class III, and with the directors serving three-year terms. As a result, approximately one-third of DocGo’s the Board is elected each year. The classification of directors has the effect of making it more difficult for stockholders to change the composition of DocGo’s the Board. DocGo’s The Charter and Bylaws provide that the number of directors on the Board shall be fixed solely by resolution adopted from time to time by the Board by a majority of the directors then in office.

Removal of Directors; Vacancies

DocGo’s

The Charter provides that directors may be removed only for cause and only upon the affirmative vote of holders of 66 2/3% of the voting power of the stock outstanding and entitled to vote thereon. In addition, DocGo’s the Charter provides that any newly-created directorships and any vacancies on the Board shall be filled only by the affirmative vote of the majority of the remaining directors then in office. Therefore, stockholders are not able to elect new directors to fill any resulting vacancies that may be created as a result of any such removal of directors or as a result of a vacancy resulting from a director’s death, resignation, retirement or disqualification.

Supermajority Vote Requirement to Amend the Bylaws and Certificate of Incorporation

The affirmative vote of at least 66 2/3% of the voting power of the stock outstanding and entitled to vote thereon, voting as a single class, is required for stockholders to adopt, amend or repeal (i) the Bylaws and (ii) Section 5.2 of Article V, Article VI, Article VIII, Article IX, Article X or Article XI of the Charter. The Board is expressly authorized to adopt, amend or repeal the Bylaws.

Stockholder Action by Written Consent

The DGCL permits any action required to be taken at any annual or special meeting of the stockholders to be taken without a meeting, without prior notice and without a vote if a consent in writing, setting forth the action so taken, is signed by the holders of outstanding stock having not less than the minimum number of votes that would be necessary to authorize or take such action at a meeting at which all shares of stock entitled to vote thereon were present and voted, unless the certificate of incorporation provides otherwise. DocGo's The Charter precludes stockholder action by written consent in lieu of a meeting of stockholders.

Special Meetings

The Charter provides that a special meeting of the stockholders of DocGo may be called at any time only by the Board. Only such business shall be conducted at a special meeting of stockholders as shall have been brought before the meeting by or at the direction of the Board.

Delaware Anti-Takeover Statute

We are subject to Section 203 of the DGCL, which prohibits persons deemed to be "interested stockholders" from engaging in a "business combination" with a publicly-held Delaware corporation for three years following the date these persons became interested stockholders unless the business combination is, or the transaction in which the person became an interested stockholder was, approved in a prescribed manner or another prescribed exception applies. Generally, an "interested stockholder" is a person who, together with affiliates and associates, owns, or within three years prior to the determination of interested stockholder status did own, 15% or more of a corporation's voting stock. Generally, a "business combination" includes a merger, asset or stock sale, or other transaction resulting in a financial benefit to the interested stockholder. The existence of this provision may have an anti-takeover effect with respect to transactions not approved in advance by the Board.

Listing of Securities

DocGo's

The Common Stock is listed on the Nasdaq Stock Market under the symbol "DCGO."

4

Exhibit 10.7

EXECUTIVE EMPLOYMENT AGREEMENT

This Executive Employment Agreement (the "**Agreement**") is entered into as of August 3, 2023 (the "**Effective Date**"), by and between Stephen Sugrue ("**Executive**") and DocGo Inc., a Delaware corporation (the "**Company**").

WHEREAS, Executive has been serving as the Chief Compliance Officer of DocGo Inc. pursuant to that certain promotion letter, effective December 5, 2021, by and between the Company and Executive (the "**Prior Agreement**");

WHEREAS, the Company wishes to employ, and Executive wishes to accept employment with the Company, as Chief Compliance Officer of the Company, pursuant to the terms and conditions set forth in this Agreement, effective as of the Effective Date.

NOW, THEREFORE, in consideration of the mutual promises and covenants contained herein, it is hereby agreed by and between the parties hereto as follows:

ARTICLE I

DEFINITIONS

For purposes of the Agreement, the following terms are defined as follows:

1.1. "Board" means the Board of Directors of the Company.

1.2. "Cause" means the termination of Executive's employment for one of the following reasons: (i) willful failure to comply with, breach of or continued refusal to comply with, in each case, in any material respect, the material terms of this Agreement, of any written agreement or covenant with the Company or any affiliate (including, without limitation, any employment, consulting, confidentiality, non-competition, non-solicitation, non-disparagement or similar agreement or covenant); (ii) violation of any lawful material policies, standards or regulations of the Company which have been furnished to Executive, including policies related to discrimination, harassment, performance of illegal or unethical activities, and ethical misconduct; (iii) indictment for, conviction of or plea of no contest to a felony under the laws of the United States or any state;

(iv) fraud, embezzlement, dishonesty or breach of fiduciary duty against the Company or its affiliates or material misappropriation of property belonging to the Company or its affiliates; (v) Executive's willful failure to perform Executive's duties as specifically directed in any reasonable and lawful written directive of the Board or the person to whom Executive reports; or (vi) willful misconduct or gross negligence in connection with the performance of Executive's duties, in each case of (i), (v), (vi), after the receipt of written notice from the Board and Executive's failure to cure (if curable) within 30 days of Executive's receipt of the written notice, providing that the Company must provide Executive with at least 30 days to cure and if Executive cures, Cause shall not exist under (i), (v), (vi), as applicable.

1.3. "Change in Control" shall have the meaning ascribed to that term in the DocGo Inc. 2021 Stock Incentive Plan (the "**Plan**") or any successor equity compensation plan of the Company.

1.4. "COBRA" means the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended.

1.5. "Code" means the Internal Revenue Code of 1986, as amended.

1.6. "Covered Termination" means (i) an Involuntary Termination Without Cause or (ii) a voluntary termination for Good Reason. For the avoidance of doubt, neither (x) the termination of Executive's employment as a result of Executive's death or Disability nor (y) the expiration of this Agreement due to non-renewal pursuant to the terms of Section 2.2 of this Agreement will be deemed to be a Covered Termination.

1.7. "Disability" shall mean a termination of Executive's employment due to Executive's absence from Executive's duties with the Company on a full-time basis for at least 180 consecutive days as a result of

Executive's incapacity due to physical or mental illness which is determined to be total and permanent by a physician selected by the Company or its insurers.

1.8. "Good Reason" means any of the following taken without Executive's written consent: (i) failure or refusal by the Company to comply in any material respect with the material terms of this Agreement, (ii) a material diminution in Executive's duties, title, authority or responsibilities, (iii) a material reduction in Executive's Base Salary (unless the annual base salary of all other executive officers is similarly reduced), or (iv) the Company requiring Executive to be located at any office or location more than 35 miles from the Company's current headquarters in New York, New York, provided that any request or directive from the Company to not work in such office pursuant to any stay-at-home or work from home or similar law, order, directive, request or recommendation from a governmental entity shall not give rise to Good Reason under this Agreement. Notwithstanding the foregoing, Executive's resignation shall not constitute a resignation for "Good Reason" as a result of any event described in the preceding sentence unless (x) Executive provides written notice thereof to the Company within 30 days after the first occurrence of such event, (y) to the extent correctable, the Company fails to remedy such circumstance or event within 30 days following the Company's receipt of such written notice and (z) the effective date of Executive's resignation for "Good Reason" is not later than 90 days after the initial existence of the circumstances constituting Good Reason.

1.9. "Involuntary Termination Without Cause" means Executive's dismissal or discharge by the Company other than for Cause or by reason of Executive's death or Disability.

1.10. "Section 409A" means Section 409A of the Code and the Department of Treasury regulations and other interpretive guidance issued thereunder, including without limitation any such regulations or other guidance that may be issued after the Effective Date.

1.11. "Separation from Service" means Executive's termination of employment constitutes a "separation from service" within the meaning of Treasury Regulation Section 1.409A-1(h).

ARTICLE II

EMPLOYMENT BY THE COMPANY

2.1. Position and Duties. Subject to terms set forth herein, Executive shall serve in an executive capacity and shall perform such duties as are customarily associated with the position of Chief Compliance Officer of the Company and such other duties as are assigned to Executive by the Board and/or the Company's Chief Executive Officer. During the term of Executive's employment with the Company, Executive will devote Executive's best efforts and substantially

all of Executive's business time and attention (except for vacation periods and absences due to reasonable periods of illness or other incapacities permitted by the Company's general employment policies or as otherwise set forth in this Agreement) to the business of the Company.

2.2. Term. The initial term of this Agreement shall commence on the Effective Date and shall terminate on the earlier of (i) the third anniversary of the Effective Date and (ii) the termination of Executive's employment under this Agreement. On the third anniversary of the Effective Date and each annual anniversary of such date thereafter (in either case, provided Executive's employment has not been terminated under this Agreement prior thereto), this Agreement shall automatically be extended for one additional year unless either Executive or the Company gives written notice of non-renewal to the other at least 60 days prior to the automatic extension date. The period from the Effective Date until the earlier of (a) termination of Executive's employment under this Agreement and (b) the expiration of the term of this Agreement due to non-renewal pursuant to this Section 2.2 is referred to as the "Term."

2.3. Employment at Will. The Company shall have the right to terminate Executive's employment with the Company at any time, with or without cause, and, in the case of a termination by the Company, with or without prior notice. In addition to Executive's right to resign for Good Reason, Executive shall have the right to resign at any time and for any reason or no reason at all, upon 90 days' advance written notice to the Company; provided, however, that if Executive has provided a resignation notice to the Company, the Company may determine, in its sole discretion, that such termination shall be effective on any date prior to the effective date of termination provided in such notice (and, if such earlier date is so required, then it shall not change the basis for Executive's termination of employment nor be construed or interpreted as a termination of Executive's employment by the Company) and any requirement to continue salary or benefits shall cease as of such earlier date. Upon certain terminations of Executive's employment with the Company, Executive may become eligible to receive the severance benefits provided in Article IV of this Agreement.

2.4. Deemed Resignations. Except as otherwise determined by the Board or as otherwise agreed to in writing by Executive and the Company or any of its affiliates prior to the termination of Executive's employment with the Company or any of its affiliates, any termination of Executive's employment shall constitute, as applicable, an automatic resignation of Executive: (a) as an officer of the Company and each of its affiliates; (b) from the Board; and (c) from the board of directors or board of managers (or similar governing body) of any affiliate of the Company and from the board of directors or board of managers (or similar governing body) of any corporation, limited liability entity, unlimited liability entity or other entity in which the Company or any of its affiliates holds an equity interest and with respect to which board of directors or board of managers (or similar governing body) Executive serves as such designee or other representative of the Company or any of its affiliates. Executive agrees to take any further actions that the Company or any of its affiliates reasonably requests to effectuate or document the foregoing.

2.5. Employment Policies. The employment relationship between the parties shall also be governed by the general employment policies and practices of the Company, including those relating to protection of confidential information and assignment of inventions, except that when the terms of this Agreement differ from or are in conflict with the Company's general employment policies or practices, this Agreement shall control.

ARTICLE III

COMPENSATION

3.1. Base Salary. As of the Effective Date, Executive shall receive for services to be rendered hereunder an annualized base salary of \$372,000 ("**Base Salary**"), payable on the regular payroll dates of the Company (but no less often than monthly), subject to increase in the sole discretion of the Board or a committee of the Board.

3.2. Annual Bonus. For each calendar year ending during the Term, Executive shall be eligible to receive an annual performance bonus (the "**Annual Bonus**") targeted at 50% of Base Salary or such other amount as determined in the sole discretion of the Board or a committee of the Board (the "**Target Bonus**"), on such terms and conditions determined by the Board or a committee of the Board. The actual amount of any Annual Bonus (if any) will be determined in the discretion of the Board or a committee of the Board and will be (i) subject to achievement of any applicable bonus objectives and/or conditions determined by the Board or a committee of the Board and (ii) subject to Executive's continued employment with the Company through the date the Annual Bonus is paid (except as otherwise provided in Section 4.1). The Annual Bonus for any calendar year will be paid at the same time as bonuses for other Company executives are paid related annual bonuses generally.

3.3. Standard Company Benefits. During the Term, Executive shall be entitled to all rights and benefits for which Executive is eligible under the terms and conditions of the standard Company benefits and compensation practices that may be in effect from time to time and are provided by the Company to its executive employees generally, as well as any additional benefits provided to Executive consistent with past practice. Notwithstanding the foregoing, this Section 3.3 shall not create or be deemed to create any obligation on the part of the Company to adopt or maintain any benefits or compensation practices at any time.

3.4. Paid Time Off. During the Term, Executive shall be entitled to such periods of paid time off ("**PTO**") each year as provided from time to time under the Company's PTO policies and as otherwise provided for executive officers, as it may be amended from time to time.

3.5. Equity Awards. Executive will be eligible to receive equity incentive grants as determined by the Board or the Compensation Committee of the Board in its sole discretion. All equity awards granted to Executive will be subject to the terms and conditions of the Plan and the applicable award agreement approved by the Board or the Compensation Committee of the Board, which shall be consistent with this Section 3.5. Nothing herein shall be construed to give any Executive any rights to any amount or type of grant or award except as provided in an award agreement and authorized by the Board or the Compensation Committee of the Board.

ARTICLE IV

SEVERANCE AND CHANGE IN CONTROL BENEFITS

4.1. Severance Benefits. Upon Executive's termination of employment, Executive shall receive any accrued but unpaid Base Salary and other accrued and unpaid compensation, including any accrued but unpaid vacation. If the termination is due to a Covered Termination, provided that Executive (A) delivers an effective general release of all claims against the Company and its

affiliates in a form provided by the Company (a “**Release of Claims**”) that becomes effective and irrevocable within 60 days following the Covered Termination and (B) continues to comply with Articles V through VII of this Agreement, Executive shall be entitled to receive the severance benefits described in Section 4.1(a) or (b), as applicable.

(a) Covered Termination Not Related to a Change in Control. If Executive’s employment terminates due to a Covered Termination which occurs at any time other than during the period beginning three months prior to a Change in Control and ending 12 months after a Change in Control (the “**CIC Protection Period**”), Executive shall receive the following:

(i) An amount equal to six months of Executive’s Base Salary at the rate in effect (or required to be in effect before any diminution that is the basis of Executive’s termination for Good Reason) at the time of Executive’s termination of employment, payable in equal installments over six months pursuant to the Company’s standard payroll procedures, less applicable withholdings, as soon as administratively practicable following the date on which the Release of Claims becomes effective and, in any event, no later than the 60th day following the date of the Covered Termination; provided, however, if such 60 day period falls in two different calendar years, payment will be made in the later calendar year.

(ii) Notwithstanding anything set forth in an award agreement or incentive plan to the contrary, (A) a pro-rata portion of Executive’s Annual Bonus for the fiscal year in which Executive’s termination occurs based on actual achievement of the applicable bonus objectives and/or conditions determined by the Board or a committee of the Board for such year (determined by multiplying the amount of the Annual Bonus that would be payable for the full fiscal year by a fraction, the numerator of which shall be equal to the number of days during the fiscal year of termination that Executive is employed by, and performing services for, the Company and the denominator of which is 365 days) and (B) the amount of any Annual Bonus earned, but not yet paid, for the fiscal year prior to Executive’s termination, in each case, payable, less applicable withholdings, at the same time bonuses for such year are paid to other senior executives of the Company, but in no event later than March 15 of the year following the year of Executive’s termination of employment.

(iii) Subject to Executive’s timely election of continuation coverage under COBRA, the Company shall directly pay, or reimburse Executive for the premium for Executive and Executive’s covered dependents to maintain continued health coverage pursuant to the provisions of COBRA through the earlier of (A) the six-month anniversary of the date of Executive’s termination of employment and (B) the date Executive and Executive’s covered dependents, if any, become eligible for healthcare coverage under another employer’s plan(s). Notwithstanding the foregoing, if the Company is otherwise unable to continue to cover Executive under its group health plans without penalty under applicable law (including without limitation, Section 2716 of the Public Health Service Act), then, in either case, an amount equal to each remaining Company subsidy shall thereafter be paid to Executive in substantially equal monthly installments.

(b) Covered Termination Related to a Change in Control. If Executive’s employment terminates due to a Covered Termination that occurs during the CIC Protection Period, Executive shall receive the following:

(i) An amount equal to (A) 0.5 times (B) the sum of (i) Executive's Base Salary at the rate in effect (or required to be in effect before any diminution that is the basis of Executive's termination for Good Reason) at the time of Executive's termination of employment and

(ii) Executive's Target Bonus in effect for the year in which Executive's termination of employment occurs, payable in a lump sum payment, less applicable withholdings, as soon as administratively practicable following the date on which the Release of Claims becomes effective and, in any event, no later than the 60th day following the date of the Covered Termination; provided, however, if such 60 day period falls in two different calendar years, payment will be made in the later calendar year.

(ii) Notwithstanding anything set forth in an award agreement or incentive plan to the contrary, (A) a pro-rata portion of Executive's Annual Bonus for the fiscal year in which Executive's termination occurs based on actual achievement of the applicable bonus objectives and/or conditions determined by the Board or a committee of the Board for such year (determined by multiplying the amount of the Annual Bonus that would be payable for the full fiscal year by a fraction, the numerator of which shall be equal to the number of days during the fiscal year of termination that Executive is employed by, and performing services for, the Company and the denominator of which is 365 days) and (B) the amount of any Annual Bonus earned, but not yet paid, for the fiscal year prior to Executive's termination, in each case, payable, less applicable withholdings, at the same time bonuses for such year are paid to other senior executives of the Company, but in no event later than March 15 of the year following the year of Executive's termination of employment.

(iii) Subject to Executive's timely election of continuation coverage under COBRA, the Company shall directly pay, or reimburse Executive for the premium for Executive and Executive's covered dependents to maintain continued health coverage pursuant to the provisions of COBRA through the earlier of (A) the six-month anniversary of the date of Executive's termination of employment and (B) the date Executive and Executive's covered dependents, if any, become eligible for healthcare coverage under another employer's plan(s). Notwithstanding the foregoing, if the Company is otherwise unable to continue to cover Executive under its group health plans without penalty under applicable law (including without limitation, Section 2716 of the Public Health Service Act), then, in either case, an amount equal to each remaining Company subsidy shall thereafter be paid to Executive in substantially equal monthly installments.

4.2. 280G Provisions. Notwithstanding anything in this Agreement to the contrary, if any payment or distribution Executive would receive pursuant to this Agreement or otherwise ("**Payment**") would (a) constitute a "parachute payment" within the meaning of Section 280G of the Code, and (b) but for this sentence, be subject to the excise tax imposed by Section 4999 of the Code (the "**Excise Tax**"), then such Payment shall either be (i) delivered in full, or (ii) delivered as to such lesser extent which would result in no portion of such Payment being subject to the Excise Tax, whichever of the foregoing amounts, taking into account the applicable federal, state and local income taxes and the Excise Tax, results in the receipt by Executive on an after-tax basis, of the largest payment, notwithstanding that all or some portion of the Payment may be taxable under Section 4999 of the Code. The accounting firm engaged by the Company for general audit purposes as of the day prior to the

effective date of the Change in Control shall perform the foregoing calculations. The Company shall bear all expenses with respect to the determinations by

such accounting firm required to be made hereunder. The accounting firm shall provide its calculations to the Company and Executive within 15 calendar days after the date on which Executive's right to a Payment is triggered (if requested at that time by the Company or Executive) or such other time as requested by the Company or Executive. Any good faith determinations of the accounting firm made hereunder shall be final, binding and conclusive upon the Company and Executive. Any reduction in payments and/or benefits pursuant to this Section 4.2 will occur in the following order: (1) reduction of cash payments; (2) cancellation of accelerated vesting of equity awards other than stock options; (3) cancellation of accelerated vesting of stock options; and (4) reduction of other benefits payable to Executive. Nothing in this Section 4.2 shall require the Company or any of its affiliates to be responsible for, or have any liability or obligation with respect to, Executive's Excise Tax liabilities under Section 4999 of the Code.

4.3. Section 409A. Notwithstanding any provision to the contrary in this Agreement:

(a) All provisions of this Agreement are intended to comply with Section 409A or an exemption therefrom and shall be construed and administered in accordance with such intent. Any payments under this Agreement that may be excluded from Section 409A either as separation pay due to an involuntary separation from service or as a short-term deferral shall be excluded from Section 409A to the maximum extent possible. Notwithstanding the foregoing, the Company makes no representations that the payments and benefits provided under this Agreement are exempt from, or compliant with, Section 409A and in no event shall the Company or any of its affiliates be liable for all or any portion of any taxes, penalties, interest or other expenses that may be incurred by Executive on account of non-compliance with Section 409A.

(b) If Executive is deemed at the time of Executive's Separation from Service to be a "specified employee" for purposes of Section 409A(a)(2)(B)(i) of the Code, to the extent delayed commencement of any portion of the benefits to which Executive is entitled under this Agreement is required in order to avoid a prohibited distribution under Section 409A(a)(2)(B)(i) of the Code which would subject Executive to a tax obligation under Section 409A, such portion of Executive's benefits shall not be provided to Executive prior to the earlier of (i) the expiration of the six- month period measured from the date of Executive's Separation from Service or (ii) the date of Executive's death. Upon the expiration of the applicable Code Section 409A(a)(2)(B)(i) period, all payments deferred pursuant to this Section 4.3(b) shall be paid in a lump sum to Executive, and any remaining payments due under the Agreement shall be paid as otherwise provided herein.

(c) Any reimbursements payable to Executive pursuant to the Agreement shall be paid to Executive no later than 30 days after Executive provides the Company with a written request for reimbursement, and to the extent that any such reimbursements are deemed to constitute "nonqualified deferred compensation" within the meaning of Section 409A (i) such amounts shall be paid or reimbursed to Executive promptly, but in no event

later than December 31 of the year following the year in which the expense is incurred, (ii) the amount of any such payments eligible for reimbursement in one year shall not affect the payments or expenses that are eligible for payment or reimbursement in any other taxable year, and (iii) Executive's right to such payments or reimbursement shall not be subject to liquidation or exchange for any other benefit; provided, that the foregoing clause shall not be violated with regard to expenses reimbursed under any arrangement covered by Section 105(b) of the Code solely because such expenses are subject to a limit related to the period in which the arrangement is in effect.

(d) For purposes of Section 409A (including, without limitation, for purposes of Treasury Regulation Section 1.409A-2(b)(2)(iii)), Executive's right to receive installment payments under the Agreement shall be treated as a right to receive a series of separate payments and, accordingly, each installment payment hereunder shall at all times be considered a separate and distinct payment.

4.4. Mitigation. Executive shall not be required to mitigate damages or the amount of any payment provided under this Agreement by seeking other employment or otherwise, nor shall the amount of any payment provided for under this Agreement be reduced by any compensation earned by Executive as a result of employment by another employer or by any retirement benefits received by Executive after the date of the Covered Termination, or otherwise.

ARTICLE V

PROPRIETARY INFORMATION AND CONFIDENTIALITY OBLIGATIONS

5.1. Proprietary Information. All Company Innovations shall be the sole and exclusive property of the Company without further compensation and are "works made for hire" as that term is defined under the United States copyright laws. Executive shall promptly notify the Company of any Company Innovations that Executive solely or jointly Creates. "**Company Innovations**" means all Innovations, and any associated intellectual property rights, which Executive may solely or jointly Create, during Executive's employment with the Company, which (i) relate, at the time Created, to the Company's business or actual or demonstrably anticipated research or development, or (ii) were developed on any amount of the Company's time or with the use of any of the Company's equipment, supplies, facilities or trade secret information, or (iii) resulted from any work Executive performed for the Company. "**Create**" means to create, conceive, reduce to practice, derive, develop or make. "**Innovations**" means processes, machines, manufactures, compositions of matter, improvements, inventions (whether or not protectable under patent laws), works of authorship, information fixed in any tangible medium of expression (whether or not protectable under copyright laws), mask works, trademarks, trade names, trade dress, trade secrets, know-how, ideas (whether or not protectable under trade secret laws), and other subject matter protectable under patent, copyright, moral rights, mask work, trademark, trade secret or other laws regarding Proprietary Rights, including new or useful art, combinations, discoveries, formulae, manufacturing techniques, technical developments, discoveries, artwork, software and designs. Executive hereby assigns (and will assign) to the Company all Company Innovations. Executive shall perform (at the Company's expense),

during and after Executive's employment, all acts reasonably deemed necessary or desirable by the Company to assist the Company in obtaining and enforcing the full benefits, enjoyment, rights and title throughout the world in the Company Innovations. Such acts may include execution of documents and assistance or cooperation (i) in the filing, prosecution, registration, and memorialization of assignment of patent, copyright, mask work or other applications, (ii) in the enforcement of any applicable Proprietary Rights, and (iii) in other legal proceedings related to the Company's Innovations. "**Proprietary Rights**" means patents, copyrights, mask work, moral rights, trade secrets and other proprietary rights. No provision in this Agreement is intended to require Executive to assign or offer to assign any of Executive's rights in any invention for which Executive can establish that no trade secret information of the Company were used, and which was developed on Executive's own time, unless the invention relates to the Company's actual or demonstrably anticipated research or development, or the invention results from any work performed by Executive for the Company.

5.2. Confidentiality. In the course of Executive's employment with the Company and the performance of Executive's duties on behalf of the Company and its affiliates hereunder, Executive will be provided with, and will have access to, Confidential Information (as defined below). In consideration of Executive's receipt and access to such Confidential Information, and as a condition of Executive's employment, Executive shall comply with this Section 5.2.

(a) Both during the Term and thereafter, except as expressly permitted by this Agreement, Executive shall not disclose any Confidential Information to any person or entity and shall not use any Confidential Information except for the benefit of the Company or its affiliates. Executive shall follow all Company policies and protocols regarding the security of all documents and other materials containing Confidential Information (regardless of the medium on which Confidential Information is stored). Except to the extent required for the performance of Executive's duties on behalf of the Company or any of its affiliates, Executive shall not remove from facilities of the Company or any of its affiliates any information, property, equipment, drawings, notes, reports, manuals, invention records, computer software, customer information, or other data or materials that relate in any way to the Confidential Information, whether paper or electronic and whether produced by Executive or obtained by the Company or any of its affiliates. The covenants of this Section 5.2(a) shall apply to all Confidential Information, whether now known or later to become known to Executive during the period that Executive is employed by or affiliated with the Company or any of its affiliates.

(b) Notwithstanding any provision of Section 5.2(a) to the contrary, Executive may make the following disclosures and uses of Confidential Information:

(i) disclosures to other employees, officers or directors of the Company or any of its affiliates who have a need to know the information in connection with the businesses of the Company or any of its affiliates;

(ii) disclosures to customers and suppliers when, in the reasonable and good faith belief of Executive, such disclosure is in connection with Executive's performance of Executive's duties;

(iii) disclosures and uses that are approved in writing by the Board; or

(iv) disclosures to a person or entity that has (x) been retained by the Company or any of its affiliates to provide services to the Company and/or its affiliates and (y) agreed in writing to abide by the terms of a confidentiality agreement.

(c) Upon the expiration of the Term, and at any other time upon request of the Company, Executive shall promptly and permanently surrender and deliver to the Company all documents (including electronically stored information) and all copies thereof and all other materials of any nature containing or pertaining to all Confidential Information and any other Company property (including any Company-issued computer, mobile device or other equipment) in Executive's possession, custody or control and Executive shall not retain any such documents or other materials or property of the Company or any of its affiliates. Within 10 days of any such request, Executive shall certify to the Company in writing that all such documents, materials and property have been returned to the Company or otherwise destroyed.

(d) **"Confidential Information"** means all confidential, competitively valuable, non- public or proprietary information that is conceived, made, developed or acquired by or disclosed to Executive (whether conveyed orally or in writing), individually or in conjunction with others, during the period that Executive is employed or engaged by the Company or any of its affiliates (whether during business hours or otherwise and whether on the Company's premises or otherwise) including: (i) technical information of the Company, its affiliates, its investors, customers, vendors, suppliers or other third parties, including computer programs, software, databases, data, ideas, know-how, formulae, compositions, processes, discoveries, machines, inventions (whether patentable or not), designs, developmental or experimental work, techniques, improvements, work in process, research or test results, original works of authorship, training programs and procedures, diagrams, charts, business and product development plans, and similar items; (ii) information relating to the Company or any of its affiliates' businesses or properties, products or services (including all such information relating to corporate opportunities, operations, future plans, methods of doing business, business plans, strategies for developing business and market share, research, financial and sales data, pricing terms, evaluations, opinions, interpretations, acquisition prospects, the identity of customers or acquisition targets or their requirements, the identity of key contacts within customers' organizations or within the organization of acquisition prospects, or marketing and merchandising techniques, prospective names and marks) or pursuant to which the Company or any of its affiliates owes a confidentiality obligation; and (iii) other valuable, confidential information and trade secrets of the Company, its affiliates, its customers or other third parties. Moreover, all documents, videotapes, written presentations, brochures, drawings, memoranda, notes, records, files, correspondence, manuals, models, specifications, computer programs, e-mail, voice mail, electronic databases, maps, drawings, architectural renditions, models and all other writings or materials of any type including or

embodying any of such information, ideas, concepts, improvements, discoveries, inventions and other similar forms of expression are and shall be the sole and exclusive property of the Company or its other applicable affiliates and be subject to the same restrictions on disclosure applicable to all Confidential Information pursuant to this Agreement. For purposes of this Agreement, Confidential Information shall not include any information that (A) is or becomes generally available to the public other than as a result of a disclosure or wrongful act of Executive or any of Executive's agents; (B) was available to Executive on a non-confidential basis before its disclosure by the Company or any of its affiliates; (C) becomes available to Executive on a non-confidential basis from a source other than the Company or any of its affiliates; provided, however, that such source is not bound by a confidentiality agreement with, or other obligation with respect to confidentiality to, the Company or any of its affiliates; or (D) is required to be disclosed by applicable law.

(e) Notwithstanding the foregoing, nothing in this Agreement shall prohibit or restrict Executive from lawfully: (i) initiating communications directly with, cooperating with, providing information to, causing information to be provided to, or otherwise assisting in an investigation by, any governmental authority regarding a possible violation of any law; (ii) responding to any inquiry or legal process directed to Executive from any such governmental authority; (iii) testifying, participating or otherwise assisting in any action or proceeding by any such governmental authority relating to a possible violation of law; or (iv) making any other disclosures that are protected under the whistleblower provisions of any applicable law. Additionally, pursuant to the federal Defend Trade Secrets Act of 2016, an individual shall not be held criminally or civilly liable under any federal or state trade secret law for the disclosure of a trade secret that: (A)

is made (1) in confidence to a federal, state or local government official, either directly or indirectly, or to an attorney and (2) solely for the purpose of reporting or investigating a suspected violation of law; (B) is made to the individual's attorney in relation to a lawsuit for retaliation against the individual for reporting a suspected violation of law; or (C) is made in a complaint or other document filed in a lawsuit or proceeding, if such filing is made under seal. Nothing in this Agreement requires Executive to obtain prior authorization before engaging in any conduct described in this paragraph, or to notify the Company that Executive has engaged in any such conduct.

5.3. Nondisparagement. Subject to Section 5.2(e) above, Executive agrees that from and after the Effective Date, Executive will not, directly or indirectly, make, publish, or communicate any disparaging or defamatory comments regarding the Company or any of its current or former directors, officers, members, managers, partners, or executives. The foregoing shall not be violated by truthful statements in response to legal process, required governmental testimony or filings or administrative or arbitral proceedings (including, without limitation, depositions in connection with such proceedings).

5.4. Remedies. Executive's duties under this Article V shall survive termination of Executive's employment with the Company and the termination of this Agreement. Because of the difficulty of measuring economic losses to the Company and its affiliates as a result of a breach or threatened breach of the covenants

set forth in this Article V, Section 6.2 and Article VII, and because of the immediate and irreparable damage that would be caused to the Company and its affiliates for which they would have no other adequate remedy, Executive acknowledges that a remedy at law for any breach or threatened breach by Executive of Article V, as well as Executive's obligations pursuant to Section 6.2 and Article VII below, would be inadequate, and Executive therefore agrees that the Company shall be entitled to seek injunctive relief in case of any such breach or threatened breach from any court of competent jurisdiction, without the necessity of showing any actual damages or that money damages would not afford an adequate remedy, and without the necessity of posting any bond or other security. The aforementioned equitable relief shall not be the Company's or any of its affiliates' exclusive remedy for a breach but instead shall be in addition to all other rights and remedies available to the Company and each of its affiliates at law and equity.

5.5. Modification. The covenants in this Article V, Section 6.2 and Article VII, and each provision and portion hereof, are severable and separate, and the unenforceability of any specific covenant (or portion thereof) shall not affect the provisions of any other covenant (or portion thereof). If it is determined by an arbitrator or a court of competent jurisdiction in any state that any restriction in this Article V, Section 6.2 and Article VII is excessive in duration or scope or is unreasonable or unenforceable under the laws of that state, it is the intention of the parties that such restriction may be modified or amended by the arbitrator or the court to render it enforceable to the maximum extent permitted by the law of that state.

ARTICLE VI OUTSIDE ACTIVITIES

6.1. Other Activities.

(a) Except as otherwise provided in Section 6.1(b), Executive shall not, during the term of this Agreement undertake or engage in any other employment, occupation or business enterprise, other than ones in which Executive is a passive investor, unless Executive obtains the prior written consent of the Board.

(b) Executive may engage in civic and not-for-profit activities so long as such activities do not interfere with the performance of Executive's duties hereunder. In addition, subject to advance approval by the Board, Executive shall be allowed to serve as a member of the board of directors of one (1) for-profit entity at any time during the term of this Agreement, so long as such service does not materially interfere with the performance of Executive's duties hereunder; provided, however, that the Board, in its discretion, may require that Executive resign from such director position if it determines that such resignation would be in the best interests of the Company.

6.2. Competition/Investments. During the term of Executive's employment by the Company and for six months thereafter, Executive shall not (except on behalf of the Company) directly or indirectly, whether as an officer, director, stockholder, partner, proprietor, associate, representative, consultant, or in any capacity whatsoever engage in, become financially interested in, be employed by or have any business connection with

any other person, corporation, firm, partnership or other entity whatsoever which compete directly with the Company or any of its affiliates, throughout the world, in any line of business engaged in (or planned to be engaged in as of the date of termination) by the Company; provided, however, that anything above to the contrary notwithstanding, Executive may own, as a passive investor, securities of any publicly-traded competitor corporation, so long as Executive's direct holdings in any one such corporation do not, in the aggregate, constitute more than 1% of the voting stock of such corporation.

6.3. Defense of Claims; Cooperation. During the Term and thereafter, upon reasonable request from the Company, Executive shall use commercially reasonable efforts to cooperate with the Company and its affiliates in the defense of any claims or actions that may be made by or against the Company or any of its affiliates that relate to Executive's actual or prior areas of responsibility or knowledge. Executive shall further use commercially reasonable efforts to provide reasonable and timely cooperation in connection with any actual or threatened claim, action, inquiry, review, investigation, process, or other matter (whether conducted by or before any court, arbitrator, regulatory, or governmental entity, or by or on behalf of the Company or any of its affiliates), that relates to Executive's actual or prior areas of responsibility or knowledge. The Company shall reimburse Executive's reasonable out of pocket expenses incurred in connection with such cooperation.

ARTICLE VII

NONINTERFERENCE

Executive shall not, during the term of Executive's employment by the Company and for a period of six months thereafter, except in the furtherance of Executive's duties hereunder, directly or indirectly, individually or on behalf of any other person, firm, corporation or other entity, (i) solicit, aid or induce any customer of the Company or its subsidiaries to purchase goods or services then sold by the Company or its subsidiaries from another person, firm, corporation or other entity or assist or aid any other person or entity in identifying or soliciting any such customer,

(ii) solicit, aid or induce any employee, representative or agent of the Company or its subsidiaries to leave such employment or retention or to accept employment with or render services to or with any other person, firm, corporation or other entity unaffiliated with the Company, or hire or retain any such employee, representative or agent, or take any action to materially assist or aid any other person, firm, corporation or other entity in identifying, hiring or soliciting any such employee, representative or agent, or (iii) interfere, or aid or induce any other person or entity in interfering, with the relationship between the Company and its subsidiaries and any of their respective vendors, joint venturers or licensors in a material way. An employee, representative or agent shall be deemed covered by this Article VII while so employed or retained and for a period of six months thereafter. If it is determined by a court of competent jurisdiction in any state that any restriction in Article VII or this Article VII is excessive in duration or scope or is unreasonable or unenforceable under applicable law, it is the intention of the parties that such restriction may be modified or amended by the court to render it enforceable to the maximum extent permitted by the law of that state.

ARTICLE VIII GENERAL PROVISIONS

8.1. Notices. Any notices provided hereunder must be in writing and shall be deemed effective upon the earlier of personal delivery (including personal delivery by facsimile or electronic mail) or the third day after mailing by first class mail, to the Company at its primary office location and to Executive at Executive's address as listed on the Company's books and records.

8.2. Tax Withholding. Executive acknowledges that all amounts and benefits payable under this Agreement are subject to deduction and withholding to the extent required by applicable law.

8.3. Severability. Whenever possible, each provision of this Agreement will be interpreted in such manner as to be effective and valid under applicable law, but if any provision of this Agreement is held to be invalid, illegal or unenforceable in any respect under any applicable law or rule in any jurisdiction, such invalidity, illegality or unenforceability will not affect any other provision or any other jurisdiction, but this Agreement will be reformed, construed and enforced in such jurisdiction as if such invalid, illegal or unenforceable provisions had never been contained herein.

8.4. Indemnification/D&O Insurance. The Company hereby agrees to indemnify the Executive and hold the Executive harmless to the extent provided under the organizational documents of the Company against and in respect of any and all actions, suits, proceedings, claims, demands, judgments, costs, expenses (including reasonable attorney's fees), losses, and damages resulting from the Executive's good faith performance of the Executive's duties and obligations with the Company, whether such claim relates to events occurring before or after the date of this Agreement. In all events, the Executive shall be provided with indemnification protection no less favorable than the indemnification protection provided to the Company's directors and other officers. The Company shall cover the Executive under directors' and officers' liability insurance both during and, while potential liability exists, after the term of this Agreement in the same amount and to the same extent as the Company covers its directors and other officers. The Company hereby reaffirms that this Agreement does not in any way limit the Company's indemnification obligations to the Executive for matters arising prior to the date of this Agreement

that were subject to indemnification. The foregoing obligations shall survive the termination of the Executive's employment with the Company.

8.5. Waiver. Any waiver of this Agreement must be executed by the party to be bound by such waiver. If either party should waive any breach of any provisions of this Agreement, they shall not thereby be deemed to have waived any preceding or succeeding breach of the same or any other provision of this Agreement or any similar or dissimilar provision or condition at the same or any subsequent time. The failure of either party hereto to take any action by reason of any breach will not deprive such party of the right to take action at any time.

8.6. Complete Agreement. This Agreement constitutes the entire agreement between Executive and the Company and is the complete, final, and exclusive embodiment of their agreement with regard to this subject matter, and will supersede all prior agreements, understandings, discussions, negotiations and undertakings, whether written or oral, between the parties with respect to the subject matter hereof (including, for the avoidance of doubt, the Prior Agreement). This Agreement is entered into without reliance on any promise or representation other than those expressly contained herein or therein, and cannot be modified or amended except in a writing signed by a duly-authorized officer of the Company and Executive.

8.7. Counterparts. This Agreement may be executed in separate counterparts, any one of which need not contain signatures of more than one party, but all of which taken together will constitute one and the same Agreement.

8.8. Headings. The headings of the sections hereof are inserted for convenience only and shall not be deemed to constitute a part hereof nor to affect the meaning thereof.

8.9. Successors and Assigns. This Agreement is intended to bind and inure to the benefit of and be enforceable by Executive and the Company, and their respective successors, assigns, heirs, executors and administrators, except that Executive may not assign Executive's rights or delegate Executive's duties or obligations hereunder without the prior written consent of the Company.

8.10. Effect of Termination. The provisions of Section 2.4 and Articles IV, V, VII and VIII and those provisions necessary to interpret and enforce them, shall survive any termination of this Agreement and any termination of the employment relationship between Executive and the Company.

8.11. Third-Party Beneficiaries. Each affiliate of the Company that is not a signatory to this Agreement shall be a third-party beneficiary of Executive's obligations under Sections 2.4 and 8.15 and Articles V, VI and VII and shall be entitled to enforce such obligations as if a party hereto.

8.12. Executive Acknowledgement. Executive acknowledges and agrees that (a) Executive was represented by counsel in connection with the negotiation of this Agreement, and (b) that Executive has read and understands this Agreement, is fully aware of its legal effect, and has entered into it freely based on Executive's own judgment.

8.13. Reserved.

8.14. Choice of Law. All questions concerning the construction, validity and interpretation of this Agreement will be governed by the law of the State of Delaware without regard to the conflicts of law provisions thereof. With respect to any claim or dispute related to or arising under this Agreement, the parties hereby consent to the arbitration provisions of Section 8.15 and recognize and agree that should any resort to a court

be necessary and permitted under this Agreement, then they consent to the exclusive jurisdiction, forum and venue of the state and federal courts (as applicable) located in Delaware.

8.15. Arbitration. Subject to Section 5.4 (which, for the avoidance of doubt, shall control with respect to the matters specified therein) any dispute between the Executive and the Company shall be resolved pursuant to the Mutual Dispute Resolution Agreement between the Executive and the Company.

[Signature page follows]

IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written above.

DOCGO INC.

By: /s/ Anthony Capone

Name: Anthony Capone

Title: Chief Executive

Officer

Aug 15, 2023

Accepted and Agreed:

/s/ Stephen Sugrue

Stephen Sugrue

Aug 15, 2023

Exhibit 10.10

DIRECTOR FORM

10.17

DOCGO INC.

2021 STOCK INCENTIVE PLAN

GRANT NOTICE FOR

RESTRICTED

PERFORMANCE STOCK UNIT AWARD

FOR GOOD AND VALUABLE CONSIDERATION, DocGo Inc. (the “**Company**”) hereby grants to the Participant named below the target number of Restricted Stock Units (the “**RSUs**” performance stock units (“**PSUs**”) specified below (the “**Award**”) as performance-based Restricted Stock Units under the DocGo Inc. 2021 Stock Incentive Plan (the “**Plan**”). Each **RSU Earned PSU** represents the right to receive one share of Common Stock, upon the terms and subject to the conditions set forth in this Grant Notice, the Plan and the Standard Terms and Conditions (the “**Standard Terms and Conditions**”) promulgated under such Plan and attached hereto as Exhibit A. This Award is granted pursuant to the Plan and is subject to and qualified in its entirety by the Standard Terms and Conditions. Capitalized terms not otherwise defined herein shall have the meanings set forth in the Plan.

Name of Participant:	
Grant Date:	
Target Number of RSUs: PSUs:	(the “ Target PSUs ”)
Vesting Schedule: Award Type:	<p>Subject</p> <p>The Award represents the right to receive shares of Common Stock in an amount from % of the Plan Target PSUs. The Award shall vest and become earned and nonforfeitable upon (i) the Participant's satisfaction of the Service Requirement (as defined below) and the Committee's certification of the final level of achievement of the Performance Goal (as defined below). PSUs that become earned upon satisfaction of the Service Requirement and the Standard Terms Performance Goal are referred to herein as “Earned PSUs”. Standard Terms Conditions, the RSUs shall vest date the Committee certified the final level of achievement of the Performance Goal is referred to herein as the “Certification Date.”</p>
Performance Period:	
Service Requirement:	<p>The “Service Requirement” is set forth on , so long as Participant does not have a Termination of Employment from the Grant Date through such vesting date.</p> <p><u>Exhibit B</u> attached hereto.</p>
Performance Goal:	The “ Performance Goal ” is set forth on <u>Exhibit B</u> attached hereto.

IN ORDER TO RECEIVE THE BENEFITS OF THIS AGREEMENT, PARTICIPANT MUST EXECUTE AND RETURN THIS GRANT NOTICE (THE “**ACCEPTANCE REQUIREMENTS**”). IF YOU FAIL TO SATISFY THE ACCEPTANCE REQUIREMENTS WITHIN 60 DAYS AFTER THE GRANT DATE, THEN (1) THIS GRANT NOTICE WILL BE OF NO FORCE OR EFFECT AND THIS AWARD WILL BE AUTOMATICALLY FORFEITED TO THE COMPANY WITHOUT CONSIDERATION, AND (2) NEITHER PARTICIPANT NOR THE COMPANY WILL HAVE ANY

FUTURE RIGHTS OR OBLIGATIONS UNDER THIS GRANT NOTICE OR THE STANDARD TERMS AND CONDITIONS.

By accepting this Grant Notice, Participant acknowledges that Participant has received and read, and agrees that this Award shall be subject to, the terms of this Grant Notice, the Plan, and the Standard Terms and Conditions.

DOCGO INC.

By:
Name:
Title:

PARTICIPANT

DOCGO INC.
By:
Name:
Title:
PARTICIPANT
[Name]

[Name]

Signature Page to
Grant Notice for

RESTRICTED
Performance Stock Unit Award

Exhibit 10.12

EMPLOYEE FORM

DOCGO INC.
2021 STOCK INCENTIVE PLAN
GRANT NOTICE FOR
INCENTIVE STOCK OPTIONS

FOR GOOD

PERFORMANCE GOAL AND VALUABLE CONSIDERATION, DocGo, Inc. (the “Company”), hereby grants to Participant named below the Incentive Stock Option (the “Option”) to purchase any part or all of the number of shares of Common Stock that are covered by this Option at the Exercise Price per share, each specified below, and upon the terms and subject SERVICE REQUIREMENT

STANDARD TERMS AND CONDITIONS FOR

RESTRICTED The PSUs granted pursuant to the conditions Grant Notice to which this Exhibit B is attached will be eligible to become Earned PSUs as set forth in this Grant Notice, the DocGo, Inc. 2021 Stock Incentive Plan (as amended from time to time, the “Plan”) and the Standard Terms and Conditions (the “Standard Terms and Conditions”) promulgated under such Plan and attached hereto as Exhibit A. This Option is granted pursuant to the Plan and is subject to and qualified in its entirety by the Standard Terms and Conditions. This Option is intended to qualify as an incentive stock option under Section 422 satisfaction, and the Code to the maximum extent permitted thereunder. Service Requirement. Capitalized terms not otherwise defined herein shall have the meaning meanings set forth in the Plan. Capitalized terms not otherwise defined herein shall have the meaning meanings set forth in the Plan.

Name of Participant:	
Grant Date:	AS OF RESTRICTED STOCK UNITS

1	Number of Shares of Common Stock	OCK UNITS
	covered by Option:	
	Exercise Price Per Share:	
	Expiration Date:	
	Vesting Schedule:	
	(Notice) representing the right to receive or	
	the Grant Notice, these Standard Terms	
	Conditions and the Grant Notice, any reference to the Company shall include a reference to any Subsidiary	

2. VESTING AND SETTLEMENT OF RESTRICTED STOCK UNITS

2. VESTING AND SETTLEMENT OF PERFORMANCE STOCK UNITS

(a) The Award shall not be vested as of the Grant Date set forth in the Grant Notice and shall be forfeitable unless and until otherwise vested pursuant to the terms of the Grant Notice and these Standard Terms and Conditions. After the Grant Date, subject to termination or acceleration as provided in these Standard Terms and Conditions and the Plan, the Award shall become vested and earned as described in the Grant Notice with respect to that number of Restricted Stock Units as set forth in the Grant Notice. Restricted Stock Units that have vested and are no longer subject to forfeiture are referred to herein as “**Vested RSUs**.” Restricted Stock Units awarded hereunder that are not vested and remain subject to forfeiture are referred to herein as “**Unvested RSUs**.”

(b) As soon as administratively practicable following the vesting of the RSUs pursuant to the Grant Notice Vesting Date (as defined in Exhibit B and this Section 22), but in no event later than the 15th day of the third calendar month of the calendar year following the calendar year in which the RSUs become Vested RSUs, Vesting Date occurs, the Company shall deliver to the Participant a number of shares of Common Stock equal to the number of RSUs that vested on such date.

Earned PSUs.

(c) If the Participant's Participant experiences a Termination of Employment is as a result of the Participant's death or Disability all then Unvested RSUs prior to the final Vesting Date set forth on Exhibit B, subject to the Participant's (or the Participant's personal representative's) execution and nonrevocation of a general release of claims in a form provided by the Company within the time period set forth therein, the Service Requirement shall become Vested RSUs be deemed satisfied as of the date Termination Date (as defined below) and the Vesting Date shall be treated as the later of such the Termination Date or the Certification Date.

(d) If the Participant experiences a Termination of Employment.

(d) In Employment as a result of an Involuntary Termination (as defined below) prior to the event of final Vesting Date and otherwise on or within 24-months following a Change in Control, all then Unvested RSUs subject to the Participant's execution and nonrevocation of a general release of claims in a form provided by the Company within the time period set forth therein, the Service Requirement shall become Vested RSUs be deemed satisfied as of the date Termination Date and the Vesting Date shall be treated as the later of such Change in Control.

the Termination Date or the Certification Date.

(e) Upon the Participant's Termination of Employment for any other reason not set forth in Section 2(c), or 2(d) prior to the final Vesting Date, any then Unvested RSUs held by outstanding Target PSUs

IN ORDER TO RECEIVE THE BENEFITS OF THIS AGREEMENT, PARTICIPANT MUST EXECUTE AND RETURN THIS GRANT NOTICE (THE "ACCEPTANCE REQUIREMENTS"). IF YOU FAIL TO SATISFY THE ACCEPTANCE REQUIREMENTS WITHIN 60 DAYS AFTER THE GRANT DATE, THEN (1) THIS GRANT NOTICE WILL BE OF NO FORCE OR EFFECT AND THE OPTION GRANTED HEREIN WILL BE AUTOMATICALLY FORFEITED TO THE COMPANY WITHOUT CONSIDERATION, AND (2) NEITHER PARTICIPANT NOR THE COMPANY WILL HAVE ANY FUTURE RIGHTS OR OBLIGATIONS UNDER THIS GRANT NOTICE OR THE STANDARD TERMS AND CONDITIONS.

By accepting this Grant Notice, Participant acknowledges that he or she has received and read, and agrees that this Option shall be subject to, the terms of this Grant Notice, the Plan, and the Standard Terms and Conditions and the Covenants Agreement.

DOCGO, INC.

By: _____

Name: _____

Title: _____

which have not become Earned PSUs or for which the Participant's Service Requirement has not been satisfied shall be forfeited and canceled as of the Termination Date.

PARTICIPANT

[Name] _____

(f) As used in this Section 2:

SIGNATURE PAGE TO

GRANT NOTICE FOR

(i) "Involuntary Termination" means a termination of Employment by the Company without Cause (and not as a result of death or Disability).

INCENTIVE STOCK OPTIONS

(ii) "Termination Date" means the date of such the Participant's Termination of Employment.

EXHIBIT A

STANDARD TERMS AND CONDITIONS FOR

RESTRICTED STOCK UNITS

3. RIGHTS AS STOCKHOLDER; DIVIDEND EQUIVALENTS

3. RIGHTS AS STOCKHOLDER; DIVIDEND EQUIVALENTS

Participant shall not be, nor have any of the rights or privileges of, a stockholder of the Company in respect of any RSUs PSUs unless and until shares of Common Stock settled for such RSUs Earned PSUs shall have been issued by the Company to Participant (as evidenced by the appropriate entry on the books of the Company or of a duly authorized transfer agent of the Company).

4. RESTRICTIONS ON RESALES OF SHARES

4. RESTRICTIONS ON RESALES OF SHARES

The Company may impose such restrictions, conditions or limitations as it determines appropriate as to the timing and manner of any resales by the Participant or other subsequent transfers by the Participant of any shares of Common Stock issued pursuant to Vested RSUs, Earned PSUs, including (a) restrictions under an insider trading policy, (b) restrictions designed to delay and/or coordinate the timing and manner of sales by Participant and other holders and (c) restrictions as to the use of a specified brokerage firm for such resales or other transfers.

5. NONTRANSFERABILITY OF AWARD

5. INCOME TAXES

To the extent required by applicable federal, state, local or foreign law, the Participant shall make arrangements satisfactory to the Company for the satisfaction of any withholding tax obligations that arise by reason of the grant or vesting of the Award. The Company shall not be required to issue shares or to recognize the disposition of such shares until such obligations are satisfied.

6. NONTRANSFERABILITY OF AWARD

The Participant understands, acknowledges **EXHIBIT A** that, except as otherwise provided in the Plan or as permitted by the Committee, the Award may not be transferred, pledged or otherwise directly or indirectly encumbered or disposed of other than as provided in the Plan.

DOC GO, INC.

2021 STOCK INCENTIVE PLAN

STANDARD TERMS AND CONDITIONS FOR

INCENTIVE STOCK OPTIONS

These Standard Terms and Conditions apply to the Options granted pursuant to DocGo, Inc. 2021 Stock Incentive Plan (the “**Plan**”), which are identified as incentive stock options and are evidenced by a Grant Notice or an action of the Committee that specifically refers to these Standard Terms and Conditions. In addition to these Standard Terms and Conditions, the Option shall be subject to the terms of the Plan, which are incorporated into these Standard Terms and Conditions by this reference. Capitalized terms not otherwise defined herein shall have the meaning set forth in the Plan.

1. TERMS OF OPTION

DocGo, Inc. (the “**Company**”) has granted to the Participant named in the Grant Notice provided to said Participant herewith (the “**Grant Notice**”) an Incentive Stock Option (the “**Option**”) to purchase up to the number of shares of Common Stock at an exercise price per share, each as set forth in the Grant Notice. The Option is subject to the conditions set forth in the Grant Notice, these Standard Terms and Conditions, and the Plan. For purposes of these Standard Terms and Conditions and the Grant Notice, any reference to the Company shall include a reference to any Subsidiary.

2. INCENTIVE STOCK OPTION

The Option is intended to qualify as an incentive stock option under Section 422 of the Internal Revenue Code of 1986, as amended (the “**Code**”), and will be interpreted accordingly. Section 422 of the Code provides, among other things, that the Optionee shall not be taxed upon the exercise of a stock option that qualifies as an incentive stock option provided the Optionee does not dispose of the shares of Common Stock acquired upon exercise of such option until the later of two years after such option is granted to the Optionee and one year after such option is exercised. Notwithstanding anything to the contrary herein, Section 422 of the Code provides that incentive stock options (including, possibly, the Option) shall not be treated as incentive stock options if and to the extent that the aggregate fair market value of shares of Common Stock (determined as of the time of grant) with respect to which such incentive stock options are exercisable for the first time by the Optionee during any calendar year (under all plans of the Company and its subsidiaries) exceeds \$100,000, taking options into account in the order in which they were granted. Thus, if and to the extent that any shares of Common Stock issued under a portion of the Option exceeds the foregoing \$100,000 limitation, such shares shall not be treated as issued under an incentive stock option pursuant to Section 422 of the Code.

3. EXERCISE OF OPTION

(a) The Option shall not be exercisable as of the Grant Date set forth in the Grant Notice. After the Grant Date, to the extent not previously exercised, and subject to termination or acceleration as provided in these Standard Terms and Conditions and the Plan, the Option shall be exercisable only to the extent it becomes vested, as described in the Grant Notice or the terms of the Plan, to purchase up to that number of shares of Common Stock as set forth in the Grant Notice; provided, that (except as set forth in Section 4(a) below) the Participant remains employed with the Company and does not experience a Termination of Employment. The vesting period and/or exercisability of an Option may be adjusted by the Committee to reflect the decreased level of employment during any period in which the Participant is on an approved leave of absence or is employed on a less than full time basis.

8. NO LIABILITY OF COMPANY
applicable.

9. NO LIABILITY OF COMPANY **Service Requirement**

(b) To exercise the Option (or any part thereof), the Participant shall deliver to the Company a “Notice of Exercise” in a form specified by the Committee, specifying the number of whole shares of Common Stock the Participant wishes to purchase and how the Participant’s shares of Common Stock should be registered (in the Participant’s name only or in the Participant’s and the Participant’s spouse’s names as community property or as joint tenants with right of survivorship).

(c) The exercise price (the “**Exercise Price**”) of the Option is set forth in the Grant Notice. The Company shall not be obligated to issue any shares of Common Stock until the Participant shall have paid the total Exercise Price for that number of shares of Common Stock. The Exercise Price may be paid in Common Stock, cash or a combination thereof, including an irrevocable commitment by a broker to pay over such amount from a sale of the Common Stock issuable under the Option, the delivery of previously owned Common Stock, withholding of shares of Common Stock deliverable upon exercise of the Option (but only to the extent share withholding is made available to the Participant by the Company), or in such other manners as may be permitted by the Committee.

(d) Fractional shares may not be exercised. Shares of Common Stock will be issued as soon as practical after exercise. Notwithstanding the above, the Company shall not be obligated to deliver any shares of Common Stock during any period when the Company determines that the exercisability of the Option or the delivery of shares of Common Stock hereunder would violate Company policy or any federal, state or other applicable laws.

4. EXPIRATION OF OPTION

The Option shall expire and cease to be exercisable as of the earlier of (i) the Expiration Date set forth in the Grant Notice or (ii) the date specified below in connection with the Participant’s Termination of Employment:

(a) If the Participant’s Termination of Employment is as a result of the Participant’s death or Disability, subject to the Participant’s (or the Participant’s personal representative’s) execution and nonrevocation of a general release of claims in a form provided by the Company, (i) the entire Option shall be fully vested and (ii) the Participant may exercise any portion of the Option until the first anniversary of the Termination Date (as defined below).

(b) If the Participant’s Termination of Employment is as a result of an Involuntary Termination (as defined below) on or within 24-months following a Change in Control, subject to the Participant’s execution and nonrevocation of a general release of claims in a form provided by the Company, (i) the entire Option shall be fully vested and (ii) the Participant may exercise any portion of the Option until the date that is 90 days following the Termination Date.

(h) The headings preceding the text of the sections hereof are inserted solely for convenience of reference, and shall not constitute a part of these Standard Terms and Conditions.

(c) If the Participant’s Termination of Employment is by the Company for Cause, the entire Option, whether or not then vested, shall be forfeited. The use herein of the word “including” following any general statement shall be construed to limit such statement, term or matter to the specific items or matters set forth immediately following such word or to similar items or matters, whether or not non-limiting language (such as “without limitation”, “but not limited to”, or words of similar import) is used with reference thereto, but rather shall be deemed to refer to all other items or matters that could reasonably fall within the broadest possible scope of the term.

such general statement, term or matter. References herein to any agreement, instrument or other document as amended, supplemented and modified from time to time to the extent permitted by the provisions thereof and not prohibited by the Plan or these Standard Terms and Conditions shall be immediately forfeited and canceled as of the Termination Date.

(c) These Standard Terms and Conditions shall inure to the benefit of and be binding upon the parties hereto and their respective permitted heirs, beneficiaries, successors and assigns.

(d) If the Participant's Termination of Employment is for any reason other than as set forth in Section 4(a), 4(b), or 4(c), the Participant may exercise any portion of the Option that is vested and exercisable at the time of such Termination of Employment until the date that is 90 days following the Termination Date.

(e) Any portion of the Option that is not vested and exercisable at the time of a Termination of Employment (after taking into account any accelerated vesting under the Plan or any other agreement between the Participant and the Company) shall be forfeited and canceled as of the Termination Date.

Except as permitted by the Committee or as permitted under the Plan, the Participant may not assign or transfer the Option to anyone other than by will or the laws of descent and distribution and the Option shall be exercisable only by the Participant during his or her lifetime. The Company may cancel the Participant's Option if the Participant attempts to assign or transfer it in a manner inconsistent with this Section 7.

7. NON-TRANSFERABILITY OF OPTION

8. OTHER AGREEMENTS SUPERSEDED

The Grant Notice, these Standard Terms and Conditions, the Covenants Agreement and the Plan constitute the entire understanding between the Participant and the Company regarding the Option. Any prior agreements, commitments or negotiations concerning the Option are superseded; provided, however, that the terms of the Covenants Agreement are in addition to and complement (and do not replace or supersede) all other agreements and obligations between the Company and any of its affiliates and the Participant with respect to noncompetition, nonsolicitation and noninterference.

9. LIMITATION OF INTEREST IN SHARES SUBJECT TO OPTION

Neither the Participant (individually or as a member of a group) nor any beneficiary or other person claiming under or through the Participant shall have any right, title, interest, or privilege in or to any shares of Common Stock allocated or reserved for the purpose of the Plan or subject to the Grant Notice or these Standard Terms and Conditions except as to such shares of Common Stock, if any, as shall have been issued to such person upon exercise of the Option or any part of it. Nothing in the Plan, in the Grant Notice, these Standard Terms and Conditions or any other instrument executed pursuant to the Plan shall confer upon the Participant any right to continue in the Company's employ or service nor limit in any way the Company's right to terminate the Participant's employment at any time for any reason.

10. NO LIABILITY OF COMPANY

The Company and any affiliate which is in existence or hereafter comes into existence shall not be liable to the Participant or any other person as to: (a) the non-issuance or sale of shares of Common Stock as to which the Company has been unable to obtain from any regulatory body having jurisdiction the authority deemed by the Company's counsel to be necessary to the lawful issuance and sale of any shares hereunder; and (b) any tax consequence expected, but not realized, by the Participant or other person due to the receipt, exercise or settlement of any Option granted hereunder.

11. GENERAL NONQUALIFIED STOCK OPTIONS

(a) In the event that any provision of these Standard Terms and Conditions is declared to be illegal, invalid or otherwise unenforceable by a court of competent jurisdiction, such provision shall be reformed, if possible, to the extent necessary to render it legal, valid and enforceable, or otherwise deleted, and the remainder of these Standard Terms and Conditions shall not be affected except to the extent necessary to reform or delete such illegal, invalid or unenforceable provision.

(b) The headings preceding the text of the sections hereof are inserted solely for convenience of reference, and shall not constitute a part of these Standard Terms and Conditions, nor shall they affect its meaning, construction or effect. Words in the masculine gender shall include the feminine gender, and where appropriate, the plural shall include the singular and the singular shall include the plural. The use herein of the word "including" following any general statement, term or matter shall not be construed to limit such statement, term or matter to the specific items or matters set forth immediately following such word or to similar items or matters, whether or not non-limiting language (such as "without limitation", "but not limited to", or words of similar import) is used with reference thereto, but rather shall be deemed to refer to all other items or matters that could reasonably fall within the broadest possible scope of such general statement, term or matter. References herein to any agreement, instrument or other document means such agreement, instrument or other document as amended, supplemented and modified from time to time to the extent permitted by the provisions thereof and not prohibited by the Plan or these Standard Terms and Conditions.

(c) These Standard Terms and Conditions shall inure to the benefit of and be binding upon the parties hereto and their respective permitted heirs, beneficiaries, successors and assigns.

(d) These Standard Terms and Conditions shall be construed in accordance with and governed by the laws of the State of Delaware, without regard to principles of conflicts of law.

(e) In the event of any conflict between the Grant Notice, these Standard Terms and Conditions and the Plan, the Grant Notice and these Standard Terms and Conditions shall control. In the event of any conflict between the Grant Notice and these Standard Terms and Conditions, the Grant Notice shall control.

(f) All questions arising under the Plan or under these Standard Terms and Conditions shall be decided by the Committee in its total and absolute discretion.

12. ELECTRONIC DELIVERY

By executing the Grant Notice, the Participant hereby consents to the delivery of information (including information required to be delivered to the Participant pursuant to applicable securities laws) regarding the Company and the Subsidiaries, the Plan, the Option and the Common Stock via Company web site or other electronic delivery.

IN ORDER TO RECEIVE THE BENEFITS OF THIS AGREEMENT, PARTICIPANT MUST EXECUTE AND RETURN THIS GRANT NOTICE (THE "ACCEPTANCE REQUIREMENTS"). IF YOU FAIL TO SATISFY THE ACCEPTANCE REQUIREMENTS WITHIN 60 DAYS AFTER THE GRANT DATE, THEN (1) THIS GRANT NOTICE WILL BE AUTOMATICALLY FORFEITED TO THE COMPANY WITHOUT CONSIDERATION, AND (2) NEITHER PARTICIPANT NOR THE COMPANY WILL HAVE ANY FUTURE RIGHTS OR OBLIGATIONS UNDER THIS GRANT NOTICE OR THE STANDARD TERMS AND CONDITIONS.

Name	Jurisdiction
By accepting this Grant Notice, Participant acknowledges that he or she has received and read, and agrees that this Option shall be subject to, the terms of the Plan, and the Standard Terms and Conditions and the Covenants Agreement.	Delaware, United States
AF PR	Puerto Rico, United States Territory
Ambulnz, LLC	DOCGO INC.
AF WI LNZ, LLC	By: _____
AF WI, LLC	Name: _____
Ambulnz AL, LLC	Title: _____
Ambulnz CO, LLC	Wisconsin, United States
Ambulnz Community Partners Ltd	Wisconsin, United States
Ambulnz Health, GA, LLC	PARTICIPANT
	[Name] _____
	Alabama, United States
	Colorado, United States
	England and Wales
	Delaware, Georgia, United States
Ambulnz Holdings, LLC	Delaware, United States
Ambulnz NJ, LLC	New Jersey, United States
Ambulnz NJ-PA, LLC	Delaware, United States
Ambulnz NY 2, LLC	Delaware, United States
Ambulnz NY 3, LLC	Delaware, United States
Ambulnz NY 5, LLC	New York, United States
Ambulnz NY, LLC	Delaware, United States
Ambulnz PA, LLC	Pennsylvania, United States
Ambulnz RE 1, LLC	New York, United States
Ambulnz TN, LLC	Tennessee, United States
Ambulnz TX, LLC	Texas, United States
Ambulnz UK LTD	England and Wales
Ambulnz UK, LLC	Delaware, United States
Ambulnz WI, LLC	Wisconsin, United States
Ambulnz, Inc.	Delaware, United States
Ambulnz-FMC AL, LLC	Alabama, United States
Ambulnz-FMC MO LLC	Missouri, United States
Ambulnz-FMC North America LLC	Delaware, United States
Ambulnz-FMC NY, LLC	New York, United States
Ambulnz-FMC TN, LLC	Tennessee, United States
Ambulnz-PA WC, LLC	Pennsylvania, United States
ARM Insurance, Inc.	Vermont, United States
AZ Ambulette, LLC	New York, United States
Century Ambulnace Services Inc. Cardiac RMS LLC	New York, United States
Century Ambulance Services Inc.	New York, United States
Community Ambulnace Services, Ltd Ambulance Service Ltd	England and Wales
CRMS DG, LLC	New York, United States
Dara Development OU	Estonia
Dara Technologies, LLC	Delaware, United States

DocGo EMS Training Center, LLC
 DocGo Mobile Health Supplies, LLC
 EMS DIRECT, LLC
 Exceptional Medical Transportation, LLC
 First on Call Medical Services, LLC
 Government Medical Services, LLC
 Heartwatch Solutions, Inc.
 Healthwork LLC
 L.J.H. Ambulance, Inc.
 Location Medical Services Limited
 MedResponse
 Rapid Reliable Testing CA, LLC
 Rapid Reliable Testing FL, LLC
 Rapid Reliable Testing NY, LLC
 Rapid Reliable Testing, LLC
 Ryan Brother Bros. Ambulance, LLC
 Ryan Bros. Fort Atkinson, LLC
 Virtual Care Management, LLC

EXHIBIT A
DOCGO INC.
2021 STOCK INCENTIVE PLAN
STANDARD TERMS AND CONDITIONS FOR
NONQUALIFIED STOCK OPTIONS

New York, United States
 New York, United States
 Texas, United States
 New Jersey, United States
 California, United States
 Delaware, United States
 California, United States
 Delaware, United States
 Wisconsin, United States
 England and Wales
 California, United States
 Delaware, United States
 Delaware, United States

These Standard Terms and Conditions apply to the Options granted pursuant to DocGo Inc. 2021 Stock Incentive Plan (the "Plan"), which are identified First on Call Medical Services, LLC. For purposes of these Standard Terms and Conditions, the Option shall be subject to the terms of the Plan, which are incorporated into these Standard Services, LLC conditions by this reference. Capitalized terms not otherwise defined herein shall have the meaning set forth in the Plan.

1. TERMS OF OPTION
 DocGo Inc. (the "Company") has granted to the Participant named in the Grant Notice provided to said Participant herewith (the "Grant Notice") a Nonqualified Stock Option (the "Option") to purchase up to the number of shares of Common Stock at an exercise price set forth in the Grant Notice. The Option is subject to the conditions set forth in the Grant Notice, these Standard Terms and Conditions, and the Plan. For purposes of these Standard Terms and Conditions and the Grant Notice, any reference to the Company shall include a reference to any Subsidiary.

2. NONQUALIFIED STOCK OPTION
 The Option is not intended to be an incentive stock option under Section 422 of the Code and will be interpreted accordingly.

3. EXERCISE OF OPTION
 (a) The Option shall not be exercisable as of the Grant Date set forth in the Grant Notice. After the Grant Date, to the extent not previously exercised, and subject to the terms of the Plan, the Option shall be exercisable only to the extent it becomes exercisable as provided in these Standard Terms and Conditions and the Plan, the Option shall be exercisable only to the extent it becomes exercisable as provided in the Grant Notice or the Plan. The Option shall be exercisable up to that number of shares of Common Stock as set forth in the Grant Notice; provided, that (except as set forth in Section 4(a) below) the Participant remains employed with the Company and does not experience a Termination of Employment. The vesting period and/or exercisability of an Option may be adjusted by the Committee to reflect the decreased level of employment during any period in which the Participant is on an approved leave of absence or is employed on a less than full time basis.

(b) To exercise the Option (or any part thereof), the Participant shall deliver to the Company a "Notice of Exercise" in a form specified by the Committee, specifying the number of whole shares of Common Stock the Participant wishes to purchase and how the Participant's shares of Common Stock should be registered (in the Participant's name only or in the Participant's and the Participant's spouse's names as community property or as joint tenants with right of survivorship).

Exhibit 21.1

Rapid Temps, LLC
 Rapid Reliable Testing CA, LLC
 Rapid Reliable Testing FL, LLC
 Rapid Reliable Testing NY, LLC
 Rapid Reliable Testing, LLC
 Ryan Brother Bros. Ambulance, LLC
 Ryan Bros. Fort Atkinson, LLC
 Virtual Care Management, LLC

New Mexico, United States
 California, United States
 Florida, United States
 New York, United States
 Delaware, United States
 Wisconsin, United States
 Wisconsin, United States
 Delaware, United States

Exhibit 23.1

(c) The exercise price (the "Exercise Price") of the Option shall be the Exercise Price of the Common Stock until the Participant shall have paid the total Exercise Price for that number of shares of Common Stock. The Exercise Price may be paid in Common Stock or a combination thereof, including an irrevocable commitment by a broker to issue under the Option, the delivery of previously owned Common Stock, withholding of shares of Common Stock deliverable upon exercise of the Option, or any combination thereof, in accordance with the terms of the Plan. We hereby consent to the incorporation by reference in the Registration Statements No. 333-262108 on Form S-3 (No. 333-261363) and Form S-8 (No. 333-262108) of DocGo, Inc. and subsidiaries (the "Company") of our report reports dated March 14, 2023 February 28, 2024, but only to the extent share withholding is made available to the Participant by the Company, or in such other manner as may be determined by the Committee, relating to the consolidated financial statements, and the effectiveness of DocGo, Inc. and subsidiaries appearing the Company's internal control over financial reporting, which appear in this Annual Report on Form 10-K of DocGo, Inc. and subsidiaries for the year ended December 31, 2022 December 31, 2023, dated to deliver any shares of Common Stock during any period when the Company determines that the exercisability of the Option or the delivery of shares of Common Stock hereunder would violate Company policy or any federal, state or other applicable laws.

4. EXPIRATION OF OPTION

The Option shall expire and cease to be exercisable as of the earlier of (i) the Expiration Date set forth in the Grant Notice or (ii) the date specified below in connection with the Participant's Termination of Employment:

(a) If the Participant's Termination of Employment is as a result of the Participant's death or Disability, subject to the Participant's (or the Participant's personal representative's) execution and nonrevocation of a general release of claims in a form provided by the Company, (i) the entire Option shall be fully vested and (ii) the Participant may exercise any portion of the Option until the first anniversary of the Termination Date (as defined below).

(b) If the Participant's Termination of Employment is as a result of an Involuntary Termination (as defined below) on or within 24-months following a Change in Control, subject to the Participant's execution and nonrevocation of a general release of claims in a form provided by the Company, (i) the entire Option shall be fully vested and (ii) the Participant may exercise any portion of the Option until the date that is 90 days following the Termination Date.

(c) If the Participant's Termination of Employment is by the Company for Cause, the entire Option, whether or not then vested and exercisable, shall be immediately forfeited and canceled as of the Termination Date.

(d) If the Participant's Termination of Employment is for any reason other than as set forth in Section 4(a), 4(b), or 4(c), the Participant may exercise any portion of the Option that is vested and exercisable at the time of such Termination of Employment until the date that is 90 days following the Termination Date.

(e) Any portion of the Option that is not vested and exercisable at the time of a Termination of Employment (after taking into account any accelerated vesting under this Section 4, Section 15 of the Plan or any other agreement between the Participant and the Company) shall be forfeited and canceled as of the Termination Date.

(f) As used in this Section 4:

(i) "Involuntary Termination" means a Termination of Employment by the Company without Cause (and not as a result of death or Disability).

(ii) "Termination Date" means the date of the Participant's Termination of Employment.

5. RESTRICTIONS ON REALES OF SHARES ACQUIRED PURSUANT TO OPTION EXERCISE

The Company may impose such restrictions, conditions or limitations as it determines appropriate as to the timing and manner of any resales by the Participant or other subsequent transfers by the Participant of any shares of Common Stock issued as a result of the exercise of the Option, including (a) restrictions on the timing and manner of sales by the Participant, (b) restrictions on the use of a specified brokerage firm for such sales or other transfers, and (c) restrictions as to the use of a specified brokerage firm for such sales or other transfers.

6. I, Anthony Capone, certify that:

1. I have reviewed this Annual Report on Form 10-K of DocGo Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the connection with the exercise of the Option (provided that shares of Common Stock may be withheld only to the extent that such withholding will not result in adverse accounting treatment for the Company). The Participant acknowledges that the Company shall have the right to deduct any taxes required to be withheld by law in connection with the exercise of the Option from any amounts payable by it to the Participant (including future cash wages).

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; and the laws or descent and distribution and the Option shall be exercisable only by the Participant during his or her lifetime. The Company may cancel the Participant's Option if the Participant attempts to assign or transfer it in a manner inconsistent with this Section 7.

4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; and

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

The Company and any affiliate which is in existence or hereafter comes into existence shall not be liable to the Participant or any other person as to: (a) the non-issuance or sale of shares of Common Stock as to which the Company has been unable to obtain from any regulatory body having jurisdiction the

9. LIMITATION OF INTEREST IN SHARES SUBJECT TO OPTION

Neither the Participant (individually or as a member of a group) nor any beneficiary or other person claiming under or through the Participant shall have any right by others within those entities, particularly during the period in which this report is being prepared; the Plan or subject to the Grant Notice or these Standard Terms and Conditions except as to such shares of Common Stock, if any, as shall have been issued to such person upon exercise of the Option or

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

10. NO LIABILITY

The Company and any affiliate which is in existence or hereafter comes into existence shall not be liable to the Participant or any other person as to: (a) the non-issuance or sale of shares of Common Stock as to which the Company has been unable to obtain from any regulatory body having jurisdiction the

authority (c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about but not realized, by the Participant or other person due to the receipt, exercise or settlement of any Option granted hereunder.

11. GENERAL. the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such

(a) Evaluation; and any provision of these Standard Terms and Conditions is declared to be illegal, invalid or otherwise unenforceable by a court of competent jurisdiction, such provision shall be reformed, if possible, to the extent necessary to render it legal, valid and enforceable, or otherwise deleted, and the remainder of these Standard Terms and Conditions shall not be affected except to the extent necessary to reform or delete such illegal, invalid or unenforceable provision.

(d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is

(b) reasonably likely to materially affect, the registrant's internal control over financial reporting; and for convenience of reference, and shall not constitute a part of these Standard Terms and Conditions, nor shall they affect its meaning, construction or effect.

5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent statement functions); or matter shall not be construed to limit such statement, term or matter to the specific items or matters

set forth immediately following such word or to similar items or matters, whether or not non-limiting language (such as

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are "without limitation" but not limited to, or words of similar import) is used with reference thereto, but rather shall be deemed to refer to all other items or matters that could reasonably fail within the broadest possible scope of such

general statement, term or matter. References herein to any agreement, instrument or other document means such agreement, instrument or other document, as amended, supplemented and modified from time to time to the extent permitted by the provisions thereof and not prohibited by the Plan or these Standard Terms and Conditions.

1.

I have reviewed this Annual Report on Form 10-K of D
Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the respective financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. (d) These Standard Terms and Conditions shall be construed in accordance with and governed by the State of Delaware, without regard to principles of conflicts of law.

(e) In the event of any conflict between the Grant Notice, these Standard Terms and Conditions and the Plan, the Grant Notice and these Standard Terms and Conditions shall control. In the event of any conflict between the Grant Notice and these Standard Terms and Conditions, the Grant Notice shall control.

(f) All questions arising under the Plan or under these Standard Terms and Conditions shall be the Committee in its total and absolute discretion.

11. CLAWBACK

The Earned PSUs and any shares of Common Stock received upon settlement of the Earned PSUs shall be subject to recoupment in accordance with any clawback policy adopted by the Company, specifically increasing the Company's

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

12.E5.ctr The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

ELFCTRONIC DELIVERY

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

By executing the Grant Notice, the Participant hereby consents to the delivery of information (including, without limitation, information over financial reporting) to be delivered to the Participant pursuant to applicable securities laws) regarding the

Company and the Subsidiaries, the Plan, the Option and the Common Stock of the Company via Company web site or other

Date: March 14, 2023 February 28, 2024

By: Lee Bienstock

Anthony Capone Lee Bienstock

A-5

Chief Executive Officer

(Principal Executive Officer)

EXHIBIT B

Exhibit 31.2

CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER

PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Norman Rosenberg, certify that:

1. I have reviewed this Annual Report on Form 10-K of DocGo Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
 - (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 - (b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial

statements for external purposes in accordance with generally accepted accounting principles;

- (c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
- (d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

- (a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
- (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

1.

I have reviewed this Annual Report on Form 10-K of D
Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.

The
registrant's
other
certifying
officer and I
are
responsible for
establishing
and
maintaining
disclosure
controls and
procedures (as
defined in
Exchange
Act Rules 13a-
15(e) and 15d-
15(e)) and
internal
control over
financial
reporting (as
defined in
Exchange Act
Rules 13a-
15(f) and 15d-
15(f)) for the
registrant and
have:

- (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 - (b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 - (c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
 - (d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
- (a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
 - (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: March 14, 2023 February 28, 2024

By: /s/ Norman Rosenberg

 Norman Rosenberg
 Chief Financial Officer
 (Principal Financial and Accounting Officer)

Exhibit 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Annual Report on Form 10-K of DocGo Inc. (the "Company") for the year ended December 31, 2022 December 31, 2023, as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Anthony Capone, Lee Bienstock, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. §1350, as adopted pursuant to §906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:

- 1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and
- 2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

1.

The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: March 14, 2023 February 28, 2024

/s/ Anthony Capone
Lee Bienstock
Anthony Capone Lee Bienstock
Chief Executive Officer
(Principal Executive Officer)

Exhibit 32.2

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Annual Report on Form 10-K of DocGo Inc. (the "Company") for the year ended December 31, 2022 December 31, 2023, as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Norman Rosenberg, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. §1350, as adopted pursuant to §906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:

1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and
2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

1.

The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: March 14, 2023 February 28, 2024

By: /s/ Norman Rosenberg
Norman Rosenberg
Chief Financial Officer
(Principal Financial and Accounting Officer)

Exhibit 97.1

DOCGO INC.
COMPENSATION RECOUPMENT (CLAWBACK) POLICY
(Effective November 15, 2023)

Recoupment of Incentive-Based Compensation

It is the policy of DocGo Inc. (the “Company”) that, in the event the Company is required to prepare an accounting restatement of the Company’s financial statements due to material non-compliance with any financial reporting requirement under the federal securities laws (including any such correction that is material to the previously issued financial statements, or that would result in a material misstatement if the error were corrected in the current period or left uncorrected in the current period), the Company will recover on a reasonably prompt basis the amount of any Incentive-Based Compensation Received by a Covered Executive during the Recovery Period that exceeds the amount that otherwise would have been Received had it been determined based on the restated financial statements.

Policy Administration and Definitions

This Policy is administered by the Compensation Committee (the “Committee”) of the Company’s Board of Directors, subject to ratification by the Board of Directors with respect to application of this Policy to the Company’s Chief Executive Officer, and is intended to comply with, and as applicable to be administered and interpreted consistent with, and subject to the exceptions set forth in, Listing Standard 5608 adopted by the Nasdaq Stock Market to implement Rule 10D-1 under the Securities Exchange Act of 1934, as amended (collectively, “Rule 10D-1”).

For purposes of this Policy:

“Incentive-Based Compensation” means any compensation granted, earned, or vested based in whole or in part on the Company’s attainment of a financial reporting measure that was Received by a person (i) on or after October 2, 2023 and after the person began service as a Covered Executive, and (ii) who served as a Covered Executive at any time during the performance period for the Incentive-Based Compensation. A financial reporting measure is (i) any measure that is determined and presented in accordance with the accounting principles used in preparing the Company’s financial statements and any measure derived wholly or in part from such a measure, and (ii) any measure based in whole or in part on the Company’s stock price or total shareholder return.

Incentive-Based Compensation is deemed to be “Received” in the fiscal period during which the relevant financial reporting measure is attained, regardless of when the compensation is actually paid or awarded.

“Covered Executive” means any “officer” of the Company as defined under Rule 16a-1(f) under the Securities Exchange Act of 1934, as amended.

“Recovery Period” means the three completed fiscal years immediately preceding the date that the Company is required to prepare the accounting restatement described in this Policy, all as determined pursuant to Rule 10D-1, and any transition period of less

than nine months that is within or immediately following such three fiscal years.

If the Committee determines the amount of Incentive-Based Compensation Received by a Covered Executive during a Recovery Period exceeds the amount that would have been Received if determined or calculated based on the Company's restated financial results, such excess amount of Incentive-Based Compensation shall be subject to recoupment by the Company pursuant to this Policy. For Incentive-Based Compensation based on stock price or total shareholder return, where the amount of erroneously awarded compensation is not subject to mathematical recalculation directly from the information in an accounting restatement, the Committee will determine the amount based on a reasonable estimate of the effect of the accounting restatement on the relevant stock price or total shareholder return. In all cases, the calculation of the excess amount of Incentive-Based Compensation to be recovered will be determined without regard to any taxes paid with respect to such compensation. The Company will maintain and will provide to the Nasdaq Stock Market documentation of all determinations and actions taken in complying with this Policy. Any determinations made by the Committee under this Policy shall be final and binding on all affected individuals.

The Company may effect any recovery pursuant to this Policy by requiring payment of such amount(s) to the Company, by set-off, by reducing future compensation, or by such other means or combination of means as the Committee determines to be appropriate. The Company need not recover the excess amount of Incentive-Based Compensation if and to the extent that the Committee determines that such recovery is impracticable, subject to and in accordance with any applicable exceptions under the Nasdaq Stock Market listing rules, and not required under

Rule 10D-1, including if the Committee determines that the direct expense paid to a third party to assist in enforcing this Policy would exceed the amount to be recovered after making a reasonable attempt to recover such amounts. The Company is authorized to take appropriate steps to implement this Policy with respect to Incentive-Based Compensation arrangements with Covered Executives.

Any right of recoupment or recovery pursuant to this Policy is in addition to, and not in lieu of, any other remedies or rights of recoupment that may be available to the Company pursuant to the terms of any other policy, any employment agreement or plan or award terms, and any other legal remedies available to the Company; provided that the Company shall not recoup amounts pursuant to such other policy, terms or remedies to the extent it is recovered pursuant to this Policy. The Company shall not indemnify any Covered Executive against the loss of any Incentive-Based Compensation pursuant to this Policy.

DISCLAIMER

THE INFORMATION CONTAINED IN THE REFINITIV CORPORATE DISCLOSURES DELTA REPORT™ IS A COMPARISON OF TWO FINANCIALS PERIODIC REPORTS. THERE MAY BE MATERIAL ERRORS, OMISSIONS, OR INACCURACIES IN THE REPORT INCLUDING THE TEXT AND THE COMPARISON DATA AND TABLES. IN NO WAY DOES REFINITIV OR THE APPLICABLE COMPANY ASSUME ANY RESPONSIBILITY FOR ANY INVESTMENT OR OTHER DECISIONS MADE BASED UPON THE INFORMATION PROVIDED IN THIS REPORT. USERS ARE ADVISED TO REVIEW THE APPLICABLE COMPANY'S ACTUAL SEC FILINGS BEFORE MAKING ANY INVESTMENT OR OTHER DECISIONS.

©2024, Refinitiv. All rights reserved. Patents Pending.